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This thesis describes work on the asymmetric synthesis of orthogonally 
protected cyclic hydrazines, their subsequent functionalization and the study of 
their structure, to examine their potential as drug-like scaffolds. 
Chapter 1 is an introduction to cyclic hydrazines, including a discussion of 
their relevance to medicinal chemistry as sp3-rich scaffolds. It includes a 
summary of previous synthetic methodologies that have been developed to 
access cyclic hydrazines. 
Chapter 2 describes the synthesis of orthogonally protected cyclic hydrazines. 
Initially a synthetic methodology is developed for the synthesis of orthogonally 
protected diazetidines. The first method explored ring opening of epoxides with 
hydrazine nucleophiles. The second, more general method, is based on the 
Asymmetric Transfer Hydrogenation of aryl ketones, which was successful 
across a range of ring sizes and substitution patterns. Twenty-eight examples 
were synthesised, including 4- to 7-membered rings in up to 99% ee. 
Chapter 3 is focused on the deprotection and subsequent functionalization of 
these cyclic hydrazine scaffolds. Initially the functionalisation of pyrazolidines 
was explored, and suitable conditions for Buchwald-Hartwig couplings were 
developed using high throughput screening. Derivatisation was subsequently 
expanded to include acylation and reductive amination reactions and was also 
shown to be effective across all the ring sizes synthesised in chapter 2. 
Chapter 4 describes the study of the 3D structure of the cyclic hydrazine 
scaffolds. XRD, PMI plots and NMR indicated a preference for the anti, anti 
conformation in the solid state and in solution. VT NMR was used to determine 
if interconversion to other conformational isomers was possible through N-
inversion, analysis of one system provided evidence this was possible. 
Chapter 5 details possible future directions for this work and chapter 6 
contains the experimental procedures and characterisation for the novel 




















CCD Charge Coupled Device 
CM Complex Mixture 
Conv. Conversion 
COSY Correlated Spectroscopy 
Cy Cyclohexyl 
δ Chemical shift 
d Day(s) or doublet 
dd Doublet of doublets 
ddd  Doublet of doublet of doublets 
DABCO 1,2-Diazabicyclo[2.2.2]octane 




de Diastereomeric excess 
DEAD Diethyl azodicarboxylate 
DFT Density Functional Theory 




DMSO Dimethyl sulphoxide 
dppf 1,1′-Ferrocenediyl-bis(diphenylphosphine) 
dippf 1,1′-Bis(diisopropylphosphino)ferrocene 
dr Diastereomeric ratio 
DSC Differential Scanning Calorimetry 
DtBAD Di-tert-butyl azodicarboxylate 




EP Explosive Propagation 
ESI Electrospray ionisation 
Et Ethyl 
EWG Electron withdrawing group 
FT-IR Fourier Transform-Infrared 
g gram(s) 
GC-MS Gas Chromatography-Mass Spectrometry 
h Hour(s) 
HMBC Heteronuclear Multiple Bond Correlation 
HRMS High Resolution Mass-Spectrometry 
HSQC Heteronuclear Single Quantum Coherence 
HPLC High-Performance Liquid Chromatography 
HSAB Hard-Soft Acids and Bases 
Hz Hertz 
iPr Isopropyl 
IPA Isopropyl Alcohol 
IR Infrared  
J Joules 
J Coupling constant 
K Kelvin 
LC-MS Liquid Chromatography-Mass Spectrometry 
LDA Lithium Diisopropylamide 
LLAMA Lead-Likeness and Molecular Analysis 
log logarithm 
M.p. Melting point 









MS Mass Spectrometry 
Ms Methanesulphonyl 
m/z Mass/charge ratio 
nBu Normal butyl 
ng nanogram(s) 
NHC N-heterocyclic carbene 
nm nanometres 
NMR Nuclear Magnetic Resonance 
NOE Nuclear Overhauser Effect 
NOESY Nuclear Overhauser Effect Spectroscopy 
NR No Reaction 
Ns para-nitrosulphonyl 




p-NBA para-Nitrobenzoic acid 
pg Protecting group 
Ph Phenyl 
phth Phthalimide 
pKa Acid Dissociation constant 
PMI Principle Moment of Inertia 
ppm Parts per million 





Ret Retention time 
Rf Retention factor 
ROESY Rotating frame Overhauser Enhancement 
Spectroscopy 




SM Starting Material 
SNAr Nucleophilic aromatic substitution 
T Temperature 
t Time 
TBAI Tetrabutylammonium iodide 




TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TLC Thin Layer Chromatography 
TMS Tetramethylsilane 




VT Variable Temperature 




Chapter 1: Introduction 
1.1 Sp3-Rich Frameworks in Medicinal Chemistry 
Over the last decade there has been increasing interest in the synthesis and 
study of new and more diverse scaffolds for drug discovery programmes. This 
has been fuelled by increasing interest in ‘molecular complexity’ and how this 
fits into the success of candidate molecules within high throughput screening – 
the pre-eminent method for developing new small molecule drug candidates.1 
The idea is that more complex molecules, which are generally defined as those 
with a high percentage of sp3 carbon centres (measured as Fsp3) are likely to be 
more topologically complex, which means they possess a more complex 3D 
structure. They also often contain more chiral centres, which has been found to 
correlate with higher success in drug discovery programmes. Analysis shows 
that the mean fraction of sp3 centres increases as one progresses further through 
the drug discovery pipeline (Figure 1.1). 
 
Figure 1.1 Fraction of sp3 carbon atoms in drug candidates at each stage of development, 
analysis conducted in 2009 by Lovering et al.1 
In addition to the focus on Fsp3, other methods of measuring molecular 
complexity have also been used, including the use of PMI (Principal Moments 
of Inertia) plots.2 This uses relatively simple computational processes to 
calculate the 3D shape of a molecule, and it generates a simple scatter plot that 
can be used on sample sizes of over 1 million molecules (Figure 1.2). Analysis 
of small molecule drugs currently on the market (N = 1,045,172) revealed a lack 
of diversity in shape among these compounds, with almost all of them clustered 
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on the left hand axis.3 This means that the majority of the molecules analysed 
are flat in shape, with rod and disc like shapes dominant, with almost none 
possessing even moderately spherical character. 
 
Figure 1.2 PMI plot of over 1 million small molecule drugs, showing their lack of shape 
diversity, plot by Brown and co-workers.3 
This general lack of shape diversity is somewhat unsurprising given the most 
commonly used reactions to synthesise drug candidates. This was shown by 
analysis from Jordan and Roughley of the reactions used by GlaxoSmithKline, 
AstraZeneca and Pfizer to make 3566 published compounds in 139 papers.4 This 
showed that the most used reactions included acylation processes (22.4% of 
total), C-C sp2 couplings (11.5% of total) and N-Ar couplings (6.3% of total) all 
of which often add flat and rigid functional groups. 
1.2 Synthesis of sp3-Rich Frameworks 
There has been significant recent interest in synthetic methods that can access 
sp3-rich frameworks, with a number of elegant strategies reported. Generally, 
most strategies have involved the synthesis of saturated cyclic frameworks as 
these structural motifs can often be made enantioselectively and are also more 
likely to be bioactive. They also offer multiple points for diversification, 
allowing a wide variety of functionalisation reactions to be employed.  
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Aggarwal et al. have demonstrated that strain release chemistry is a highly 
efficient way to generate functionalised cyclic systems. They reported a 
palladium catalysed sigma bond cleavage of the bicyclo[1.1.0]butane boronic 
ester, which was generated in situ from sulphoxide 1.5 This reaction was shown 
to be compatible with wide range of boronic esters and aryl triflate coupling 
partners, which were combined to give thirty-three different sp3-rich 
cyclobutane frameworks diastereoselectively (Scheme 1.1). 
 
Scheme 1.1 Synthesis of functionalised cyclobutanes from sulphoxide 1.5 
Further work by the group showed that this synthetic methodology can also 
be applied to generate functionalised azetidine frameworks, by substituting 
sulphoxide 1 for analogous azabicyclo[1.1.0]butyl sulphoxide 4.6 Instead of a 
palladium catalysed strain release, they were able to use acetic acid to open the 
[1.1.0] ring system and generate the acetic acid salt. After a simple ‘silica catch’ 
purification the compounds could then be treated with Boc anhydride to give the 
corresponding protected azetidines (Scheme 1.2). They further showed that a 
variety of nitrogen functionalisation reactions could be applied to these systems 
as well as transformations of the boronic acid. 
 
Scheme 1.2 Synthesis of functionalised azetidine frameworks from 4.6 
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Work by Gaunt et al. has focused on the pyrrolidine framework, and by using 
spirocycles they were able to generate conformationally restricted scaffolds that 
are sp3-rich. They used iridium photocatalysts Ir(dmeppy)3 or 
[Ir(dmeppy)2{dtbpy}]PF6 with Hantzch ester 10 to react homoallyl amines 8 
with ketones 7.7 By varying these two components they were able to generate 
forty-two different pyrrolidine scaffolds (9), showing the exceptional functional 
group tolerance of this process (Scheme 1.3).  
 
Scheme 1.3 Synthesis of spirocyclic pyrrolidines 9 with Ir photocatalysis.7 
They subsequently used this iridium photochemistry to generate functionally 
diverse tertiary alkylamines 14, which are also sp3-rich, although not as 
conformationally constrained as the pyrrolidine examples. They again used a 
low catalyst loading of a structurally similar Ir(ppy)3 iridium catalyst with 
Hantzch ester 10.8 This time they combined benzylamines 12 with aldehydes 11 
and alkenes 13 to generate the tertiary centre, again showing that this process 




Scheme 1.4 Synthesis of tertiary alkylamines 14 using Ir photocatalysis.8 
Spring et al. reported the synthesis of spirocyclic heterocycles and 
carbocycles as sp3-rich frameworks, and demonstrated they are highly rigid, 
three-dimensional scaffolds that can be further diversified.9 Building blocks 15 
were chosen as the starting point, as Grubbs ring closing metathesis could be 
used to form the carbocycles, while Boc protection, ester reduction and 
cyclisation was used to generate an oxazolidine moiety for the second ring and 
give 16 (Scheme 1.5). They also showed that other similar heterocycles could be 
generated by modifying the cyclisation precursor. The double bond of the 
carbocycle was then functionalised using various well-precedented reactions, 
including Wacker oxidation, dihydroxylation, epoxidation, aziridination and 
bromination. Analysis using LLAMA (see section 4.2) showed that these 
fragments possess excellent shape diversity and three-dimensionality. 
 
Scheme 1.5 Synthesis of spirocyclic scaffolds 16.9 
They also used cycloaddition chemistry to generate complementary 
spirocyclic scaffolds from acyclic, electron rich alkene 17 and hydroxylamine 
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18, which gave a dihydroisoxazole intermediate which was not isolated.10 This 
substrate could then be converted to spirocycle 19 by carbamate formation 
(Scheme 1.6). They also used electron poor cyclic amines 20 for the 
cycloaddition reaction with nitrile oxide 21, which gave spirocyclic amine 
scaffolds 22. 
 
Scheme 1.6 Synthesis of spirocycles using cycloaddition reactions.10 
1.3 Cyclic Hydrazines in Medicinal Chemistry 
Cyclic hydrazines are a class of heterocycle, containing two adjacent 
nitrogens along with one or more carbon atoms. The five most widely studied 
cyclic hydrazines are: diaziridines, diazetidines, pyrazolidines, 
hexahydropyridazines and diazepines (Figure 1.3). 
 
Figure 1.3 The five most commonly studied cyclic hydrazines. 
There have been many synthetic routes developed to access this class of 
compound (vide infra), including a number of enantioselective methods. Their 
structure offers a lot of potential for the development of novel drug scaffolds. 
Cyclic hydrazines could potentially be used to provide non-planar, sp3-rich 
scaffolds, with opportunities to diversify the ring at multiple locations and 
develop libraries of chemically novel scaffolds. As explored in this thesis, the 
use of substituents on the carbon adjacent to the hydrazine moiety (C3) is likely 
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to provide molecules which display their chirality in an orchestrated way (see 
section 1.9). 
Other heterocycles including thiazolidines,11,12 diazabicyclooctanes,13 
azetidines,14 oxetanes15 and other sp3-rich frameworks (vide supra) are currently 
the subject of much interest in medicinal chemistry, due to their structural 
novelty and enhanced physiochemical and pharmacokinetic properties they 
often confer on drug leads.  
Hydrazines have only been used a handful of times in approved 
pharmaceuticals, which may be due to the perception that they are toxic and 
challenging to manufacture safely (hydrazine itself is an extremely combustible 
and hazardous chemical and is often used as rocket fuel).17 There are several 
bioactive natural products (including sanglifehrin A 2819 and actinoramide A 
3018) that contain the cyclic hydrazine moiety (Figure 1.4), in addition to 
proprietary lead compound 2920 and a small number of approved drugs (e.g. 
cilazapril 3121). Access to a novel library of cyclic hydrazines would also open 
up new areas of intellectual property space, which is a key issue confronting the 
pharmaceutical industry, with patent busting approaches becoming prevalent.16 
 
Figure 1.4 Hydrazine containing natural products, proprietary lead compounds and drugs. 
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There are a number of reviews on the synthesis of hydrazines22, 23 and cyclic 
hydrazines.24 Here we introduce the more common methods for the synthesis of 
each ring size, with a focus on enantioselective syntheses of substituted cyclic 
hydrazines. 
1.4 Synthesis of Diaziridines 
The application of diaziridines is not described in this thesis, however their 
synthesis has been described in the literature. Here we present a small selection 
of these synthetic approaches, focusing on more recent publications. The first 
synthesis of a diaziridine was reported in 1961 when Schmidt used acetone, 
ammonia and chloramine to synthesise 3,3-dimethyl-1,2-diaziridine 32 (Scheme 
1.7).25 
 
Scheme 1.7 Synthesis of 3,3-dimethyl-1,2-diaziridine 32.25 
Combining a carbonyl compound with an amine nucleophile is still a 
commonly used method to access diaziridines. Moura-Letts et al. used 
hydroxylamine-O-sulfonic acid (35) as their aminating reagent and screened a 
variety of solvents and additives, using benzyl amine and various aldehydes and 
ketones as substrates.26 They showed that adding an inorganic base was much 
more effective than an organic one, with NaHCO3 proving to be the most 
effective base. Using their optimised conditions, they were able to generate a 
series of diaziridines 34 diastereoselectively (Scheme 1.8). 
 
Scheme 1.8 Synthesis of diaziridines 34 using HOSA.26 
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Maiti et al. developed a photocatalytic method, to generate diaziridines 39.27 
They used rose bengal (38) as photocatalyst, which was excited using blue LEDs 
(Scheme 1.9). This was used in combination with the oxidising agent 
(diacetoxyiodo)benzene, to catalyse the reaction of alkyl amines 37 with 1,2-
diols 36. They synthesised a diverse library containing 27 diaziridines, including 
examples with chiral substituents on the nitrogens.  
 
Scheme 1.9 Synthesis of diaziridines 39 using rose bengal (38) as a photocatalyst.27 
Other recent approaches have shown it is possible to synthesise diaziridines 
enantioselectively. Jørgensen  et al. have developed a method for 
enantioselective diaziridination of N-tosyl aldimines 40, which utilises chiral 
phase transfer catalyst 42 in order to generate diaziridines 43 in moderate to good 
yields, and excellent enantioselectivity (Scheme 1.10).28 Generally, the 
enantioselectivity was highest for meta- and para-substituted aromatic rings, 
while ortho-substituted compounds and cyclohexyl displayed inferior 
enantiomeric enrichment. The group were also able to demonstrate that 
orthogonal deprotection of both nitrogen atoms was feasible. Computational 
data suggested that ring inversion of the diaziridine products was a high energy 




Scheme 1.10 Synthesis of diaziridines 43 via enantioselective diaziridination.28 
1.5 Synthesis of Diazetidines 
Diazetidines represent a challenging synthetic target, as they are a highly 
strained heterocycle, however a number of approaches have been reported, 
generally by using either a [2+2] cycloaddition or a ring closure strategy. The 
first synthesis of a diazetidine was reported in 1960 by Kauer and Schneider.29 
The concerted [2+2] cycloaddition of 44 and 45 is forbidden by the Woodward-
Hoffman rules30, 31 but still gave diazetidine 46, suggesting this is a step-wise 
and not a concerted process (Scheme 1.11). 
 
Scheme 1.11 Synthesis of 46 using a [2+2] cycloaddition reaction.29 
More recently Tang et al. have developed another [2+2] route to diazetidines 
49, via the reaction of an allenoates 47 with azodicarboxylates 48.32 This method 
was effective for a wide variety of allenoates and azodicarboxylates and also 
generated the Z isomers with high selectivity (Scheme 1.12). 
 
Scheme 1.12 Synthesis of diazetidines 49 via a DABCO catalysed process.32 
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Zheng et al. synthesised tricyclic diazetidine 51 by [2+2] cycloaddition as 
part of a study into reaction acceleration using the ‘on water reaction’33 (Scheme 
1.13).34 To study the effects, they explored the reaction of DEAD with 50. The 
reaction was carried out in a flow focusing microdevice, but detailed 
characterisation of the product was not attempted as the purpose of the study was 
to study the reaction kinetics.  
 
Scheme 1.13 Reaction of 50 with DEAD to give tricyclic diazetidine 51.34 
The synthesis of diazetidines by ring closure has also been reported. Previous 
work in the Shipman group investigated the ring-closure reaction using a variety 
of substrates.35 It was found that there is competition between closure through 
the carbamate oxygen to give oxadiazine (54), and closure to give the desired 
diazetidine (53). Using softer leaving groups tended to give a higher yield of the 
diazetidine, and larger and more diffuse cations tended to favour formation of 
the diazetidine. The best results were obtained using an iodide leaving group and 
caesium carbonate as the base, however, even under optimised conditions the 
desired diazetidine 53 was obtained in a relatively modest 50% yield, with 
oxadiazine 54 as the undesired by-product (Scheme 1.14). Using sulphonamides 
instead of carbamates improved the reaction further, with 98% yield obtained 
when R = Ts, as it is not possible to form an oxadiazine in this case. 
 
Scheme 1.14 Optimised synthesis of 1,2-diazetidines 53.35 
20 
 
This corrected earlier work carried out by Ma et al.,36 who attempted to 
synthesise a series of 1,2-diazetidines 58 using diazodicarboxylates 55 and 
aldehydes 56 to generate alcohol precursors 57. These substrates were then 
cyclised via an intramolecular Mitsonobu reaction, with the overall yields for 
this 2-step process above 85% (Scheme 1.15). However, it was shown by 
Shipman that they had misassigned the product structures and actually 
synthesised the corresponding oxadiazines 59. 
 
Scheme 1.15 Attempted synthesis of diazetidines 58.36 
In addition, they also reported an enantioselective synthesis of diazetidine 63 
by using (R)-proline in the amination reaction; the product was formed in 96% 
yield (Scheme 1.16). Again however, this was actually forming the 
corresponding oxadiazine 64 and was not diazetidine 63. 
 
Scheme 1.16 Attempted synthesis of diazetidine 63 which gave oxadiazine 64.36 
Subsequently Ma et al. published examples of diazetidine synthesis, via the 
cyclisation reaction of 2,3-allenylic hydrazines 65 with aryl iodides 66, catalysed 
by Pd(PPh3)4.
37 After screening a variety of bases, it was found that Cs2CO3 was 
the most effective base for the Heck reaction. These conditions were used to 
synthesise a variety of diazetidines 67 in good yields and with complete 




Scheme 1.17 Synthesis of diazetidines 67 using a Heck reaction.37 
There has also been more recent work in the Shipman group, including the 
synthesis of a series of 3-methylene-1,2-diazetidines 70 using a copper catalysed 
ring closure of 2-halo-2-propenyl hydrazines 69.38 The hydrazine containing 
cyclisation precursors were prepared by Mitsonobu reaction of allyl alcohol 
precursors 68. Using this approach, a series of precursors were generated. The 
cyclisation process was most successful using allyl bromides, and in the presence 
of caesium carbonate, DMEDA and CuI, diazetidines 70 were produced in 
excellent yields (Scheme 1.18). This efficient 2-step process provided a useful 
route to diazetidines which contain an exocyclic double bond, allowing for 
further functionalisation. 
 
Scheme 1.18 Copper catalysed ring-closure to form 1,2-diazetidines 70.38 
Subsequently, the Shipman group have developed an enantioselective route 
to substituted diazetidines, which uses rac-vinyl epoxides 71 as the starting 
material.39 Opening 71 with protected hydrazines 72 using palladium chemistry 
developed by Trost et al.40 gave intermediate 74, followed by cyclisation using 




Scheme 1.19 Enantioselective synthesis of vinyl 1,2-diazetidines 75.39 
It was subsequently shown that vinyl diazetidines 75 could be functionalised 
in a variety of ways, in order to diversify the substituent at C3. Cross-metathesis 
using Grubbs-Hoyveda catalyst 78 was used to react vinyl 1,2-diazetidines 75 
with terminal alkene coupling partners to give 79. In addition, ozonolysis was 
used to cleave the vinyl group of 75 to an aldehyde, which could then be 
transformed into amine 76 using reductive amination, or to alcohol 77 via a 
sodium borohydride reduction (Scheme 1.20).  
 
Scheme 1.20 Functionalisation of vinyl diazetidines.39 
1.6 Synthesis of Pyrazolidines 
The synthesis of pyrazolidines has been more widely reported than for 
corresponding smaller ring sizes, as the synthesis of less strained 5-membered 
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rings is generally less challenging. They are typically synthesised either by [3+2] 
cycloaddition or by ring closure in a similar manner to diazetidines. The first 
reported synthesis of pyrazolidine 25 itself was in 1943 by Buhle et al.41 who 
combined 1,3-dibromopropane with hydrazine. The first example of a 
pyrazolidine based drug, phenylbutazone (82), was synthesised shortly after 
World War Two and approved for human use as a highly effective NSAID (Non-
Steroidal Anti-Inflammatory Drug).42 It was synthesised by the condensation of 
80 and 81 in the presence of sodium ethoxide (Scheme 1.21). 
 
Scheme 1.21 Synthesis of phenylbutazone (82).42 
Since these early efforts, several other methodologies have been developed 
to synthesise more structurally complex examples of pyrazolidines. The 
synthesis of pyrazolidines by [3+2] cycloaddition has been utilised as it is a 
simple and highly effective method that generates complex pyrazolidines in a 
single step. Work by Kau and Martinelli showed it was possible to generate 
highly functionalised pyrazolidines using semicarbazide 83.43 Reacting this with 
methyl glyoxylate hemiacetal (84) formed intermediate 85, which could then be 
trapped with styrene to give pyrazolidine 86 in an excellent yield (Scheme 1.22). 
 
Scheme 1.22 Synthesis of pyrazolidine 86 via a [3+2] cycloaddition.43 
In 2004 Kobayashi and Yamashita developed a highly enantioselective 
method for the synthesis of highly substituted pyrazolidines, utilising chiral 
zirconium catalyst 89.44 This was shown to be an effective catalyst for the 
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reaction of hydrazones 87 with ketene dimethyl dithioacetal 88, which gave the 
desired pyrazolidines 90 in good to excellent yields and with excellent 
enantioselectivity (Scheme 1.23). They were able to provide evidence for a [3+2] 
mechanism (as opposed to a stepwise one), by changing R for much bulkier 
groups. This gave a significant reduction in reaction rate which was consistent 
with a concerted mechanism. 
 
Scheme 1.23 Enantioselective synthesis of pyrazolidines 90 using Zr catalyst 89.44 
This methodology was also shown to be effective in the reaction of vinyl 
ethers 92 with hydrazones 91. This transformation introduced a second 
stereocentre into the final pyrazolidines 93, and although these were only 
obtained with moderate diastereoselectivities, the ees and yields were generally 
excellent (Scheme 1.24).  
 
Scheme 1.24 Synthesis of pyrazolidines 93 using Zr catalyst 89.44 
Ma et al. used a palladium and copper catalysed reaction to construct highly 
substituted pyrazolidines.45 Using Pd(PPh3)4, CuOTf and chiral ligand (S,S)-Ph-
Box 95 they were able to effect an enantioselective amination of allene 94 with 
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DBAD. The mechanism proceeds via carbopalladation to generate a π-allyl 
palladium intermediate, which is trapped by an intramolecular coupling to 
generate functionalised pyrazolidines 96. This was completed with excellent 
yields and enantioselectivities, but only modest diastereoselectivity (Scheme 
1.25). 
 
Scheme 1.25 Synthesis of substituted pyrazoldines 96 using a Pd and Cu catalysed process.45 
Ma et al. followed this work with a similar strategy to synthesise 
pyrazolidines.46 Using palladium acetate and ligand (R,R)-98, they were able to 
synthesise ten examples of highly functionalised pyrazolidines 99 in good yields 
(Scheme 1.26). The enantioselectivity of the process was excellent across all the 
examples and was more diastereoselective than their previous work. 
 
Scheme 1.26 Synthesis of pyrazolidines 99 using Pd-catalysed cyclisation.46 
Jørgensen and co-workers developed an organocatalysed [3+2] cycloaddition 
of a nitro-olefin 100 with a hydrazone 101.47 By utilising organocatalyst 102 
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they were able to synthesise a series of 4-nitropyrazolidines 103 which were 
formed using a hydrogen bond catalysed 1,3-dipolar cycloaddition. They were 
able to synthesise eighteen different products bearing a variety of functional 
groups with excellent yields and selectivity (Scheme 1.27). 
 
Scheme 1.27 Synthesis of 4-nitropyrazolidines 103 using organocatalyst 102.47 
Tsogoeva et al. developed an efficient method to construct fused bicyclic 
pyrazolidines by utilising the Lewis acid TMSOTf to catalyse the [3+2] 
cycloaddition of hydrazones 104 with cyclopentadiene.48 Using 10 mol% of the 
Lewis acid, they were able to synthesise nine pyrazolidines 105 in generally 
excellent yields, with the reaction found to form the syn product (Scheme 1.28).  
 
Scheme 1.28 Synthesis of fused bicyclic pyrazolidines 105.48 
Radhakrishnan et al. developed a catalytic domino process to synthesise 
tetracyclic pyrazolidine systems.49 The synthesis utilises a palladium catalysed 
reaction between ortho-iodophenols 107 with spirocyclic olefins 106 bearing a 
cyclopropane ring (Scheme 1.29). This system is set up to undergo a complex 
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domino process where the palladium first catalyses a Heck reaction to form a 
bicylic intermediate. The phenol oxygen triggers the ring opening of the bicycle, 
before further palladium catalysed processes provides 108.  
 
Scheme 1.29 Synthesis of tetracyclic pyrazolidines 108 using a catalytic domino process.49 
In a subsequent paper, the same group described a similar process, 
demonstrating the synthesis of spirocyclic pyrazolidines 112.50 This time they 
mainly focused on a 2-step process, first utilising a Lewis acid catalysed 
desymmetrisation of a fulvene derived diazabicyclic olefin 109. This process 
could be used to synthesise a variety of cyclisation precursors 111 (Scheme 
1.30). This precursor could then undergo a tandem cyclisation process catalysed 
by palladium to yield 112. Finally, they also synthesised several examples using 
a one-pot process. 
 





1.7 Synthesis of Hexahydropyridazines 
The first synthesis of hexahydropyridazine 26 was reported by Alder and 
Niklas in 1954.51 They heated buta-1,3-diene with DEAD to give 
tetrahydropyridazine 113, which could then be converted to 26 by reducing the 
double bond with Raney Nickel followed by hydrolysis with HCl (Scheme 1.31). 
This kind of concerted cycloaddition is rarely used in more modern synthetic 
strategies, which tend to be sequential processes with a final ring closure step. 
 
Scheme 1.31 The first synthesis of hexahydropyridazine 26.51 
There are however some more modern cycloaddition approaches that give 
tetrahydropyridazines. Work by Xiao et al. demonstrated that 
tetrahydropyridazines could be synthesised enantioselectively using an Inverse 
Electron-Demand hetero-Diels-Alder (IEDDA) reaction (Scheme 1.32).52 
Combining hydrazones 114 with ethyl vinyl ether 115 gave 
tetrahydropyridazines 117 in excellent yield and with good enantioselectivity 
when ligand 116 was employed. 
 
Scheme 1.32 Synthesis of tetrahydropyridazines 117 using the IEDDA reaction.52 
Recent work by Moreau et al. has shown that a multicatalytic approach can 
be used to assemble hexahydropyridazine scaffolds (Scheme 1.33).53 Starting 
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with a stereoselective α-amination of aldehydes 118 catalysed by organocatalyst 
119 they synthesised hydrazine intermediates 120. This intermediate could then 
be converted to a hexahydropyridazine using a palladium catalysed cyclisation 
to give hexahydropyridazines 121. They were subsequently able to show that no 
purification of intermediate 120 was needed and that hexahydropyridazines 121 
could be synthesised in similar overall yields using sequential multicatalysis. 
The enantioselectivity of the process was excellent (up to 94% ee), however the 
diastereoselectivity was more modest. They were also able to demonstrate that 
some variation in the aryl group of 118 and in the aryl iodide in the last step was 
tolerated. 
 
Scheme 1.33 Synthesis of hexahydropyridazines 121 with organocatalysis and Pd catalysis.53 
Mangion et al. reported the synthesis of unnatural amino acid (R)-piperazic 
acid (124),54 with the ring opening of vinyl epoxide (71) using catalyst 7340 
(Scheme 1.34). The opening of vinyl epoxide with an allyl substituted protected 
hydrazine 122 was optimised carefully and product 123 was isolated in good 
yield and with excellent enantioselectivity for the R enantiomer. After this, four 
further steps were required to synthesise (R)-piperazic acid (124), all of which 




Scheme 1.34 Synthesis of (R)-piperazic acid (124) using Trost’s ligand (S,S)-73.
54
  
Ley et al. synthesised chiral tetrahydropyridazines in a one-pot process by 
utilising organocatalyst 125.55 Initially they used isovaleraldehyde which 
underwent α-hydrazination with azodicarboxylates 51 before reacting in situ 
with vinyl phosphonium salt 126 to give 127 which was not isolated. This 
intermediate underwent in situ an intramolecular Wittig reaction to give 
tetrahydropyridazines 128 (Scheme 1.35).  
 
Scheme 1.35 One-pot synthesis of tetrahydropyridazines 128.55 
Similar work by Hamada et al. also exploited the organocatalysed α-
hydrazination of 5-bromopentanal with DBAD.56 Using (S)-proline as the 
organocatalyst they were able to generate a linear hydrazine precursor, which 
was immediately treated with sodium borohydride to reduce the aldehyde and 
give 129 in excellent yield and enantioselectivity (Scheme 1.36). Four additional 





Scheme 1.36 Synthesis of the TFA salt of (R)-piperazic acid 124.56 
Jørgensen/Hayashi catalyst 132 was used by Han et al. to generate 
hexahydropyridazine based frameworks (Scheme 1.37).57 Their strategy 
combined aldehydes 130, with nitroolefins 131 and azodicarboxylates 51 which 
underwent an amine catalysed Michael reaction, then subsequent α-amination 
and intramolecular hemiaminalisation. After optimisation they were able to 
generate hexahydropyridazines (133) in good yield and with excellent 
enantioselectivity and diastereoselectivity across multiple examples.  
 
Scheme 1.37 Synthesis of hexahydropyridazines 133.57 
Doyle et al. used rhodium catalysed carbene chemistry with hydrazones to 
generate tetrahydropyridazines in a two-step process (Scheme 1.38).58 Diazo 
compound 135 and hydrazones 134 reacted with rhodium catalyst 136, but gave 
137 instead of the desired tetrahydropyridazine 138. After further optimisation 
of the cyclisation process, a Lewis acid catalysed Mannich reaction with 
scandium triflate yielded the desired tetrahydropyridazines 138 in excellent yield 




Scheme 1.38 Synthesis of hexahydropyridazines 138 using rhodium catalyst 136.58 
Doyle et al. followed up on this work with a completely concerted process, 
this time utilising N-iminoquinolinium ylide 139 instead of hydrazones (Scheme 
1.39).59 Although this reaction involves a dearomatization process, it is driven 
by the reactivity of zwitterion 139. After only minor changes to their optimised 
conditions they were able to isolate bicyclic products 141 in excellent yield and 
enantioselectivity. 
 
Scheme 1.39 Synthesis of bicyclic tetrahydropyridazines 141 using rhodium catalyst 136.59 
1.8 Synthesis of Diazepines and Higher Homologues 
The synthesis of diazepines and larger ring homologues like diazocanes (8-
membered cyclic hydrazines) have not been frequently reported in the literature. 
The first example of a diazepine appeared in 1962, when Zinner and Deucker 
reported the synthesis of diethyl 1,2-diazepine-1,2-dicarboxylate (143).60 Their 
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synthesis combined 142 with 1,5-dibromopentane to yield the desired diazepine 
(Scheme 1.40).  
 
Scheme 1.40 First reported synthesis of a diazepine.60 
A similar synthesis of diazocane 144 was first reported by Stoddard and 
Overberger in 1970.61 They used 1,6-dibromohexane and hydrazine 142, which 
were combined with sodium hydride in diglyme to give 144 in a modest 22% 
yield (Scheme 1.41). There have been a small number of other reported 
approaches to the synthesis of diazocanes62 and larger rings,63 however 
discussion of these systems is outside of the scope of this thesis and we will 
instead focus on diazepines. 
 
Scheme 1.41 First reported synthesis of a diazocane.61 
Bonnet et al. reported a synthesis of bicyclic diazepine systems using a 
rhodium catalysed cyclohydrocarbonylation process (Scheme 1.42).64 Using 
precursor 145, which is derived from alanine, the cyclohydrocarbonylation gave 
bicyclic diazepine 147, in good yield when BiPhePhos catalyst 146 was used. 





Scheme 1.42 Synthesis of bicyclic diazepine 147 using a cyclohydrocarbonylation process. 
Gleason and Caldre reported the synthesis of enantiomerically enriched 
diazepine 151 using a Corey-Bakshi-Shibata (CBS) reduction to reduce phenyl 
ketone precursor 148 to give alcohol 149 (Scheme 1.43).65 The approach 
reported here has similarities to the approach we report in chapter 2 where we 
used ATH to generate alcohols enantioselectively (see Section 2.4). They used 
151 as an organocatalyst for an asymmetric Cope rearrangement. Although the 
highest enantioselectivity of any of the organocatalysts tested was achieved with 
151, it was only able to afford rearranged product 153 in a modest yield of 54% 
and an enantiomeric excess of 47%. 
 
Scheme 1.43 CBS reduction of ketone 148 as the key step in the synthesis of 151 and use of 




1.9 Conformation of Cyclic Hydrazines 
The conformation of hydrazines has been studied using both computational 
and experimental methods. X-ray crystallography is one of the most widely used 
experimental methods, as it clearly shows the most stable solid-state 
conformation of a compound. Although this may vary from the lowest energy 
conformation in solution due to crystal packing effects. Below we report 
examples of XRD structures across a range of ring sizes, which shows the strong 
preference for nitrogen substituents to be displayed anti to each other. 
This has been demonstrated in three previously published studies from the 
Shipman group35, 39, 66 which contained solid-state structures of 53, 75, 154 and 
155 (Figure 1.5). These structures clearly show the strong preference for the 
substituents on the nitrogens to be orientated anti to each other, which can be 
seen in the large torsion angles between the nitrogen substituents for each 
example. In addition, each of the nitrogens has a large amount of 
pyramidalisation,i clearly showing unusually high sp3 character. 
 
Figure 1.5 Solid-state structures of 53, 75, 154 and 155.35, 39, 66 
 
i This is 360 ° - [a+b+c], where a, b and c are the angles between the nitrogen 
substituents. A larger angle indicates more sp3 character at the nitrogen centre. 
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These conformational features can also be observed in larger ring sizes. 
Pyrazolidines 156 and 157 reported by Coldham et al.67  and 
hexahydropyridazine 158 reported by Greck et al.53  all show a similar  
conformational bias in the solid state to the diazetidines, although the extent of 
pyramidisation is generally lower for the amide nitrogens (Figure 1.6).  
 
Figure 1.6 Crystal structures of 156, 157 and 158.53, 67 
This is driven partly by the strong preference for substituents to orientate as 
far from each other as possible, to reduce steric crowding. However, in 
hydrazines this conformational bias is extremely pronounced because of the 
nitrogen lone pairs, which to reduce electrostatic repulsion strongly prefer to be 
anti to each other. This has been shown using ab initio DFT calculations on 
hydrazine and related systems by Rauk and Jarvie.68 They showed that the 
equilibrium conformation of hydrazine has a dihedral angle of 95° between the 
nitrogen lone pairs, and that an angle of approximately 90° is optimal for 
hydrazines 159, 160 and 161 (Figure 1.7). 
 
Figure 1.7 Hydrazine compounds analysed using ab initio DFT by Rauk and Jarvie.68 
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Rademacher provided further evidence for the strong conformational bias of 
cyclic hydrazines, he used photoelectron spectroscopy (PE) to measure the 
dihedral angle between the nitrogen lone pairs of diazetidine 162, pyrazolidine 
analogue 163 and hexahydropyridazine analogue 164 for comparison (Figure 
1.8).69 The dihedral angle steadily increased with ring size, which would be 
expected as larger ring sizes allow for a greater amount of conformational 
flexibility, allowing the lone pairs to distance themselves further from each 
other. 
 
Figure 1.8 Dihedral angles of methyl substituted cyclic hydrazines.69 
This strong preference can however be overcome in certain cyclic hydrazines. 
Recent work by Del Valle et al. on δ-azaprolines using DFT, X-ray 
crystallography and NMR showed that 165 has a nitrogen torsion angle of only 
10.7° and no observable pyramidisation at either nitrogen (Figure 1.9).70 This 
was due to hydrogen bonding between the amine hydrogen and the carbonyl of 
the acyl substituent, which overcame the hydrazines natural propensity to adopt 
an anti,anti conformation between substituents.  
 
Figure 1.9 Structure of azaproline 165.70 
These planar hydrazines structures are also observed in some polycyclic 
systems like those developed by Kim et al.71 and Pagenkopf et al.72 Apart from 
these rare exceptions however, cyclic hydrazines adopt a conformation that 
reduces lone pair repulsion, by placing substituents anti to each other. 
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1.10 Fluxionality of Cyclic Hydrazines 
The study of nitrogen inversion within cyclic systems has been studied 
extensively, and several reviews have been published.73, 74 It has been shown that 
there are four main factors that affect the size of inversion barriers: steric effects; 
conjugation effects, angular constraints and heteroatoms. The barrier to 
inversion for a system is generally studied by NMR or by computational methods 
like DFT. Several studies have been conducted into the barriers to inversion of 
cyclic hydrazines, which have shown that the barriers to inversion are generally 
high, but fluxional behaviour can often still be observed. 
In order to study the effect of substituents on the rate of inversion for 
diazetidines, Hall and Bigard synthesised 162, 166, 167 and 168 (Figure 1.10).75 
They used VT NMR to determine the barrier to inversion for the four substrates 
and found a strong correlation between the size of the substituent and the 
magnitude of the barrier to inversion. The observed increase in the barrier to 
inversion is not linear, with the barrier for tert-butyl substituted diazetidine 168 
significantly larger than for any other example. 
 
Figure 1.10 Diazetidines used to study nitrogen inversion barriers by NMR.75 
Analysis of the NMR spectra of 162 and 166-168 showed a clear AABB 
coupling pattern for the methylene hydrogens, with a large difference in coupling 
constant between J14 and J23 (Figure 1.11). Using the Karplus equation they were 
able to use this information to calculate that the ring is highly puckered with 
dihedral angles of 166, 161, 152 and 159° for 162 and 166-168 respectively. This 
means that larger substituents on the nitrogens reduce the substituent torsion 
angle but not significantly. This also provides further evidence that substituents 
preferentially oritentate anti to each other, although analysis of coupling 
constants can be more ambiguous than crystallography due to the inherent error 




Figure 1.11 Likely orientation of alkyl diazetidines, with a highly puckered ring structure.75 
Williams et al. also studied the barriers to inversion of cyclic hydrazines, 
however this time they focused on aza-β-lactams – a compound class closely 
related to diazetidines.76 The barriers of inversion they reported for these 
compounds were very high at around 80 kJ mol-1 (Figure 1.12). The only 
exception to this was diphenyl substituted compound 173, which had a 
significantly lower barrier of inversion of 54.4 kJ mol-1. This is likely due to the 
phenyl substituents stabilising the transition state of this inversion process. 
 
Figure 1.12 Barriers of inversion for a series of closely related aza-β-lactams.76 
Kostyanovsky et al. studied the barrier to inversion for pyrazolidines (Figure 
1.13).77 Compound 175 is the exact homologue of diazetidine 167, so the barrier 
to inversion can be directly compared to determine the effect of ring size. The 
barrier to inversion is 2.3 kJ mol-1 lower in the pyrazolidine substrate, showing 
that increasing ring size will tend to decrease the barrier to inversion. The barrier 
of inversion for compounds 174 and 176 were also calculated. The barrier for 
174 is significantly lower, which is likely due to conjugation of the nitrogen with 
the carbonyl substituent, which reduces the extent of nitrogen pyramidisation. 
For substrate 176, which has a higher barrier, the authors hypothesized that the 
OH group could plausibly hydrogen bond to one of the nitrogen lone pairs and 




Figure 1.13 Barriers of inversion for a series of pyrazolidines.77 
Further work by Kostyanovsky et al. subsequently analysed other closely 
related pyrazolidines (Figure 1.14).78 tert-Butyl pyrazolidine 177 was found to 
exist as a single conformer, the NMR spectra did not show any evidence of other 
conformers even when heated to 100 °C. Diazetidine 168 only split into multiple 
conformers when heated to 155 °C so this result fits with the work by Hall and 
Brigard (Figure 1.10). Similarly, 178, with methyl groups at C3 and C5 was also 
extremely stable and did not undergo nitrogen inversion at 100 °C. 
 
Figure 1.14 Pyrazolidines which did undergo inversion at 100 °C.78 
Further evidence that the barrier to inversion decreases as ring size increases 
can be found by comparing diazetidine 162 with hexahydropyridazine analogue 
179 studied by Anderson (Figure 1.15).79 The barrier to inversion for 179 is 48.5 
kJ mol-1, is significantly lower than the 68.6 kJ mol-1 barrier for 162, so the 
increase in ring size lowered the barrier to inversion. 180 and 181 were also 
studied, deuterated analogue 180 had a slightly higher barrier to inversion, while 
the addition of methyl substituents at C4 and C5 raised the barrier again for 181. 
 
Figure 1.15 Barriers to inversion for hexahydropyridazines 179-181.79 
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Hexahydropyridazine 179 can also be directly compared with dimethyl-
cyclohexane 182, where the methyl groups are trans to each other. This 
compound will also invert from the more stable di-equatorial conformation 185 
to di-axial conformation 186, which is higher in energy due to 1,3-diaxial strain. 
The corresponding inversion process has a barrier of 11.3 kJ mol-1,80 and this 
significantly lower barrier than the corresponding barrier for 183 to 184 shows 
that the adjacent nitrogen’s in 179 have a large impact on the barrier to inversion 
(Figure 1.16). 
 
Figure 1.16 Barrier to inversion comparison between 179 and 182. 
The fluxional behaviour of cyclic hydrazines is well documented and the 
observable trends are similar to those reported in other cyclic systems. Ring size 
and the size of nitrogen substituents have predictable effects, and the adjacent 
nitrogens significantly raise the energy required to invert their substituents due 
to interactions between their lone pairs. 
1.11 Research Aims 
Whilst there are many excellent examples of syntheses developed for a 
variety of cyclic hydrazines there is not currently a general methodology that can 
be applied to the synthesis of multiple cyclic hydrazine ring sizes. This makes 
the development of diverse cyclic hydrazine libraries challenging, as multiple 
different synthetic strategies would be required for each ring size. We sought to 
develop an approach to synthesising cyclic hydrazine scaffolds, with 
orthogonally protected nitrogen atoms which could then be further diversified 
using well precedented nitrogen functionalisation chemistry. 
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We were especially interested in extending this to the development of C3-
substituted cyclic hydrazines, as this would not only give access to a further point 
of diversification but would also influence the orientation of the nitrogen 
substituents (Figure 1.17). Previous work in the group on 75 (Figure 1.5), had 
shown that adding a substituent at the C3 position of a diazetidine 
enantioselectively enforces the anti,anti conformation in the solid state. We 
wanted to test whether this conformation is favoured for cyclic hydrazines with 
different ring sizes and substituents (187) in order to to see if this is a general 
feature of this class of compounds. 
 
Figure 1.17 Proposed orientation of cyclic hydrazine scaffold 187 with a C3 substituent. 
We envisioned that these compounds would be interesting for medicinal 
chemistry as sp3-rich, heterocyclic and non-planar frameworks. They would also 
effectively contain three stereogenic centres despite only requiring a single 
enantioselective transformation during their synthesis, as the orientation of the 
nitrogen substituents is determined by the C3 substituent. We also wanted to 
study the dynamic behaviour of these systems in solution, by determining 
whether inversion of the nitrogen substituents can occur and if so, how high the 
barrier to inversion might be.  
To synthesise these cyclic hydrazines we would need to synthesise 
orthogonally protected precursor 188, which could then be functionalised 
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iteratively to give 187 (Figure 1.18). We wanted to use a ring closure strategy to 
synthesise 188 from 189, as the same cycloaddition methodologies cannot be 
applied to multiple ring sizes. Compound 189 could be synthesised by adding 
hydrazine 191 to a precursor like 190, however, enantioselective installation of 
leaving group X is likely to be the most significant challenge to this strategy. 
 
Figure 1.18 Retrosynthetic analysis of target 187. 
In the special case where R = H the synthetic challenge is significantly 
simplified, as an enantioselective methodology is not required. This would still 
generate a hydrazine scaffold with two points for diversification and would also 
allow optimisation of the ring closing and functionalisation steps. This is where 
we decided to begin our research, with a view to developing an enantioselective 
methodology once this had been optimised.  
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Chapter 2: Synthesis of Cyclic Hydrazines 
2.1 Synthesis of Orthogonally Protected Diazetidines 
Our initial focus was the synthesis of diazetidines, which would have two 
points of diversity via functionalisation of the nitrogen atoms. Although these 
were likely to be synthetically challenging compounds to synthesise (in 
comparison with larger ring sizes) this would provide us a good opportunity to 
develop a robust synthetic method and would also give us access to unusual 
scaffolds. Additionally, the synthesis of orthogonally protected pyrazolidines is 
already well precedented, for example the synthesis of 193 by Sherrill (Scheme 
2.1).81 
 
Scheme 2.1 Synthesis of pyrazolidine 193 by Sherrill.81 
There is no precedent that we are aware of for the synthesis of orthogonally 
protected diazetidines. Work reported previously in the group has shown it is 
possible to synthesis diazetidines with two identical protecting groups (Scheme 
1.14). The condensation of 1,2-disulphonylhydrazines with 1,2-dibromoethane 
to give diazetidines 195 was reported by Cui et al. (Scheme 2.2).83 However this 
is not compatible with carbamate protecting groups or orthogonally protected 
hydrazines so we needed to develop a different approach.  
 
Scheme 2.2 Synthesis of sulphonyl functionalised diazetidines 196.83 
Initially we targeted Cbz/Boc protected system 196, as both protecting groups 
are orthogonal and there are a large number of methods available for their 
removal.82 This would also be analogous to pyrazolidine 193 and similar to 53 
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(Scheme 1.14), although a different synthetic strategy would be required. Using 
the synthesis of orthogonally protected linear hydrazides developed by Licandro 
et al.84 we synthesised protected hydrazine 196 from 2-hydroxyethylhydrazine 
(Scheme 2.3). This was converted to iodide 197 in good yield; however, the 
cyclisation generated a mixture of diazetidine 198 and the undesired oxadiazine 
199 in a 50:50 crude ratio (by 1H NMR). Isolation of diazetidine 198 proved 
challenging owing to its similar polarity to oxadiazine 199, and it was only 
isolated in a modest yield of 32%. 
 
Scheme 2.3 Synthesis of Cbz/Boc protected diazetidine 194. 
This was not unexpected as earlier work group had shown that this issue 
occurred with carbamate protected diazetidine precursors (Scheme 1.14).35 The 
use of the Mitsunobu reaction on substrates similar to 196 was found to 
exclusively generate the oxadiazine, so this method was not attempted on 
substrate 196. A crystal structure of 198 was obtained to unambiguously 
determine that the desired diazetidine was synthesised (Figure 2.1). This had 
similar parameters to 53, which had two Boc groups, although the torsion angle 
and nitrogen pyramidisation values are slightly smaller.  
 
Figure 2.1 Crystal structure of 198. 
In order to improve the synthesis we decided to attempt an alternative ring 
closure strategy, replacing the Cbz group with a Ts group, as this had previously 
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been shown to be a superior protecting group for the cyclisation.35 This synthesis 
proved to be much more efficient (Scheme 2.4), and was completed to give 
diazetidine 202 in an overall yield of 58% in only two steps. Not only does this 
require one less step than the synthesis of 198, but the overall yield of that 
process was only 22%. The purification after cyclisation by chromatography was 
also much simpler as diazetidine 202 is the major product. 
 
Scheme 2.4 Synthesis of Ts/Boc protected diazetidine 202. 
2.2 Synthesis of C3-Substituted Diazetidines from Epoxides 
Next, we turned our attention to the synthesis of diazetidines which have C3 
substituents. This extra substituent would greatly improve library diversity. In 
addition it was expected to control the stereochemistry at all three substituents. 
This assertion is based on the previous synthesis of 75 in the group, which had 
shown the strong conformational bias for anti,anti substituents (Figure 1.5). 
 As these compounds would have a stereocentre at C3, the synthesis was 
likely to be significantly more challenging. Initially, we used racemic styrene 
oxide to find a reliable method for the synthesis of the target. Our proposed 
approach was to open the epoxide ring using hydrazine monohydrate to generate 
203, which had been previously reported by White et al.85 We then envisioned 
that this substrate could be sequentially functionalised with orthogonal 
protecting groups and cyclised in a similar manner to the unsubstituted system 
to give diazetidine 204 (Scheme 2.5).  
 
Scheme 2.5 Proposed synthetic strategy for diazetidine 204. 
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This proposed route had several potential benefits, it would be a short 
synthesis that exploits chemistry we had already developed (Scheme 2.3 and 
2.4). In addition, there are a large number of strategies for enantioselective 
epoxide synthesis with excellent yields and selectivity, including Jacobsen’s 
kinetic resolution86 and Jacobsen-Katsuki epoxidation.87, 88 It did however have 
some potential drawbacks, including the use of hydrazine monohydrate – which 
is a hazardous reagent and is also prone to explosive decomposition when 
heated.89 The published ring opening also required the use of ten equivalents of 
hydrazine monohydrate and was an exothermic process. 
We began exploring the synthesis of C3-phenyl substituted diazetidines using 
rac-styrene oxide. The ring opening and subsequent Boc protection was 
successful (Scheme 2.6), although the Boc protection proved significantly more 
challenging than for 2-hydroxyethylhydrazine, which we used to synthesise 200. 
This was because isolation of hydrazinyl alcohol 205 from the excess hydrazine 
monohydrate used in the reaction was challenging and performing the Boc 
protection on the crude mixture complicated purification. Kugelrohr distillation 
proved to be the most effective method of removing the excess hydrazine 
monohydrate. Purification of 206 by recrystallisation from toluene was effective 
but the isolated yield was only 45%. Purification by flash chromatography gave 
material with minor impurities but the yield could be significantly improved to 
75% and this material was of sufficient purity for subsequent transformations. 
Cbz protection of the other nitrogen was also successful, giving 207 with a yield 
of 70%. Attempts to convert the alcohol to the iodide were not successful, as 
subjecting the precursor to iodination conditions caused cyclisation to the 




Scheme 2.6 Attempted synthesis of 209, which gave 208. 
Next, we attempted to form the tosylate as an alternative leaving group. 
Tosylation was attempted on both the fully protected 207 and Boc protected 
amine 206 (Scheme 2.7), however, neither approach was successful, although in 
the second case tosylation on the nitrogen gave 211.  
 
Scheme 2.7 Attempted tosylation reactions. 
We solved this by using 211, which could be converted directly to diazetidine 
212 using the Mitsunobu reaction in a 72% yield (Scheme 2.8). To achieve 
optimal conversion to the product, highly dilute conditions (0.01 M THF), and 
an excess of both DEAD and PPh3 (2.5 equiv each) were needed, these 
conditions together gave an isolated yield of 72%.  
 
Scheme 2.8 Successful synthesis of racemic diazetidine 212 via the Mitsunobu reaction. 
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After this initial success, we repeated the synthesis with commercially 
available (R)-phenyloxirane which had an ee of 98% as measured by chiral 
HPLC (Scheme 2.9). Analysis by chiral HPLC of (S)-212 confirmed that no 
significant racemisation occurred during the sequence which was completed in 
an overall yield of 46% over the four steps. The yields were almost identical to 
those obtained in the racemic synthesis as expected. In order to unambiguously 
determine the structure and expected stereochemistry of (S)-212 we also 
obtained a crystal structure. The Flack parameter obtained for this structure was 
0.016(11), which is small and with a small associated error, meaning we can 
have a high degree of confidence that the stereocentre is S. This also showed that 
in the solid state the nitrogen substituents adopt an anti,anti conformation, as in 
vinyl diazetidine 75. Observed torsions and nitrogen pyramidisations were also 
similar (Figure 1.5). 
 
Scheme 2.9 Synthesis of (S)-212 from (R)-phenyloxirane. 
After this success we attempted to explore the scope of this synthetic route 
by varying the substituent at the C3, which was achieved by varying the starting 
epoxide. Initially racemic epoxides were used as these are all commercially 
available. The ring opening of the epoxide and Boc protection proved to vary 
somewhat in yield for each of the seven substrates tested, with yields ranging 
from 74% for cyclohexyl substituted 216c down to 30% for decyl substituted 
216b (Scheme 2.10). We were pleased to note however that this methodology 
50 
 
tolerated a wide range of aryl and alkyl functional groups across the seven 
examples that we tested. 
 
Scheme 2.10 Synthesis of 213-216c. 
The tosylation and cyclisation was unexpectedly difficult for some substrates 
(Scheme 2.11). For the o-tolyl substituted compound 213 the tosylation was 
unsuccessful despite multiple attempts, although there is no obvious reason why 
this substrate should be particularly challenging. For naphthyl substituted 219, 
the yield of both the Ts protection and cyclisation were low (16% and 31% 
respectively), which was likely due to poor solubility. This made purification by 
chromatography challenging; recrystallisation may have been a better 
purification method but there was insufficient material to attempt this. The 
synthesis of the glycidyl phenyl ether substituted diazetidine 218 was 
subsequently completed using the (R)-epoxide, and the (S)-218 diazetidine 
showed no evidence of racemisation when analysed by chiral HPLC, with 99% 
ee for both the epoxide and the resultant diazetidine. Alkyl substituted 
diazetidines 220a-c were also isolated in moderate yields over the two-step 
process, which makes this a complementary methodology to our subsequent 




Scheme 2.11 Scope of bisprotected hydrazines via Ts protection and cyclisation. 
Although we had developed a route to several C3-substituted diazetidines and 
shown that the sequence is stereospecific, the synthetic route had several 
drawbacks. The product from the Boc protection step was challenging to purify, 
which resulted in reproducibility issues. In addition, the ring opening step 
required ten equivalents of hydrazide monohydrate, which is both hazardous and 
prone to explosive decomposition, so substituting it was a priority. Finally, the 
synthesis required four steps, which makes the overall process time consuming 
with multiple purifications. Despite this the synthesis of (S)-212 and (S)-218 
were both completed on gram scale. 
2.3 Attempted Hydrazinyl Kinetic Resolution Using Jacobsen’s Catalyst 
We decided to explore an alternative method to open the epoxide which 
would potentially generate the diazetidines in higher yields and fewer steps 
while also removing the need to use hydrazide monohydrate. We initially 
considered Jacobsen’s catalyst and fully protected hydrazide 222 to open 
epoxide 221, which would allow us to isolate enantiopure linear hydrazine 
precursors 223 from racemic epoxides (Scheme 2.12). These could then by 
cyclised to diazetidines 224 in the same manner as 212. Bajaj et al.,90, 91 had 
previously shown that aminolytic kinetic resolution (AKR) could be done with 
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protected amines, and so it seemed plausible the reaction might tolerate protected 
hydrazides. 
 
Scheme 2.12 Proposed 2-step synthesis of diazetidines using kinetic resolution. 
Initially we used conditions reported by Bajaj et al.,91 which used Jacobsen’s 
catalyst (R,R)-SalenCoII (226),92 with six different hydrazides (Table 2.1). The 
use of hydrazine monohydrate (entry 1) was unsuccessful, which was likely due 
to its high reactivity. tert-Butyl carbazate (entry 2) was more promising, with the 
desired compound detected by LCMS, however even after seven days the 
reaction was incomplete. Furthermore, it was not possible to determine the ratio 
of product to starting material using NMR or HPLC. The use of Ts/Boc protected 
hydrazide was the most promising (entry 6), although again the reaction was not 
complete. The reaction was readily monitored by NMR as the regioisomer of the 
expected product 211 had already been synthesised, and signals in 
approximately the correct places could be clearly seen in the 1H NMR of the 






Reaction R1 R2 Result 
1 H H Complex mixture 
2 H Boc Incomplete 
3 H Ts No reaction 
4 Boc Boc No reaction 
5 Ts Ts No reaction 
6 Ts Boc 1:1 SM:P (by 1H NMR) 
Table 2.1 Optimisation of the kinetic resolution using different hydrazides. 
After this promising initial result we attempted to find better conditions that 
would accelerate the rate of reaction (Table 2.2), however, changing either 
solvent, additive, or temperature either slowed the rate of reaction or stopped the 
reaction entirely. Increasing catalyst loading from 4 to 10 mol% (entry 8) did 
provide modest improvements but did not give complete conversion. 
 
Entry Solvent Additive x Result (by 1H NMR) 
1 CH2Cl2 p-NBA 4 Trace amount of product 
2 THF p-NBA 4 4:1 ratio of SM:P 
3 iPrOH p-NBA 4 7:1 ratio of SM:P 
4 THF TFA 4 No reaction 
5 THF Oxalic acid 4 No reaction 
6 THF p-NBA 10 2.5:1 ratio of SM:P 
7a THF p-NBA 4 9:1 ratio of SM:P 
Table 2.2 Solvent and additive screen for the kinetic resolution. aReaction run at 40 °C 
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Although some of the results obtained showed the transformation is occuring, 
the reaction was too slow (under all conditions) to be synthetically useful. The 
reason for the sluggish reactivity was not clear; it is possible the hydrazide 
substrates were binding to the catalyst and deactivating it, preventing sufficient 
catalyst turnover to drive the reaction to completion. Ultimately, we decided to 
attempt no further optimisation, and instead to explore alternative synthetic 
strategies. 
2.4 Synthesis of Diazetidines Using ATH  
The next strategy that we explored was asymmetric transfer hydrogenation 
(ATH), which would allow the synthesis of diazetidines from protected keto 
hydrazides 229 (Scheme 2.13). This would be converted to give alcohol 230 
using ATH, similar to those from the epoxide opening work. Ring closure using 
the Mitsunobu reaction would generate diazetidine 231.  
 
Scheme 2.13 Proposed synthesis of 231 with ATH as the key step. 
Early studies were conducted by Dr Rajkumar Sundaram but are included 
here to provide context. Initial attempts used hydrazine 227, with a Boc group 
and a Ts group (Scheme 2.14).39 We reasoned that the more acidic NHTs group 
would be deprotonated and thus would provide regioselectivity. This proved to 
be the case in the initial alkylation reaction with 2-bromoacetophenone to give 
232; however, the cyclisation exclusively generated oxadiazine 235. This was 
not unexpected as it had been observed when similar substrates were used in the 
group.35 Although this strategy was not successful, we were very encouraged by 
the efficacy of the ATH reaction in the synthesis of alcohol 234, utilising catalyst 




Scheme 2.14 Synthesis of dihyrooxirane 235. Completed by Dr Rajkumar Sundaram. 
In order to achieve ring closure to the desired diazetidine we needed the Ts 
group to be on the terminal nitrogen. One way to achieve this was to use 
hydrazine 236 with a phthalimide and Boc group (Scheme 2.15).94 As the 
phthalimide protected nitrogen is not nucleophilic the Boc protected nitrogen 
preferentially reacts with the bromo ketone. Substrate 237 was then converted to 
alcohol 238 using catalyst 233, which could then be converted to alcohol 211 
after exchange of the protecting groups. Attempts to remove the phthalimide 
group prior to the ATH reaction were unsuccessful, forming a by-product that 
appeared to be hydrazone 239 from the 1H NMR of the crude reaction mixture. 
The deprotection of the phthalimide group again required the use of hydrazine 
monohydrate, however this can be removed with an aqueous workup, so using 
it here is less problematic than in our previous work (Scheme 2.6). 
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Scheme 2.15 Synthesis of alcohol 211 using protected hydrazine 236. 
 We also investigated an alternative approach using a hydrazine with three 
orthogonal protecting groups 240.95 Alkylation of 2-bromoacetophenone with 
240 followed by removal of the Boc group generated keto hydrazide 241 
(Scheme 2.16). This strategy was better than the phthalimide synthesis above as 
it introduces the key ATH step later in the synthesis, so less of the valuable chiral 
material is wasted. It also obviates the need to use hydrazine monohydrate in 
large excess. 
 
Scheme 2.16 Synthesis of keto hydrazide 241. Completed by Dr Rajkumar Sundaram. 
With ketone 241 synthesised we next optimised the ATH reaction (Table 2.3). 
Seven different ATH catalysts were tested, with the catalysts from the Wills 
group giving the best results. Catalyst (S,S)-233 was the most effective (entry 3). 




Entry Catalyst Solvent Yield [%]a ee [%]b 
1 S,S-243 CH2Cl2 86 97 (R) 
2 R,R-244 CH2Cl2 16
c 91 (S) 
3 S,S-233 CH2Cl2 97 99 (R) 
4 S,S-245 CH2Cl2 7 97 (R) 
5 R,R-246 CH2Cl2 97 97 (S) 
6 R,R-247 CH2Cl2 80 99 (S) 
7 R,R-248 CH2Cl2 16 98 (S) 
8    S,S-233 CHCl3 96 99 (R) 
9    S,S-233 EtOAc 88 99 (R) 
10    S,S-233 MeCNd 66 98 (R) 
11    S,S-233 MeOHe 92 99 (R) 
aIsolated yield after column chromatography. bee determined by HPLC analysis using chiralpak 
ADH. cReaction run for 48 h. dReaction run at 0.3 M. eReaction run at 0.2 M. 
Table 2.3 Optimisation of the ATH. Completed by Dr Rajkumar Sundaram. 
We were able to unambiguously confirm the structure and absolute 
configuration of alcohol 242 by X-ray crystallography (Figure 2.2). The 
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observed stereochemistry is consistent with previous work in the Wills group 
using catalyst (S,S)-233.93 They have previously hypothesised that catalyst 
binding is mainly influenced by a favourable CH/π interaction, so the observed 
sense of asymmetric induction which follows this expected model confirms that 
the hydrazine group is not disrupting this binding model. 
 
Figure 2.2 Proposed catalyst binding and XRD of (R)-242, by Dr Rajkumar Sundaram. 
2.5 Scope of the Diazetidine Synthesis 
At this point, I largely took over the work of Dr Rajkumar Sundaram and we 
explored the scope of the diazetidine synthesis. We started by using a variety of 
aryl ketones, which were commercially available. The synthesis of the keto 
hydrazides was shown to be tolerant of a wide variety of aryl groups, including 
heteroaryl substituents (Scheme 2.17). The yields were generally quite modest 
for the 2-step process, with only the p-methoxy (256) compound giving a high 
yield. These lower yields were due to the formation of a small amount of a by-
product during the Boc deprotection, which we were unable to isolate. In order 
to remove it the substrates had to be recrystallised which led to material loss. 
The deprotection of benzofuran 258 was completed with HCl in dioxane as TFA 




Scheme 2.17 Synthesis of keto hydrazide precursors. aBoc deprotection completed using 2 M 
HCl in dioxane. bSynthesised by Dr Rajkumar Sundaram. 
With these compounds in hand the scope of the ATH reaction was explored 
(Scheme 2.18). Most substrates performed extremely well using (S,S)-233, the 
only exception proved to be ortho-substituted derivatives. These still gave the 
required alcohols in excellent yields, however the enantioselectivity for the ATH 
was significantly lower, perhaps suggesting these substrates are coordinating 
less effectively to the ketone. This was improved by changing to (R,R)-247 with 
a para-methoxy substituent, which has previously been shown to be more 
effective for ortho-substituted substrates.96 This provided a significant increase 
in enantioselectivity, especially for the ortho-chloro substrate 266.ii 
 
ii In order to determine ee, two different methods were used. Either the opposite 
enantiomer of each compound was synthesised using the opposite catalyst 
enantiomer i.e. (R,R)-233 instead of (S,S)-233. Alternatively, the substrate was 
reduced using sodium borohydride in methanol to generate an authentic racemic 




Scheme 2.18 Scope of the ATH reaction. aCatalyst (R,R)-247 used. bSynthesised by Dr 
Rajkumar Sundaram. 
The cyclisation reaction proved more challenging (Scheme 2.19). Three 
substrates, benzofuran 279, 4-methoxy 277 and 4-fluoro 273, proved difficult to 
isolate due to the presence of a by-product which could not be removed using 
column chromatography. Further purification and optimisation was not 
attempted. There was also significant variation in the yield for the cyclisation, in 
general the substrates with halogens on the aromatic ring (with the exception of 
4-fluoro 273) were the most successful, while other substrates, (thiophene 272, 
biphenyl 278, and phenyl 280) were only isolated in moderate yields.iii  
 
iii The ee was determined either by synthesising both enantiomers and mixing or 
by synthesising the racemate and using this as a standard for chiral HPLC. See 
experimental section for further details. 
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Scheme 2.19 Scope of the Mitsunobu reaction for diazetidines. aSynthesised by Dr Rajkumar 
Sundaram. bee estimated using chiral HPLC 
In addition, the thiophene (272) and benzofuran (279) substituted compounds 
racemised significantly during the cyclisation process. All these substrates have 
strongly electron donating substituents, which would stabilise the carbocation 
formed in an SN1 reaction (Scheme 2.20). The other substrates in Scheme 2.19 
are not strongly electron donating, and are unable to stabilise a carbocation, thus 




Scheme 2.20 Proposed rationale for racemisation in the Mitsunobu reaction. 
Next, diazetidines containing Boc rather than Cbz groups were targeted, 
which was achieved by using triply protected hydrazine 281 (Scheme 2.21). This 
was synthesised in a similar manner to 240,95 and then converted to keto 
hydrazide 282. The most challenging step proved to be the removal of the Cbz 
group by hydrogenation with palladium on carbon. 283 was susceptible to 
further reduction to rac-211, which is surprising as aryl ketones are usually 
stable to hydrogenation with palladium. Reducing the reaction time to 2 h 
minimised the production of rac-211 while ensuring full conversion of 282 to 
283, however in order to remove traces of rac-211 prior to the ATH, the material 
needed to be recrystallised reducing the yield. Overall however, this sequence 
was lower yielding (33% over 5 steps) than the epoxide opening method (46% 
in 4 steps, Scheme 2.9) and the phthalimide approach (72% in 4 steps, Scheme 
2.15). 
 
Scheme 2.21 Synthesis of diazetidine 212 using hydrazine 281. 
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2.6 Synthesis of C3-Substituted Pyrazolidines 
Having demonstrated that our strategy employing an ATH reaction was 
suitable for the synthesis of aryl substituted diazetidines, we next explored 
whether the synthesis of larger ring sizes would be possible using the same 
general method. For pyrazolidines we planned to use a hydrazine with just two 
protecting groups. We thought this would be sufficient for the cyclisation 
reaction to produce the desired five-membered ring, as it should be favoured 
even with a carbamate protected terminal nitrogen – unlike when oxadiazine 235 
was observed from the cyclisation of precursor 234 (Scheme 2.14). Three 
different protected hydrazines were reacted with 3-chloropropiophenone to give 
keto-hydrazines 284-286 in good to excellent yields and with excellent 
regiocontrol (Scheme 2.22). This allowed us to determine how tolerant the 
subsequent steps were to different protecting groups and allow us to test multiple 
deprotection and functionalisation strategies on the protected cyclic hydrazines. 
Scheme 2.22 Synthesis of keto hydrazides 284-286 with different protecting groups.  
For 287, in which the carbamate and sulphonamide groups are transposed, 
triply protected hydrazine 240 was used and 287 was isolated in excellent yield 
after Boc removal (Scheme 2.23). 
 
Scheme 2.23 Synthesis of keto hydrazine 287 using triply protected hydrazine 240. 
Next, we varied the aryl group to further develop the scope of the reaction, 
which proved to be possible in good to excellent yields (Scheme 2.24). The Ts 
64 
 
and Boc protected hydrazine 227 was used for all these examples as it gave the 
best yields for the phenyl derivative (Scheme 2.22, 286). The aryl chlorides were 
either commercially available or were synthesised using known procedures (see 
experimental section for details). Keto hydrazines 288-294 were all obtained in 
good to excellent yields. 
 
Scheme 2.24 Synthesis of keto hydrazides 288-294. aSynthesised by Dr Stefan Roeser. 
These eleven substrates were then subjected to the optimised ATH conditions 
and almost all of them transformed to the corresponding alcohols in excellent 
yields and with high ee (Scheme 2.25). The only exceptions were 305 and 296, 
which gave lower yields of 71% and 86% respectively, but with high ee. 
Conversely 302 was obtained in an excellent yield, but in lower ee.iv 
 
iv In order to determine ee, two different methods were used. Either the opposite 
enantiomer of each compound was synthesised using the opposite catalyst 
enantiomer ie (R,R)-233 instead of (S,S)-233. Alternatively, the substrate was 
reduced using sodium borohydride in methanol to generate an authentic racemic 
sample for comparison using chiral HPLC. See experimental section for details. 
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Scheme 2.25 ATH scope for the pyrazolidine precursors. aSynthesised by Dr Stefan Roesner. 
In order to improve the enantioselectivity of the synthesis of 302 several 
tethered catalysts were screened (Scheme 2.26). The best ee of 93% was 
achieved with (R,R)-247, which had proven to be similarly effective for the 
ortho-substituted diazetidine precursors 261 and 266. 
 
Scheme 2.26 Optimisation of the ATH of 291. 
The cyclisation of these alcohols was expected to be less challenging than it 
was for the diazetidines, as the formation of 5-membered rings is significantly 
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more kinetically favoured than for 4-membered rings. This proved to be the case, 
yields were generally excellent for the eleven examples synthesised (Scheme 
2.27). Even at higher concentrations of 0.1 M for 306 and 309 the yields were 
unchanged, which makes the process more practical, especially on larger scales. 
As expected thiophene example 311 was prone to racemisation, as previously 
observed for diazetidine 272, with 73% ee and 62% ee respectively from 
alcohols 300 (98% ee) and 262 (90% ee).v  
 
Scheme 2.27 Synthesis of chiral pyrazolidines 306-316 using the Mitsunobu reaction. 





v The ee was determined either by synthesising both enantiomers and mixing or 
by synthesising the racemate and using this as a standard for chiral HPLC. See 
experimental section for further details. 
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2.7 Synthesis of C3-Substituted Hexahydropyridazines and Diazepines 
Having synthesised the 4- and 5-membered chiral heterocycles we next 
explored the synthesis of 6-membered hydrazines (hexahydropyridazines), 7-
membered hydrazines (diazepines) and 8-membered hydrazines (diazocanes). 
We first attempted to repeat the SN2 reaction with 4-chloro-1-phenylbutan-1-one 
and 227, which had worked well to synthesise keto-hydrazines with shorter 
linkers. However, this proved difficult with our standard conditions only 
yielding starting material (Table 2.4, entry 1). Attempts to use more forcing 
reaction conditions were also unsuccessful (entries 2-6), additives like TBAI 
also had little effect, while heating to higher temperatures generally caused 
decomposition. Using NaH as the base instead of K2CO3 gave very slow 
conversion, however, the reaction was not fast enough to be synthetically viable. 
 
Entry Base Solvent Additive T t Resulta  
1 K2CO3 MeCN None rt (48 h) to 
40 °C (24 h) 
NR 
2 K2CO3 MeCN TBAI rt (24 h) to 
reflux (24 h) 
NR (rt) 
CM (reflux) 
3 Cs2CO3 MeCN TBAI rt (24 h) to 
reflux (24 h) 
NR (rt) 
CM (reflux) 
4 Cs2CO3 DMF TBAI rt 24 h Trace 317 
5 NaH DMF TBAI rt 24 h Trace 317 
Table 2.4 Attempted formation of ketone 317. aBy NMR. 
At this point we decided to explore alternative strategies for the synthesis of 
the desired keto-hydrazides. We were able to synthesise 4-hydroxy-1-
phenylbutan-1-one, using a method developed by Sakai et al.97 This alcohol was 
then reacted with 240 using a Mitsunobu reaction, with subsequent Boc 
deprotection yielding keto hydrazide 318 in a 49% yield over 2 steps (Scheme 
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2.28). This process was also effective with 5-hydroxy-1-phenyl-pentan-1-one98 
and 6-hydroxy-1-phenylhexan-1-one,99 giving 319 and 320 in 70% and 35% 
yields respectively. 
 
Scheme 2.28 Synthesis of keto-hydrazides with longer carbon linkers. 
A complementary method for the synthesis of the derivatives was developed 
by Dr Stefan Roesner, who used alkyl iodides instead of alcohols as starting 
materials. These iodides were synthesised using known literature procedures100-
102 from the corresponding chlorides. This allowed the keto hydrazine precursors 
for 6- and 7-membered rings to be synthesised (317 and 321), along with 4-
fluoro derivative 322 (Scheme 2.29).  
 
Scheme 2.29 Synthesis of keto hydrazides 317, 321 and 322. Completed by Dr Stefan Roesner 
With these keto hydrazines synthesised we were then able to subject them to 
the ATH conditions developed previously. All the substrates tested were 
converted to chiral alcohols in excellent yields and enantioselectivities (Scheme 
2.30). The only exception was 325, the compound with the longest linker, which 
was isolated in a more modest 71% yield. It was not possible to determine the 
ee of alcohol 325, despite multiple attempts using HPLC.vi  
 
vi In order to determine ee, two different methods were used. Either the opposite 




Scheme 2.30 ATH of long chain keto hydrazines. aee could not be determined. bSynthesis by 
Dr Stefan Roesner 
The cyclisation of these substrates was expected to be more challenging as 
the target ring size increased, however we did not observe an especially clear 
trend (Scheme 2.31). Acceptable yields of the 6- and 7-membered heterocycles 
329 and 330 were achieved, however, attempts to synthesise diazocane 331 were 
not successful. The mass of the desired product was detected by LCMS, however 
purification by flash chromatography led to a complex mixture that could not 
confidently be assigned to 331 due to the large number of aliphatic CH2’s in the 
1H NMR. No further attempts to isolate this compound were conducted, however 
higher dilution may have made this possible. The Ts and Boc protected 
compounds 332-334 were also isolated, in similar yields. As expected, none of 
the compounds underwent any significant degree of racemisation under the 
cyclisation, as no strongly electron donating aryl substituents were used.vii 
 
enantiomer ie (R,R)-233 instead of (S,S)-233. Alternatively, the substrate was 
reduced using sodium borohydride in methanol to generate an authentic racemic 
sample for comparison using chiral HPLC. See experimental section for details. 
vii ee was determined either by synthesising both enantiomers and mixing or by 
synthesising the racemate and using this as a standard for chiral HPLC. See 




Scheme 2.31 Mitsunobu cyclisation for larger ring sizes. aSynthesis by Dr Stefan Roesner. 
2.8 DSC Analysis of Hydrazine Precursors and Cyclic Hydrazines  
In this chapter we have explored the synthesis a large number of novel 
hydrazines, a compound class that has previously been shown to decompose 
explosively in some cases.25, 103, 104 Before we proceeded further with larger scale 
syntheses, we wanted to analyse whether any of the compounds we had made 
were prone to explosive decomposition. To do this we used differential scanning 
calorimetry (DSC), which would allow us to identify any potentially problematic 
exotherms produced by these compounds upon heating. This technique rapidly 
heats the sample over a wide temperature range and measures any endotherms 
or exotherms by measuring the change in energy compared with a reference 
sample. From a safety perspective, it can be used to identify potentially 
dangerous exotherms, as it measures both their magnitude and their onset 
temperature. This can be seen with p-toluenesulphonylhydrazide (335), which 
has previously been shown to produce a problematic exotherm (Figure 2.3).105 
The exotherm has a relatively low onset temperature of 155 °C and also a large 
normalized magnitude (932 J g-1), which means the compound is potentially 




Figure 2.3 DSC of p-toluenesulphonylhydrazide 335. 
Further analysis was undertaken on seven hydrazines we had synthesised in 
order to determine if any of these had significant exotherms associated with 
them. This was done by comparing the exotherms obtained from DSC analysis 
against Yoshida’s explosion propagation correlation.106 This plots a normalised 
heat of decomposition (log QDSC) against a normalised exotherm onset (log 
(TDSC-25)), which can be represented graphically on the same graph as the linear 
Yoshida correlation. Any compounds which appear below the line are unlikely 
to propagate explosively, although compounds that are near the line are still 
potential explosion hazards. The plot of our compounds clearly showed that they 
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are all extremely unlikely to be explosive, giving us greater confidence that 
scaling up could be done safely (Figure 2.4). 
Figure 2.4 DSC analysis of cyclic hydrazines and their synthetic intermediates using 
Yoshida’s explosion propagation correlation. 
Having shown that these compounds did not have any potentially problematic 
exotherms we were able to synthesise 280 and 306 on larger scales (up to 5 g), 
along with Boc protected derivatives 212 and 308. While conducting this scale 
up work we also found that by increasing the reaction time of the ATH to 72 h 
it was possible reduce the loading of catalyst (S,S)-233 to just 0.5 mol%, without 
any erosion in yield or enantioselectivity.   
2.9 Towards the Total Synthesis of RipK1 Inhibitor 337. 
As an initial demonstration of the utility of our chiral cyclic hydrazine 
synthesis in medicinal chemistry we attempted the synthesis of RipK1 inhibitor 
337 (Scheme 2.32), which had been shown to be a micromolar inhibitor of the 

























Yoshida's Explosion Propagation Correlation
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degenerative and inflammatory diseases, including Alzheimer’s disease, 
Parkinson’s disease and ALS (Amyotrophic Lateral Sclerosis). 
 This bicyclic system contains an aryl substituted pyrazolidine and was 
therefore potentially accessible using our ATH strategy. The synthesis reported 
in patent WO 2018/213634 A1 required six steps to synthesise the racemate 
(Scheme 2.32), which then had to be resolved into the two enantiomers using 
preparatory chiral HPLC. The relative activity of the two enantiomers was not 
reported, which we would be able to assess by making both enantiomers and 
determining which was biologically active. 
 
Scheme 2.32 Reported synthesis of RipK1 inhibitor 337.107 
We synthesised orthogonally protected precursor 313 in 3 steps with 93% ee 
using the methodology previously outlined in this chapter. Next, we sought to 
build the 7-membered ring using an iterative deprotection and functionalisation 
strategy. We were then able to selectively remove the tosyl group and introduce 
the carbon chain through reductive amination using aldehyde 338 (synthesised 
in 2 steps108, 109). We synthesised ester 340 in 51% yield, switching from THF to 
DCM improved the yield to 61% over the two steps (Scheme 2.33). Attempts to 
use iodide 339110 in the formation of 340 was successful but significantly lower 




Scheme 2.33 Synthesis of cyclisation precursor 340. 
Removal of the Boc group with hydrochloric acid in 1,4-dioxane to form the 
HCl salt was successful (Scheme 2.34). However subsequent attempts to cyclise 
to 337 failed, which was likely due to the formation of imine 341, although this 
was not isolated and characterised. This type of oxidation product was 
subsequently observed in other pyrazolidine examples (Scheme 3.1). Both the 
mass spec and the crude NMR strongly suggested it was the major product.  
 
Scheme 2.34 Attempted cyclisation of 340 which gave imine 341. 
Deprotection of the methyl ester to give the corresponding carboxylic acid 
prior to Boc removal was effective, however attempts to use this substrate for a 
peptide coupling with HATU again led to imine 341, with lactam 337 not 




Scheme 2.35 Attempted cyclisation of using a HATU which gave imine 341. 
As this strategy was ineffective, we attempted to alter the final steps by 
synthesising hydrazine 343 instead, which would not require deprotection of the 
more hindered nitrogen (Scheme 2.36). Hydrazine 343 was synthesised from 
acid chloride 342111 and p-toluenesulphonylhydrazine, and this was then 
converted to ketone 345 by coupling it with chloride 344. ATH was completed 
using catalyst (R,R)-247 as this had been the most effective for 3,5-difluoro 
compound 313, and for this example it delivered an excellent 98% ee. 
Subsequent cyclisation using the Mitsunobu reaction gave hydrazine 346 with a 
slightly reduced ee of 95%. 
 
Scheme 2.36 Synthesis of 346 as a precursor to RipK1 inhibitor 337. 
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Next, we converted the alkene of 346 to an aldehyde, which gave 347 in 
moderate yield (Scheme 2.37). Attempts to treat this aldehyde with magnesium 
in methanol to remove the tosyl group were not successful, and instead yielded 
a complex mixture. Subsequently we converted aldehyde 347 to the 
corresponding alcohol 348, however this also yielded a complex mixture upon 
attempts to remove the tosyl group.  
 
Scheme 2.37 Attempted synthesis of Rip K1 inhibitor 337 from hydrazine 346. 
Further work to complete this synthesis is currently ongoing in the group, 
however, target 337 has not yet been synthesised.  
2.10 Conclusions 
We have developed a general, enantioselective, high yielding 3-step synthesis 
of aryl substituted cyclic hydrazides. Twenty-eight different examples were 
synthesised, across four different ring sizes (4- to 7-membered), with good 
variation in the aryl groups and protecting groups (both sulphonamides and 
carbamates) tolerated by this synthetic methodology. This method can also be 
used to make either enantiomer of each cyclic hydrazide with excellent 
selectivity simply by switching to the opposite enantiomer of the ATH catalyst. 
The synthesis of the keto hydrazides was achieved by utilising simple, 
reliable SN2 chemistry. Compounds with two aliphatic carbons or less between 
the electrophilic halogen and the ketone reacted with the protected hydrazides 
regardless of which leaving group was used, with even less reactive chlorides 
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proving effective in the synthesis. The regioselectivity in the SN2 reaction was 
also excellent, with the sulphonamide protected nitrogen of the hydrazine 
reacting preferentially over the carbamate nitrogen in all cases and without the 
minor regioisomer being observed. In order to reverse this regioselectivity it was 
necessary to use hydrazines with three protecting groups (240 and 281) or 
phthalimide protected hydrazine 236. For compounds with longer linkers some 
optimisation was required due to their lower reactivity, however switching to 
more reactive iodides and changing the solvent to DMF was sufficient to achieve 
good yields (Scheme 2.29). Alcohols were also shown to be reactive under 
Mitsunobu conditions, although this method proved to be less practical as it 
required more steps and led to lower yields (Scheme 2.28). 
The ATH reaction proved to be extremely robust and converted the aryl 
ketones to the chiral alcohols, in most cases in excellent yields. The measured 
enantiomeric excesses were almost exclusively >90%, at low catalyst loadings 
of only 1 mol% of (S,S)-233 in the majority of cases. Better results were obtained 
using catalyst (R,R)-247 in three examples, two with ortho substituents (261 and 
266) and  difluoroaryl derivative 302.  
The cyclisation using the Mitsunobu reaction proved to be the most 
challenging step, particularly for the smallest and largest ring sizes. Synthesis of 
1,2-diazetidines was the most challenging, with sulphonamides required on the 
terminal nitrogen in order to cyclise to the required 4-membered ring. Even at 
high dilution, yields proved to be variable. 5-Membered rings were generally 
synthesised in excellent yields, while 6- and 7-membered rings also worked well. 
The most significant drawback of the cyclisation was the epimerisation that 
occurred for substrates bearing strongly electron donating aryl groups like 
thiophenes, where significant erosion of ee was observed. 
We also developed a complementary method to synthesise orthogonally 
protected chiral diazetidines. We were able to ring open readily available chiral 
epoxides using hydrazine monohydrate, then subsequently install the Boc and 
Ts protecting groups sequentially in good yields, which generates alcohols 
complementary to those synthesised using the ATH method. This method 
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provides an alternative approach to synthesising aryl substituted diazetidines and 
is also tolerant of alkyl groups in this position (e.g. CH2OPh). 
Finally good progress towards the synthesis of RipK1 inhibitor 337 has been 
achieved, although completion of the synthesis has thus far proven elusive. 
Synthesis from hydrazine 313 was not successful, with the final cyclisation step 
generating undesired imine 341. The alternative strategy obivated the need for 
this final cyclisation, however the final detosylation proved equally problematic 





Chapter 3 Towards Libraries of Cyclic Hydrazines 
3.1 Deprotection and Cross-Coupling of Pyrazolidines 
Having synthesised a set of more than twenty orthogonally protected cyclic 
hydrazines we next sought to deprotect and functionalise them by adding 
fragments to each nitrogen. Our initial studies used pyrazolidines, as they had 
been synthesised in high overall yields in just three steps on up to 5 g scale. We 
had prepared examples with different pairs of protecting groups to clarify which 
combinations were most suitable. Studies began with cyclic hydrazine 306 with 
Ts and Cbz protecting groups. Initially we attempted to selectively remove the 
Ts group, using conditions that had previously been applied to similar 
substrates,39 however we observed a 1:1 mixture of 349 alongside methyl 
carbamate 350 resulting from transesterification of the benzyl group (Scheme 
3.1). These were separated using preparative HPLC and both subsequently 
underwent Buchwald-Hartwig cross couplings using literature conditions 
optimised for similar substrates,112 to give 351 and 352 respectively. Despite 
employing reducing conditions to remove the Cbz group of 351 via 
hydrogenation, oxidation to imine 353 was observed, which removed the 
stereocentre.  
 
Scheme 3.1 Deprotection and functionalisation of pyrazolidine 306. 
Instead of attempting to further optimise this sequence, we instead switched 
to pyrazolidine 308 protected by Ts and Boc groups. We expected the Boc group 
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to be more stable during the Ts group removal due to the increased size of the 
tert-butyl group. This proved to be the case, and the amine was readily formed 
after only two hours (Scheme 3.2). Purification was challenging as the substrate 
was not stable to chromatography, however when used directly in the cross 
coupling112 without purification we were able to isolate pyridine 354 in an 
encouraging 63% yield.  
 
Scheme 3.2 Deprotection and functionalisation of pyrazolidine 308. 
Next, we sought to further optimise the Buchwald-Hartwig coupling. This 
was done in collaboration with Nessa Carson while on placement at Erl Wood 
with Eli Lilly and Co. We were able to conduct ninety-six experiments in parallel 
with amine 355, using high throughput equipment and in-house software.113 This 
allowed us to screen twelve different catalyst/ligand systems, with four different 
bases and two solvents (toluene and 1,4-dioxane) simultaneously. This screening 
highlighted several potentially viable sets of reaction conditions (Figure 3.1) and 
provided valuable information about optimal conditions for the cross coupling 
of cyclic hydrazines. The size of the pie charts indicates how much of the 
material analysed by LCMS could be assigned to one of the products in the 
scheme, with green representing product 354. Smaller pie charts reveal other 
unknown impurities are present. From this data we were able to conclude that: 
toluene is marginally better as a solvent than 1,4-dioxane, sodium tert-butoxide 
is the best base, and Pd-162, Pd-170 and Pd-171 are the best catalyst/ligand 
combinations (Figure 3.2 for catalyst structures). These catalysts were developed 
by Johnson Matthey as highly active catalysts stable to air and moisture.114 They 




Figure 3.1 96 well screen of conditions for the cross coupling of 355. Completed in 




Figure 3.2 Structures of the twelve catalysts/ligands screened. 
Repeating the synthesis of 354 from 355 on a 100 mg scale in a round bottom 
flask using Pd-170 with sodium tert-butoxide and toluene, provided 354 in an 
improved yield of 85%. Next, we explored the scope of this reaction, choosing 
several aryl halide coupling partners of differing reactivity. These conditions 
proved to be extremely effective for all substrates studied, giving 357-361 in 




Scheme 3.3 Scope of the Buchwald-Hartwig coupling of 355 using Pd-170. 
In collaboration with Nessa Carson another high throughput screen was 
carried out. This time we subjected twenty different aryl halides to the optimised 
cross coupling conditions with 355, which showed most aryl halides (15/20 in 
>40% conversion) could be used in this coupling (Scheme 3.4).  
Scheme 3.4 Aryl halide screen using 355 completed with Nessa Carson. 
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Subsequent analysis however showed that this screen was not an especially 
reliable predictor of coupling partner suitability. 2-Bromobenzonitrile was 
identified as a moderately well tolerated halide in the screen (40-59% 
conversion), however it was in fact an excellent coupling partner (359 isolated 
in 95% yield – Scheme 3.3). Additionally, couplings with halides 5-bromo-1H-
benzo[d][1,2,3]triazole, 1-bromo-2,4-difluorobenzene and 6-bromobenzo-
[d]oxazole were attempted on a 100 mg scale in a round bottom flask, however 
362-364 were not seen by LCMS or when the crude mixture was analysed by 1H 
NMR (Scheme 3.5). The reasons for the large discrepancy between the data from 
the screen and the results of the scale up experiments is not clear. It is possible 
that the LCMS method used to analyse the high throughput screen was 
highlighting false positive results for some examples and incorrectly identifying 
impurities in others. The screening method was not designed to screen the results 
obtained with different coupling partners and it is clear from this data it is not 
suitable for this. 
 
Scheme 3.5 Attempted synthesis of 362-364. 
Attempts to expand the scope to pyrazolidines with other aryl groups proved 
more challenging. Biphenyl substituted pyrazolidine 312 could be deprotected 
to using magnesium in methanol, however the cross-coupling only gave product 





Scheme 3.6 Deprotection and coupling of biphenyl substituted pyrazolidine 312. 
Further optimisation was undertaken to identify a better catalyst system for 
this coupling, as deprotection of 312 to give 366 was essentially quantitative. 
Solvent and base optimisation was not attempted, toluene and sodium tert-
butoxide were assumed to be optimal for this coupling based on previous 
evidence (Figure 3.1). Pd(OAc)2/Xantphos had been identified as an effective 
catalyst system in cyclic hydrazine cross couplings that we were optimising 
simultaneously (Scheme 3.24). Using this catalyst also proved effective here, 
with 365 isolated in 86% yield (Scheme 3.7). 
 
Scheme 3.7 Optimised cross coupling of 366 using Pd(OAc)2 and Xantphos. 
3.2 Other Functionalisation Reactions Using Aryl Pyrazolidines 
 Having optimised the Buchwald-Hartwig coupling of 313 and 366, we next 
turned to other widely used nitrogen functionalisation reactions to further 
expand the product scope. We started with reductive amination and utilising 
conditions developed by Abdel-Magid et al.,115 we were able to couple amine 
313 with a series of aldehydes to give 367-371 (Scheme 3.8). Attempts to form 
372 by using cyclohexanone was unsuccessful which is likely due to the 
difficulty in forming the hindered imine. In order to drive the reaction to 
completion in a synthetically viable timescale it was necessary to use five 
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equivalents of the aldehyde and sodium triacetoxyborohydride, which meant 
there was often a significant amount of alcohol by-product from the reduction of 
the aldehyde in the reaction mixture. Separation using flash chromatography 
proved challenging but was successful, although some substrates required 
multiple purifications leading to greater material loss (see experimental section). 
 
Scheme 3.8 Scope of the reductive amination using 313. 
We next explored the acylation of amine 313. Four examples were 
synthesised which showed a variety of aryl groups were tolerated and gave the 
hydrazines 373-376 in good yields (Scheme 3.9).  
 
Scheme 3.9 Scope of the acylation reaction using 313. 
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Having shown a range of chemistries can be used to functionalise the less 
hindered nitrogen of pyrazolidine 308, we next turned to functionalisation at the 
nitrogen adjacent to the C3 substituent. We knew this would be more difficult as 
we had already observed that removing the protecting group on this nitrogen left 
the resulting amine prone to oxidation to the corresponding imine (Scheme 3.1). 
However, by converting the free amine to its TFA or HCl salt we were able to 
acylate this nitrogen in good yields, using the TFA salt for 377 and the HCl salt 
for 378 (Scheme 3.10).  
Scheme 3.10 Acylation of the nitrogen atom adjacent to C3. 
This transformation was successful for four other examples, with 379-382 all 
synthesised in good yields (Scheme 3.11). The HCl salt was used for these 
transformations as it was found to give better yields than using TFA for 380. 
 
Scheme 3.11 Acylation on the nitrogen atom next to C3. aDeprotection with TFA/CH2Cl2. 
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Having found suitable conditions for acylation, we next attempted the 
Buchwald-Hartwig coupling on this nitrogen atom. This reaction employs a 
rather hindered nitrogen nucleophile, and there is a competing oxidation side 
reaction to the undesired imine, so this transformation was expected to require 
significant optimisation. We speculated that use of the salt of the amine might 
inhibit this competing process by limiting the concentration of free amine in 
solution but we expected this to be significantly more challenging as there is 
only limited literature precedent for cross couplings using ammonium salts.116 
Initial attempts using 359 were unsuccessful, with only trace amounts of 383 
detected by LCMS when using our previously optimised Buchwald-Hartwig 
conditions to attempt to couple both 2-bromopyridine and 4-bromobenzonitrile 
(Scheme 3.12). Similarly disappointing results were observed using either the 
HCl or TFA salt of 383. 
 
Scheme 3.12 Attempted cross coupling of both the TFA and HCl salts of 359. 
As this approach was not successful, we examined the coupling of 
pyrazolidine 376 with 3-bromobenzotrifluoride (Scheme 3.13). Although the 
yield for this transformation was only 5%, it gave us an authentic sample of 
coupled product 384. This allowed us to analyse the sample by GCMS and 
construct a calibration curve (Table 6.3), which meant further screening could 





Scheme 3.13 Synthesis of pyrazolidine 384. 
We conducted a small screen of catalysts, bases and solvents on 385 in order 
to improve this transformation. As we had observed previously (Figure 3.1), 
sodium tert-butoxide and toluene remained the best base and solvent 
combination, outperforming potassium carbonate and 1,4-dioxane in all cases 
(Table 3.1). Palladium acetate and Xantphos was the most effective catalyst 
system (entries 4, 6 and 7). Finally, we observed that the HCl salt gave better 
conversion than the corresponding TFA salt (entries 4 and 6). We were able to 
use GCMS and 1H NMR to assign plausible structures to some of the major by-
products formed in the reaction; imine 386 was an unsurprising by-product, 
however the formation of imine 387 was not expected. Its presence suggests that 
with certain catalytic systems (entries 1 and 5), the palladium can insert into the 
amide bond of 386, followed by cross coupling on the less hindered nitrogen to 
give 387. This type of decarbonylative cross coupling of amides with palladium 
catalysts has previously been reported in the literature for other amides and there 









Entry X Conditions Conv.b Yield 
1 TFA Pd-170, NaOtBu 23 5 
2 TFA Pd-170, NaOtBua 7 - 
3 TFA Pd-170, K2CO3 9 - 
4 TFA Pd(OAc)2, Xantphos, NaOtBu 42 22 
5 TFA Pd(OAc)2, Xphos, NaOtBu 38 - 
6 HCl Pd(OAc)2, Xantphos, NaOtBu 59 40 
7 HCl Pd(OAc)2, Xantphos, NaOtBu
a 53 - 
8 HCl Pd(OAc)2, Xantphos, K2CO3 8 - 
9 HCl Pd(OAc)2, Xantphos, K2CO3
a 0 - 
Table 3.1 Optimisation of the coupling of 385. aIn dioxane. bBy GCMS analysis 
Although we had significantly improved the isolated yield, it was still only  a 
relatively modest 40% under the optimised conditions. In order to increase the 
yield beyond this we were again able to collaborate with Nessa Carson and 
conduct a larger screen of catalysts. As 385.HCl was difficult to synthesise on a 
large scale and we had already determined that 1,4-dioxane was inferior to 
toluene as a solvent for this transformation, we decided to omit it, meaning we 
screened forty eight reaction conditions. We only made one other change to the 




Figure 3.3 Further optimisation of the Buchwald-Hartwig coupling of HCl salt 385. 
Completed in collaboration with Eli Lilly/AMRI.  
It is clear when comparing Figure 3.1 with Figure 3.3 that 385.HCl was a 
more challenging substrate than 355. The majority of the catalysts screened only  
gave low conversions, with sodium tert-butoxide in particular proving to be an 
ineffective base for this transformation. Instead caesium carbonate was a more 
effective, while only a limited number of catalyst systems gave encouraging 
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results. We selected Pd-180 and caesium carbonate as the best conditions and 
we applied this to the synthesis of 384 on a 100 mg scale in a round bottom flask, 
achieving a much improved yield of 77% (Scheme 3.14). Moreover, we were 
able to show that it was effective for the transformation of 388.HCl into 389 in 
an 80% yield. 
 
Scheme 3.14 Synthesis of 384 and 389 using optimised Buchwald-Hartwig reaction. 
These findings highlight the power of high throughput catalyst screening 
technologies for challenging cross couplings. In the case of 384, it enabled us to 
improve our initial yield approximately 15-fold (from 5% in Scheme 3.13 to 
77% in Scheme 3.14). 
3.3 Functionalisation of Hexahydropyridazines and Diazepines 
Having extensively optimised the functionalisation of pyrazolidines, we next 
used this methodology on hexahydropyridazines and diazepines (Scheme 3.15). 
This work was mainly completed by Dr Stefan Roesner and clearly demonstrated 
that larger ring sizes could broadly be functionalised in a similar manner. In 
order to test the suitability of the deprotection and functionalisation chemistry 
that had been developed for pyrazolidines, we used Ts and Boc protected 
substrates 332-334. These were chosen as we had already determined that Ts 
and Boc protected pyrazolidine 308 was the best substrate, so we used analogous 
systems for the larger ring sizes. This allowed us to use an identical iterative 




Scheme 3.15 Synthesis of functionalised hexahydropyridazines and diazepines aArBr, 
Pd(OAc)2, Xantphos, NaOtBu, toluene, 90 °C, 20 h. bRCOCl, DIPEA, CH2Cl2, 0 °C to rt, 18 h. 
cSynthesised by Dr Stefan Roesner. dRCHO, NaBH(OAc)3, THF, rt, 20 h. eRCOCl, CH2Cl2, rt, 
18 h. fYield over three steps after Boc removal. 
It was particularly notable that both hexahydropyridazine 393 and diazepine 
396 were found to be stable after deprotection to the amine, which was not 
observed for any pyrazolidine examples. Clearly the larger ring sizes are 
significantly less prone to oxidation type processes which occured so readily for 
pyrazolidines. This is possibly due to the conformation of these larger rings, they 
might be in a less favoured conformation for the required elimination. The 
Buchwald-Hartwig reaction also required less optimisation for these larger ring 
sizes, with palladium acetate and Xantphos being effective for all of the 
transformations tested. Pd-170 and Pd-180 were both tested but were found to 
be ineffective for multiple transformations, which demonstrates their high 
specificity for pyrazolidines, they are clearly very sensitive to changes in ring 
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size. The reductive amination and acylation reactions that had previously been 
developed required no further optimisation and were equally as effective on 
these larger ring sizes. 
A total of sixteen cyclic hydrazines were produced which were derivatised on 
both nitrogens using the methods developed herein. For four of these examples 
(380, 384, 390 and 396), we confirmed that racemisation did not occur by 
comparison of their ee by HPLC before and after N-functionalisation. 
3.4 Functionalisation of Unsubstituted Diazetidines. 
The final cyclic hydrazines we attempted to functionalise were the 
diazetidines, which we expected to be challenging substrates due to their lack of 
stability in comparison to the other cyclic hydrazines. Initial work was focused 
on simple orthogonally protected systems 198 and 202. This allowed us to 
investigate the deprotection and functionalisation of these substrates. Synthesis 
of both diazetidines 198 and 202 was completed on a gram scale, allowing the 
opportunity to investigate multiple deprotection strategies. For diazetidine 198, 
both protecting groups were orthogonally removed in high yields to generate 
amines 398 and 399 using standard procedures (Scheme 3.16).  
 
Scheme 3.16 Removal of the Boc and Cbz groups of 198. 
For diazetidine 202, deprotection of the tosyl group using magnesium in 
methanol to give amine 400 was completed in excellent yield (Scheme 3.17).  
 
Scheme 3.17 Removal of the Ts group of 202. 
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For diazetidine 202, the Boc group was also removed using TFA, and the 
resulting salt 401•2TFA was purified and fully characterised (Scheme 3.18). The 
TFA salt was subsequently converted to amine 401 in quantitative yield by 
washing with saturated sodium hydrogen carbonate solution. This work suggests 
that diazetidines without a carbamate group are more prone to decomposition 
than those that possess one. 
Scheme 3.18 Removal of the Boc group of 202 via TFA salt 401•2TFA. 
 The TFA salt proved prone to decomposition when stored at room 
temperature for prolonged periods. The decomposition product could possibly 
be from C-N bond cleavage, as shown by the 1H NMR of partially decomposed 
401•2TFA which suggests a linear amine has been formed (Figure 3.4). 
However, we were unable to isolate and characterise the compound, so the exact 
structure has not been conclusively determined.  
 
Figure 3.4 NMR of 401•2TFA at t = 26 d. Marked peaks show the newly formed product. 
Attempts to obtain a crystal structure of amine 401 were not successful, 
however a structure for 401•2TFA was successfully acquired. This showed that 
two TFA molecules co-ordinate to the diazetidine (Figure 3.5), which is unusual 
as normally only one TFA anion co-ordinates to the amine. As one of the 
nitrogen’s is now an ammonium salt measuring information about the 
conformation of this substrate is less meaningful. We cannot measure a 
meaningful torsion angle for this example as the amine is quaternised, however 
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we can see that for this example the extent of pyramidisation for the other 
nitrogen is significantly lower than for diazetidines 275 and 212. 
 
Figure 3.5 Crystal structure of 401•2TFA. 
Functionalisation of these diazetidines proved to be a significant challenge. 
Initially, we attempted a simple tosylation reaction to give orthogonally 
protected diazetidine 402. The yield, however, was modest for this 
transformation (Scheme 3.19).  
 
Scheme 3.19 Tosylation of 399 to give 402. 
Next, we attempted an SNAr reaction to install a pyridine or pyrimidine 
substituent. Despite trying different combinations of bases and solvents we were 
unable to isolate 403 (Table 3.2). Initially we used mild conditions based on 
similar work on the SNAr of an azetidine substrate.
119 These conditions however 
were not successful and such mild conditions are typically not used for SNAr 
reactions (entries 1 and 2), with starting material recovered in both cases. Before 
we attempted further transformations, a test reaction from the literature was 
performed, the reaction of 2-chloropyrimidine and diethylamine.120 The 
conditions in entry 3 gave the expected product in 80% yield. However, this did 
not translate successfully to the diazetidine and instead led to a complex mixture 
of products. The use of other conditions also led to the formation of complex 




Entry X Base Solvent t / h T / °C Result 
1 C Na2CO3 1,2-DCE 12 rt 398  
2 C CsF CH3CN 24 rt 398  
3 N CsF CH3CN 8 75 Mixture 
4 N CsF DMSO 24 rt Mixture 
5 N CsF DMSO 24 75 Mixture 
6 N CsOAc DMSO 24 90 Mixture 
Table 3.2 Attempted SNAr using 398 to give 403. 
Further development of the SNAr reaction with cyclic hydrazines was 
undertaken by MChem student Scott Phillips during his research project within 
the group. He used pyrazolidine 308 as his starting point as we believed this 
would be more stable and less prone to decomposition than a diazetidine under 
the harsh SNAr conditions. He was ultimately unsuccessful, despite trying a 
wider range of substrates and conditions than those reported above. 
We were however able to react amines 401 and 398 with phenylisocyanate, 
which gave 404 and 405 in good yield (Scheme 3.20). Although 
phenylisocyanate is a particularly reactive electrophile it was still encouraging 
to see that it is possible to functionalise deprotected diazetidines effectively. 
 
Scheme 3.20 Reaction of 401 and 398 with phenylisocyanate to give 404-405. 
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Attempted removal of the Ts group from 404 using magnesium in methanol 
was unsuccessful, leading to a complex mixture of products. Similarly, attempts 
to remove the Boc group of 405 were also unsuccessful (Scheme 3.21).   
 
Scheme 3.21 Attempted deprotection of 404 and 405. 
3.5 Functionalisation of C3-Substituted Diazetidines 
After some promising preliminary results for the deprotection and 
functionalisation of unsubstituted diazetidines, we next turned to the C3-
substituted diazetidines, which were expected to be amenable to similar 
synthetic strategies. Initially, we focused on Cbz and Ts protected diazetidine 
280 as most of our available substrates had this combination of protecting 
groups. However, this proved to be a poor choice, as it was for pyrazolidine 306, 
as neither the Ts or the Cbz group could be cleanly removed (Scheme 3.22). 
Using palladium on carbon to remove the Cbz group by hydrogenation to 407 
proceeded extremely slowly, even with 100 weight% loadings of palladium on 
carbon. Using magnesium in methanol removed the Ts group again led to the 
transesterification of the Cbz group, forming a mixture of 408 and 409. The ratio 
depended strongly on reaction time, but at a reaction time of 30 minutes methyl 
ester 409 was still seen as a 10% impurity and at long reaction times of 24 hours 
this increased to approximately 50%. Neither compound could be cleanly 




Scheme 3.22 Attempted deprotection of 280. 
Given the results we had previously obtained for the pyrazolidine examples 
(Scheme 3.2) we decided instead to focus on diazetidine 212, which had Ts and 
Boc protecting groups. Removal of the Ts group on this substrate proceeded 
without issue to give amine 410 in near quantitative yield (Scheme 3.23). 
 
Scheme 3.23 Ts removal on 212 to give 410. 
Optimisation of this cross coupling proved to be challenging (Table 3.3). The 
protecting groups on diazetidine 212 are transposed relative to those of 
pyrazolidine 308, so this cross coupling is on the more hindered nitrogen atom. 
We screened a variety of catalysts, ligands, bases and solvents, and initial 
analysis of the crude reaction mixtures by GCMS showed two promising results 
(entries 1 and 4). Both GCMS traces showed only one significant peak which 
had a mass corresponding to 411, however when isolation was attempted the 
yield never surpassed 41%. This is possibly due to decomposition of amine 410 
into smaller and more volatile components under the harsh reaction conditions. 
Volatile compounds would elute during the void time at the start of the GCMS 
run so would not be observed in the trace. It is also possible that polymeric by-
products were formed, which would not be sufficiently volatile to be observed. 
Palladium acetate and Xantphos with sodium tert-butoxide had been particularly 
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effective previously, and again they were the best conditions that we identified, 
although the isolated yield was significantly lower here.  
 
Entry Conditions Result 
(%Yield) 
1 Pd(OAc)2, Xantphos, NaOtBu, toluene 411 (41) 
2 Pd(OAc)2, Xantphos, Cs2CO3, toluene Complex mix 
3 Pd(OAc)2, Xantphos, NaOtBu, dioxane Complex mix  
4 Pd2(dba)3, Xantphos, NaOtBu, toluene 411 (35) 
5 Pd(OAc)2, tBuXphos, NaOtBu, toluene Complex mix 
6 Pd(OAc)2, Johnphos, NaOtBu, toluene Complex mix 
7 Pd(OAc)2, dppf, NaOtBu, toluene Complex mix 
8 Pd(OAc)2, dppf, Cs2CO3, toluene Complex mix 
9 Pd2(dba)3, dppf, Cs2CO3, dioxane Complex mix 
Table 3.3 Optimisation of the Buchwald-Hartwig coupling of 410. 
Next, we explored the removal of the Boc group. This proved to be 
surprisingly challenging, with decomposition when we attempted to isolate 
either 412•TFA or the amine 412 after treatment with saturated sodium hydrogen 
carbonate solution (Scheme 3.24). In contrast, diazetidine 413, which was 
synthesised using the same methodology was sufficiently stable to be 




Scheme 3.24 Synthesis of 411 and 413 and attempted deprotection to their TFA salts. 
Subjecting glycidyl phenyl ether substituted diazetidine rac-218 to the cross 
coupling conditions yielded rac-415, in a very modest 12% yield over 2 steps 
(Scheme 3.25). Further attempts to optimise this reaction were not attempted. 
 
Scheme 3.25 Cross coupling of rac-218 to give rac-415. 
We were also able to functionalise rac-218 by reductive amination with 
isobutyraldehyde to give rac-416, again in modest yield. Curiously, the same 
transformation was not successful using diazetidine 212, the expected mass of 
417 was seen on LCMS, but we were unable to isolate it (Scheme 3.26). 
 
Scheme 3.26 Reductive amination of rac-218 and 212. 
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Attempts to deprotect rac-415 and rac-416 were not successful with HCl in 
dioxane, and instead led to the formation of complex mixtures of by-products 
(Scheme 3.27). 
 
Scheme 3.27 Attempted deprotection of rac-415 and rac-416. 
3.6 Conclusions 
We have shown that it is possible to derivatise a selection of the cyclic 
hydrazines synthesised in Chapter 2, by employing a sequential deprotection and 
functionalisation strategy involving the removal of Boc and Ts groups. This was 
achieved on of the ring sizes we synthesised and was also shown to be tolerant 
of changes to the C3 aryl group. Overall we synthesised fourteen examples, 
twelve of which had two functional groups installed sequentially and two of 
which had one functional group installed and the second protecting group 
removed (Scheme 3.28). We succesfully used three common nitrogen 
functionalisation chemistries: Buchwald-Hartwig cross coupling, reductive 
amination and acylation reactions. These were all chosen as they are frequently 
used in the synthesis of lead compounds in medicinal chemistry. 
 
Scheme 3.28 Summary of functionalisation reactions for 5-7 membered cyclic hydrazines. 
We extensively optimised the Buchwald-Hartwig coupling of the less 
hindered nitrogen of 308 by employing a high throughput screen (Scheme 3.1), 
we were then able to synthesise six cross coupled products in yields of up to 95% 
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(Scheme 3.3). Further optimisation was required for the cross coupling of 
biphenyl substituted pyrazolidine 312, but this could also be achieved in an 86% 
yield (Scheme 3.7). 
Additionally, functionalisation by using reductive aminations and acylations 
were also shown to be effective methods for introducing substituents on to the 
nitrogen. Generally these reactions required little optimisation and the 
transformations were achieved in up to 76% yields for reductive amination 
(Scheme 3.8) and up to 80% for acylation (Scheme 3.9).  
Functionalisation of the more hindered nitrogen was a greater challenge, as 
the free amine was not stable for all pyrazolidines tested and underwent 
spontaneous oxidation to form the undesired achiral imine. It was found that by 
synthesising the HCl or TFA salt, followed by subsequent acylation in the 
presence of base that the desired pyrazolidines could be obtained in yields of up 
to 84% (Schemes 3.10-11). Buchwald-Hartwig coupling required further high 
throughput optimisation (Figure 3.3), but Pd-180 catalyst delivered yields of up 
to 80% (Scheme 3.14).  
Functionalisation of diazepines and hexahydropyridazines was achieved 
using broadly similar methods and with similar yields, with eight examples 
synthesised (Scheme 3.15). They were also found to be stable as unprotected 
amines 393 and 397. 
Functionalisation of diazetidines 212 and 218 was achieved by using cross 
couplings (Schemes 3.24-3.25) and 218 was functionalised by reductive 
amination (Scheme 3.26). Additionally, 198 and 202 could be condensed with 
isocyanates (Scheme 3.20). Attempted deprotections on these 
monofunctionalised substrates was unsuccessful (Scheme 3.27 and Scheme 
3.21). It is likely these systems were particularly problematic due to the ring 
strain inherent in these systems, however full characterisation of the by-products 
makes it hard to analyse exactly what processes are compromising the 




Chapter 4: Structure & Dynamics of Cyclic Hydrazines 
4.1 Crystal Structures of Cyclic Hydrazines 
With the synthesis of a diverse library of cyclic hydrazines explored, we next 
intended to undertake further analysis to determine their conformation both in 
solution and solid state, and their dynamics in solution. Based on previous work 
in the group,39 and previous published work (see section 1.9), we hypothesised 
that C3-substituted cyclic hydrazines would have a strong preference for 
anti,anti-187 over the other three possible conformations (Figure 1.17). 
We initially used XRD to determine the structures of diazetidine 275, 
pyrazolidines 309, 377 and 380, hexahydropyridazine 422 and diazepine 396 
(Figure 4.1). This allowed us to gain detailed information about the precise 3D 
structure of these compounds in the solid state. These six examples were chosen 
because they are representative for cyclic hydrazines of different ring sizes 
containing an array of different functional groups. They were also chosen as they 
were sufficiently crystalline to be analysed by XRD, which not all members of 





Figure 4.1 Crystal structures of cyclic hydrazines 275, 309, 377, 380, 422 and 396. 
As hypothesised all of these cyclic hydrazines adopted an anti,anti 
conformation in the solid state, regardless of ring size and functional groups. We 
were also able to determine other parameters using the crystal data including the 
extent of nitrogen pyramidisation. Unsurprisingly, smaller rings tended to have 
larger angles and hence more nitrogen sp3 character, although substituent effects 
were also significant (particularly amide substituents which unsurprisingly 
displayed minimal sp3 character). The pyrazolidines tend to have larger torsion 
angles between the nitrogen substituents 
4.2 PMI Plots of Cyclic Hydrazine Libraries 
We next turned to computational methods to analyse the library. This enabled 
us to analyse our entire library of functionalised cyclic hydrazines 
simultaneously (Figure 4.2), which we hoped would allow us to gather 
complementary structural data and fresh insights. It also meant we could analyse 
the shapes of compounds that we had not actually synthesised. To analyse this 
library of cyclic hydrazines we used LLAMA, which is software developed by 
the Nelson group at the University of Leeds.121 This software was specifically 
designed to analyse the suitability of a compound in drug discovery programs, 
and it does this in two ways. Firstly, it assesses the ‘lead-likeness’ of all 
compounds in a library, which is done by assigning penalties for parameters like 
cLogPviii and  the number of heavy atoms. Secondly, it generates PMI data which 
 
viii LogP is the logarithm of the partition coefficient of a compound between n-
ocatnol and water, also known as lipophilicity or hydrophilicity. cLogP is a 
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provides information about the 3D conformation. Of these we were mainly 
interested in the latter, as we had designed the library primarily to generate 
diverse 3D structures and not for lead-likeness. Most of the compounds are not 
defined as lead-like, we were however gratified to observe that only three of the 
cyclic hydrazines do not obey Lipinski’s rule-of-five (394, 395 and 396).122 
 
Figure 4.2 Library of cyclic hydrazines used for computational analysis. 
 
computed version of this partition coefficient, which can be calculated using a 
variety of computational methods. 
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To calculate the PMI plot, the ground state conformer is generated using the 
program CORINA,123 which has been designed to handle a broad range of 
organic molecules, and is widely used by pharmaceutical and chemical 
companies. From these structures the lowest energy conformer was taken and 
the moments of inertia along the x, y and z axes were calculated by the 
programme. The PMI I1 coordinates were calculated by dividing inertia (x) by 
inertia (z), while PMI I2 coordinates were calculated by dividing inertia (y) by 
inertia (z). This calculated data was exported from LLAMA and processed using 
Microsoft Excel to generate the PMI plot of the structures (Figure 4.3). 
 
Figure 4.3 PMI plot of cyclic hydrazine library, mean PMI indicated (◆). 
Significant shape diversity was observed in across the library, furthermore, 
no molecules were found on the left axis – which is where flatter molecules are 
found (Figure 1.2). Having grouped the data by ring size, no clear trends were 
observed, which given the modest size of the library is not surprising. Substituent 
effects should generally be pronounced in this type of analysis as the moments 
of inertia are heavily biased by heavy atoms. Our findings reveal that significant 
shape diversity can be introduced into the library by varying the four synthetic 
parameters (aryl substituent, ring size and both nitrogen substituents).  
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The LLAMA software also produced 3D representations of the molecules in 
the library, which we visualised with Mercury. This allowed us to compare the 
agreement between computational and XRD data. For diazetidine 275 and 
hexahydropyridazine 422, overlap between the structures was good (Figure 4.4).  
 
Figure 4.4 Comparison of XRD and computed structures for 275 and 422. To generate this 
figure, atoms N1 and C3 of the ring are overlaid. 
Other examples displayed weaker correlation between solid-state and 
computational structures. These included pyrazolidine 377 and diazepine 396 
(Figure 4.5), although both computed and solid-state structures did adopt an anti, 
anti conformation. It is not clear if 5/7-membered rings are generally modelled 
worse by the software or if it is simply coincidence these compounds are worse. 
 
Figure 4.5 Comparison of XRD and computed structures for 377 and 396. 
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Next, we expanded our LLAMA analysis to virtual libraries based on the 
cyclic hydrazine scaffolds. Each of the four previously synthesised ring sizes 
with an (R)-phenyl substituent were inputted and automatically functionalised 
on one or both nitrogen atoms with a variety of substituents, using reductive 
aminations, cross-couplings and acylations – as these has been used in the 
synthesis of our mini library. Each of the four libraries contained 256 unique 
functionalised cyclic hydrazines with the same set of substituents introduced 
across each ring size. Analysis of the average shape across the four ring sizes 
(Figure 4.6) provides evidence that larger ring sizes generally have increasingly 
spherical shapes across the series from 4- to 6- membered rings. This trend does 
not continue for 7-membered rings, suggesting that shape diversity does not 
increase significantly beyond 6-membered rings. 
 
Figure 4.6 Mean PMI of computed cyclic hydrazine libraries (n = 256). 
The difference between the averages is caused by greater shape diversity in 
the libraries of the larger ring sizes (Figure 4.7). In the diazepine library there 
are still a number of linear and disc-like compounds, but far more are seen in the 
spherical section (adamantyl-like) part of the PMI plot. Clearly the larger ring 




Figure 4.7 PMI plots of the four libraries analysed. 
4.3 NOESY and VT NMR Analysis of Cyclic Hydrazines. 
To gather information about the structure of these cyclic hydrazines in 
solution, we turned to NMR spectroscopy. We anticipated that this would allow 
us to gather solution state structural insights using NOESY and would also allow 
us to study the fluxional behaviour using VT NMR. The first substrate we 
studied was pyrazolidine 377, which adopts the anti,anti conformation in the 
solid state (Figure 4.1). The substrate has sufficient numbers of hydrogens close 
to the branch points of the substituents to give us a good chance of observing 
NOE’s between them. Complete assignment of the spectrum in CDCl3 at 298 K 
had already been completed after the synthesis (Figure 4.8) so initially NOESY 
experiments were measured under these conditions. Assignment of H8, H10, H11 




Figure 4.8 1H NMR (600 MHz, CDCl3, 298 K) of 377 with assignments. 
Next, the NOESY spectrum was acquired with a mixing time of 0.9 s and 
several informative NOE’s were observed, including from H2 to H7 and H4 to 
H12 (Figure 4.9). Although these NOE’s provide strong evidence for the anti 
relationship of the phenyl substituent relative to the the para-methoxybenzoyl 
substituent, no NOEs were observed from any of the pyridine protons (H1, H3, 
H5 and H6), which means that the position of the pyridine substituent could not 
be determined. Perhaps H8 is closest to the pyridyl ring, and since it is extremely 




Figure 4.9 NOESY NMR (600 MHz, CDCl3, 298 K) of 377, 0.9 s mixing time. 
To obtain a sharper spectrum of 377, we used d6-DMSO as the solvent. A 
sharper spectrum was observed at 333 K. However, the NOESY spectrum did 
not reveal any new information, as cross peaks from the pyridine hydrogens still 
were not seen. 
Next, we cooled the sample down in order to see if we could freeze out the 
two or more conformers that were causing the peak broadening at 298 K. At 233 
K in CDCl3 the spectrum cleanly resolved into two isomers, in a ratio of 56:44, 
which could be further assigned using COSY and NOESY spectra (Figure 4.10). 
There are two possible explanations for the observation of isomers here, they 
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either arise from slow interconversion of two isomers arising from nitrogen 
inversion or amide bond rotation. 
 
 
Figure 4.10 1H NMR (600 MHz, CDCl3, 233 K) of 377 with assignments. 
The NOESY spectrum was recorded at 233 K, with mixing times of 0.3 s and 
0.6 s. With the 0.3 s mixing time, interconversion between isomers did not occur, 
making it possible to observe cross peaks for individual isomers. From this 
spectrum an interesting NOE was observed between H2 and H8, which was only 




Figure 4.11 NOESY NMR (600 MHz, CDCl3, 233 K) of 377, 0.3 s mixing time. 
This does not determine what the minor isomer is, as in both possible isomers 
you would not expect and NOE between H2 and H8. Again, no NOE’s were seen 
from any of the pyridine protons. Increasing the mixing time to 0.6 s showed an 
NOE between H4 and H5, which suggests the pyridine and phenyl rings are on 
the same face. However, at this longer mixing time interconversion between 
isomers is seen, making it impossible to tell if the NOE was only occurring in 
the major isomer or if it occurred in the minor isomer as well. This means it was 
not possible to conclusively determine from this which minor isomer was 
present.  
As we had an interconverting pair of isomers in an unequal proportion it was 
possible to determine the barrier to their interconversion. To do this we acquired 
1H NMR spectra from 223 K to 293 K in 10 K increments (Figure 4.12). This 




Figure 4.12 1H NMR (600 MHz, CDCl3) of 377 from 223 K to 293 K. 
From this we estimated the temperature of coalescence (TC) to be 258 K. In 
order to determine the barrier to inversion we used Eyring’s equations, modified 
by Shanan Atidi and Bar-Eli124 to account for the unequal proportion of isomers 
(Equation 1): 
𝛥𝐺𝐴








R = 4.57 cal mol-1 K-1, TC = 258 K, Δυ = 30 Hz (peak difference is 0.05 ppm 





‡ = 12.9 𝑘𝑐𝑎𝑙 𝑚𝑜𝑙−1 = 54.1 𝑘𝐽 𝑚𝑜𝑙−1 
Barriers to N-inversion in cyclic hydrazines are typically higher than this 
(Section 1.10). Amide bond rotation is generally a lower energy process in cyclic 
hydrazines than nitrogen inversion, as shown by Lehn and Anderson in their 
studies of tetrahydropyridazines.125 This means that the relatively low barrier to 
inversion seen here suggests this is the more likely explanation for the origin of 
the two isomers. The error associated with this measurement is relatively small 
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at ± 1.0 kJ mol-1 for the coalescence temperature (with a lower bound of 253 K 
and an upper bound of 263 K for coalescence). There is also an error from the 
temperature reading of the spectrometer, however this will be significantly 
smaller than 5 K so it is insignificant compared with the Tc error. 
Next, we analysed cyclic hydrazine 380, to try and get clear NOESY data that 
would demonstrate than an anti,anti conformation is being adopted in solution. 
The challenge with this substrate is that the protons on the iso-butyl substituent 
and the protons on the hydrazine ring (H9/H10 and H7/H8) are in very similar 
chemical environments. After some experimentation we determined that CDCl3 
and d6-acetone were unsuitable to resolve these signals, but d6-benzene at 343 K 
gave a well resolved spectrum. Only one set of signals are observed under these 
conditions so either fast exchange is occurring or there is a single conformation 
(Figure 4.13).   
 
Figure 4.13 1H NMR (500 MHz, d6-benzene, 343 K) of 380 with assignments. 
The NOESY spectrum (0.6 s mixing time) showed several important NOE’s. 
An NOE between H6 and H8 indicated that they are on the same face of the 
molecule (Figure 4.14). An NOE was also observed between H8 and H2, which 
shows that they are also on the same face. Taken together, this implies that H6 




Figure 4.14 NOESY NMR (500 MHz, d6-benzene, 343 K) of 380, 0.6 s mixing time. 
This spectrum also provided evidence for the positioning of the iso-butyl 
substituent, with NOE’s seen from H3 of the phenyl to H9 and possibly to H10 
(Figure 4.15). 
 
Figure 4.15 NOESY NMR (500 MHz, d6-benzene, 343 K) of 380, 0.6 s mixing time. 
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Taken together this gives clear evidence that 380 is in the anti,anti 
conformation in solution, under these experimental conditions. Analysis of 380 
at low temperature revealed one major and two minor isomers seen at 233 K in 
both CDCl3 and d6-acetone in an 84:11:5 ratio (Figure 4.16). Observation of two 
minor isomers suggests that at least one minor invertomer is present, if we 
assume one is derived from amide bond rotation. Therefore, other N-invertomers 
are energetically accessible, at least for this system. Attempts to analyse the 
NOESY spectrum acquired at 233 K were not fruitful. 
 
Figure 4.16 1H NMR (500 MHz, CDCl3, 233 K) of 380, showing H6 only. 
4.4 Conclusions 
We have tested the hypothesis that 3-substituted cyclic hydrazines have a 
strong preference for the anti,anti conformation. XRD analysis of six cyclic 
hydrazines showed that this was adopted universally across all four ring sizes 
synthesised and regardless of which substituents were present. The crystal data 
also showed the unusually high extent of nitrogen pyramidisation in several 
examples (275, 309 and 377), suggesting the conformational restraints imposed 
by the system are overcoming the normally strong preference for sp2 hybridised 
amide bonds. 
Computational analysis using LLAMA generated a PMI plot of the library of 
synthesised cyclic hydrazines. This showed the library we had synthesised 
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contained significant shape diversity and did not contain any molecules that are 
defined as flat by PMI analysis. Further analysis of virtual larger libraries 
generated by the program of phenyl-substituted diazetidines, pyrazolidines, 
hexahydropyridazines and diazepines revealed that shape diversity increases 
with ring size, up to 6-membered rings, after which no notable increase is 
observed. Even for the 4- and 5-membered rings, the libraries still display 
significant shape diversity and access a large amount of chemical space. 
Analysis using NOESY showed that cyclic hydrazine 380 adopted an 
anti,anti conformation in solution, confirmed by key NOE’s between the 
nitrogen substituents and the hydrogens on the ring. Low temperature NMR 
analysis of this compound showed it existed as three isomers in an 84:11:5 ratio, 
however resolving the structure of these compounds was not possible. NMR 
spectra of 377 at low temperature only showed two isomers, in a 56:44 ratio. 
Further analysis by VT NMR and NOESY strongly suggested that these were 
amide bond rotamers and not invertomers from N-fluxionality. The barrier to 
inversion was found to be 54 kJ mol-1, which provided further evidence that 




Chapter 5: Future Work 
Further diversification of the aryl group would also allow us to incorporate 
more substituents at the C3-position. The ability to incorporate a carboxylic acid 
functionality would be particularly useful, as this structural feature is seen in a 
number of cyclic hydrazine containing natural products (Figure 1.3). This could 
potentially be achieved by oxidation of the aryl group using ruthenium tetroxide, 
which has been shown to be an effective oxidising agent for this 
transformation.126-128 This synthetic methodology is currently being optimised 
by other members of the group, with pyrazolidine 308 chosen initially as the test 
substrate (Scheme 5.1).  
 
Scheme 5.1 Proposed synthesis of carboxylic acid 423. 
It would also be desirable to further optimise the synthesis of diazetidines, 
particularly with alternative deprotection and functionalisation strategies. The 
orthogonal deprotection and functionalisation strategy attempted in chapter 3 
was only partially successful with the synthesis of 414. In order to develop this 
further it would be necessary to develop an alternative strategy, possibly by 
exploiting the regioselective protection of 2-hydrazineylethan-1-ol to form 196 
(Scheme 3.1) to install functional groups instead of protecting groups to give 
424 (Scheme 5.2). This could then be cyclised using the Mitsunobu reaction to 
give functionalised diazetidine 425, providing R2 is not a carbamate.  
 
 
Scheme 5.2 Proposed synthesis of 425. 
121 
 
These libraries would not contain a chiral centre, which would obviate the 
need for an enantioselective synthetic methodology to be developed. There is 
also evidence from LLAMA that these libraries would not need a substituent at 
C3 to have a diverse range of PMI co-ordinates (Figure 5.1). Although some 
examples are clearly flat, there are a number of much more 3D examples, and 
LLAMA could be used to identify and target them. 
 
Figure 5.1 PMI plot of computed diazetidine library (n = 96), mean PMI indicated (◆). 
This can also be seen when the same analysis is conducted on a 
hexahydropyridazine scaffold (Figure 5.2). As we previously observed for the 
phenyl substituted libraries (Section 4.2) there is a difference between the 




Figure 5.2 PMI plot of computed hexahydropyridazine library (n = 96), mean PMI indicated 
(◆). 
Devising a synthetic methodology which did not require the use of the 
Mitsunobu reaction would be beneficial, as it has poor atom economy, requires 
large amounts of solvent and made purification challenging. This could 
potentially be achieved by synthesising cyclic hydrazones and reducing them 
asymmetrically to the corresponding hydrazines. We have carried out some 
initial studies on hydrazone 426,129 however our previously developed ATH 
methodology with catalysts 233, 243-248 was ineffective (Scheme 5.3).  
 
Scheme 5.3 Attempted synthesis of amine 427 from hydrazone 426. 
Another possible synthetic strategy we have recently considered is using C-
H activation to install substituents at the 3-position of the hydrazine ring, 
converting 428 to 429. This would potentially allow the introduction of a more 
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diverse range of substituents to the library, and it could also be used to introduce 
a second substituent to our existing cyclic hydrazine building blocks 430 
diastereoselectively to give 431 (Scheme 5.4).  
 
Scheme 5.4 Proposed functionalisation of cyclic hydrazines via C-H activation. 
There has been significant recent interest in C-H activation,130 and a number 
of these could feasibly be applicable to cyclic hydrazines. Recent approaches 
include photocatalytic methods from MacMillan131 and Doyle,132 and directing 
group based chemistry from Yu,133, 134 all of which utilise cyclic amines as 
substrates. We felt however that the recent work of Seidel et al. outlined a 
strategy that had the greatest potential for our substrates.135 They were able to 
functionalise a broad range of cyclic N-H amines 432 by deprotonation, followed 
by addition of a hydride acceptor and then the addition of an organolithium 
nucleophile to give 436. They showed that this methodology was applicable to 
a broad range of amines and was compatible with a wide range of readily 
available organolithium reagents (Scheme 5.5). 
 
Scheme 5.5 Synthesis of functionalised cyclic amines by Seidel et al.135 
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Applying this to cyclic hydrazines would be a highly complementary 
approach to the ones outlined in this thesis. It would allow us to introduce 
substituents at the 3-position, although this would not be enantioselective. In a 
subsequent paper they showed that the scope of this chemistry could be 
expanded to include alkynes, indoles and benzofurans, which we have not yet 
incorporated into cyclic hydrazine scaffolds.136  
Due to time constraints, the synthesis of RipK1 inhibitor 337 could not be 
completed, however further investigation is currently underway within the 
group. Current investigations are focused on replacement of the Ts group with a 




Chapter 6: Experimental 
General Experimental 
All reactions were performed under an atmosphere of nitrogen in oven-dried 
glassware unless otherwise stated. Anhydrous solvents were purchased from 
Sigma-Aldrich or Acros Organics in Sure-SealTM bottles for use as reaction 
solvents. All other solvents were reagent grade and used as received. Petroleum 
ether refers to the fraction that boils in the range 40-60 °C. Commercially 
available starting materials were used without purification. 
TLC was performed on pre-coated aluminium-backed plates (Merck Silicagel 
60 F254), visualised by UV 254 nm then stained with phosphomolybdic acid 
(PMA) dip. Flash column chromatography was performed using Aldrich 40-63 
µm Silica Gel. 
Nuclear magnetic resonance (NMR) spectra were recorded on Bruker DPX 
(300 or 400 MHz) or AV (500 MHz, 600 MHz) spectrometers. Chemicals shifts 
(δ) are reported in parts per million (ppm) relative to the solvent residual peaks 
(CDCl3 δH: 7.26 ppm, δC: 77.16 ppm; DMSO-d6 δH: 2.50 ppm, δC: 39.52 ppm). 
Coupling constants (J) are reported in Hertz (Hz). Splitting patterns are 
abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet (q), multiplet 
(m), broad (br), or some combination of these. 
Low-resolution mass spectra were recorded on an Agilent Technologies 6130 
Quadrupole LC-MS instrument. High-resolution mass spectra were recorded 
using a Bruker MaXis Impact. Infrared spectra were recorded on a Perkin Elmer 
Spectrum 100 FT-IR spectrometer and are given in cm-1. Melting points were 
recorded with a Gallenkamp MPD350 apparatus and are reported as observed. 







dicarboxylate (197) 19684 (7.90 g, 25.0 mmol, 1.0 equiv), 
triphenylphosphine (7.88 g, 30.0 mmol, 1.2 equiv), imidazole (2.55 g, 37.5 
mmol, 1.5 equiv.) and iodine (7.62 g, 30.0 mmol, 1.2 equiv) were combined in 
THF (50 mL) to give a purple solution which was stirred for 1 h. Saturated 
sodium sulphite solution (50 mL) was then added which gave a pale yellow 
solution that was stirred for 10 min. The layers were separated, and the aqueous 
layer was extracted with ethyl acetate (3 x 10 mL), then the combined organic 
phases were washed with brine (20 mL), dried over Na2SO4 and concentrated in 
vacuo to give a yellow oil. Purification by column chromatography on silica gel 
(8:1 petroleum ether:ethyl acetate) gave 197 as a dark yellow oil (7.21 g, 17.3 
mmol, 69%); Rf 0.14 (12% EtOAc in petroleum ether);  IR (film) 3290, 2980, 
1704, 1434, 1149; 1H NMR (500 MHz, CDCl3) δH 7.38 (5H, m, Ar-H), 5.20 
(2H, s, CH2Ph), 3.86 (2H, br m, CH2N), 3.32 (2H, br m, CH2I), 1.45 (9H, br s, 
C(CH3)3); 
13C NMR (125 MHz, CDCl3) δC 152.8 (C=O), 133.8 (Ar-C), 126.9 
(Ar-CH), 126.9 (Ar-CH), 66.2 (CH2), 51.2 (CH2), 50.4 (CH2), 26.4 (CH3), 1 Ar-





dicarboxylate (198) and tert-butyl 2-
(benzyloxy)-5,6-dihydro-4H-1,3,4-oxadiazine-
4-carboxylate (199) 197 (1.00 g, 2.38 mmol, 1.0 equiv.) and Cs2CO3 (1.55 g, 
4.76 mmol, 2.0 equiv.) were combined in acetonitrile (80 mL) and stirred for 24 
h, at which point the reaction was shown to be complete by TLC. The crude 
mixture was passed through a plug of silica and celite using ethyl acetate as an 
eluent. The resulting liquid was concentrated in vacuo to give a yellow oil (0.68 
g, 98% yield, 50:50 ratio of the two products determined by 1H NMR). The two 
products were separated by column chromatography on silica gel (diethyl ether), 
which gave the 2 desired products, 198 (224 mg, 0.76 mmol, 29%); Rf 0.88 
(diethyl ether); M.p. 88.2-89.7 °C; IR (film) 2974, 2925, 1742, 1713, 1439, 
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1379, 1285, 1118 cm-1; 1H NMR (500 MHz, CDCl3) δH 7.38 (5H, m, Ph, Ar-
H), 5.23 (2H, s, CH2Ph), 4.26 (2H, m, NCH2), 4.20 (2H, m, NCH2), 1.48 (9H, s, 
C(CH3)3); 
13C NMR (125 MHz, CD3CN) δC 161.2 (C=O), 160.3 (C=O), 136.9 
(Ar-C), 129.0 (Ar-CH), 128.7 (Ar-CH), 128.4 (Ar-CH), 81.9 (C), 67.9 (CH2), 
50.0 (CH2), 49.9 (CH2), 27.8 (CH3); HRMS (ESI
+) calculated for C15H20N2O4 
(M+Na)+: 315.1318; found: 315.1315. 
Single crystals of 198 were grown from dichloromethane/petroleum ether (1:9 
ratio). A suitable crystal was selected and mounted on a glass fibre with 
Fromblin oil and placed on an Xcalibur Gemini diffractometer with a Ruby CCD 
area detector. The crystal was kept at 150(2) K during data collection. Using 
Olex2, the structure was solved with the ShelXT structure solution program 
using Intrinsic Phasing and refined with the ShelXL refinement package using 
Least Squares minimisation. 
Crystal Data for 198 (M =292.33 g/mol): monoclinic, space group P21/c (no. 
14), a = 12.0143(2) Å, b = 10.60779(18) Å, c = 12.1452(3) Å, β = 96.0212(15)°, 
V = 1539.31(5) Å3, Z = 4, T = 150(2) K, μ(CuKα) = 0.760 mm-1, Dcalc = 
1.261 g/cm3, 32897 reflections measured (7.398° ≤ 2Θ ≤ 161.944°), 3284 unique 
(Rint = 0.0413, Rsigma = 0.0166) which were used in all calculations. The final R1 
was 0.0402 (I > 2σ(I)) and wR2 was 0.1109 (all data). 
199 (326 mg, 1.11 mmol, 47%); Rf  0.84 (diethyl ether); M.p. 103.5-105.1 °C; 
IR (film) 2998, 2930, 1688, 1654, 1428, 1296; 1H NMR (500 MHz, CDCl3) δH 
7.40 (5H, m, Ar-H), 5.20 (2H, s, CH2Ph), 4.37 (2H, t, J 4.7, NCH2), 3.79 (2H, t, 
J 4.8, NCH2), 1.57 (9H, s, C(CH3)3); 
13C NMR (125 MHz, CDCl3) δC 135.6 (Ar-
C), 128.7 (Ar-CH), 128.4 (Ar-CH), 128.3 (Ar-CH), 81.1 (C), 69.7 (CH2), 65.4 
(CH2), 28.4 (CH3), C=O not seen; HRMS (ESI
+) calculated for C15H20N2O4 
(M+Na)+: 315.1315; found: 315.1315. 
 
tert-Butyl 1-(2-hydroxyethyl)-2-tosylhydrazine-1-
carboxylate (201) 20084 (1.15 g, 6.5 mmol, 1.0 equiv.), 
THF (10 mL), and pyridine (3.25 mL, 39 mmol, 6.0 equiv.) 
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were stirred and cooled with an ice bath. p-toluenesulfonylchloride (1.25 g, 6.5 
mmol, 1.0 equiv.) was added portion wise over 5 min and the solution was stirred 
for a further 10 min. The ice bath was then removed and the resulting pale yellow 
solution was stirred for 3 h. 1 M HCl (10 mL), water (10 mL) and DCM (10 mL) 
were added and the layers were separated. The aqueous was washed with DCM 
(3 x 10 mL) and then the combined organic extracts were dried over MgSO4 and 
concentrated in vacuo to give a pale yellow solid. This was further purified by 
recrystallisation from hot toluene (50 mL) to give 201 as a white solid (1.38 g, 
4.6 mmol, 71%); Rf 0.34 (30% EtOAc in petroleum ether); M.p. 123.3-124.2 °C; 
IR (film) 3385, 3120, 2923, 2875, 1674, 1400, 1337; 1H NMR (500 MHz, 
CDCl3) δH 7.80 (2H, d, J 8.2, Ar-H), 7.32 (2H, d, J 8.2, Ar-H), 3.98 (2H, t, J 
8.0, NCH2), 3.83 (2H, t, J 8.0, CH2OH), 2.41 (3H, s, CH3), 1.40 (9H, s, C(CH3)3); 
13C NMR (125 MHz, CDCl3) δC 145.2 (C=O), 130.0 (Ar-CH), 128.8 (Ar-CH), 
82.9 (C), 60.0 (CH2) 54.0 (CH2), 27.9 (CH3), 21.7 (CH3), 2 Ar-C not seen; 
HRMS (ESI+) calculated for C14H22N2O5S (M+Na)
+: 353.1142; found: 
353.1149. 
 
tert-Butyl 2-tosyl-1,2-diazetidine-1-carboxylate (202) 201 
(0.75 g, 2.30 mmol, 1.0 equiv.), triphenylphosphine (1.52 g, 5.80 
mmol, 2.5 equiv.), and THF (20 mL) were stirred and cooled over an ice bath. 
Diethylazadicarboxylate (0.91 mL, 5.80 mmol, 2.5 equiv.) was added dropwise 
and the resulting pale yellow solution was warmed to rt and stirred for 24 h. The 
solution was then concentrated in vacuo to give a yellow oil, which was purified 
by column chromatography on silica gel (3:1 petroleum ether:ethyl acetate) to 
give 202 as a white crystalline solid (0.59 g, 1.91 mmol, 83%); M.p. 109-110 
°C; IR (film) 2979, 2928, 1712, 1597, 1330, 1305, 1087; 1H NMR (500 MHz, 
CDCl3) δH 7.80 (2H d, J 8.2, Ar-CH), 7.32 (2H, d, J 8.1, Ar-CH), 3.98 (2H, t, J 
8.0, NCH2), 3.83 (2H, t, J 8.0, NCH2), 2.41 (3H, s, CH3), 1.40 (9H, s, C(CH3)3); 
13C NMR (125 MHz, CDCl3) δC 159.1 (C=O), 145.2 (Ar-C), 130.1 (Ar-CH), 
130.0 (Ar-C), 129.6 (Ar-CH), 82.9 (Ar-C), 48.9 (CH2), 47.6 (CH2), 27.9 (CH3), 
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21.7 (CH3); HRMS (ES





phenylethyl)hydrazine-1,2-dicarboxylate (207) Sodium 
hydroxide (170 mg, 4.24 mmol, 1.0 equiv.) was dissolved 
in dichloromethane (10 mL) and water (10 mL), then (Rac)-206 (1.07 g, 4.24 
mmol, 1.0 equiv.) was added. Benzyl chloroformate (0.61 mL, 4.24 mmol, 1.0 
equiv.) in dichloromethane (5 mL) was added dropwise to give a cloudy white 
solution, which was stirred for 22 h. The layers were then separated and the 
organic was washed with water (20 mL) and 1 M HCl (20 mL), then dried over 
Na2SO4 and concentrated in vacuo to give 207 as a white crystalline solid (1.15 
g, 2.98 mmol, 70%), which was essentially pure, however, a small sample was 
recrystallized from hot toluene for analysis. M.p. 141.3-142.5 °C; IR (film) 
3321, 3197, 3029, 2979, 1700, 1223, 1010; 1H NMR (500 MHz, CDCl3) δH 7.36 
(10H, m, Ar-H), 6.66 (1H, br s, NH), 5.13 (2H, m, CH2Ph), 4.91 (1H, m, CHOH), 
3.54 (2H, m, NCH2), 1.37 (9H, br s, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δC 
155.0 (C=O), 140.9 (Ar-C), 128.7 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 
127.6 (Ar-CH), 126.0 (Ar-CH), 125.8 (Ar-CH), 74.0 (C), 71.3 (CH), 68.3 (CH2), 
29.7 (CH2) 28.1 (CH3), 1 C=O and 1 Ar-C not seen; HRMS (ES
+) calculated for 
C21H26N2O5 (M+Na)
+: 409.1734; found: 409.1726.  
 
(Rac)-Benzyl (2-oxo-5-phenyloxazolidin-3-
yl)carbamate (208) (Rac)-207 (1.00 g, 2.71 mmol, 1.0 
equiv) was dissolved in THF (20 mL) and stirred. 
Triphenylphosphine (0.85 g, 3.26 mmol, 1.2 equiv), 
imidazole (0.28 g, 4.05 mmol, 1.5 equiv) and iodine (0.83 g, 3.26 mmol, 1.0 
equiv) were added and the resulting purple solution was stirred for 1 h. Saturated 
sodium sulfite solution (20 mL) was added, which gave a colourless solution and 
the mixture was stirred for a further 10 min. The layers were separated, and the 
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aqueous phase was extracted with ethyl acetate (3 x 20 mL), then the combined 
organic extracts were washed with brine (20 mL), dried over Na2SO4 and 
concentrated in vacuo to give a pale yellow oil. Purification by column 
chromatography on silica gel (1:1 petroleum ether:ethyl acetate) gave 208 (0.43 
g, 1.36 mmol, 42%) as a white crystalline solid. M.p. 128-129 °C; IR (film) 
3227, 1724, 1454; 1H NMR (500 MHz, d6-DMSO) δH 9.90 (1H, br s, NH) 7.42 
(10H, m, Ar-H), 5.69 (1H, t, J 7.1, CHPh), 5.16 (2H, s, CH2Ph), 4.11 (1H, t, J 
8.0, NCHH), 3.63 (1H, t, J 8.0, NCHH); 13C NMR (125 MHz, d6-DMSO) δC 
157.1 (C=O), 155.6 (C=O), 138.7 (Ar-C), 136.5 (Ar-C), 129.5 (Ar-CH), 129.3 
(Ar-CH), 129.0 (Ar-CH), 128.7 (Ar-CH), 128.6 (Ar-CH), 126.9 (Ar-CH), 74.0 
(CH2), 67.0 (CH), 53.0 (CH2); HRMS (ES
+) calculated for C17H16N2O4 
(M+Na)+: 335.1005; found: 335.1002. 
General procedure 1: Ring opening and Boc protection of epoxides 
 
The epoxide (1.0 equiv) was added dropwise to a solution of hydrazine 
monohydrate (10.0 equiv) and anhydrous EtOH (0.1 M), that had been cooled to 
0 °C using an ice bath. The reaction mixture was stirred at 0 °C for 2 h then 
concentrated in vacuo. Anhydrous EtOH (0.1 M) was then added and the 
solution was cooled to 0 °C using an ice bath. Di-tert-butyl dicarbonate (1.0 
equiv) in EtOH (20 mL) was added via syring pump over 2 h. The solution was 
then left to warm to rt adn stirred for 16 h. The crude product was concentrated 
in vacuo then purified by column chromatography (5% MeOH/ CH2Cl2 or 19% 
EtOAc/petroleum ether with 1% Et3N) to give the hydrazine.   
 
(R)-tert-Butyl 1-(2-hydroxy-2-phenylethyl)hydrazine-1-
carboxylate (206) Following general procedure 1, Ethanol (2 
mL), hydrazine monohydrate (4.70 mL, 100 mmol, 10.0 
equiv), (R)-2-phenyloxirane (1.14 mL, 20 mmol, 1.0 equiv) then Ethanol (15 
mL) and di-tert-butyl dicarbonate (4.37 g, 20.0 mmol, 1.0 equiv) gave 206 (3.83 
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g, 15.0 mmol, 75%) as a white crystalline solid. N.B. this was further purified 
by recrystallisation from toluene to give an analytical sample M.p. 101-103 °C; 
[α] 27D
 = - 1.29 (c 0.40, CHCl3); IR (fim) 3411, 3330, 2975, 1660, 1347, 1164; 
1H NMR (500 MHz, CDCl3) δH 7.36 (5H, m, Ar-H), 5.04 (1H, m, CHOH), 4.28 
(1H, s, OH), 4.24 (2H, s, NH2), 3.77 (1H, dd, J 14.4, 7.9, NCHH), 3.62 (1H, dd, 
J 14.4, 7.9, CHH), 1.44 (9H, s, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δC 156.8 
(C=O), 141.9 (Ar-C), 128.4 (Ar-CH), 127.6 (Ar-CH), 125.8 (Ar-CH), 81.2(C), 
76.1 (CH), 74.1 (CH2), 28.3 (CH3); HRMS (ES
+) calculated for C13H20N2O3 
(M+Na)+: 275.1366; found: 275.1365. The racemic compound was synthesised 




Following general procedure 1, hydrazine monohydrate 
(4.86 mL, 100 mmol, 10.0 equiv), ethanol (5 mL), (R)-glycidyl phenyl ether 
(1.35 mL, 10 mmol, 1.0 equiv) then di-tert-butyldicarbonate (2.18 g, 10 mmol) 
and ethanol (6 mL) gave 214 as a colourless oil (1.66 g, 59%); Rf 0.21 (5% 
MeOH/dichloromethane); IR (film) 3332, 2976, 1689, 1495, 1242, 1163, 995; 
[α]32D + 10.9 (c 0.09, CHCl3); δH (500 MHz, CDCl3)  7.30 (2H, t, J 5.0, Ar-H), 
6.97 (1H, t, J 5.0, Ar-H), 6.93 (2H, d, J 8.0, Ar-H), 4.34-4.19 (1H, m, CHOH), 
4.03-3.98 (2H, m, NCH2), 3.94 – 3.57 (5H, m, NH2, OH and OCH2), 1.48 (9H, 
s, CH3).); δC (126 MHz, CDCl3) 158.5 (C=O), 156.9 (Ar-C), 129.5 (Ar-CH), 
121.1 (Ar-CH), 114.5 (Ar-CH), 81.3 (C), 69.9 (CH), 55.1 (CH2), 52.3 (CH2), 
28.3 (CH3); HRMS (ES





yl)ethyl)hydrazine-1-carboxylate (215) Following 
general procedure 1, hydrazine monohydrate (4.50 
mL, 93 mmol, 10.0 equiv.), ethanol (5 mL), 
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naphthyl oxirane (1.59 g, 9.3 mmol, 1.0 equiv) in ethanol (30 mL) then ethanol 
(10 mL) and di-tert-butyldicarbonate (2.23 g, 10.2 mmol) in ethanol (6 mL) gave 
215 as a white solid (1.82 g, 65%). Rf 0.62 (10% MeOH/dichloromethane); M.p. 
89-92 °C; IR (film) 3399, 2972, 1664, 1309, 1161, 1128;  δH (500 MHz, CDCl3) 
7.90-7.84 (4H, m, Ar-H), 7.59-7.40 (3H, m, Ar-H), 5.19 (1H dd, J 7.6, 2.2, 
CHOH), 3.86 (1H, dd, J 14.5, 2.5 Hz NCHH), 3.70 (1H, dd, J 16.0, 6.0, NCHH), 
1.42 (9H, s, CH3); δC (126 MHz, CDCl3) 156.8 (C=O), 139.3 (Ar-C), 133.3 (Ar-
C), 133.0 (Ar-C), 128.1 (Ar-CH), 127.9 (Ar-CH), 127.7 (Ar-CH), 126.1 (Ar-
CH), 125.9 (Ar-CH), 124.7 (Ar-CH), 124.0 (Ar-CH), 81.3 (C), 74.1 (CH), 56.7 
(CH2), 28.2 (CH3); HRMS (ES
+) calculated for  C17H22N2O3Na (M+Na)
+: 




Following general procedure 1, hydrazine 
monohydrate (3.41 mL, 70 mmol, 10.0 equiv), ethanol 
(5 mL), 4-fluorophenyloxirane (960 mg, 7 mmol, 1.0 equiv) in ethanol (5 mL) 
then ethanol (6 mL) and di-tert-butyldicarbonate (1.68 g, 7.7 mmol, 1.1 equiv) 
in ethanol (6 mL) gave 216 as a white solid (1.66 g, 5.7 mmol, 59%). Rf  0.35 
(5% MeOH/dichloromethane); M.p. 131-134 °C; IR (film) 3378, 2978, 1740, 
1666, 1508, 1303, 1164, 1090; δH (500 MHz, CDCl3) 7.37 (2H, dd, J 7.8, 5.8, 
Ar-H), 7.07 (2H, t, J 8.6, Ar-H), 5.00 (1H, dd, J 7.7, 2.1, CHOH), 3.73 (1H, dd, 
J 14.4, 2.6 Hz, NCHH), 3.57 (1H, dd, J 14.4, 7.8, NCHH), 1.48 (9H, s, CH3). δC 
(126 MHz, CDCl3) 162.3 (d, J 239.4, Ar-CF), 156.7 (C=O), 137.6 (d, J = 3.1 
Hz, Ar-C), 127.5 (d, J 8.1 Hz, Ar-CH), 115.3 (d, J 21.4, Ar-CH), 81.4 (C), 73.5 
(CH), 56.6 (CH2), 28.3 (CH3); δF (376 MHz, CDCl3) -115.2 (Ar-F); HRMS 
(ES+) calculated for  C13H19N2O3FNa (M+Na)






yl)hydrazine-1-carboxylate (216a) Following general 
procedure 1, hydrazine monohydrate (1.45 mL, 30 mmol, 10.0 equiv), ethanol 
(30 mL) and (Rac)-1,2-epoxy-5-hexene (0.34 mL, 3.0 mmol, 1.0 equiv) then 
ethanol (30 mL) and di-tert-butyldicarbonate (0.66 g, 3.0 mmol, 1.0 equiv) in 
ethanol (20 mL) gave 216a as a colourless oil (427 mg, 63%); Rf 0.15 (19% 
EtOAc/petroleum ether with 1% Et3N); IR (film) 3367, 3198, 2978, 2932, 1706, 
1451, 1231, 1003; δH (400 MHz, CDCl3)  5.50 (1H, ddt, J 16.9, 10.2, 6.6, 
H2C=CH), 5.01 (1H, dd, J 17.1, 1.4, HHC=CH), 4.94 (1H, d, J 10.0, HHC=CH), 
4.14 (2H, s, NH2), 3.90-3.78 (2H, m, CHOH and OH), 3.50 (1H, dd, J 14.3, 2.3, 
CHHNBoc), 3.32 (1H, dd, J 14.2, 7.6, CHHNBoc), 2.25-2.05 (2H, m, 
CH2CHOH), 1.57-1.45 (2H, m, H2C=CHCH2), 1.43 (9H, s, CH3); δC (100 MHz, 
CDCl3) 156.7 (C=O), 138.3 (H2C=CH), 114.8 (H2C=CH), 81.1 (C), 70.9 (CH), 
54.8 (CH2), 33.8 (CH2), 29.7 (CH2), 28.3 (CH3); HRMS (ES
+) calculated for  
C11H22N2O3 (M+Na)




carboxylate (216b) Following general procedure 1, hydrazine monohydrate 
(1.45 mL, 30 mmol, 10.0 equiv), ethanol (30 mL) and (Rac)-1,2-epoxydodecane 
(0.65 mL, 3 mmol, 1.0 equiv) then ethanol (30 mL) and di-tert-butyldicarbonate 
(0.66 g, 3 mmol, 1.0 equiv) in ethanol (10 mL) gave 216b as a colourless oil 
(270 g, 30%); Rf 0.51 (5% MeOH/CH2Cl2); IR (film) 3372, 3202, 2978, 1706, 
1495, 1289, 1161; δH (400 MHz, CDCl3)  3.88-3.72 (1H, m, CHOH), 3.66-3.49 
(1H, m, CHHNBoc), 3.40-3.25 (1H, m, CHHNBoc), 1.52-1.40 (11H, m, (CH3)3, 
CH2CHOH), 1.32-1.20 (16H, m, (CH2)8), 0.88 (3H, t, J 6.5, CH3); δC (100 MHz, 
CDCl3) 156.9 (C=O), 81.0 (C), 71.4 (CH), 55.0 (CH2), 31.9 (CH2), 29.7 (CH2), 
29.6 (CH2), 29.3 (CH2), 28.3 (CH3), 25.5 (CH2), 22.6 (CH2), 14.1 (CH3); HRMS 
(ES+) calculated for  C17H36N2O3 (M+Na)





carboxylate (216c) Following general procedure 1, hydrazine 
monohydrate (0.26 mL, 8.8 mmol, 10.0 equiv), ethanol (2 mL) 
and cyclohexene  oxide (112 µL, 0.88 mmol, 1.0 equiv) then 
ethanol (10 mL) and di-tert-butyldicarbonate (193 mg, 0.88 mmol, 1.0 equiv) in 
ethanol (10 mL) gave 216c as a colourless oil (150 mg, 0.65 mmol, 74%); Rf 
0.45 (5% MeOH/CH2Cl2); IR (film) 3368, 3198, 2978, 1705, 1364, 1232, 1157, 
995; δH (400 MHz, CDCl3)  6.43 (2H, s, NH2), 3.26-3.15 (1H, m, CHOH), 2.45-
2.33 (1H, m, CHNBoc), 1.98-1.71 (2H, m, CH2CHOH), 1.65-1.58 (2H, m, 
CH2CHNBoc), 1.39 (9H, s, CH3), 1.21-1.10 (4H, m, CH2CH2); δC (100 MHz, 
CDCl3) 158.1 (C=O), 80.8 (C), 71.2 (CH), 65.8 (CH), 33.4 (CH2), 29.2 (CH2), 
28.4 (CH3), 24.8 (CH2), 24.5 (CH2); HRMS (ES
+) calculated for  C11H22N2O3 
(M+Na)+: 253.1523; found: 253.1520. 
 
General procedure 2: Tosyl protection 
 
The hydrazine (1.0 equiv), in THF (0.1 M) and para-toluenesulfonylchloride 
(1.1 equiv) were combined and stirred over an ice bath. Pyridine (5.0 equiv) was 
then added dropwise over 1 minute. After 2 h a mix of 1 M HCl was added, then 
the mixture was extracted with dichloromethane (3 x 10 mL). The combined 
organic extracts were then dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by column chromatography on silica gel (20-40% 
EtOAc/petroleum ether) to give the tosylated product. 
 
(R)-tert-Butyl 1-(2-hydroxy-2-phenylethyl)-2-
tosylhydrazine-1-carboxylate (211) Following general 
procedure 2, 206 (200 mg, 0.79 mmol, 1.0 equiv.), pyridine 
(6 mL) and para-toluenesulfonylchloride (316 mg, 1.66 mmol, 2.1 equiv.) gave 
211 as a white solid (280 mg, 0.67 mmol, 85%); Rf = 0.21 (25% EtOAc in 
petroleum ether); M.p. 138-139 °C; [α]D
28 = - 4.81 (c 0.12, CHCl3); IR (film) 
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3456, 3128, 2975, 1709, 1089; 1H NMR (500 MHz, CDCl3) δH 7.82 (2H, d, J 
8.2, Ar-H), 7.36 (7H, m, Ar-H), 5.17 (1H, dd, J 9.9, 3.6, CHPh), 3.86 (1H, br m, 
NCHH), 3.74 (1H, d, J 9.9, NCHH), 2.44 (3H, s, CH3), 1.18 (9H, br s, C(CH3)3); 
13C NMR (125 MHz, CDCl3) δC 144.6 (C=O), 141.4 (Ar-C), 132.2 (Ar-C), 
132.1 (Ar-C) 130.0 (Ar-CH), 129.8 (Ar-CH), 128.6 (Ar-CH), 128.0 (Ar-CH), 
126.0 (Ar-CH), 82.9 (C), 75.2 (CH), 58.8 (CH2) 27.8 (CH3), 21.6 (CH3); HRMS 
(ES+) calculated for C20H26N2O5S (M+Na)
+: 429.1451; found: 429.1455.  
 
tert-Butyl-(R)-1-(2-hydroxy-3-phenoxypropyl)-2-
tosylhydrazine-1-carboxylate (437) Following 
generalprocedure 2, 214 (660 mg, 2.30 mmol, 1.0 
equiv), THF (25 mL) and para-toluenesulfonylchloride (496 mg, 2.60 mmol, 1.1 
equiv) gave 437 as a colourless oil (807 mg, 79%); Rf 0.28 (33% 
EtOAc/petroleuem ether); IR (film) 3247, 2979, 1704, 1598, 1242, 1089, 1040; 
[α]32D - 19.7 (c 0.23, CHCl3);  δH (500 MHz, CDCl3) 7.82 (2H, d, J  8.2, Ar-H), 
7.41-7.29 (4H, m, Ar-H), 7.00 (1H, t, J 7.3, Ar-H), 6.93 (2H d, J 8.2, Ar-H), 
4.45-4.37 (1H, m, CHOH), 4.24-3.69 (4H, m, OCH2 and NCH2), 2.46 (3H, s, 
CH3), 1.27 (9H, s, CH3); δC (126 MHz, CDCl3) 158.4 (C=O), 144.7 (Ar-C), 
129.6 (Ar-CH), 128.8 (Ar-CH), 121.3 (Ar-CH), 114.6 (Ar-CH), 114.5 (Ar-CH), 
83.0 (C), 69.5 (CH2), 69.0 (CH2), 27.6 (CH3), 21.6 (CH3), 1 CH and 2 Ar-C not 
seen; HRMS (ES+) calculated for  C21H28N2O6SNa (M+Na)





Following general procedure 2, 215 (700 mg, 2.3 
mmol, 1.0 equiv), THF (50 mL) and para-toluenesulfonylchloride (477 mg, 2.5 
mmol, 1.1 equiv) gave 438 as a white solid (166 mg, 16%). Rf 0.47 (33% 
EtOAc/petroleum ether); M.p. 145-147 °C; IR (film) 3471, 2927, 1708, 1672, 
1383, 1155, 1125;  δH (500 MHz, MeOD) 7.94-7.71 (6H, m, Ar-H), 7.60-7.25 
136 
 
(5H, m, Ar-H), 5.15 (1H, s, CHOH), 4.23-3.48 (2H, m, NCH2), 2.41 (3H, s, 
CH3), 1.16 (minor rotamer) and 0.77 (9H, s, CH3); δC (126 MHz, MeOD) 144.1 
(Ar-C), 139.7 (Ar-C), 133.4 (Ar-C), 133.2 (Ar-C), 129.2 (Ar-CH), 128.3 (Ar-
CH), 127.7 (Ar-CH), 127.5 (Ar-CH), 127.2 (Ar-CH), 125.7 (Ar-CH), 125.5 (Ar-
CH), 124.0 (Ar-CH), 81.4 (C), 72.7 (CH), 63.9 (CH2), 26.3 (CH3), 20.1 (CH3), 
1 C=O, 1 Ar-C and 1 Ar-CH not seen; HRMS (ES+) calculated for  
C24H28N2O5SNa (M+Na)




(439) Following general procedure 2, 216 (660 mg, 
2.3 mmol, 1.0 equiv), THF (25 mL) and para-
toluenesulfonylchloride (496 mg, 2.6 mmol, 1.1 equiv) gave 439 as a white solid 
(807 mg, 1.80 mmol, 79%). Rf 0.29 (33% EtOAc/petroleum ether); M.p.157-158 
°C; IR (film) 3455, 3126, 2930, 1709, 1510, 1367, 1224; δH (500 MHz, CDCl3) 
7.81 (2H, d, J 8.2, Ar-H), 7.40-7.32 (4H, m, Ar-H), 7.07 (2H, t, J 8.6, Ar-H), 
5.16 (1H, dd, J 9.1, 3.4, CHOH), 3.75 (2H, m, NCH2), 2.45 (3H, s, CH3), 1.18 
(9H, s, CH3); δC (126 MHz, CDCl3) 162.4 (d, J 252.0, Ar-CF), 144.7 (Ar-C), 
137.1 (Ar-C), 129.6 (Ar-CH), 128.8 (Ar-CH), 127.7 (d, J 8.1, Ar-CH), 115.4 (d, 
J 21.4, Ar-CH). 83.1 (C), 73.8 (CH), 59.1 (CH2), 27.6 (CH3), 21.6 (CH3), 1 C=O 
and 1 Ar-C not seen; δF (376 MHz, CDCl3) -114.5 (Ar-F); HRMS (ES
+) 
calculated for  C20H25N2O5FSNa (M+Na)
+: 447.1360; found: 447.1358. 
 
tert-Butyl-(Rac)-1-(2-hydroxyhex-5-en-1-yl)-2-
tosylhydrazine-1-carboxylate (439a) Following 
general procedure 2, 216a (258 mg, 1.12 mmol, 1.0 equiv), THF (11 mL), para-
toluenesulfonylchloride (235 mg, 1.23 mmol, 1.1 equiv) and pyridine (0.45 mL, 
5.6 mmol, 5.0 equiv) gave 439a as a colourless oil (261 mg, 61%); Rf 0.22 (20% 
EtOAc/petroleum ether); IR (film) 3393, 3179, 2971, 2937, 1707, 1317, 1242, 
977; δH (400 MHz, CDCl3) 7.72 (2H, d, J 8.1, Ar-H), 7.25 (2H, d, J 8.5, Ar-H), 
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5.77 (1H, ddt, J 16.9, 10.2, 6.6, H2C=CH), 4.99 (1H, dd, J 17.1, 1.0, HHC=CH), 
4.92 (1H, d, J 10.1, HHC=CH), 4.01-3.91 (1H, br m, CHOH), 3.62-3.43 (2H, br 
m, CH2NBoc), 2.36 (3H, s, CH3), 2.19 (1H, td, J 14.2, 7.0, CHHCHOH), 2.08 
(1H, td, J 14.8, 7.6, CHHCHOH), 1.46 (2 H, dd, J 14.5, 7.2, H2C=CHCH2), 1.11 
(9H, s, (CH3)3); δC (100 MHz, CDCl3) 155.4 (C=O), 144.5 (Ar-C), 138.1 
(H2C=CH), 129.5 (Ar-CH), 128.7 (Ar-CH), 115.0 (H2C=CH), 82.7 (C), 69.0 
(CH – seen on HSQC), 57.2 (CH2 – seen on HSQC), 33.8 (CH2), 29.7 (CH2), 
27.6 (CH3), 21.5 (CH3), 1 Ar-C not seen; HRMS (ES
+) calculated for  
C18H28N2SO5 (M+Na)




carboxylate (439b) Following general procedure 2 216b (270 mg, 0.85 mmol, 
1.0 equiv), THF (8 mL), para-toluenesulfonylchloride (179 mg, 0.94 mmol, 1.1 
equiv) and pyridine (0.34 mL, 4.3 mmol, 5.0 equiv) gave 439b as a colourless 
oil (162 mg, 40%); Rf 0.33 (30% EtOAc/petroleuem ether); IR (film) 3341, 
2982, 1727, 1694, 1403, 1242, 1129; δH (400 MHz, CDCl3) 7.79 (2H, d, J 7.8, 
Ar-H), 7.31 (2H, d, J 7.9, Ar-H), 4.05-3.93 (1H, m, CHOH), 3.70-3.52 (2H, m, 
CH2NBoc), 2.42 (3H, s, CH3), 1.45-1.39 (2H, m, CH2CHOH), 1.32-1.20 (17H, 
m, (CH3)3, (CH2)4), 1.20-1.12 (8H, m, (CH2)4), 0.89 (3H, t, J 6.5, CH3); δC (100 
MHz, CDCl3) 155.4 (C=O), 144.4 (Ar-C), 137.0 (Ar-C), 129.5 (Ar-CH), 128.7 
(Ar-CH), 82.6 (C), 71.6 (CH), 46.6 (CH2), 34.9 (CH2), 29.6 (CH2), 29.6 (CH2), 
29.6 (CH2), 29.6 (CH2), 29.3 (CH2), 27.6 (CH3), 25.5 (CH2), 22.7 (CH2), 21.5 
(CH3), 14.1 (CH3); HRMS (ES
+) calculated for  C24H42N2O5S (M+Na)
+: 
493.2707; found: 493.2707. 
 
tert-Butyl-(Rac)-1-(2-hydroxycyclohexyl)-2-
tosylhydrazine-1-carboxylate (439c) 216c (108 mg, 0.47 
mmol, 1.0 equiv), THF (5 mL), para-toluenesulfonylchloride 
(99 mg, 0.52 mmol, 1.1 equiv) and pyridine (189 µL, 2.4 
mmol, 5.0 equiv) gave 439c as a white solid (127 mg, 0.33 mmol, 70%); Rf 0.29 
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(20% EtOAc/petroleum ether); M.p. 173-174 °C;  IR (film) 3167, 2941, 1727, 
1699, 1495, 1184; δH (400 MHz, CDCl3) 8.17 (2H, d, J 8.1, Ar-H), 7.64 (2H, d, 
J 8.1, Ar-H), 4.89 (1H, d, J 1.8, CHOH), 4.27-4.18 (1H, m, CHNBoc), 3.75-3.65 
(1H, m, CHHCHOH), 3.60-3.52 (1H, m, CHHCHOH), 2.76 (3H, s, CH3), 2.47-
2.38 (2H, m, CH2CHNBoc), 2.13-2.04 (4H, m, CH2CH2), 1.66 (9H, s, CH3); δC 
(100 MHz, CDCl3) 156.0 (C=O), 144.3 (Ar-C), 135.1 (Ar-C), 129.4 (Ar-CH), 
128.5 (Ar-CH), 82.4 (C), 69.2 (CH), 65.1 (CH), 32.6 (CH2), 27.8 (CH3), 24.8 
(CH2), 24.0 (CH2), 21.5 (CH3); HRMS (ES
+) calculated for  C18H28N2O5S 
(M+Na)+: 407.1611; found: 407.1616. 
 
General procedure 3: Mitsunobu reaction 
 
The hydrazine (1.0 equiv), THF (0.01 M), triphenylphosphine (2.5 equiv) and 
diethylazodicarboxylate or diisopropylazodicarboxylate (2.5 equiv) were 
combined and stirred at rt. After 24 h it was concentrated in vacuo. The crude 
product was purified by column chromatography on silica gel (20-40% 
EtOAc/petroleum ether) to give the cyclised product. 
 
tert-Butyl (S)-3-phenyl-2-tosyl-1,2-diazetidine-1-carboxylate 
(212) Following general procedure 3, 211 (48 mg, 0.12 mmol, 
1.0 equiv), triphenylphosphine (79 mg, 0.30 mmol, 2.5 equiv), 
THF (12 mL, 0.01 M) and diethylazadicarboxylate (48 µL, 0.30 mmol, 2.5 
equiv) gave 212 as a white crystalline solid (31 mg, 80 µmol, 67%); M.p. 166-
167 °C; [α]D
28 = + 7.62 (c 0.21, CHCl3); Enantiomeric excess (99% ee) was 
determined by HPLC analysis (25 °C). [Chiralcel OD column 2-
propanol/hexane = 2/98; flow rate = 1.0 mL/min; detection wavelength = 254 
nm] tR 15.8 min; tR 19.0 min. IR (film) 2980, 2932, 1733, 1395, 1358; 
1H NMR 
(500 MHz, CDCl3) δH 7.93 (2H d, J 8.2, Ar-CH), 7.37 (7H, m, Ar-CH), 5.06 
(1H, dd, J 8.7, 5.9, CHPh), 4.21 (1H, t, J 8.7, NCHH), 3.96 (1H, dd, J 8.5, 5.9, 
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NCHH), 2.51 (3H, s, CH3), 1.45 (9H, s, C(CH3)3); 
13C NMR (125 MHz, CDCl3) 
δC 159.3 (C=O), 145.2 (Ar-C), 137.6 (Ar-C), 130.8 (Ar-CH), 130.1 (Ar-CH), 
130.0 (Ar-C), 129.6 (Ar-CH), 128.9 (Ar-CH), 126.4 (Ar-CH), 82.9 (C), 61.3 
(CH), 56.3 (CH2), 28.0 (CH3), 21.8 (CH3); HRMS (ES
+) calculated for 
C20H24N2O4S (M+Na)
+: 411.1349; found: 411.1352.  
Single crystals of 212 were grown from dichloromethane/hexane. A suitable 
crystal was selected and mounted on a glass fibre with Fromblin oil and placed 
on a Rigaku Oxford Diffraction SuperNova diffractometer with a duel source 
(Cu at zero) equipped with an AtlasS2 CCD area detector. The crystal was kept 
at 150 K during data collection. Using Olex2, the structure was solved with the 
ShelXT structure solution program using Intrinsic Phasing and refined with the 
ShelXL refinement package using Least Squares minimisation. 
Crystal Data for 212 (M =388.47 g/mol): orthorhombic, space group P212121 
(no. 19), a = 6.21070(10) Å, b = 16.8428(4) Å, c = 18.7007(4) Å, V = 
1956.20(7) Å3, Z = 4, T = 150(2) K, μ(CuKα) = 1.707 mm-1, Dcalc = 
1.319 g/cm3, 20599 reflections measured (7.064° ≤ 2Θ ≤ 147.372°), 3913 unique 
(Rint = 0.0663, Rsigma = 0.0392) which were used in all calculations. The final R1 
was 0.0326 (I > 2σ(I)) and wR2 was 0.0818 (all data). 
 
tert-Butyl (R)-3-(phenoxymethyl)-2-tosyl-1,2-
diazetidine-1-carboxylate (218) Following general 
procedure 3, 437 (337 mg, 0.77 mmol, 1.0 equiv), 
triphenylphosphine (507 mg, 1.90 mmol, 2.5 equiv), THF (77 mL, 0.01M) and 
diethylazadicarboxylate (303 µL, 1.90 mmol, 2.5 equiv) gave 218 as a white 
crystalline solid (203 mg, 0.47 mmol, 62%); Rf 0.29 (15% EtOAc/petroleum 
ether); M.p.119-122 °C; IR (film) 2979, 1739, 1597, 1492, 1150, 1087; [α]32D – 
7.7 (c 0.11, CHCl3); Enantiomeric excess (98% ee) was determined by HPLC 
analysis (25 °C). [Chiralcel OD column 2-propanol/hexane = 10/90; flow rate = 
1.0 mL/min; detection wavelength = 254 nm] tR 20.5 min; tR 23.0 min; δH (500 
MHz, CDCl3) 7.91 (2H, d, J 8.2, Ar-H), 7.41 (d, J = 8.1 Hz, 2H), 7.31 (2H, t, J 
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8.0, Ar-H), 7.01 (1H, t, J 7.3, Ar-H), 6.93 (2H, d, J 8.0, Ar-H), 4.41-4.27 (2H, 
m, NCH2), 4.18-4.10 (2H, m, OCH2), 3.93 (1H, t, J 8.4, NCHCH2), 2.50 (3H, s, 
CH3), 1.43 (s, 9H); δC (126 MHz, CDCl3) 159.2 (C=O), 158.3 (Ar-C), 145.2 
(Ar-C), 130.5 (Ar-C), 130.0 (Ar-CH), 129.7 (Ar-CH), 129.5 (Ar-CH), 121.5 
(Ar-CH), 114.8 (Ar-CH), 82.7 (C), 67.7 (CH2), 58.3 (CH), 51.3 (CH2), 27.9 
(CH3), 21.7 (CH3); HRMS (ES
+) calculated for  C21H26N2O5S (M+Na)
+: 
444.1455; found: 444.1449. 
 
tert-Butyl (Rac)-3-(naphthalen-2-yl)-2-tosyl-1,2-
diazetidine-1-carboxylate (219) Following general 
procedure 3, 438 (120 mg, 0.26 mmol, 1.0 equiv), 
triphenylphosphine (170 mg, 0.65 mmol, 2.5 equiv), 
THF (26 mL, 0.01 M) and diethylazadicarboxylate (102 µL, 0.65 mmol, 2.5 
equiv) gave 219 as a white crystalline solid (35 mg, 80 µmol, 31%). Rf 0.47 
(25% EtOAc/petroleum ether); M.p. 145-147 °C; IR (film) 2977, 1741, 1395, 
1321, 1153; δH (400 MHz, d6-DMSO) 8.10-7.70 (5H, m, Ar-H), 7.72-7.40 (4H, 
m, Ar-H), 7.24-7.16 (2H, m, Ar-H), 7.01 (1H, t, J 7.3, Ar-H), 5.70-5.65 (minor 
rotamer) and 5.32-5.25 (1H, m, CHAr), 4.50-4.41 (minor rotamer) and 4.30-4.20 
(1H, m, NCHH), 4.00-3.92 and 3.82-3.77 (minor rotamer, 1H, m, NCHH), 3.93 
(1H, t, J 8.4, NCHCH2), 2.48 and 2.45 (minor rotamer, 3H, s, CH3), 1.42 and 
1.29 (minor rotamer, 9H, s, CH3); δC (100 MHz, d6-DMSO) 159.2 (C=O), 
145.9, 145.5 (minor, Ar-C), 135.6, 134.7 (minor, Ar-C), 134.5 (minor), 133.7 
(Ar-C), 133.3 (minor), 133.0 (Ar-C), 131.4 (minor), 130.3 (Ar-C), 130.6 
(minor), 130.5 (Ar-CH), 130.2, 129.2 (minor, Ar-CH), 128.4 (Ar-CH), 128.2, 
128.1 (minor, Ar-CH), 127.5, 127.4 (minor, Ar-CH), 127.2, 127.2 (minor, Ar-
CH), 126.9 (minor), 126.2 (Ar-CH), 125.8 (minor), 124.5 (Ar-CH), 123.3 (Ar-
CH), 82.7, 81.9 (minor, C), 62.1, 57.1 (minor, CH), 56.8 (CH2), 28.0, 27.9 
(minor, CH3), 21.7, 21.6 (minor, CH3); HRMS (ES
+) calculated for  
C24H26N2O4S (M+Na)





diazetidine-1-carboxylate (220) Following general 
procedure 3, 439 (337 mg, 0.77 mmol, 1.0 equiv), 
triphenylphosphine (507 mg, 1.93 mmol, 2.5 equiv), THF 
(77 mL, 0.01 M) and diethylazadicarboxylate (303 µL, 
1.93 mmol, 2.5 equiv) gave 220 as a white crystalline solid (118 mg, 36%). Rf 
0.20 (25% EtOAc/pet ether); M.p. 153-156 °C; IR (film) 3493, 2965, 1710, 
1326, 1168, 1043; δH (500 MHz, CDCl3) 7.81 (2H, d, J 8.1, Ar-H), 7.39-7.31 
(4H, m, Ar-H), 7.06 (2H, t, J 8.6, Ar-H), 5.16 (1H, dd, J 9.0, 3.4, NCHAr), 3.95-
3.63 (2H, m, CH2), 2.44 (3H, s, CH3), 1.18 (9H, s, CH3); δC (126 MHz, CDCl3) 
162.4 (d, J 252.0, Ar-CF), 144.8 (Ar-C), 137.1 (d, J 2.7, Ar-C), 129.6 (Ar-CH), 
128.8 (Ar-CH), 127.7 (d, J 8.1 Hz, Ar-CH), 115.4 (d, J 21.5, Ar-CH), 83.1 (C), 
74.2 (CH), 58.9 (CH2), 27.6 (CH3), 21.6 (CH3), 1 C=O and 1 Ar-C not seen; 
HRMS (ES+) calculated for  C20H23N2O4FSNa (M+Na)




diazetidine-1-carboxylate (220a) Following general 
procedure 3, 439a (23 mg, 60 µmol, 1.0 equiv), THF (6 
mL, 0.01 M), triphenylphosphine (39 mg, 0.15 mmol, 2.5 equiv) and 
diisopropylazodicarboxylate (30 µL, 0.15 mmol, 2.5 equiv) gave 220a as a white 
solid (18 mg, 49 µmol, 82%); Rf 0.31 (15% EtOAc/petroleum ether); M.p. 84-
86 °C; IR (film) 3336, 3242,  2958, 2848, 1710, 1437, 1174; δH (400 MHz, 
CDCl3) 7.83 (2H, d, J 8.2, Ar-H), 7.35 (2H, d, J 8.1, Ar-H), 5.77 (1H, ddt, J 
16.8, 10.2, 6.5, H2C=CH), 5.05 (1H, dd, J 17.1, 1.3, HHC=CH), 4.99 (1H, d, J 
10.2, HHC=CH), 3.97 (1H, dt, J 13.2, 6.6, CHOH), 1H NMR (400 MHz, CDCl3) 
3.79 (1H, t, J  8.3, CHHNBoc), 3.61 (1H, dd, J  8.5, 5.5, CHHNBoc), 2.45 (3H, 
s, CH3), 2.22-2.09 (2H, m, J 14.2, 7.0, CH2CHNTs), 1.95 (1H, td, J 14.2, 7.0, 
H2C=CHCHH), 1.83-1.75 (1H, m, H2C=CHCHH), 1.41 (9H, s, (CH3)3); δC (100 
MHz, CDCl3) 159.2 (C=O), 145.0 (Ar-C), 136.9 (H2C=CH), 130.8 (Ar-C), 129.9 
(Ar-CH), 129.5 (Ar-CH), 115.7 (H2C=CH), 82.6 (C), 59.7 (CH), 54.2 (CH2), 
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33.8 (CH2), 28.4 (CH2), 27.9 (CH3), 21.7 (CH3); HRMS (ES
+) calculated for  
C18H26N2O4 (M+Na)




Following general procedure 3, 439b (34 
mg, 72 µmol, 1.0 equiv), THF (8 mL, 0.01 
M), triphenylphosphine (47 mg, 0.18 mmol, 2.5 equiv) and 
diisopropylazodicarboxylate (36 µL, 0.18 mmol, 2.5 equiv) gave 220b as a 
colourless oil (30 mg, 67 µmol, 93%); Rf 0.17 (10% EtOAc/petroleuem ether); 
IR (film) 3382, 2956, 1747, 1721, 1459, 1495, 1213, 1186; δH (500 MHz, 
CDCl3) major rotamer reported 7.85 (2H, d, J 8.2, Ar-H), 7.36 (2H, d, J 8.1, Ar-
H), 4.02 – 3.93 (1H, m, CHNTs), 3.81 (1H, t, J 8.3, CHHNBoc), 3.63 (1H dd, J 
8.5, 5.4, CHHNBoc), 2.46 (3H, s, CH3), 1.80 (1H, dt, J 9.9, 7.2, CHHCHNTs), 
1.75 – 1.65 (1H, m, CHHCHNTs), 1.42 (9H, s, (CH3)3), 1.26 (16H, s, (CH2)8), 
0.88 (3H, t, J 7.5, CH3); δC (126 MHz, CDCl3) 159.3 (C=O), 144.9 (Ar-C), 130.9 
(Ar-C), 130.0 (Ar-CH), 129.5 (Ar-CH), 128. (Ar-CH), 82.6 (C), 60.4 (CH), 54.2 
(CH2), 34.6 (CH2), 31.9 (CH2), 29.6 (CH2), 29.5 (CH2), 29.5 (CH2), 29.3 (CH2), 
29.3 (CH2), 28.0 (CH3), 24.1 (CH2), 22.7 (CH2), 21.7 (CH3), 14.1 (CH3). HRMS 
(ES+) calculated for  C24H40N2O4S (M+Na)
+: 475.2588; found: 475.2592. 
 
tert-Butyl-(Rac)- 8-tosyl-7,8-diazabicyclo[4.2.0]octane-7-
carboxylate (220c) Following general procdure 3, 439c (38 mg, 
0.10 mmol, 1.0 equiv), THF (10 mL), triphenylphosphine (66 mg, 
0.25 mmol, 2.5 equiv) and diisopropylazodicarboxylate (50 µL, 0.25 mmol, 2.5 
equiv) gave 220c as a white solid (32 mg, 87 µmol 87%); Rf 0.42 (30% 
EtOAc/petroleum ether); M.p. 138-139 °C;  IR (film) 3368, 2955, 1729, 1152, 
1118; δH (400 MHz, CDCl3) 7.80 (2H, d, J 8.2, Ar-H), 7.34 (2H, d, J 8.1, Ar-
H), 4.13-4.03 (2H, m, CHNBoc, CHNTs), 2.44 (3H, s, CH3), 2.10-2.01 (2H, m, 
CH2CHNTs), 1.96-1.86 (2H, m, CH2CHNBoc), 1.65-1.43 (4H, m, CH2CH2), 
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1.44 (9H, s, CH3); δC (100 MHz, CDCl3) 156.7 (C=O), 144.8 (Ar-C), 130.6 (Ar-
C), 129.9 (Ar-CH), 129.5 (Ar-CH), 82.1 (C), 59.6 (CH), 58.2 (CH), 27.3 (CH3), 
24.2 (CH2), 21.7 (CH3), 16.4 (CH2), 16.2 (CH2), 1 CH2 not seen; HRMS (ES
+) 
calculated for  C18H26N2O4 (M+Na)
+: 389.1505; found: 389.1505. 
 
tert-Butyl (1,3-dioxoisoindolin-2-yl) (2-oxo-2-
phenylethyl)carbamate (237) 2-Bromoacetophenone 
(209 mg, 1.05 mmol), acetonitrile (10 mL), tert-butyl 
(1,3-dioxoisoindolin-2-yl)carbamate94 (236) (170 mg, 1 
mmol) and potassium carbonate (145 mg, 1.05 mmol) were combined and stirred 
at rt. After 3 h, the reaction was quenched with water (10 mL), extracted with 
dichloromethane (3 x 10 mL), dried over MgSO4 and concentrated in vacuo to 
give 237 as a white solid (270 mg, 0.71 mmol, 71%). M.p. 85-88 °C; IR (film) 
3066, 3007, 2897, 2919, 1795, 1724, 1701, 1281; δH 1H NMR (400 MHz, 
CDCl3) 8.02 (2H, d, J 7.4, Ar-CH), 7.95-7.87 (3H, m, Ar-CH), 7.84-7.75 (3H, 
m, Ar-CH), 7.61 (1H, t, J 7.2, Ar-CH), 7.50 (1H, q, J 7.9, Ar-CH), 5.19 and 5.08 
(minor rotamer) (2H, s, COCH2), 1.51-1.35 (9H, m, CH3); 
13C NMR δC (125 
MHz, CDCl3) 191.1 (CO), 189.4 (CO), 163.2 (CO), 162.8 (CO), 151.3 and 150.9 
(minor rotamer) (Ar-C), 133.1 (minor rotamer) and 133.1 (Ar-C), 132.8 and 
132.7 (minor rotamer) (Ar-CH), 128.1 (minor rotamer) and 128.0 (Ar-C), 126.9 
(minor rotamer) and 126.8 (Ar-CH), 126.3 and 126.3 (minor rotamer) (Ar-CH), 
122.0 and 122.0 (minor rotamer) (Ar-CH), 83.5 (minor rotamer) and 83.1 (C), 
54.4 (minor rotamer) and 52.0 (CH2), 26.1 (minor rotamer) and 25.9 (CH3), 1 
Ar-CH not seen; MS (ES+) m/z = 403 ([M+Na]+, 100); HRMS (ES+) calculated 
for  C21H20N2O5Na (M+Na)
+: 403.1264; found: 403.1266. 
 
1-Benzyl 2-(tert-butyl) 1-tosylhydrazine-1,2-dicarboxylate 
(281). tert-Butyl 2-tosylhydrazine-1-carboxylate (227)137 (3.22 
g, 11.3 mmol, 1.0 equiv), triethylamine (1.65 mL, 11.8 mmol, 
1.05 equiv), 4-dimethylaminopyridine (138 mg, 1.1 mmol, 0.1 equiv) and 
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dichloromethane (20 mL) were stirred at 0 °C. Then benzyl chloroformate (1.69 
mL, 11.8 mol, 1.05 equiv) in dichloromethane (20 mL) was added via syringe 
pump over 1 h. The reaction mixture was then quenched with sodium hydrogen 
carbonate (20 mL), extracted with dichloromethane (3 x 20 mL), dried over 
MgSO4 and concentrated in vacuo to give a colourless oil. The crude product 
was purified by column chromatography (15% EtOAc/pet ether) to give 281 
(4.35 g, 10.4 mmol, 92%) as a colourless oil. Rf = 0.12 (15% EtOAc in petroleum 
ether); IR (film) 3336, 2981, 1736, 1365, 1155 cm-1; δH (500 MHz; CDCl3) 7.92 
(2H, d, J 8.0, Ar-H), 7.36-7.25 (7H, m, Ar-H), 6.95 and 6.63 (minor rotamer) 
(1H, s, NH), 5.28-5.13 (2H, m, CH2Ph), 2.44 (3H, s, CH3) 1.49 (9H, s, C(CH3)3); 
δC (125 MHz; CDCl3) 153.5 (C=O), 151.5 (C=O), 145.3 (Ar-C), 131.7 (Ar-C), 
134.2 (Ar-C), 129.6 (Ar-CH), 129.2 (Ar-CH), 128.7 (Ar-CH), 128.6 (Ar-CH), 
128.4 (Ar-CH), 82.8 (C), 69.6 (CH2), 28.0 (CH3), 21.7 (CH3); HRMS (ESI
+) 
calculated for C20H24N2NaO6S [M+Na]
+ 443.1247; found 443.1245. 
 
General Procedure 4: Synthesis of keto hydrazines using triply protected 
hydrazine 240 
 
Scheme 6.1 General procedure for keto hydrazine synthesis using 240. 
To a solution of hydrazine 24095 (1.0 equiv) in anhydrous CH3CN (0.1 M) was 
added halide (1.1 equiv) followed by potassium carbonate (1.1 equiv). The 
reaction mixture was stirred at rt until completion of the reaction (6-24 h). Water 
(10 mL) was then added and the mixture was extracted with dichloromethane (3 
× 10 mL). The combined organic layers were washed with brine (10 mL), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography (15-40% EtOAc/ pet ether) to give the tetrasubstituted 
hydrazide. To this compound (1.0 equiv) in dichloromethane (0.1 M) was added 
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trifluroacetic acid (10 equiv) at 0 °C. After 2 h, the reaction mixture was 
concentrated in vacuo. The crude product was purified by column 
chromatography (15-40% EtOAc/ pet ether) to give the following compounds. 
 
Benzyl 1-(2-(3,4-dichlorophenyl)-2-oxoethyl)-2-
tosylhydrazine-1-carboxylate (249). Following 
general procedure 4, hydrazide 240 (204 mg, 0.76 
mmol, 1.0 equiv), 2-bromo-3`,4`-
dichloroacetophenone (212 mg, 0.79 mmol, 1.1 equiv), potassium carbonate 
(109 mg, 0.79 mmol, 1.1 equiv) and acetonitrile (8.0 mL, 0.1 M), then 
trifluoroacetic acid (586 µL, 7.60 mmol, 10 equiv) and dichloromethane (8.0 
mL, 0.1 M) gave 249 (157 mg, 0.31 mmol, 41%) as a white solid. Rf = 0.22 (15% 
EtOAc in petroleum ether); M.p. 174-177 °C. IR (film) 3257, 2928, 1710, 1421, 
1183 cm-1; δH (500 MHz; CDCl3) 7.97 (1H, d, J 8.9, Ar-H), 7.81-7.67 (3H, m, 
Ar-H), 7.58 (1H, d, J 8.2, Ar-H) 7.37-7.01 (7H, m, Ar-H), 5.07-4.87 (4H, m, 
NCH2 and CH2Ph), 2.43 and 2.39 (minor rotamer) (3H, s, CH3); δC (125 MHz, 
CDCl3) 191.8 (C=O, major rotamer), 191.4 (C=O, minor rotamer), 156.7 (C=O), 
144.7 (Ar-C), 138.9 (Ar-C) 133.8 (Ar-C), 133.7 (Ar-C), 131.1 (Ar-CH), 130.0 
(Ar-CH), 129.6 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.1 (Ar-CH), 126.9 
(Ar-CH), 68.9 (CH2), 58.8 (CH2, major rotamer), 58.0 (CH2, minor rotamer), 
21.8 (CH3), 2 Ar-C not seen; HRMS (ESI
+) calculated for C23H20
35Cl2N2O5S 
[M+Na]+ 529.0362; found 529.0357. 
 
Benzyl 1-(2-(2-fluorophenyl)-2-oxoethyl)-2-
tosylhydrazine-1-carboxylate (250). Following general 
procedure 4, hydrazide 240 (300 mg, 0.72 mmol, 1.0 
equiv), 2-bromo-2`-fluoroacetophenone (171 mg, 0.79 mmol, 1.1 equiv), 
potassium carbonate (109 mg, 0.79 mmol, 1.1 equiv) and acetonitrile (8.0 mL, 
0.1 M), then trifluoroacetic acid (555 µL, 7.20 mmol, 10.0 equiv) and 
dichloromethane (8.0 mL, 0.1 M) gave 250 (204 mg, 0.45 mmol, 62%) as a white 
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solid. Rf = 0.21 (15% EtOAc in petroleum ether); M.p. 122-123 °C; IR (film) 
3211, 2966, 1721, 1693, 1609, 1499, 1255, 1200 cm-1; δH (600 MHz; D6-DMSO 
at 100 °C) 9.97 (1H, s, NH), 7.80 (1H, t, J 7.5 Ar-H), 7.73-7.67 (3H, m, Ar-H), 
7.38-7.27 (7H, m, Ar-H), 7.21-7.14 (2H, m, Ar-H), 4.84 (2H, s, CH2Ph), 4.81 
(2H, s, NCH2) 2.36 (3H, s, CH3); δC (150 MHz, D6-DMSO at 100 °C) 144.0 
(Ar-C), 136.1 (d, J 9.0, Ar-CH) 130.6 (Ar-CH), 129.7 (Ar-CH), 128.5 (Ar-CH), 
128.2 (Ar-CH), 128.2 (Ar-CH), 127.8 (Ar-CH), 125.4 (Ar-CH), 117.2 (d, J 24 
Ar-CH), 68.0 (CH2), 61.7 (CH2), 21.4 (CH3), 2 C=O, 4 Ar-C not seen; δF (376 
MHz, D6-DMSO) -108.8 (C-F); HRMS (ESI+) calculated for C23H21FN2O5S 
[M+Na]+ 479.1047; found 479.1048. 
 
Benzyl 1-(2-(4-fluorophenyl)-2-oxoethyl)-2-
tosylhydrazine-1-carboxylate 252 Following 
general procedure 4, hydrazide 240 (300 mg, 0.72 
mmol, 1.0 equiv), 2-bromo-4`-fluoroacetophenone (171 mg, 0.79 mmol, 1.1 
equiv), potassium carbonate (109 mg, 0.79 mmol, 1.1 equiv) and acetonitrile 
(8.0 mL, 0.1 M), then trifluoroacetic acid (555 µL, 7.20 mmol, 10.0 equiv) and 
dichloromethane (8.0 mL, 0.1 M) gave 252 (141 mg, 0.31 mmol, 43%) as a white 
solid. Rf = 0.20 (15% EtOAc in petroleum ether); M.p. 124-127 °C. IR (film) 
3250, 2944, 1721, 1692, 1595, 1339, 1270 cm-1; δH (500 MHz; CDCl3) 8.03 
(1H, d, J 23.3 Ar-H), 7.86-7.68 (4H, m, Ar-H), 7.41-7.03 (7H, m, Ar-H), 5.10-
4.87 (4H, m, NCH2 and CH2Ph), 2.43 and 2.39 (minor rotamer) (3H, s, CH3).; 
δC (125 MHz, CDCl3) 192.1 (C=O), 156.8 (C=O) 144.6 (Ar-C), 137.0 (Ar-CH) 
136.7 (Ar-C, seen on HMBC), 135.5 (Ar-C), 129.5 (Ar-CH), 128.5 (Ar-CH), 
128.1 (Ar-CH), 126.5 (Ar-CH), 123.3 (Ar-C) 68.9 (CH2), 58.9 (CH2, major 
rotamer), 58.1 (CH2, minor rotamer), 21.8 (CH3), 3 Ar-C not seen; δF (282 MHz, 
CDCl3) -102.8 (CF); HRMS (ESI
+) calculated for C23H21FN2O5S [M+Na]
+ 





tosylhydrazine-1-carboxylate (253). Following 
general procedure 4, hydrazide 240 (300 mg, 0.72 mmol, 
1.0 equiv), 2,3‘-bromoacetophenone (220 mg, 0.79 
mmol, 1.1 equiv), potassium carbonate (109 mg, 0.79 mmol, 1.1 equiv) and 
acetonitrile (8.0 mL, 0.1 M), then trifluoroacetic acid (555 µL, 7.20 mmol, 10 
equiv) and dichloromethane (8.0 mL, 0.1 M) gave 253 (201 mg, 0.39 mmol, 
54%) as a white solid. Rf = 0.18 (15% EtOAc in petroleum ether); M.p. 131-133 
°C. IR (film) 3230, 2964, 2919, 1719, 1682, 1494, 1343, 1215 cm-1; δH (500 
MHz; CDCl3) 8.03 (1H, d, J 8.3, Ar-H), 7.86-7.68 (4H, m, Ar-H), 7.41-7.02 (8H, 
m, Ar-H), 5.09-4.85 (4H, m, NCH2 and CH2Ph), 2.43 and 2.39 (minor rotamer) 
(3H, s, CH3); δC (125 MHz, CDCl3) 192.1 (C=O), 156.8 (C=O), 144.6 (Ar-C), 
137.0 (Ar-CH), 131.1 (Ar-CH), 130.5 (Ar-CH), 129.5 (Ar-CH), 128.6 (Ar-CH), 
128.5 (Ar-CH), 128.4 (Ar-CH), 128.0 (Ar-CH), 126.5 (Ar-CH), 123.3 (Ar-C), 
68.9 (CH2), 58.9 (CH2) and 58.1 (CH2, minor rotamer), 21.8 (CH3), 3 Ar-C not 
seen; HRMS (ESI+) calculated for C23H21
79BrN2O5S [M+Na]





1-carboxylate (254). Following general procedure 
4, hydrazine 240 (300 mg, 0.72 mmol, 1.0 equiv), 2-
bromo-4‘-(trifluoromethyl)acetophenone (211 mg, 0.79 mmol, 1.1 equiv), 
potassium carbonate (109 mg, 0.79 mmol, 1.1 equiv) and acetonitrile (8.0 mL, 
0.1 M), then trifluoroacetic acid (555 µL, 7.20 mmol, 10 equiv) and 
dichloromethane (8.0 mL, 0.1 M) gave 254 (204 mg, 0.40 mmol, 56%) as a white 
solid. Rf = 0.19 (15% EtOAc in petroleum ether); M.p. 203-205 °C. IR (film) 
3263, 2925, 1710, 1687, 1324, 830, 811 cm-1; δH (500 MHz; CDCl3) 8.05-7.97 
(2H, m, Ar-H), 7.81-7.68 (4H, m, Ar-H), 7.36-7.03 (7H, m, Ar-H), 5.11-4.87 
(4H, m, NCH2 and CH2Ph), 2.43 and 2.39 (minor rotamer) (3H, s, CH3); δC (125 
MHz, CDCl3) 192.4 (C=O, seen on HMBC), 144.0 (Ar-C, seen on HMBC), 
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136.7 (Ar-C, seen on HMBC), 135.5 (Ar-C), 129.6 (Ar-CH), 128.6 (Ar-CH), 
128.5 (Ar-CH), 128.4 (Ar-CH), 128.1 (Ar-CH), 128.0 (Ar-CH), 126.0 (Ar-CH), 
68.9 (CH2), 59.1 (CH2) and 58.3 (CH2, minor rotamer), 21.8 (CH3), CF3, 2 Ar-
C and C=O not seen; δF (376 MHz; CDCl3) -63.3 (CF3); HRMS (ESI
+) 
calculated for C24H21F3N2O5S [M+Na]
+ 529.1015; found 529.1016. 
 
Benzyl 1-(2-(2-chlorophenyl)-2-oxoethyl)-2-
tosylhydrazine-1-carboxylate (255). Following 
general procedure 4, hydrazide 240 (300 mg, 0.72 mmol, 
1.0 equiv), 2-bromo-2`-chloroacetophenone (184 mg, 0.79 mmol, 1.1 equiv), 
potassium carbonate (109 mg, 0.79 mmol, 1.1 equiv) and acetonitrile (7.2 mL, 
0.1 M), then trifluoroacetic acid (555 µL, 7.20 mmol, 10 equiv) and 
dichloromethane (7.2 mL, 0.1 M) gave 240 (191 mg, 0.40 mmol, 56%) as a white 
solid. Rf = 0.42 (25% EtOAc in petroleum ether); M.p. 89-93 °C; IR (film) 3195, 
2941, 1728, 1704, 1417, 1382, 1219 cm-1; δH (500 MHz; d6-DMSO) 10.63 and 
10.52 (minor rotamer) (1H, s, NH), 7.76-7.43 (5H, m, Ar-H), 7.36-7.10 (8H, m, 
Ar-H), 5.15-4.35 (4H, m, NCH2 and CH2Ph), 2.30 (3H, s, CH3); δC (125 MHz, 
d6-DMSO) 195.7 (C=O), 155.6 (C=O), 144.0 (Ar-C), 137.8 (Ar-C), 136.1 (Ar-
C), 135.8 (Ar-C), 133.8 (Ar-CH), 131.2 (Ar-CH), 130.8 (Ar-C), 130.2 (Ar-CH), 
129.8 (Ar-CH), 129.4 (Ar-CH), 128.7 (Ar-CH), 128.1 (Ar-CH), 127.8 (Ar-CH), 




+ 495.0752; found 495.0737. 
 
Benzyl 1-(2-(benzofuran-2-yl)-2-oxoethyl)-2-
tosylhydrazine-1-carboxylate (258). Following 
general procedure 4, hydrazide 240 (300 mg, 0.72 
mmol, 1.0 equiv), 2-bromo-1-(2,3-
dihydrobenzofuran-2-yl)ethan-1-one (190 mg, 0.79 mmol, 1.1 equiv), potassium 
carbonate (109 mg, 0.79 mmol, 1.1 equiv) and acetonitrile (7.2 mL, 0.1 M),  
Deprotection of the Boc group was achieved using 1 M HCl in dioxane (4 mL) 
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instead of trifluoroacetic acid and dichloromethane to give 258  (189 mg, 0.40 
mmol, 50%) as a white solid. Rf = 0.37 (25% EtOAc in petroleum ether);  M.p. 
126-128 °C. IR (film) 3274, 3201, 2953, 1721, 1681, 1391, 1235 cm-1; δH (500 
MHz; CDCl3) 7.80 (1H, d, J 7.6, Ar-H), 7.73 (2H, d, J 7.6 Ar-H), 7.58 (2H, d, J 
7.8, Ar-H), 7.52 (1H, t, J 7.8, Ar-H), 7.38-7.04 (8H, m, Ar-H),, 5.15-4.85 (4H, 
m, NCH2 and CH2Ph), 2.43 and 2.39 (minor rotamer) (3H, s, CH3).; δC (125 
MHz, CDCl3) 184.8 (C=O), 155.8 (C=O), 150.5 (Ar-C) 144.6 (Ar-C), 135.1 (Ar-
C), 133.8 (Ar-C), 129.5 (Ar-CH), 128.9 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-
CH) 128.1 (Ar-CH), 128.0 (Ar-CH), 126.7 (Ar-C) 124.3 (Ar-CH) 123.5 (Ar-
CH), 113.7 (Ar-CH), 112.5 (Ar-CH), 68.9 (CH2), 58.7 and 58.0 (minor rotamer) 
(CH2), 21.8 (CH3), 1 Ar-C not seen; HRMS (ESI
+) calculated for C25H22N2O6S 
[M+Na]+ 501.1091; found 501.1092. 
 
Benzyl 1-(3-oxo-3-phenylpropyl)-2-tosylhydrazine-1-
carboxylate (287). Following general procedure 4, 
hydrazide 240 (300 mg, 0.72 mmol, 1.0 equiv), 3-
chloropropiophenone (133 mg, 0.79 mmol, 1.1 equiv), potassium carbonate (109 
mg, 0.79 mmol, 1.1 equiv) and acetonitrile (7.2 mL, 0.1 M), then trifluoroacetic 
acid (555 µL, 7.20 mmol, 10 equiv) and dichloromethane (7.2 mL, 0.1 M) gave 
287 (293 mg, 0.65 mmol, 90%) as a white solid. Rf = 0.20 (15% EtOAc in 
petroleum ether); M.p. 122-123 °C; IR (film) 3231, 3034, 1702, 1666, 1380, 
1307, 1184 cm-1; δH (500 MHz; CDCl3) 7.95 (2H, d, J 7.8 Ar-H), 7.75 (2H, d, 
J 8.0, Ar-H), 7.60 (1H, t, J 7.3, Ar-H), 7.49 (2H, t, J 7.6, Ar-H), 7.33 (3H, d, J 
4.9, Ar-H), 7.22 (2H, d, J 8.0, Ar-H), 7.15 (2H, s, Ar-H), 4.91 (2H, br s, 
CO2CH2), 4.08 (2H, br s, NCH2), 3.40 (2H, br s, COCH2), 2.42 (3H, s, Ar-CH3); 
δC (125 MHz, CDCl3) 198.3 (C=O, seen on HMBC), 144.5 (Ar-C), 136.4 (Ar-
C), 135.2 (Ar-C), 133.5 (Ar-CH), 129.6 (Ar-CH), 128.7 (Ar-CH), 128.5 (Ar-
CH), 128.4 (Ar-CH), 128.1 (Ar-CH), 128.1 (Ar-CH), 68.5 (CH2), 46.8 (CH2), 
35.9 (CH2), 21.7 (CH3), 1 C=O, 1 Ar-H and 1 Ar-C not seen; HRMS (ESI
+) 
calculated for C24H24N2O5S [M+Na]





carboxylate (283). Hydrazine 280 (310 mg, 0.74 mmol, 1.0 
equiv), 2-bromoacetophenone (161 mg, 0.81 mol, 1.1 
equiv), potassium carbonate (112 mg 0.81 mmol, 1.1 equiv) and acetonitrile (8.0 
mL, 0.1 M) were stirred at room temperature for 24 h. The solution was then 
quenched with water (10 mL), extracted with dichloromethane (3 x 10 mL), 
dried over MgSO4 and concentrated in vacuo to give a colourless oil. The 
product was purified by column chromatography (10% EtOAc in petroleum 
ether) to give a white solid. This was stirred under an atmosphere of hydrogen 
with 3 wt% palladium on charcoal (30 mg) and ethyl acetate (3.0 mL). The 
reaction was carefully monitored by TLC, as over-reduction to (rac)-211 was 
seen to occur after Cbz removal. Generally, the reaction was complete in 
approximately 2 h. The crude reaction mixture was then filtered through a plug 
of Celite and concentrated in vacuo to give a colourless oil, which was purified 
by column chromatography (25% EtOAc in petroleum ether) to give 283 (153 
mg, 0.38 mmol, 51%) as a white solid. Rf = 0.52 (25% EtOAc in petroleum 
ether); M.p. 148-150 °C; IR (film) 3219, 2981, 1710, 1695, 1329, 1156 cm-1; δH 
(500 MHz; CDCl3) 7.93 (2H, d, J 7.4, Ar-H), 7.85 (2H, d, J 8.2, Ar-H), 7.64 
(1H, q, J 8.0, Ar-H), 7.55-7.49 (2H, m, Ar-H), 7.41-7.30 (2H, m, Ar-H), 7.21 
and 7.00 (minor rotamer) (1H, s, NH), 5.01 (2H, s, CH2N), 2.50-2.42 (3H, m, 
CH3), 1.20 and 1.15 (minor rotamer) (9H, s, C(CH3)3); δC (125 MHz; CDCl3) 
193.9 (minor rotamer) and 193.6 (C=O), 155.6 and 154.7 (minor rotamer, C=O), 
144.5 (minor rotamer) and 144.4 (Ar-C), 134.5 (Ar-C), 134.0 (Ar-CH), 133.6 
(Ar-C), 134.2 (Ar-CH), 133.9 (Ar-C), 129.7 (minor rotamer) and 129.3 (Ar-CH), 
128.9 and 128.7 (minor rotamer, Ar-CH), 128.8 and 128.6 minor rotamer, Ar-
CH), 128.0 (minor rotamer) and 127.9 (Ar-CH), 83.1 (minor rotamer) and 82.8 
(C), 58.9, and 58.1 (minor rotamer, CH2), 27.6 and 27.5 (minor rotamer, CH3), 
21.6 (CH3); HRMS (ESI






General procedure 5: Synthesis of keto hydrazines using protected 
hydrazines 
 
Scheme 6.2 General procedure for the synthesis of keto hydrazines. 
To a solution of protected hydrazine (1.0 equiv) in acetonitrile (0.1 M) was 
added the organic halide (1.0 equiv) followed by potassium carbonate (1.1 
equiv). The reaction mixture was stirred at rt until completion of the reaction (6-
24 h, monitored by TLC). Water (10 mL) was then added and the mixture was 
extracted with dichloromethane (3 x 10 mL). The combined organic layers were 
washed with brine (10 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by column chromatography (30-40% EtOAc/ pet 




Following general procedure 5, tert-butyl 2-((4-
nitrophenyl)sulfonyl)hydrazine-1-carboxylate138 (250 mg, 0.79 mmol, 1.0 
equiv), acetonitrile (7.9 mL, 0.1 M), 3-chloropropiophenone (133 mg, 0.83 
mmol, 1.05 equiv) and potassium carbonate (112 mg, 0.87 mmol, 1.1 equiv) 
yielded 286 as a white solid (249 mg, 0.56 mmol, 70%). Rf = 0.39 (25% EtOAc 
in petroleum ether); M.p; 157-159 °C; IR (film) 3316, 2984, 1735, 1679, 1526, 
1317, 1208 cm-1; δH (500 MHz; CDCl3) 7.80 (4H, t, J 9.1, Ar-CH), 7.61 (2H, d, 
J 8.3, Ar-CH), 7.32 (2H, d, J 7.8, Ar-CH), 6.36 (1H, br s, NH), 3.88 (2H, br s, 
COCH2), 3.34 (2H, t, J 6.3, CH2NNs), 1.27 (9H, br s, C(CH3)3); δC (125 MHz, 
CDCl3) 197.0 (C=O, seen on HMBC), 196.6 (C=O, seen on HMBC), 144.6 (Ar-
C), 135.1 (Ar-C), 133.8 (Ar-C), 132.0 (Ar-CH), 129.7 (Ar-CH), 129.6 (Ar-CH), 
128.7 (Ar-CH), 128.6 (Ar-CH),. 81.8 (C), 46.2 (NCH2), 37.3 (CH2), 27.9 (CH3), 
1 C=O not seen; HRMS (ESI+) calculated for C21H25
79BrN2O5S [M+Na]
+ 





1-carboxylate (284) Following general procedure 5, 
Benzyl 2-tosylhydrazine-1-carboxylate95 (1.00 g, 3.10 
mmol, 1.0 equiv), 3-choropropiophenone (0.52 g, 3.10 mmol, 1.0 equiv), 
potassium carbonate (0.45 g, 3.26 mmol, 1.05 equiv) and acetonitrile (31 mL, 
0.1 M) to give 284 as a white solid (1.31 g, 2.90 mmol, 94%). Rf = 0.27 (25% 
EtOAc in petroleum ether). M.p. 144-146 °C. IR (film) 3310, 2941, 1744, 1680, 
1328, 1164 cm-1; δH (500 MHz; CDCl3) 7.89 (2H, br s, Ar-CH), 7.75 (2H, d, J 
8.0, Ar-CH), 7.57 (1H, t, J 7.4, Ar-CH), 7.44 (2H, t, J 7.3, Ar-CH), 7.34-7.29 
(3H, m, Ar-CH), 7.27-7.15 (4H, m, Ar-CH), 6.57 (1H, br s, NH), 4.97 (2H, br s, 
COOCH2), 3.87 (2H, br s, CH2NTs), 3.37 (2H, br s, COCH2), 2.41 (3H, s, Ar-
CH3); δC (125 MHz, CDCl3) 144.7 (Ar-C), 136.3 (Ar-C), 135.4 (Ar-C), 133.5 
(Ar-CH), 129.8, (Ar-CH), 128.7 (Ar-CH), 128.5 (Ar-CH), 128.4 (Ar-CH), 128.4 
(Ar-CH), 128.2 (Ar-CH), 128.1 (Ar-CH), 67.8 (CH2), 46.6 (CH2), 37.0 (CH2), 
21.7 (Ar-CH3), 2 C=O and 1 Ar-C not seen; HRMS (ESI
+) calculated for 
C24H24N2O5S [M+Na]




Following general procedure 5, tert-butyl 2-
tosylhydrazine-1-carboxylate138 (150 mg, 0.52 
mmol, 1.0 equiv), acetonitrile (5.2 mL, 0.1 M), 4’-bromo-3-
chloropropiophenone (129 mg, 0.52 mmol, 1.0 equiv) and potassium carbonate 
(75 mg, 0.55 mmol, 1.05 equiv) yielded 288 as a white solid (216 mg, 0.44 
mmol, 85%). Rf = 0.29 (25% EtOAc in petroleum ether); M.p. 165-166 °C; IR 
(film) 3267, 2975, 2927, 1732, 1714, 1368, 1159 cm-1; δH (500 MHz; CDCl3) 
7.80 (4H, t, J 9.1, Ar-CH), 7.61 (2H, d, J 8.3, Ar-CH), 7.32 (2H, d, J 7.8, Ar-
CH), 6.36 (1H, br s, NH), 3.88 (2H, br s, COCH2), 3.34 (2H, t, J 6.3, CH2NTs), 
2.43 (3H, s, Ar-CH3) 1.27 (9H, br s, C(CH3)3); δC (125 MHz, CDCl3) 197.0 
(C=O, seen on HMBC), 196.6 (C=O, seen on HMBC), 144.6 (Ar-C), 135.1 (Ar-
C), 133.8 (Ar-C), 132.0 (Ar-CH), 129.7 (Ar-CH), 129.6 (Ar-CH), 128.7 (Ar-C), 
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128.6 (Ar-CH), 81.8 (C), 46.2 (NCH2), 37.3 (CH2), 27.9 (CH3), 21.6 (CH3), 1 
C=O not seen; HRMS (ESI+) calculated for C21H25
79BrN2O5S [M+Na]
+ 
519.0560; found 519.0564. 
 
tert-Butyl 2-(3-oxo-3-(thiophen-2-yl)propyl)-2-
tosylhydrazine-1-carboxylate (289). Following 
general procedure 5, tert-butyl 2-tosylhydrazine-1-
carboxylate138 (200 mg, 0.70 mmol, 1.0 equiv), acetonitrile (7.0 mL, 0.1 M), 3-
chloro-1-(thiophen-2-yl)propan-1-one (123 mg, 0.70 mmol, 1.0 equiv) and 
potassium carbonate (102 mg, 0.74 mmol, 1.05 equiv) yielded 289 as a pale 
yellow solid (222 mg, 0.52 mmol, 75%). Rf = 0.38 (25% EtOAc in petroleum 
ether); M.p. 39-40 °C; IR (film) 3320, 2978, 1718, 1654, 1347, 1237, 1152 cm-
1; δH (500 MHz; CDCl3) 7.80 (2H, t, J 8.2, Ar-H), 7.76 (2H, d, J 3.4, Ar-H), 
7.68 (2H, d, J 4.8, Ar-H), 7.16 (1H, t, J 4.3, Ar-H), 6.35 (1H, br s, NH), 3.90 
(2H, br s, COCH2), 3.33 (2H, t, J 6.3, CH2NTs), 2.45 (3H, s, CH3) 1.28 (9H, br 
s, C(CH3)3); δC (125 MHz, CDCl3) 190.9 (C=O, seen on HMBC), 144.5 (Ar-C), 
143.7 (Ar-C), 134.2 (Ar-CH), 132.6 (Ar-CH), 129.7 (Ar-CH), 129.6 (Ar-C, seen 
on HMBC), 128.6 (Ar-CH), 128.3 (Ar-CH), 81.7 (C), 46.3 (NCH2), 38.0 (CH2), 
27.8 (CH3), 21.6 (CH3), Ar-CH and 1 C=O not seen; HRMS (ESI
+) calculated 
for C19H24N2O5S2 [M+Na]




(290). Following general procedure 5, tert-butyl 
2-tosylhydrazine-1-carboxylate138 (500 mg, 1.75 mmol, 1.00 equiv), acetonitrile 
(17.5 mL, 0.1 M), 1-([1,1'-biphenyl]-4-yl)-3-chloropropan-1-one139 (470 mg, 
1.92 mmol, 1.1 equiv) and potassium carbonate (265 mg, 1.92 mmol, 1.1 equiv) 
yielded 290 as a white solid (635 mg, 1.28 mmol, 73%). M.p. 156-157 °C; Rf = 
0.34 (25% EtOAc in petroleum ether); IR (film) 3299, 2983, 2900, 1718, 1660, 
1603, 1380, 1252 cm-1; δH (500 MHz; CDCl3) 8.04 (2H, d, J 8.3, Ar-H), 7.82 
(2H, d, J 8.2, Ar-H), 7.71 (2H, d, J 8.2, Ar-H), 7.65 (2H, d, J 7.4, Ar-H), 7.50 
(2H, t, J 7.5, Ar-H), 7.43 (1H, t, J 7.3, Ar-H), 7.35 (2H, d, J 7.8, Ar-H), 3.93 
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(2H, br s, COCH2), 3.43 (2H, t, J 6.1, CH2NTs), 2.45 (3H, s, CH3), 1.59 (9H, s, 
C(CH3)3); δC (125 MHz, CDCl3) 197.6 (C=O, seen on HMBC), 146.1 (Ar-C), 
144.5 (Ar-C), 139.8 (Ar-C), 135.1 (Ar-C), 129.7 (Ar-CH), 129.6 (Ar-C, seen on 
HMBC) 129.0 (Ar-CH), 128.7 (Ar-CH), 128.6 (Ar-CH), 128.3 (Ar-CH), 127.3 
(Ar-CH), 127.3 (Ar-CH), 81.5 (C, seen on HMBC), 46.4 (NCH2), 41.4 (CH2), 
27.9 (CH3), 21.6 (CH3), 1 C=O not seen; HRMS (ESI
+) calculated for 
C27H30N2O5S [M+Na]




(291). Following general procedure 5, tert-butyl 2-
tosylhydrazine-1-carboxylate138 (350 mg, 1.22 
mmol, 1.0 equiv), 3-chloro-1-(3,5-difluorophenyl)propan-1-one (250 mg, 1.22 
mol, 1.1 equiv), potassium carbonate (185 mg, 1.34 mmol, 1.1 equiv) and 
acetonitrile (12 mL, 0.1 M) gave 291 (409 mg, 0.90 mmol, 74%) as a white solid. 
Rf = 0.29 (15% EtOAc in petroleum ether); M.p. 158-159 °C; IR (film) 3250, 
2923, 1733, 1692, 1240, 1028 cm-1; δH (500 MHz; CDCl3) 7.81 (2H, d, J 8.2, 
Ar-H), 7.46 (2H, d, J 5.6, Ar-H), 7.35 (2H, d, J 7.8, Ar-H), 7.05 (1H, t, J 8.2, 
Ar-H), 6.39 and 5.96 (minor rotamer) (1H, s, NH), 3.95-3.62 (2H, br m, CH2N), 
3.34 (2H, t, J 6.4, COCH2), 2.45 (3H, s, CH3), 1.30 (9H, s, C(CH3)3); δC (125 
MHz; CDCl3) 164.2 (C=O), 163.1 (dd, J 251.4, 11.7, Ar-CF), 144.7 (Ar-C), 
139.3 (Ar-C), 129.7 (Ar-CH), 128.6 (Ar-CH), 111.1 (dd, J 18.9, 6.3, Ar-CH), 
108.7 (t, J 25.0, Ar-CH), 81.9 (C), 50.8 (CH2), 46.0 (CH2), 27.9 (CH3), 21.6 
(CH3), 1 C=O and 1 Ar-C not seen; δF (376 MHz; CDCl3) -107.8 (Ar-CF); 
HRMS (ESI+) calculated for C21H24N2NaO5SF2 [M+Na]
+ 477.1266; found 
477.1264. 
 
Other Aryl Ketone Syntheses 
Benzyl 1-(4-oxo-4-phenylbutyl)-2-tosylhydrazine-1-
carboxylate (318). Hydrazine 24095 (400 mg, 0.96 
mmol, 1.0 equiv), 4-hydroxy-1-phenylbutan-1-one101 158 mg, 0.96 mmol, 1.0 
equiv), triphenylphosphine (376 mg, 1.44 mmol, 1.5 equiv), diethyl 
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azodicarboxylate (224 µL, 1.44 mmol, 1.5 equiv) and tetrahydrofuran (10 mL, 
0.1 M) were combined and stirred at room temperature for 24 h. The reaction 
mixture was then concentrated in vacuo. The crude product was purified by 
column chromatography (30% EtOAc/ pet ether) to give the tetrasubstituted 
hydrazide. To this hydrazine was added trifluoroacetic acid (735 µL, 9.60 mmol, 
10.0 equiv) and dichloromethane (9.6 mL, 0.1 M), the solution was then stirred 
for 2 h. The resulting yellow solution was concentrated in vacuo to give a yellow 
oil, which was purified by column chromatography (25% EtOAc/pet ether) to 
yield 240 as a white solid (215 mg, 0.46 mmol, 48%). Rf = 0.26 (25% EtOAc in 
petroleum ether); M.p. 136-137 °C; IR (film) 3179, 3060, 2955, 1709, 1687, 
1369, 1270 cm-1; δH (500 MHz; CDCl3) 7.91 (2H, d, J 7.6 Ar-CH), 7.72 (2H, d, 
J 7.8, Ar-CH), 7.58 (1H, t, J 7.3, Ar-CH), 7.46 (2H, t, J 7.7, Ar-CH), 7.31 (3H, 
t, J 6.9, Ar-CH), 7.19 (2H, d, J 7.5, Ar-CH), 7.10-7.00 (3H, m, Ar-CH and NH), 
4.78 (2H, br s, COOCH2), 3.79 (2H, br s, CH2NCbz), 3.01 (2H, br s, COCH2), 
2.41 (3H, s, Ar-CH3), 2.15-2.08 (2H, m, COCH2CH2); δC (125 MHz, CDCl3) 
199.2 (C=O, seen on HMBC), 144.4 (Ar-C), 136.7 (Ar-C), 135.2 (Ar-C), 133.2 
(Ar-CH), 129.5 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.4 (Ar-CH), 128.0 
(Ar-CH), 128.0 (Ar-CH), 127.7 (Ar-C), 68.3 (CH2), 50.6 (CH2), 35.6 (CH2), 22.7 
(CH2), 21.7 (Ar-CH3), 1 C=O and 1 Ar-CH not seen; HRMS (ESI
+) calculated 
for C25H26N2O5S [M+Na]
+ 489.1455; found 489.1455. 
 
Benzyl 1-(5-oxo-5-phenylpentyl)-2-
tosylhydrazine-1-carboxylate (319). Hydrazine 
24095 (200 mg, 0.48 mmol, 1.0 equiv), 5-hydroxy-1-
phenylpentan-1-one101 (84 mg, 0.48 mmol, 1.0 equiv), triphenylphosphine (188 
mg, 0.72 mmol, 1.5 equiv), diethyl azodicarboxylate (112 µL, 0.72 mmol, 1.5 
equiv) and tetrahydrofuran (4.8 mL, 0.1 M) were combined and stirred at room 
temperature for 24 h. The reaction mixture was then concentrated in vacuo. The 
crude product was purified by column chromatography (30% EtOAc/ pet ether) 
to give the tetrasubstituted hydrazide. To this hydrazide was added 
trifluoroacetic acid (368 µL, 4.8 mmol, 10.0 equiv) and dichloromethane (4.8 
mL, 0.1 M), the solution was then stirred for 2 h. The resulting yellow solution 
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was concentrated in vacuo to give a yellow oil, which was purified by column 
chromatography (25% EtOAc/pet ether) to yield 319 as a white solid (140 mg, 
0.29 mmol, 61%). Rf = 0.28 (25% EtOAc in petroleum ether); M.p. 86-88 °C; 
IR (film) 3214, 2957, 1699, 1671, 1364, 1181 cm-1; δH (500 MHz; CDCl3) 7.96 
(2H, d, J 7.6, Ar-H), 7.74 (2H, d, J 8.0, Ar-H), 7.59 (1H, t, J 7.3, Ar-H), 7.49 
(2H, t, J 7.7, Ar-H), 7.38-7.30 (3H, m, Ar-H), 7.22 (2H, d, J 8.0, Ar-H), 7.15 
(2H, s, Ar-H), 6.99 (1H, s, NH), 4.90 (2H, br s, COOCH2), 3.72 (2H, br s, 
CH2NCbz), 2.99 (2H, br s, COCH2), 2.42 (3H, s, CH3), 1.79-1.67 (4H, m, 
COCH2CH2CH2); δC (125 MHz, CDCl3) 199.8 (C=O), 144.5 (Ar-C), 136.9 (Ar-
C), 135.2 (Ar-C), 133.1 (Ar-CH), 129.5 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-
CH), 128.5 (Ar-CH), 128.1 (Ar-CH), 128.0 (Ar-CH), 68.4 (CH2), 50.7 (CH2), 
37.9 (CH2), 26.5 (CH2), 21.7 (Ar-CH3), 20.9 (CH2), 1 C=O, 1 Ar-C and 1 Ar-





tosylhydrazine-1-carboxylate (320). Hydrazine 
24095 (500 mg, 1.19 mmol, 1.0 equiv), 6-hydroxy-1-phenylhexan-1-one101 (229 
mg, 1.19 mmol, 1.0 equiv), triphenylphosphine (780 mg, 2.98 mmol, 2.5 equiv), 
diethyl azodicarboxylate (462 µL, 2.98 mmol, 2.5 equiv) and THF (12 mL, 0.1 
M) were stirred at rt for 24 h. The reaction mixture was then concentrated in 
vacuo. The crude product was purified by column chromatography (30% EtOAc/ 
pet ether) to give the tetrasubstituted hydrazide. To this hydrazide was added 
trifluoroacetic acid (912 µL, 11.9 mmol, 10.0 equiv) and dichloromethane (11.9 
mL, 0.1 M), the solution was then stirred for 2 h. The resulting yellow solution 
was concentrated in vacuo to give a yellow oil, which was purified by column 
chromatography (25% EtOAc/pet ether) to yield 320 as a colourless oil (204 mg, 
0.41 mmol , 35%). Rf = 0.32 (25% EtOAc in petroleum ether). IR (film) 3219, 
235, 1711, 1681, 1339, 1159 cm-1; δH (500 MHz; CDCl3) 7.95 (2H, d, J 7.4, Ar-
H), 7.71 (2H, d, J 8.0, Ar-CH), 7.56 (1H, t, J 7.3, Ar-H), 7.47 (2H, t, J 7.7, Ar-
CH), 7.34-7.29 (3H, m, Ar-CH), 7.20 (2H, d, J 8.1, Ar-CH), 7.12 (2H, br s, Ar-
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CH), 6.93 (1H, br s, NH), 4.88 (2H, br s, CH2Ph), 3.65 (2H, br s, NCH2), 2.93 
(2H, t, J 7.2, CH2CO), 2.40 (3H, s, CH3), 1.75-1.62 (4H, m, 2 x CH2), 1.31 (2H, 
pentet, J 7.6, CH2); δC (125 MHz; CDCl3) 200.2 (C=O), 144.5 (Ar-C), 136.9 
(Ar-C), 133.0 (Ar-CH), 129.5 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.5 
(Ar-CH), 128.1 (Ar-CH), 68.3 (CH2), 64.3 (CH2), 50.9 (CH2), 38.2 (CH2), 26.1 
(CH2), 23.8 (CH2), 21.7 (CH3), C=O, 2 Ar-C, and 2 Ar-CH not seen; HRMS 
(ESI+) calculated for C27H30N2O5S [M+Na]
+ 517.1768; found 517.1767. 
 
General procedure 6: Asymmetric Transfer Hydrogenation (ATH) 
 
Scheme 6.3 General procedure for the ATH reaction. 
A solution of catalyst (0.5 - 1 mol%) in formic acid : triethylamine (5 : 2) 
azeotrope (so that [S] = 1.0 M) was stirred for 15 min. The ketone substrate (1.0 
equiv) and Dichloromethane (so that [S] = 0.25 – 0.5 M) were added and stirred 
at 23 °C. After 24 h, the reaction mixture was concentrated in vacuo. The crude 
product was purified by column chromatography (35-40% EtOAc/ pet ether) to 
give the following alcohols.  
In order to synthesise racemic samples of these compounds to determine ee, 
there were two methods employed. Either general method 3 was repeated with 
the opposite catalyst enantiomer and the two products obtained were mixed to 
generate a pseudo-racemate. Alternatively the ketones were reduced to the 
racemic alcohols. The ketone substrate (1.0 equiv), methanol (so that [S] = 0.1 
M) and sodium borohydride (2.5 equiv) were stirred at rt. After 2 h the solution 
was quenched with water (10 mL), washed with dichloromethane (3 x 10 mL), 
dried over MgSO4 and concentrated in vacuo. The crude product was purified 







(260). Following general procedure 6, aryl ketone 
249 (100 mg, 0.20 mmol, 1.0 equiv), catalyst (S,S)-23393 (1.2 mg, 2.0 µmol, 0.01 
equiv), 5 : 2 formic acid : triethylamine complex (0.2 mL, 1 M) and 
dichloromethane (0.4 mL, 0.5 M) yielded 260 as a white solid (100 mg, 0.2 
mmol, 99%). M.p. 141-142 °C; Rf = 0.21 (35% EtOAc in petroleum ether); 
[α]32D –37.7 (c 0.12, CHCl3). Enantiomeric excess (92% ee) was determined by 
HPLC analysis (25 °C). [Chiralpak OD-H column 2-propanol/hexane = 12/88; 
flow rate = 1.0 mL/min; detection wavelength = 254 nm] tR 18.4 min; tR 24.1 
min; IR (film) 3424, 3118, 2968, 2891, 1715, 1466, 1394, 1203 cm-1; δH (500 
MHz; CDCl3) 7.73 (2H, d, J 8.0, Ar-H), 7.45 (1H, s, Ar-H), 7.40 (1H, d, J 8.2, 
Ar-H), 7.36-7.32 (3H, m, Ar-H), 7.22 (2H, d, J 8.1, Ar-H), 7.19-7.05 (4H, m, 
Ar-H), 5.12 (1H, dd, J 9.1, 2.1, CHOH), 4.87 (2H, br s, CH2Ph), 3.81 (1H, t, J 
8.9, NCHH), 3.71 (1H, d, J 13.8, NCHH) 2.42 (3H, s, CH3); δC (125 MHz; 
CDCl3) 144.9 (Ar-C), 141.2 (Ar-C), 132.8 (Ar-C), 131.9 (Ar-C), 130.6 (Ar-CH), 
129.7 (Ar-CH), 129.7 (Ar-C, seen on HMBC), 128.7 (Ar-CH), 128.6 (Ar-CH), 
128.5 (Ar-CH), 128.2 (Ar-CH), 128.0 (Ar-CH), 125.3 (Ar-CH), 70.5 (CH, seen 
on HSQC), 68.9 (CH2), 58.7 (CH2), 21.8 (CH3), 1 Ar-C, C=O not seen; HRMS 
(ESI+) calculated for C23H22
35Cl2N2O5S [M+Na]
+ 531.0519; found 531.0517. 
 
Benzyl (S)-1-(2-(2-fluorophenyl)-2-hydroxyethyl)-2-
tosylhydrazine-1-carboxylate (261). Following general 
procedure 6, aryl ketone 250 (100 mg, 0.22 mmol, 1.0 
equiv), catalyst (R,R)-24796 (1.5 mg, 2.2 µmol, 0.01 equiv), 5 : 2 formic acid : 
triethylamine complex (0.22 mL, 1.0 M) and dichloromethane (0.44 mL, 0.5 M) 
yielded 261 as a colourless oil (97 mg, 0.21 mmol, 97%). Rf = 0.21 (35% EtOAc 
in petroleum ether); [α]32D +4.0 (c 0.22, CHCl3). Enantiomeric excess (90% ee) 
was determined by HPLC analysis (25 °C). [Chiralpak IA column 2-
propanol/hexane = 5/95; flow rate = 1.0 mL/min; detection wavelength = 254 
nm] tR 56.4 min; tR 61.4 min. IR (film) 3503, 3237, 2926, 1713, 1305, 1128 cm
-
1; δH (500 MHz; CDCl3) 7.73 (2H, d, J 7.9, Ar-CH), 7.47 (1H, t, J 7.3, Ar-H), 
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7.42 (1H, d, J 7.7, Ar-H), 7.38-7.26 (3H, m, Ar-H), 7.20 (2H, d, J 8.0, Ar-H), 
7.18-7.11 (3H, m, Ar-H), 7.00 (1H, t, J 10.0, Ar-H), 5.44-5.34 (1H, m, CHOH), 
4.86 (2H, br s, CH2Ph), 3.99-3.89 and 2.95-2.75 (minor rotamer) (2H, m, NCH2) 
2.40 (3H, s, CH3); δC (125 MHz; CDCl3) 159.9 (d, J 245.0, Ar-CF), 144.6 (Ar-
C), 135.0 (Ar-C), 129.6 (Ar-CH), 129.6 (Ar-CH), 128.0 (d, J 12.5, Ar-C), 127.7 
(d, J 3.8, Ar-CH), 124.5 (d, J 3.8, Ar-CH), 115.4 (d, J 21.3, Ar-CH), 68.7 (CH2), 
66.3 (CH, seen on HSQC), 57.0 (CH2), 21.7 (CH3), 1 Ar-C, 4 Ar-CH, C=O not 
seen; δF (376 MHz, CDCl3) -118.6 (CF); HRMS (ESI
+) calculated for 
C23H23FN2O5S [M+Na]
+ 481.1204; found 481.1209. 
 
Benzyl (R)-1-(2-(2-fluorophenyl)-2-hydroxyethyl)-2-
tosylhydrazine-1-carboxylate (261). Following general 
procedure 6, aryl ketone 250 (100 mg, 0.22 mmol, 1.0 
equiv), catalyst (S,S)-23393 (1.5 mg, 2.2 µmol, 0.01 equiv), 5 : 2 formic acid : 
triethylamine complex (0.22 mL, 1.0 M) and dichloromethane (0.44 mL, 0.5 M) 
yielded 261 as a colourless oil (97 mg, 0.21 mmol, 97%). [α]32D –3.17 (c 0.30, 
CHCl3). Enantiomeric excess (77% ee) was determined by HPLC analysis (25 
°C). [Chiralpak IA column 2-propanol/hexane = 5/95; flow rate = 1.0 mL/min; 
detection wavelength = 254 nm] tR 56.4 min; tR 61.4 min. 
 
Benzyl (R)-1-(2-(4-fluorophenyl)-2-hydroxyethyl)-
2-tosylhydrazine-1-carboxylate (263) Following 
general procedure 6, aryl ketone 252 (106 mg, 0.23 
mmol, 1.0 equiv), catalyst (S,S)-23393 (1.4 mg, 2.3 
µmol, 0.01 equiv), 5 : 2 formic acid : triethylamine complex (0.23 mL, 1.0 M) 
and dichloromethane (0.46 mL, 0.5 M) yielded 263 as a white solid (105 mg, 
0.23 mmol, 99%). M.p. 122-124 °C. [α]32D – 29.9 (c 0.09, CHCl3). Enantiomeric 
excess (99% ee) was determined by HPLC analysis (25 °C). [Chiralpak OD-H 
column 2-propanol/hexane = 5/95; flow rate = 1 mL/min; detection wavelength 
= 254 nm] tR 42.9 min: tR 47.5 min. IR (film) 3447, 3263, 3129, 2923, 1717, 
1601, 1508, 1398, 1217 cm-1; δH (500 MHz, CDCl3) 7.72 (2H, dd,  J 8.2, 3.3, 
Ar-CH), 7.36-7.27 (5H, m, Ar-CH), 7.25-7.06 (4H, m, Ar-CH), 7.02 (2H, t, J 
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8.5, Ar-CH), 5.13 (1H, d, J 9.0, CHOH), 4.95-4.72 (2H, m, CH2Ph), 3.86 and 
3.17 (minor rotamer) (1H, m, NCH2), 3.73 and 3.00 (minor rotamer) (1H, m, 
NCH2), 2.41 and 2.43 (minor rotamer) (3H, s, CH3); δC (150 MHz; CDCl3) 
162.5 and 162.6 (minor rotamer) (d, J 245.0, Ar-CF), 144.7 (Ar-C), 143.7 (Ar-
C) 136.8 and 136.6 (minor rotamer) (d, J 3.8, Ar-C), 136.7 (Ar-C), 129.8 (Ar-
CH), 129.6 (Ar-CH), 128.5 and 128.4 (minor rotamer) (Ar-CH), 128.1 (Ar-CH), 
127.7 and 127.6 (minor rotamer) (d, J 7.5, Ar-CH), 127.1 (Ar-CH), 115.5 and 
115.6 (minor rotamer) (d, J 21.3, Ar-CH), 72.2 (CH), 68.7 (CH2), 58.5 and 50.2 
(minor rotamer) (CH2), 21.7 (CH3); δF (376 MHz, CDCl3) -114.1 and -113.7 
(minor rotamer) (CF); HRMS (ESI+) calculated for C24H23F3N2O5S [M+Na]
+ 
531.1172; found 531.1173.  
 
Benzyl (R)-1-(2-(3-bromophenyl)-2-hydroxyethyl)-2-
tosylhydrazine-1-carboxylate (264). Following general 
procedure 6, aryl ketone 253 (80 mg, 0.15 mmol, 1.0 
equiv), catalyst (S,S)-23393 (1.0 mg, 1.5 µmol, 0.01 equiv), 
5 : 2 formic acid : triethylamine complex (0.15 mL, 1.0 M) and dichloromethane 
(0.3 mL, 0.5 M) yielded 264 as a white solid (80 mg, 0.15 mmol, 99%). Rf = 
0.20 (35% EtOAc in petroleum ether); M.p. 135-136 °C; [α]32D –16.0 (c 0.50, 
CHCl3); Enantiomeric excess (97% ee) was determined by HPLC analysis (25 
°C). [Chiralpak OD-H column 2-propanol/hexane = 9/91; flow rate = 1.0 
mL/min; detection wavelength = 254 nm] tR 19.6 min; tR 25.1 min; IR (film) 
3456, 3222, 2929, 1715, 1323, 1211, 1185 cm-1; δH (500 MHz; CDCl3) 7.73 
(2H, d, J 8.0, Ar-CH), 7.50 (1H, s, Ar-H), 7.42 (1H, d, J 7.7, Ar-H), 7.36-7.32 
(3H, m, Ar-H), 7.27-7.05 (6H, m, Ar-H) 5.11 (1H, d, J 9.5, CHOH), 4.87 (2H, 
br s, CH2Ph), 3.90-3.65 (2H, m, NCH2) 2.41 (3H, s, CH3); δC (125 MHz; CDCl3) 
144.8 (Ar-C), 143.4 (Ar-C), 131.1 (Ar-CH), 130.2 (Ar-CH), 129.7 (Ar-CH), 
129.0 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.1 (Ar-CH), 124.6 (Ar-CH), 
122.8 (Ar-C), 70.6 (CH, seen on HSQC), 68.8 (CH2), 58.5 (CH2), 21.8 (CH3), 2 
Ar-C, 1 Ar-CH, C=O not seen; HRMS (ESI+) calculated for C23H23
79BrN2O5S 






1-carboxylate (265). Following general procedure 
6, aryl ketone 254 (100 mg, 0.20 mmol, 1.0 equiv), catalyst (S,S)-23393 (1.2 mg, 
2.0 µmol, 0.01 equiv), 5 : 2 formic acid : triethylamine complex (0.2 mL, 1.0 M) 
and dichloromethane (0.4 mL, 0.5 M) yielded 265 as a white solid (97 mg, 0.19 
mmol, 96%). Rf = 0.19 (35% EtOAc in petroleum ether); M.p. 147-148 °C; 
[α]32D –18.1 (c 0.06, CHCl3). Enantiomeric excess (95% ee) was determined by 
HPLC analysis (25 °C). [Chiralpak OD-H column 2-propanol/hexane = 8/92; 
flow rate = 1.0 mL/min; detection wavelength = 254 nm] tR 20.6 min; tR 25.4 
min; IR (film) 3439, 3144, 2923, 1716, 1401, 1324, 1087 cm-1; δH (600 MHz; 
d6-DMSO at 100 °C) 9.66 (1H, s, NH), 7.68 (2H, d, J 8.2, Ar-H), 7.61 (2H, d, J 
8.1, Ar-H), 7.50 (2H, d, J 8.0, Ar-H), 7.39-7.25 (5H, m, Ar-H), 7.15 (2H, d, J 
7.5, Ar-H), 5.31 (1H, s, OH), 4.96-4.92 (1H, t, J 8.2, CHOH), 4.75-4.63 (2H, m, 
CH2Ph), 3.75-3.58 (2H, m, NCH2), 2.38 (3H, s, CH3); δC (150 MHz; D6-DMSO 
at 100 °C) 155.7 (C=O), 148.1 (Ar-C), 143.9 (Ar-C), 137.3 (Ar-C), 136.3 (Ar-
C), 129.8 (Ar-CH), 128.6 (q, J 26.3, Ar-C), 128.5 (Ar-CH), 128.2 (Ar-CH), 
127.9 (Ar-CH), 127.9 (Ar-CH), 127.3 (Ar-CH), 125.3 (q, J 3.8, Ar-CH), 124.8 
(q, J 225.0, CF3), 69.5 (CH), 67.7 (CH2), 58.0 (CH2), 21.4 (CH3); δF (286 MHz, 
D6-DMSO) -61.8 (CF3); HRMS (ESI
+) calculated for C24H23F3N2O5S [M+Na]
+ 
531.1172; found 531.1173. 
 
Benzyl (S)-1-(2-(2-chlorophenyl)-2-hydroxyethyl)-2-
tosylhydrazine-1-carboxylate (266). Following general 
procedure 6, aryl ketone 255 (100 mg, 0.20 mmol, 1.0 
equiv), catalyst (R,R)-24796 (1.3 mg, 2.0 µmol, 0.01 equiv), 5 : 2 formic acid : 
triethylamine complex (0.2 mL, 1.0 M) and dichloromethane (0.4 mL, 0.5 M) 
yielded 266 as a colourless oil (100 mg, 0.2 mmol, 99%). Rf = 0.21 (35% EtOAc 
in petroleum ether); [α]32D +35.8 (c 0.12, CHCl3). Enantiomeric excess (90% ee) 
was determined by HPLC analysis (25 °C). [Chiralpak IA column 2-
propanol/hexane = 5/95; flow rate = 1.0 mL/min; detection wavelength = 254 
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nm] tR 57.1 min; tR 65.2 min; IR (film) 3443, 3115, 2896, 1717, 1457, 1432, 
1250 cm-1; δH (500 MHz; CDCl3) 7.74 (2H, d, J 7.8, Ar-H), 7.57 (1H, d, J 7.5, 
Ar-H), 7.40 (1H, d, J 8.2, Ar-H), 7.35-7.10 (9H, m, Ar-H), 5.48 (1H, m, CHOH), 
4.88 (2H, br s, CH2Ph), 3.87 and 2.92 (minor rotamer) (2H, br s, NCH2), 2.40 
(3H, s, CH3); δC (125 MHz; CDCl3) 144.6 (Ar-C), 138.4 (Ar-C), 131.9 (Ar-C), 
129.6 (Ar-CH), 129.5 (Ar-CH), 129.1 (Ar-CH), 128.5 (Ar-CH), 128.2 (Ar-CH), 
127.6 (Ar-CH), 127.2 (Ar-CH), 69.0 (CH, seen on HSQC), 68.7 (CH2), 56.6 




+ 497.0908; found 497.0905. 
 
Benzyl (R)-1-(2-(2-chlorophenyl)-2-hydroxyethyl)-2-
tosylhydrazine-1-carboxylate (266). Following 
general procedure 6, aryl ketone 255 (100 mg, 0.20 
mmol, 1.0 equiv), catalyst (S,S)-23393 (1.3 mg, 2.0 µmol, 0.01 equiv), 5 : 2 
formic acid : triethylamine complex (0.2 mL, 1.0 M) and dichloromethane (0.4 
mL, 0.5 M) yielded 266 as a colourless oil (100 mg, 0.2 mmol, 99%). [α]32D –
14.7 (c 0.10, CHCl3). Enantiomeric excess (19% ee) was determined by HPLC 
analysis (25 °C). [Chiralpak IA column 2-propanol/hexane = 5/95; flow rate = 




(269) Following general procedure 6, aryl ketone 258 
(70 mg, 0.15 mmol), catalyst (S,S)-23393 (0.96 mg, 
0.0015 mmol), 5:2 FA:TEA complex (0.15 mL, 1 M) and CH2Cl2 (0.3 mL, 0.5 
M) yielded 269 as a colourless oil (64 mg, 0.13 mmol, 91%). [α]32D – 2.62 (c 
0.21, CHCl3). Enantiomeric excess (99% ee) was determined by HPLC analysis 
(25 °C). [Chiralpak OD-H column 2-propanol/hexane = 10/90; flow rate = 1 
mL/min; detection wavelength = 254 nm] tR 24.8 min: tR 29.1 min. IR (film) 
3456, 3222, 2929, 1715, 1323, 1211, 1185 cm-1; δH (500 MHz; CDCl3) 7.72 
(2H, d,  J 7.9, Ar-H), 7.43 (1H, d, J 7.6, Ar-H) 7.42 (1H, d, J 8.1, Ar-H), 7.36-
7.05 (9H, m, Ar-H), 6.67 (1H, s, Ar-H), 5.22 (1H, dd, J 8.5, 3.6, CHOH), 4.82 
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(2H, br s, CH2Ph), 4.29-3.90 (2H, m, NCH2) 2.39 (3H, s, CH3); δC (125 MHz; 
CDCl3) 156.1 (Ar-C), 154.9 (Ar-C), 144.6 (Ar-C), 130.6 (Ar-CH), 129.6 (Ar-
CH) 128.5 (Ar-CH), 128.0 (Ar-CH), 127.9 (Ar-C) 124.5 (Ar-CH), 123.0 (Ar-
CH), 121.2 (Ar-CH), 111.3 (Ar-CH), 103.9 (Ar-CH) 68.7 (CH2), 65.5 (CH, seen 
on HSQC), 55.4 (CH2), 21.7 (CH3), 3 Ar-C, 2 Ar-CH, C=O not seen; HRMS 
(ESI+) calculated for C25H24N2O6S [M+Na]
+ 503.1247; found 503.1249. 
 
tert-Butyl (R)-1-(2-hydroxy-2-phenylethyl)-2-
tosylhydrazine-1-carboxylate (211). Following general 
procedure 6, aryl ketone 283 (100 mg, 0.25 mmol, 1.0 equiv), (S,S)-23393 (1.6 
mg, 2.5 µmol, 0.01 equiv), 5:2 FA:TEA complex (0.25 mL, 1 M) and CH2Cl2 
(0.50 mL, 0.5 M) yielded 211 as a white solid (100 mg, 0.25 mmol, 99%). Rf = 
0.21 (25% EtOAc in petroleum ether); M.p. 138-139 °C; [α]D
28 = –4.8 (c 0.12, 
CHCl3); Enantiomeric excess (99% ee) was determined by HPLC analysis (25 
°C). [Chiralpak IA column 2-propanol/hexane = 1.5/98.5; flow rate = 1.0 
mL/min; detection wavelength = 254 nm] tR 37.7 min; tR 42.4 min; IR (film) 
3456, 3128, 2975, 1709, 1089; δH (500 MHz, CHCl3) 7.82 (2H, d, J 8.2, Ar-H), 
7.36 (7H, m, Ar-H), 5.17 (1H, dd, J 9.9, 3.6, CHPh), 3.86 (1H, br m, NCHH), 
3.74 (1H, d, J 9.9, NCHH), 2.44 (3H, s, CH3), 1.18 (9H, br s, C(CH3)3); δC (125 
MHz, CDCl3) 144.6 (C=O), 141.4 (Ar-C), 132.2 (Ar-C), 132.1 (Ar-C) 130.0 
(Ar-CH), 129.8 (Ar-CH), 128.6 (Ar-CH), 128.0 (Ar-CH), 126.0 (Ar-CH), 82.9 
(C), 75.2 (CH), 58.8 (CH2) 27.8 (CH3), 21.6 (CH3); HRMS (ES
+) calculated for 
C20H26N2O5S (M+Na)
+ 429.1451; found 429.1455. 
 
Benzyl (S)-1-(3-hydroxy-3-phenylpropyl)-2-
tosylhydrazine-1-carboxylate (298). Following general 
procedure 6, aryl ketone 287 (100 mg, 0.22 mmol), 
catalyst (S,S)-23393 (1.4 mg, 2.2 µmol), 5 : 2 formic acid : triethylamine complex 
(0.22 mL, 1.0 M) and dichloromethane (0.88 mL, 0.25 M) yielded 298 as a 
colourless oil (100 mg, 0.22 mmol, 99%). Rf = 0.23 (35% EtOAc in petroleum 
ether); [α]32D –4.6 (c 0.75, CHCl3). Enantiomeric excess was determined after 
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cyclisation to 309. IR (film) 3503, 3228, 2951, 1707, 1340, 1185 cm-1; δH (500 
MHz; CDCl3) 7.73 (2H, d, J 7.9, Ar-CH), 7.38-7.29 (5H, m, Ar-H) 7.47 (4H, dd, 
J 13.5 and 7.9, Ar-H), 7.21 (3H, d, J 7.9, Ar-H), 7.02 (1H, br s, NH), 5.01-4.59 
(3H, m, CHOH and CH2Ph), 3.84 (2H, br s, NCH2), 2.42 (3H, s, CH3) 2.09-2.03 
(2H, m, CH2CHOH); δC (125 MHz; CDCl3) 144.4 (Ar-C), 143.4 (Ar-C), 135.1 
(Ar-C), 129.5 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.5 (Ar-CH), 128.4 
(Ar-CH), 128.1 (Ar-CH), 127.8 (Ar-CH), 125.6 (Ar-CH), 72.3 (CH), 68.4 (CH2), 
48.7 (CH2), 35.0 (CH2), 21.7 (CH3), C=O and 1 Ar-C not seen; HRMS (ESI
+) 
calculated for C24H26N2O5S [M+Na]




Following general procedure 6, aryl ketone 285 (100 mg, 
0.22 mmol, 1.0 equiv), catalyst (S,S)-23393 (1.4 mg, 2.2 µmol, 0.01 equiv), 5 : 2 
formic acid : triethylamine complex (0.22 mL, 1.0 M) and dichloromethane 
(0.88 mL, 0.25 M) yielded 296 as a white solid (86 mg, 0.19 mmol, 86%). Rf = 
0.18 (35% EtOAc in petroleum ether); M.p. 112-114 °C; [α]32D –5.0 (c 0.30, 
CHCl3); enantiomeric excess was determined after cyclisation to 307. IR (film) 
3512, 3287, 2951, 1712, 1620, 1350, 1158 cm-1; δH (500 MHz; CDCl3) 8.28 
(2H, d, J 8.3, Ar-H), 8.04 (2H, t, J 9.2, Ar-H), 7.29 (3H, d, J 4.3, Ar-H), 7.28-
7.19 (2H, m, Ar-H), 6.62 (1H, s, NH), 4.84 (1H, t, J 6.1, CHOH), 3.84-3.45 (2H, 
m, NCH2), 1.95 (2H, q, J 6.1, CH2CHOH), 1.26-1.18 (9H, m, C(CH3)3); δC (125 
MHz; CDCl3) 153.5 (C=O), 150.5 (Ar-C), 143.9 (Ar-C), 128.7 (Ar-CH), 128.6 
(Ar-CH), 127.8 (Ar-CH), 125.7 (Ar-CH), 124.0 (Ar-CH), 83.3 (C) and 82.6 
(minor rotamer), 71.7 (CH), 47.5 (CH2), 36.4 (CH2), 27.9 (CH3) and 27.8 (minor 
rotamer), 1 Ar-C not seen; HRMS (ESI+) calculated for C20H25N3O7 [M+Na]
+ 
474.1305; found 474.1307. 
 
Benzyl (S)-2-(3-hydroxy-3-phenylpropyl)-2-
tosylhydrazine-1-carboxylate (295) Following general 
procedure 6, aryl ketone 284 (1.0 g, 2.20 mmol, 1.0 
equiv), (S,S)-23393 (7.0 mg, 11 µmol, 0.005 equiv) and formic acid : 
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trimethylamine (5 : 2) azeotrope (2.2 mL, 1M) and dichloromethane (8.8 mL, 
0.25 M) were stirred for 72 h gave 295 as a white solid (1.00 g, 2.20 mmol, 
99%). Rf = 0.28 (33% EtOAc in petroleum ether). M.p. 125-127 °C. [α]
32
D – 
15.24 (c 0.08, CHCl3). Enantiomeric excess was determined after cyclisation to 
306. IR (film) 3546, 3313, 2925, 1749, 1220, cm-1; δH (500 MHz; CDCl3) 7.76 
(2H, d,  J 6.2, Ar-CH), 7.37-7.22 (12H, m, Ar-H) 6.57 (1H, br s, NH), 5.10-4.90 
(3H, m, CHOH and CH2Ph), 3.71 (1H, br s, NCHH), 3.44 (1H, br s, NCHH), 
2.64 (1H, br s, CHOHCHH),  2.42 (3H, s, CH3) 1.95 (1H, br s, CHOHCHH); δC 
(125 MHz; CDCl3) 154.8 (C=O), 144.7 (Ar-C), 143.2 (Ar-C), 135.4 (Ar-C), 
133.4 (Ar-C), 129.8 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.5 (Ar-CH) 
128.2 (Ar-CH), 127.5 (Ar-CH), 125.7 (Ar-CH), 71.4 (CH), 67.8 (CH2), 48.0 
(CH2), 36.4 (CH2), 21.7 (CH3), 1 Ar-CH not seen; HRMS (ESI
+) calculated for 
C24H26N2O5S [M+Na]
+ 477.1455; found 4771453. 
 
tert-Butyl (S)-2-(3-hydroxy-3-phenylpropyl)-2-
tosylhydrazine-1-carboxylate (297). Following general 
procedure 6, aryl ketone 286 (97 mg, 0.23 mmol, 1.0 
equiv), catalyst (S,S)-23393 (1.4 mg, 2.3 μmol, 0.01 equiv), 5 : 2 formic acid : 
triethylamine complex (0.23 mL, 1.0 M) in dichloromethane (0.92 mL, 0.25 M) 
yielded 297 as a colourless oil (96 mg, 0.23 mmol, 98%). Rf = 0.22 (35% EtOAc 
in petroleum ether); [α]32D –34.4 (c 0.20, CHCl3). Enantiomeric excess (96% ee) 
was determined by HPLC analysis (25 °C). [Chiralpak IA column 2-
propanol/hexane = 15/85; flow rate = 1.0 mL/min; detection wavelength = 254 
nm] tR 15.4 min; tR 20.1 min; IR (film) 3294, 2985, 1745, 1393, 1159, 1055 cm
-
1; δH (400 MHz; CDCl3) 7.81-7.79 (2H, m, Ar-H), 7.38-7.27 (7H, m, Ar-H), 
6.45 (major) and 6.08 (minor) (1H, br s, NH), 4.97 (1H, br s, CHOH), 3.68-3.48 
(2H, m, NCH2), 2.95 (1H, br s, OH), 2.42 (3H, s, Ts-CH3), 1.97 (2H, br s, 
CHCH2), 1.32 (9H, s, (CH3)3); δC (125 MHz; CDCl3) 153.9 (C=O), 144.7 (Ar-
C), 144.6 (Ar-C), 133.8 (Ar-C), 129.7 (Ar-CH), 128.8 (Ar-CH), 128.6 (Ar-CH), 
127.5 (Ar-CH), 125.8 (Ar-CH), 81.9 (C), 71.5 (CH), 47.8 (NCH2), 36.6 (CH2), 
166 
 
28.0 (CH3), 21.8 (CH3); HRMS (ESI
+) calculated for C21H28N2NaO5S [M+Na]
+ 




carboxylate (299). Following general procedure 
6, aryl ketone 288 (100 mg, 0.20 mmol, 1.0 
equiv), catalyst (S,S)-23393 (1.27 mg, 2.0 µmol), 5 : 2 formic acid : triethylamine 
complex (0.20 mL, 1.0 M) and dichloromethane (0.80 mL, 0.25 M) yielded 299 
as a white solid (100 mg, 0.20 mmol, 99%). M.p. 121-124 °C; Rf = 0.17 (35% 
EtOAc in petroleum ether); [α]32D –25.8 (c 0.65, CHCl3). Enantiomeric excess 
(91% ee) was determined by HPLC analysis (25 °C). [Chiralpak OD-H column 
2-propanol/hexane = 10/90; flow rate = 1.0 mL/min; detection wavelength = 254 
nm] tR 25.0 min; tR 30.2 min. IR (film) 3513, 3303, 2925, 1704, 1367, 1247 cm
-
1; δH (500 MHz; CDCl3) 7.83 (2H, d, J 7.1, Ar-CH), 7.48 (2H, d, J 7.8, Ar-H), 
7.36 (2H, d, J 7.7, Ar-H), 7.36 (2H, d, J 7.6, Ar-H), 5.02 (1H, br s, CHOH), 3.88-
3.01 (2H, m, NCH2), 2.46 (3H, s, CH3) 2.05-1.82 (2H, m, CH2CHOH), 1.36 (9H, 
s, C(CH3)3); δC (125 MHz; CDCl3) 154.1 (C=O), 144.8 (Ar-C), 143.6 (Ar-C), 
133.5 (Ar-C), 131.5 (Ar-CH), 129.7 (Ar-CH), 128.7 (Ar-CH), 127.5 (Ar-CH), 
121.0 (Ar-C), 82.1 (C), 70.8 (CH), 47.8 (CH2), 36.5 (CH2), 27.9 (CH3), 21.6 
(CH3); HRMS (ESI
+) calculated for C21H27
79BrN2O5S [M+Na]





Following general procedure 6, aryl ketone 289 (100 
mg, 0.24 mmol, 1.0 equiv), catalyst (S,S)-23393 (1.5 mg, 2.4 µmol, 0.01 equiv), 
5 : 2 formic acid : triethylamine complex (0.24 mL, 1.0 M) and Dichloromethane 
(0.48 mL, 0.25 M) yielded 300 as a colourless oil (97 mg, 0.23 mmol, 97%). Rf 
= 0.21 (35% EtOAc in petroleum ether); [α]32D –6.5 (c 0.13, CHCl3). 
Enantiomeric excess (98% ee) was determined by HPLC analysis (25 °C). 
[Chiralpak IA column 2-propanol/hexane = 5/95; flow rate = 1.0 mL/min; 
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detection wavelength = 254 nm] tR 22.4 min; tR 24.5 min; IR (film) 3453, 3309, 
2926, 1704, 1354, 1252 cm-1; δH (500 MHz; CDCl3) 7.82 (2H, d, J 7.4, Ar-CH), 
7.35 (2H, d, J 6.6, Ar-H), 7.26 (1H, d, J 4.0, Ar-H), 7.08-6.94 (2H, m, Ar-H), 
6.43 (1H, s, NH), 5.27 (1H, br s, CHOH), 3.79-3.47 (2H, m, NCH2), 2.45 (3H, 
s, CH3) 2.20-2.03 (2H, m, CH2CHOH), 1.34 (9H, s, C(CH3)3); δC (125 MHz; 
CDCl3) 153.8 (C=O), 148.4 (Ar-C), 144.6 (Ar-C), 133.7 (Ar-C), 129.6 (Ar-CH), 
128.7 (Ar-CH), 126.7 (Ar-CH), 124.4 (Ar-CH), 123.5 (Ar-CH), 82.0 (C), 67.7 
(CH), 47.6 (CH2), 36.6 (CH2), 27.9 (CH3), 21.6 (CH3); HRMS (ESI
+) calculated 
for C19H26N2O5S2 [M+Na]




carboxylate (301). Following general procedure 
6, aryl ketone 290 (100 mg, 0.20 mmol, 1.0 
equiv), catalyst (S,S)-23393 (1.3 mg, 2.0 µmol, 0.01 equiv), 5 : 2 formic acid : 
triethylamine complex (0.20 mL, 1.0 M) and Dichloromethane (0.80 mL, 0.25 
M) yielded 301 as a white solid (100 mg, 0.20 mmol, 99%). M.p. 62-63 °C; Rf 
= 0.19 (35% EtOAc in petroleum ether); [α]32D –17.7 (c 0.62, CHCl3). 
Enantiomeric excess was determined after cyclisation to 312. IR (film) 3513, 
3303, 2926, 1704, 1391, 1247 cm-1; δH (500 MHz; CDCl3) 7.84 (2H, d, J 7.1, 
Ar-CH), 7.60 (4H, t, J 7.1, Ar-H) 7.47 (4H, dd, J 13.5, 7.9, Ar-H), 7.36 (3H, t, J 
7.5, Ar-H), 6.40 (1H, br s, NH), 5.07 (1H, s, CHOH), 3.81-3.42 (2H, m, NCH2), 
2.46 (3H, s, CH3) 2.09-1.96 (2H, m, CH2CHOH), 1.26 (9H, s, C(CH3)3); δC (125 
MHz; CDCl3) 153.9 (C=O), 150.5 (Ar-C), 144.6 (Ar-C), 143.5 (Ar-C), 140.3 
(Ar-C), 133.7 (Ar-C), 129.7 (Ar-CH), 128.8 (Ar-CH), 128.7 (Ar-CH), 127.2 
(Ar-CH), 127.2 (Ar-CH), 127.1 (Ar-CH), 126.2 (Ar-CH), 81.9 (C), 71.2 (CH), 
47.8 (CH2), 36.5 (CH2), 28.0 (CH3) 21.6 (CH3); HRMS (ESI
+) calculated for 
C27H32N2O5S [M+Na]






(302). Following general procedure 6, aryl ketone 
291 (572 mg, 1.26 mmol, 1.0 equiv), (R,R)-24796 
(8.4 mg, 13 µmol, 0.01 equiv), 5:2 formic acid : triethylamine complex (1.26 
mL, 1 M) and CH2Cl2 (5 mL, 0.25 M) yielded 302 as a white solid (572 mg, 1.26 
mmol, 99%). Rf = 0.46 (33% EtOAc in petroleum ether); [α]D
24 + 55.3 (c 0.03, 
CHCl3); Enantiomeric excess (93% ee) was determined by HPLC analysis (25 
°C). [Chiralpak IA column 2-propanol/hexane = 10/90; flow rate = 1.0 mL/min; 
detection wavelength = 254 nm] tR 13.5 min; tR 16.3 min. M.p. 110-111 °C; IR 
(film) 3333, 3165, 2980, 1740, 1625, 1183 cm-1; δH (500 MHz; CDCl3) 7.84 
(2H, d, J 7.4, Ar-H), 7.37 (2H, d, J 7.8, Ar-H), 6.95 (2H, d, J 6.3, Ar-H), 6.70 
(1H, t, J 7.7, Ar-H), 6.33 (1H, s, NH), 5.08 (1H, d, J 5.1, CHOH), 3.79-3.65 (1H, 
br m, CHHN), 3.48-3.37 (1H, br m, CHHN), 2.46 (3H, s, CH3), 2.04-1.95 (1H, 
br m, CHOHCHH), 1.92-1.79 (1H, br m, CHOHCHH), 1.37 (9H, s, C(CH3)3); 
δC (125 MHz; CDCl3) 163.1 (dd, J 246.2, 12.5, Ar-CF), 154.3 (C=O), 149.0 
(Ar-C), 144.9 (Ar-C), 133.3 (Ar-C), 129.7 (Ar-CH), 128.7 (Ar-CH), 108.5 (dd, 
J 21.3, 6.3, Ar-CH), 102.4 (t, J 26.3, Ar-CH), 82.3 (C), 70.4 (CH), 47.8 (CH2), 
36.4 (CH2), 27.9 (CH3), 21.6 (CH3); δF (376 MHz; CDCl3) -109.9 (Ar-CF); 
HRMS (ESI+) calculated for C21H26N2NaO5SF2 [M+Na]





carboxylate (302). Following general procedure 
6, aryl ketone 291 (266 mg, 0.59 mmol, 1.0 equiv), 
(S,S)-23393 (3.6 mg, 6 µmol, 0.01 equiv), 5:2 FA:TEA complex (0.59 mL, 1 M) 
and CH2Cl2 (2.4 mL, 0.25 M) yielded 302 as a white solid (266 mg, 0.59 mmol, 
99%). [α]D
24 – 14.2 (c 0.10, CHCl3); Enantiomeric excess (80% ee) was 
determined by HPLC analysis (25 °C). [Chiralpak IA column 2-propanol/hexane 
= 10/90; flow rate = 1.0 mL/min; detection wavelength = 254 nm] tR 13.5 min; 





tosylhydrazine-1-carboxylate (323). Following 
general procedure 6, aryl ketone 318 (60 mg, 0.13 mmol, 1.0 equiv),  (S,S)-23393 
(1.0 mg, 1.3 µmol, 0.01 equiv), 5 : 2 formic acid : triethylamine complex (0.13 
mL, 1.0 M) and dichloromethane (0.26 mL, 0.5 M) yielded 323 as a colourless 
oil (60 mg, 0.13 mmol, 99%). Rf = 0.20 (35% EtOAc in petroleum ether); [α]
32
D 
–13.0 (c 0.92, CHCl3); enantiomeric excess was determined after cyclisation to 
329; IR (film) 3510, 3285, 2946, 1717, 1375, 1184 cm-1; δH (500 MHz; CDCl3) 
7.72 (2H, d, J 8.0, Ar-H), 7.40-7.30 (8H, m, Ar-H), 7.21 (2H, d, J 8.1, Ar-H), 
7.12 (2H, d, J 6.1, Ar-H), 4.88 (2H, s, CH2Ph), 4.69 (1H, s, CHOH), 3.70 (2H, 
br s, NCH2), 2.42 (3H, s, CH3), 1.85-1.62 (4H, m, CH2CH2CHOH); δC (125 
MHz; CDCl3) 144.5 (Ar-C), 144.4 (Ar-C), 135.2 (Ar-C), 129.5 (Ar-CH), 128.6 
(Ar-CH), 128.5 (Ar-CH), 128.5 (Ar-CH), 128.1 (Ar-CH), 127.7 (Ar-CH), 125.8 
(Ar-CH), 74.2 (CH), 68.4 (CH2), 50.8 (CH2), 35.7 (CH2), 23.4 (CH2), 21.7 
(CH3), C=O, 1 Ar-C and 1 Ar-CH not seen; HRMS (ESI
+) calculated for 
C25H26N2O5S [M+Na]
+ 489.1455; found 489.1455. 
 
Benzyl (S)-1-(5-hydroxy-5-phenylpentyl)-2-
tosylhydrazine-1-carboxylate (324). Following 
general procedure 6, aryl ketone 319 (80 mg, 0.17 
mmol, 1.0 equiv), catalyst (S,S)-23393 (1.0 mg, 1.7 µmol, 0.01 equiv), 5 : 2 
formic acid : triethylamine complex (0.17 mL, 1.0 M) and dichloromethane 
(0.34 mL, 0.5 M) yielded 324 as a colourless oil (80 mg, 0.17 mmol, 99%). Rf = 
0.20 (35% EtOAc in petroleum ether); [α]32D –8.2 (c 1.13, CHCl3). Enantiomeric 
excess was determined after cyclisation to 330; IR (film) 3489, 3233, 2925, 
1707, 1340, 1215 cm-1; δH (500 MHz; CDCl3) 7.72 (2H, d, J 8.0, Ar-H), 7.38-
7.31 (8H, m, Ar-H), 7.21 (2H, d, J 8.1, Ar-H), 7.14 (2H, s, Ar-H), 6.91 (1H, s, 
NH), 4.88 (2H, s, CH2Ph), 4.69-4.61 (1H, m, CHOH), 3.65 (2H, br s, NCH2), 
2.42 (3H, s, CH3) 1.85-1.62 (4H, m, NCH2CH2 and CH2CHOH), 1.42-1.31 (2H, 
m, CH2CH2CH2); δC (125 MHz; CDCl3) 144.6 (Ar-C), 144.5 (Ar-C), 135.2 (Ar-
C), 129.5 (Ar-CH), 128.5 (Ar-CH), 128.5 (Ar-CH), 128.1 (Ar-CH), 127.6 (Ar-
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CH), 125.8 (Ar-CH), 74.3 (CH), 68.3 (CH2), 50.9 (CH2), 38.5 (CH2), 26.7 (CH2), 
22.6 (CH2), 21.7 (CH3), 1 C=O, 1 Ar-C and 2 Ar-CH not seen; HRMS (ESI
+) 
calculated for C26H30N2O5S [M+Na]
+ 505.1768; found 505.1767. 
 
Benzyl (S)-1-(6-hydroxy-6-phenylhexyl)-2-
tosylhydrazine-1-carboxylate (325). Following 
general procedure 6, aryl ketone 320 (93 mg, 0.17 mmol), (S,S)-23393 (1.20 mg, 
1.9 µmol), 5 : 2 formic acid : triethylamine complex (0.19 mL, 1 M) and 
dichloromethane (0.38 mL, 0.5 M) yielded 325 as a colourless oil (66.8 mg, 0.14 
mmol, 71%). Rf = 0.47 (35% EtOAc in petroleum ether).  [α]
32
D – 6.25 (c 0.02, 
CHCl3). Enantiomeric excess could not be determined. IR (film) 3473, 3225, 
2932, 1701, 1338, 1158 cm-1; δH (500 MHz; CDCl3) 7.70 (2H, d,  J 8.0, Ar-
CH), 7.38-7.27 (8H, m, Ar-H), 7.19 (2H, d, J 8.1, Ar-H), 7.11 (2H, s, Ar-H), 
6.91 (1H, s, NH), 4.86 (2H, s, CH2Ph), 4.63 (1H, t, J 7.0, CHOH), 3.61 (2H, br 
s, NCH2), 2.4) 173.60 (3H, s, CH3) 1.80-1.60 (4H, m, 2 x CH2), 1.45-1.29 (4H, 
m, 2 x CH2); δC (125 MHz, CDCl3) 156.3 (C=O), 144.8 (Ar-C), 144.4 (Ar-C), 
129.5 (Ar-CH), 128.5 (Ar-CH) 128.5 (Ar-CH), 128.5 (Ar-CH), 128.1 (Ar-CH), 
127.6 (Ar-CH), 125.9 (Ar-CH), 74.5 (CH), 68.3 (CH2), 64.3 (CH2), 51.0 (CH2), 
38.8 (CH2), 26.3 (CH2), 25.4 (CH2), 21.7 (CH3), 2 Ar-C and 2 Ar-CH not seen; 
HRMS (ESI+) calculated for C27H32N2O5S [M+Na]
+ 519.1924; found 519.1922. 
 
General procedure 7: Mitsunobu cyclisation 
 
To a solution of alcohol (1.0 equiv) in tetrahydrofuran (0.01 M) was added 
triphenylphosphine (1.5-2.5 equiv) and diethyl azodicarboxylate (1.5-2.5 equiv). 
The reaction mixture was stirred at rt until completion of the reaction (12-48 h, 
monitored by TLC). The reaction mixture was concentrated in vacuo. The crude 
product was purified by column chromatography (20-30% EtOAc in petroleum 





diazetidine-1-carboxylate (270). Following general 
procedure 7, 260 (100 mg, 0.20 mmol, 1.0 equiv), 
triphenylphosphine (129 mg, 0.49 mmol, 2.5 equiv), 
diethyl azodicarboxylate (76 µL, 0.49 mmol, 2.5 equiv) 
and tetrahydrofuran (20 mL, 0.01 M) yielded 270 as a white solid (75 mg, 0.15 
mmol, 78%). M.p. 133-135 °C; Rf = 0.23 (25% EtOAc in petroleum ether); 
[α]32D +33.2 (c 4.40, CHCl3); Enantiomeric excess (90% ee) was determined by 
HPLC analysis (25 °C). [Chiralpak OD-H column 2-propanol/hexane = 10/90; 
flow rate = 1.0 mL/min; detection wavelength = 254 nm] tR 25.0 min; tR 33.1 
min; IR (film) 2983, 1711, 1337, 1313, 1212 cm-1; δH (500 MHz; CDCl3) 7.86 
(2H, d, J 7.6, Ar-H), 7.50-7.27 (8H, m, Ar-H), 7.19 (2H, d, J 8.5, Ar-H), 5.25-
4.98 (3H, m, CHAr and CH2Ph), 4.25 (1H, t, J 8.9, NCHH), 3.94 (1H, t, J 8.9, 
NCHH), 2.43 (3H, s, CH3); δC (125 MHz; CDCl3) 160.1 (C=O), 145.6 (Ar-C), 
137.4 (Ar-C), 135.2 (Ar-C), 133.2 (Ar-C) 133.0 (Ar-C), 131.0 (Ar-CH), 130.2 
(Ar-C) 130.0 (Ar-CH), 129.7 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.4 
(Ar-CH), 128.0 (Ar-CH), 125.6 (Ar-CH), 68.6 (CH2), 60.0 (CH), 56.1 (CH2), 
21.8 (CH3); HRMS (ESI






carboxylate (271). Following general procedure 7, 261 (44 
mg, 0.10 mmol, 1.0 equiv), triphenylphosphine (36 mg, 0.15 
mmol, 1.5 equiv), diethyl azodicarboxylate (22 µL, 0.15 
mmol, 1.5 equiv) and tetrahydrofuran (10 mL, 0.01 M) yielded 271 as a 
colourless oil (32 mg, 70 µmol, 75%). Rf = 0.26 (25% EtOAc in petroleum 
ether); [α]32D –15.6 (c 0.15, CHCl3). Enantiomeric excess (90% ee) was 
determined by HPLC analysis (25 °C). [Chiralpak OD-H column 2-
propanol/hexane = 10/90; flow rate = 1.0 mL/min; detection wavelength = 254 
nm] tR 15.0 min; tR 21.1 min; IR (film) 3034, 2924, 1720, 1236, 1162 cm
-1; δH 
(500 MHz; CDCl3) 7.83 (2H, d, J 8.2, Ar-H), 7.55 (1H, t, J 7.5, Ar-H), 7.30-7.26 
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(7H, m, Ar-H), 7.19 (1H, s, Ar-H), 7.10 (1H, t, J 7.5, Ar-H), 6.96 (1H, t, J 10.0, 
Ar-H), 5.20-5.04 (3H, m, CH2Ph and NCHPh), 4.14 (1H, t, J 8.7, NCHH), 3.90 
(1H, dd, J 8.4, 6.0, NCHH), 2.40 (3H, s, CH3); δC (125 MHz; CDCl3) 160.1 
(C=O), 159.7 (d, J 246.3, Ar-CF), 145.5 (Ar-C), 135.4 (Ar-C), 130.4 (d, J 8.8, 
Ar-CH), 130.1 (Ar-CH), 130.0 (Ar-C), 129.7 (Ar-CH), 128.5 (Ar-CH), 128.5 (d, 
J 3.8, Ar-CH), 129.7 (Ar-CH), 128.3 (Ar-CH), 127.9 (Ar-CH), 124.7 (d, J 13.8, 
Ar-C), 124.7 (d, J 2.5, Ar-CH), 115.5 (d, J 20.0, Ar-CH), 68.4 (CH2), 57.1 (d, J 
3.8, CH), 56.1 (d, J 2.5, CH2), 21.8 (CH3); δF (376 MHz; CDCl3) -118.4 (CF); 
HRMS (ESI+) calculated for C23H21FN2O4S [M+Na]




carboxylate (274). Following general procedure 7, 264 (61 
mg, 0.12 mmol, 1.0 equiv), triphenylphosphine (77 mg, 0.29 
mmol, 2.5 equiv), diethyl azodicarboxylate (63 µL, 0.29 
mmol, 2.5 equiv) and tetrahydrofuran (12 mL, 0.01 M) 
yielded 274 as a colourless oil (47 mg, 90 µmol, 79%). Rf = 0.25 (25% EtOAc 
in petroleum ether); [α]32D +34.8 (c 0.38, CHCl3). Enantiomeric excess (97% ee) 
was determined by HPLC analysis (25 °C). [Chiralpak OD-H column 2-
propanol/hexane = 9/91; flow rate = 1.0 mL/min; detection wavelength = 254 
nm] tR 19.6 min; tR 25.1 min; IR (film) 2923, 1718, 1302, 1212 cm
-1; δH (500 
MHz; CDCl3) 7.87 (2H, d, J 8.2, Ar-H), 7.50 (1H, s, Ar-H), 7.38-7.29 (8H, m, 
Ar-H), 7.23 (1H, t, J 7.8, Ar-H), 5.19 (1H, d, J 12.3 CHHAr), 5.11 (1H, d, J 
12.3, CHHAr), 5.07 (1H, dd, J 8.7, 6.0, NCHAr) 4.23 (1H, t, J 8.7, NCHH), 3.97 
(1H, dd, J 8.7, 6.0, NCHH), 2.46 (3H, s, CH3); δC (125 MHz; CDCl3) 160.1 
(C=O) 145.5 (Ar-C), 139.5 (Ar-C), 135.3 (Ar-C), 131.9 (Ar-CH), 130.6 (Ar-
CH), 131.0 (Ar-CH), 130.3 (Ar-C) 130.0 (Ar-CH), 129.7 (Ar-CH), 129.4 (Ar-
CH), 128.6 (Ar-CH), 128.4 (Ar-CH), 127.9 (Ar-CH), 68.5 (CH2), 60.5 (CH), 









diazetidine-1-carboxylate (275). Following general 
procedure 7, 265 (60 mg, 0.12 mmol, 1.0 equiv), 
triphenylphosphine (77 mg, 0.29 mmol, 2.5 equiv), 
diethyl azodicarboxylate (63 µL, 0.29 mmol, 2.5 equiv) 
and tetrahydrofuran (12 mL, 0.01 M) yielded 275 as a white solid (48 mg, 0.10 
mmol, 82%). M.p. 117-119 °C; Rf = 0.21 (25% EtOAc in petroleum ether); 
[α]32D +18.9 (c 2.86, CHCl3). Enantiomeric excess (94% ee) was determined by 
HPLC analysis (25 °C). [Chiralpak OD-H column 2-propanol/hexane = 10/90; 
flow rate = 1.0 mL/min; detection wavelength = 254 nm] tR 19.5 min; tR 24.3 
min; IR (film) 2925, 1750, 1693, 1360, 1151, 1087 cm-1; δH (500 MHz; d6-
DMSO) 7.89 (2H, d, J 8.2, Ar-H), 7.79 (2H, d, J 8.2, Ar-H) 7.65 (2H, d, J 8.1, 
Ar-H), 7.54 (2H, d, J 8.1, Ar-H), 7.39-7.32 (5H, m, Ar-H), 5.38-5.09 (3H, m, 
CHOH and CH2Ph), 4.09 (1H, t, J 8.9, NCHH), 3.93 (1H, dd, J 8.9, 5.8, NCHH), 
2.46 (3H, s, CH3); δC (125 MHz; d6-DMSO) 159.5 (C=O) 145.6 (Ar-C), 135.6 
(Ar-C), 130.1 (Ar-CH), 129.8 (Ar-CH), 129.2 (Ar-C), 129.0 (q, J 31.9, Ar-C), 
128.4 (Ar-CH), 128.2 (Ar-CH), 127.7 (Ar-CH), 127.4 (Ar-CH), 125.6 (q, J 3.8, 
Ar-CH), 124.1 (q, J 272.2, CF3), 67.8 (CH2), 60.1 (CH), 56.1 (CH2), 21.3 (CH3), 
1 Ar-C not seen; δF (376 MHz; d6-DMSO) -61.1 (CF3); HRMS (ESI
+) 
calculated for C24H21F3N2O4S [M+Na]
+ 513.1066; found 513.1061. 
Crystal Structure of 275. Single crystals of C24H21F3N2O4S were grown from 
a 9:1 ratio of hexane and isopropyl alcohol. A suitable crystal was selected and 
mounted on a glass fibre with Fromblin oil and placed on a Rigaku Oxford 
Diffraction SuperNova diffractometer with a duel source (Cu at zero) equipped 
with an AtlasS2 CCD area detector. The crystal was kept at 150(2) K during data 
collection. Crystal Data for C24H21F3N2O4S (M = 490.49 g/mol): orthorhombic, 
space group P212121 (no. 19), a = 32.8358(3) Å, b = 11.60538(10) Å, c = 
5.85758(7) Å, V = 2232.16(4) Å3, Z = 4, T = 150(2) K, μ(CuKα) = 1.827 mm-1, 
Dcalc = 1.460 g/cm3, 72297 reflections measured (8.08° ≤ 2Θ ≤ 147.05°), 4499 
unique (Rint = 0.0917, Rsigma = 0.0256) which were used in all calculations. The 
final R1 was 0.0616 (I > 2σ(I)) and wR2 was 0.1478 (all data). Data has been 
deposited at the Cambridge Crystallographic Data Centre as CCDC 1944267. 
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Flack x: 0.015(9) Shelx2018, Hooft y: 0.009(5) Olex2. Both the Flack parameter 
and associated Hooft y parameter are small, so confidence in the handedness of 
the chiral centre is high. 
 
Benzyl (R)-3-(2-chlorophenyl)-2-tosyl-1,2-diazetidine-1-
carboxylate (276). Following general procedure 7, 266 (81 
mg, 0.17 mmol, 1.0 equiv), triphenylphosphine (112 mg, 0.43 
mmol, 2.5 equiv), diethyl azodicarboxylate (66 µL, 0.43 
mmol, 2.5 equiv) and tetrahydrofuran (17 mL, 0.01 M) yielded 276 as a 
colourless oil (50 mg, 0.11 mmol, 65%). Rf = 0.24 (25% EtOAc in petroleum 
ether); [α]32D +33.2 (c 0.44, CHCl3). Enantiomeric excess (90% ee) was 
determined by HPLC analysis (25 °C). [Chiralpak OD-H column 2-
propanol/hexane = 10/90; flow rate = 1.0 mL/min; detection wavelength = 254 
nm] tR 13.6 min; tR 17.1 min. IR (film) 2924, 1749, 1271, 1186 cm
-1; δH (500 
MHz; CDCl3) 7.92 (2H, d, J 8.2, Ar-H), 7.83 (1H, d, J 7.0, Ar-H), 7.37-7.27 
(9H, m, Ar-H), 5.25 (1H, dd, J 8.6, 5.9, CHAr), 5.21 (1H, d, J 12.4, CHHPh), 
5.11 (1H, d, J 12.4, CHHPh), 4.25 (1H, t, J 8.7, NCHH), 3.83 (1H, dd, J 8.6, 5.8, 
NCHH), 2.48 (3H, s, CH3); δC (125 MHz; CDCl3) 160.2 (C=O) 145.6 (Ar-C), 
135.4 (Ar-C), 135.3 (Ar-C), 131.0 (Ar-C) 130.1 (Ar-CH), 130.0 (Ar-C), 129.8 
(Ar-CH), 129.6 (Ar-CH), 129.2 (Ar-CH), 128.5 (Ar-CH), 128.4 (Ar-CH), 127.9 
(Ar-CH), 127.8 (Ar-CH), 127.5 (Ar-CH), 68.4 (CH2), 59.8 (CH), 56.5 (CH2), 
21.8 (CH3); HRMS (ESI






(212) Following general procedure 7, alcohol 211 (450 mg, 1.11 
mmol, 1.0 equiv), triphenylphosphine (727 mg, 2.77 mmol, 2.5 
equiv), diethylazodicarboxylate (436 µL, 2.77 mmol, 2.5 equiv) and 
tetrahydrofuran (111 mL, 0.01 M) yielded 212 as a white solid (328 mg, 0.84 
mmol, 76%). Rf = 0.25 (15% EtOAc/petroleum ether); M.p. 166-167 °C; [α]D
28 
+7.6 (c 0.09, CHCl3); Enantiomeric excess (98% ee) was determined by HPLC 
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analysis (25 °C). [Chiralpak IA column 2-propanol/hexane = 0.6/99.4; flow rate 
= 1.0 mL/min; detection wavelength = 254 nm] tR 54.5 min; tR 63.1 min. IR 
(film) 2980, 2932, 1733, 1395, 1358 cm-1; δH (500 MHz, CDCl3) 7.93 (2H, d, J 
8.2, Ar-CH), 7.37 (7H, m, Ar-CH), 5.06 (1H, dd, J 8.7, 5.9, CHPh), 4.21 (1H, t, 
J 8.7, NCHH), 3.96 (1H, dd, J 8.5, 5.9, NCHH), 2.51 (3H, s, CH3), 1.45 (9H, s, 
C(CH3)3); δC (125 MHz, CDCl3) 159.3 (C=O), 145.2 (Ar-C), 137.6 (Ar-C), 
130.8 (Ar-CH), 130.1 (Ar-CH), 130.0 (Ar-C), 129.6 (Ar-CH), 128.9 (Ar-CH), 
126.4 (Ar-CH), 82.9 (C), 61.3 (CH), 56.3 (CH2), 28.0 (CH3), 21.8 (CH3); HRMS 
(ES+) calculated for C20H24N2O4S (M+Na)
+ 411.1349; found 411.1352.  
 
Benzyl (R)-3-phenyl-2-tosylpyrazolidine-1-carboxylate (309). 
Following general procedure 7, 298 (60 mg, 0.13 mmol, 1.0 
equiv), triphenylphosphine (52 mg, 0.20 mmol, 1.5 equiv), 
diethylazodicarboxylate (31 µL, 0.20 mmol, 1.5 equiv) and tetrahydrofuran (13 
mL, 0.01 M) yielded 309 as a white solid (51 mg, 0.12 mmol, 90%). M.p. 105-
106 °C; Rf = 0.24 (25% EtOAc in petroleum ether); [α]
32
D + 52.1 (c 0.02, CHCl3). 
Enantiomeric excess (96% ee) was determined by HPLC analysis (25 °C). 
[Chiralpak IA column 2-propanol/hexane = 10/90; flow rate = 1.0 mL/min; 
detection wavelength = 254 nm] tR 13.0 min; tR 14.1 min. IR (film) 3034, 2959, 
2925, 1702, 1344, 1216, 1181 cm-1; δH (500 MHz; CDCl3) 7.84 (2H, d, J 8.2, 
Ar-CH), 7.37-7.31 (5H, m, Ar-H), 7.28-7.22 (5H, m, Ar-H), 7.21-7.18 (2H, m, 
Ar-H), 5.37 (1H, dd, J 8.0, 4.7, CHPh), 5.09 (1H, d, J 12.2, CO2CHHPh), 4.82 
(1H, d, J 12.2, CO2CHHPh), 3.98 (1H, ddd, J 11.0, 8.4, 5.7, NCHH), 3.29 (1H, 
dt, J 10.8, 8.3, NCHH), 2.45-2.39 (4H, m, CH3 and CHPhCHH), 2.17 (1H, dtd, 
J 12.7, 7.2, 5.1, CHPhCHH); δC (125 MHz; CDCl3) 157.3 (C=O), 144.8 (Ar-C), 
139.9 (Ar-C) 135.6 (Ar-C), 133.2 (Ar-C), 129.6 (Ar-CH), 129.4 (Ar-CH), 128.6 
(Ar-CH), 128.4 (Ar-CH), 128.2 (Ar-CH), 128.0 (Ar-CH), 127.6 (Ar-CH), 126.2 
(Ar-CH), 68.2 (CH2), 63.4 (CH), 47.8 (CH2), 33.8 (CH2), 21.7 (CH3); HRMS 
(ESI+) calculated for C24H24N2O4S [M+Na]
+ 459.1349; found 459.1349. 
Crystal Structure of 309. Single crystals of C24H24N2O4S were grown from a 
9:1 mix of hexane and isopropyl alcohol. A suitable crystal was selected and 
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mounted on a Mitegen loop with Fomblin oil and placed on a Rigaku 007HF 
equipped with Varimax confocal mirrors and an AFC11 goniometer and HyPix 
6000 detector. The crystal was kept at 100(2) K during data collection. Crystal 
Data for C24H24N2O4S (M = 436.51 g/mol): orthorhombic, space group P212121 
(no. 19), a = 6.0985(4) Å, b = 11.5023(5) Å, c = 30.8387(15) Å, V = 2163.2(2) 
Å3, Z = 4, T = 100(2) K, μ(CuKα) = 1.610 mm-1, Dcalc = 1.340 g/cm3, 17168 
reflections measured (5.732° ≤ 2Θ ≤ 136.448°), 3915 unique (Rint = 0.1033, 
Rsigma = 0.0835) which were used in all calculations. The final R1 was 0.0624 (I 
> 2σ(I)) and wR2 was 0.1773 (all data). Data has been deposited at the Cambridge 
Crystallographic Data Centre as CCDC 1944268. 
Flack x: -0.03(3) Shelx2018, Hooft y: -0.05(2) Olex2. Both the Flack parameter 
and associated Hooft y parameter are small, so confidence in the handedness of 
the chiral centre is high. 
 
tert-Butyl (R)-5-(thiophen-2-yl)-2-tosylpyrazolidine-1-
carboxylate (307). Following general procedure 7, 296 (42 mg, 
0.09 mmol, 1.0 equiv), triphenylphosphine (37 mg, 0.14 mmol, 
1.5 equiv), diethylazodicarboxylate (22 µL, 0.14 mmol, 1.5 equiv) and 
tetrahydrofuran (9 mL, 0.01 M) yielded 307 as a colourless oil (36 mg, 0.08 
mmol, 85%). Rf = 0.18 (25% EtOAc in petroleum ether); [α]
32
D + 7.8 (c 0.17, 
CHCl3). Enantiomeric excess (99% ee) was determined by HPLC analysis (25 
°C). [Chiralpak IA column 2-propanol/hexane = 10/90; flow rate = 1.0 mL/min; 
detection wavelength = 254 nm] tR 25.6 min; tR 28.9 min. IR (film) 2979, 2931, 
1712, 1530, 1346, 1161 cm-1; δH (500 MHz; CDCl3) 8.27 (2H, d, J 8.6, Ar-H), 
8.18 (2H, t, J 8.7, Ar-H) 7.43 (2H, d, J 6.9, Ar-H), 7.36 (2H, t, J 7.4, Ar-H), 7.31 
(1H, d, J 7.1, Ar-H), 5.04 (1H, t, J 8.6, CHPh), 4.21 (1H, br s, NCHH), 3.42 (1H, 
br s, NCHH), 2.59 (2H, dt, J 12.9, 6.5, CHPhCHH), 2.31 (1H, p, J 11.5, 
CHPhCHH), 1.27 (9H, s, C(CH3)3); δC (125 MHz; CDCl3) 155.8 (C=O seen on 
HMBC), 142.9 (Ar-C), 130.7 (Ar-CH), 128.4 (Ar-CH), 127.5 (Ar-CH), 126.6 
(Ar-CH), 123.7 (Ar-CH), 114.1 (Ar-C), 82.7 (C), 65.4 (CH), 49.3 (CH2), 36.1 
177 
 
(CH2), 27.9 (CH3), 1 Ar-C not seen; HRMS (ESI
+) calculated for C20H23N3O6 
[M+Na]+ 456.1200; found 456.1198. 
 
Benzyl (R)-5-phenyl-2-tosylpyrazolidine-1-carboxylate (306). 
Following general procedure 7, 295 (936 mg, 2.06 mmol, 1.00 
equiv), triphenylphosphine (1.35 g, 5.15 mmol, 2.50 equiv), 
diethylazodicarboxylate (839 µL, 5.15 mmol, 2.50 equiv) and tetrahydrofuran 
(21 mL, 0.01 M) gave 306 as a white solid (803 mg, 1.84 mmol, 89%). Rf = 0.21 
(25% EtOAc in petroleum ether).   M.p. 122-123 °C [α]32D + 52.78 (c 0.04, 
CHCl3). Enantiomeric excess (90% ee) was determined by HPLC analysis (25 
°C). [Chiralpak IA column 2-propanol/hexane = 5/95; flow rate = 1 mL/min; 
detection wavelength = 254 nm] tR 17.5 min: tR 19.7 min. IR (film) 3056, 2951, 
2921, 1705, 1354, 1220, cm-1; δH (500 MHz; CDCl3) 7.76 (2H, d,  J 8.0, Ar-
CH), 7.48-7.42 (2H, m, Ar-H) 7.35-7.27 (6H, m, Ar-H), 7.17 (2H, s, Ar-H), 7.10 
(2H, d, J 7.6, Ar-H), 5.13-5.00 (2H, m, CHPh and CH2Ph 1 diastereotopic 
proton), 4.94 (1H, d, J 12.3, CH2Ph), 4.15-4.05 (1H, m, NCH2 1 diastereotopic 
proton), 3.29 (1H, br s, NCH2 1 diastereotopic proton), 2.51 (1H, br s, CHPhCH2 
1 diastereotopic proton) 2.35-2.25 (4H, m, CH3 and CHPhCH2 1 diastereotopic 
proton); δC (125 MHz; CDCl3) 157.6 (C=O seen on HMBC), 144.7 (Ar-C), 
140.6 (Ar-C) 135.6 (Ar-C), 133.6 (Ar-C), 129.4 (Ar-CH), 129.4 (Ar-CH), 128.4 
(Ar-CH), 128.4 (Ar-CH) 128.1 (Ar-CH), 128.0 (Ar-CH), 127.4 (Ar-CH), 126.7 
(Ar-CH), 68.3 (CH2), 65.5 (CH), 49.5 (CH2), 35.8 (CH2), 21.7 (CH3); HRMS 
(ESI+) calculated for C24H24N2O4S [M+Na]
+ 459.1349; found 459.1340. 
 
tert-Butyl (R)-5-phenyl-2-tosylpyrazolidine-1-carboxylate 
(308). Following general procedure 7, 297 (72 mg, 0.17 mmol, 
1.0 equiv), triphenylphosphine (112 mg, 0.43 mmol, 2.5 equiv), 
diethyl azodicarboxylate (74 mg, 0.43 mmol, 2.5 equiv) in tetrahydrofuran (17 
mL, 0.01 M) yielded 308 as a colourless oil (62 mg, 0.15 mmol, 90%). Rf = 0.30 
(30% EtOAc in petroleum ether); [α]32D + 23.5 (c 0.70, CHCl3). Enantiomeric 
excess (95% ee) was determined by HPLC analysis (25 °C). [Chiralpak IA 
178 
 
column 2-propanol/hexane = 5/95; flow rate = 1.0 mL/min; detection 
wavelength = 254 nm] tR 10.9 min; tR 17.4 min. IR (film) 2987, 2900, 1706, 
1405, 1075 cm-1; δH (500 MHz; CDCl3) 7.86-7.85 (2H, m, Ar-H), 7.45-7.25 
(7H, m, Ar-H), 4.99 (1H, dd, J 8.7, 6.2, CHPh), 4.10 (1H, br s, NCHH), 3.29 
(1H, br s, NCHH), 2.48-2.26 (5H, m, CH2, CH3), 1.25 (9H, s, (CH3)3); δC (125 
MHz; CDCl3) 156.6 (C=O), 144.7 (Ar-C), 141.5 (Ar-C), 133.8 (Ar-C), 129.6 
(Ar-CH), 129.5 (Ar-CH), 128.4 (Ar-CH), 127.2 (Ar-CH), 126.8 (Ar-CH), 82.0 
(C), 65.6 (CH), 49.3 (CH2), 36.1 (CH2), 27.9 (CH3), 21.7 (CH3); HRMS (ESI
+) 
calculated for C21H26N2NaO4S [M+Na]
+ 425.1505; found 425.1504. 
 
tert-Butyl (R)-5-(4-bromophenyl)-2-tosylpyrazolidine-1-
carboxylate (310). Following general procedure 7, 299 (61 
mg, 0.12 mmol, 1.0 equiv), triphenylphosphine (47 mg, 0.18 
mmol, 1.5 equiv), diethyl azodicarboxylate (28 µL, 0.18 mmol, 
1.5 equiv) and tetrahydrofuran (12 mL, 0.01 M) yielded 310 as 
a colourless oil (52 mg, 0.11 mmol, 90%). Rf = 0.22 (25% EtOAc in petroleum 
ether); [α]32D +34.6 (c 0.25, CHCl3). Enantiomeric excess (90% ee) was 
determined by HPLC analysis (25 °C). [Chiralpak OD-H column 2-
propanol/hexane = 5/95; flow rate = 1.0 mL/min; detection wavelength = 254 
nm] tR 12.5 min; tR 15.5 min. IR (film) 2979, 2928, 1705, 1366, 1133 cm
-1; δH 
(500 MHz; CDCl3) 7.77 (2H, d, J 8.1, Ar-H), 7.39 (2H, d, J 8.4, Ar-H), 7.30 
(2H, s, Ar-H), 7.19 (2H, d, J 7.8, Ar-H), 4.88 (1H, t, J 9.8 CHAr), 4.07 (1H, br 
s, NCHH), 3.20 (1H, br s, NCHH), 2.43 (1H, sex, J 6.9, CHArCHH), 2.46 (3H, 
s, CH3), 2.05-1.82 (1H, m, CHArCHH), 1.19 (9H, s, C(CH3)3); δC (125 MHz; 
CDCl3) 156.3 (C=O, seen on HMBC), 144.8 (Ar-C), 140.4 (Ar-C), 133.6 (Ar-
C), 131.4 (Ar-CH), 129.6 (Ar-CH), 129.4 (Ar-CH), 128.6 (Ar-CH), 121.1 (Ar-
C), 82.2 (C), 65.0 (CH), 49.3 (CH2), 36.0 (CH2), 27.9 (CH3), 21.7 (CH3); HRMS 
(ESI+) calculated for C21H25
79BrN2O4S [M+Na]





carboxylate (311). Following general procedure 7, 300 (41 mg, 
0.10 mmol, 1.0 equiv), triphenylphosphine (39 mg, 0.15 mmol, 
1.5 equiv), diethylazodicarboxylate (24 µL, 0.15 mmol, 1.5 
equiv) and tetrahydrofuran (10 mL, 0.01 M) yielded 311 as a colourless oil (28 
mg, 0.07 mmol, 72%). Rf = 0.26 (25% EtOAc in petroleum ether); [α]
32
D +31.3 
(c 0.07, CHCl3). Enantiomeric excess (73% ee) was determined by HPLC 
analysis (25 °C). [Chiralpak IA column 2-propanol/hexane = 3/97; flow rate = 
1.0 mL/min; detection wavelength = 254 nm] tR 18.5 min; tR 19.5 min. IR (film) 
2978, 2925, 1704, 1256, 1133 cm-1; δH (500 MHz; CDCl3) 7.79 (2H, d, J 7.9, 
Ar-H), 7.25 (1H, d, J 5.1, Ar-H), 7.23 (2H, d, J 7.9, Ar-H), 6.99 (1H, s, Ar-H), 
6.94 (1H, t, J 3.7, Ar-H), 5.29 (1H, t, J 8.7, CHAr), 4.27 (1H, br s, NCHH), 3.32 
(1H, br s, NCHH), 2.64-2.44 (2H, m, CHArCH2), 2.42 (3H, s, CH3), 1.32 (9H, 
s, C(CH3)3); δC (125 MHz; CDCl3) 156.3 (C=O seen on HMBC), 144.6 (Ar-C), 
133.3 (Ar-C), 129.7 (Ar-CH), 129.3 (Ar-CH), 126.2 (Ar-CH), 125.1 (Ar-CH), 
124.9 (Ar-CH), 82.3 (C), 60.7 (CH), 49.2 (CH2), 35.5 (CH2), 27.9 (CH3), 21.6 
(CH3), 1 Ar-C not seen; HRMS (ESI
+) calculated for C19H24N2O4S2 [M+Na]
+ 
431.1070; found 431.1073. 
 
tert-Butyl (R)-5-([1,1'-biphenyl]-4-yl)-2-tosylpyrazolidine-
1-carboxylate (312). Following general procedure 7, 301 (84 
mg, 0.17 mmol, 1.0 equiv), triphenylphosphine (66 mg, 0.25 
mmol, 1.5 equiv), diethyl azodicarboxylate (39 µL, 0.25 
mmol, 1.0 equiv) and tetrahydrofuran (17 mL, 0.01 M) yielded 
312 as a white solid (70 mg, 0.15 mmol, 86%). M.p. 109-111 °C; Rf = 0.24 (25% 
EtOAc in petroleum ether); [α]32D +75.0 (c 0.03, CHCl3). Enantiomeric excess 
(90% ee) was determined by HPLC analysis (25 °C). [Chiralpak IA column 2-
propanol/hexane = 10/90; flow rate = 1.0 mL/min; detection wavelength = 254 
nm] tR 9.5 min; tR 10.5 min. IR (film) 2980, 2924, 1701, 1393, 1357, 1255 cm
-1 
δH (500 MHz; CDCl3) 7.90 (2H, d, J 8.2, Ar-H), 7.63 (4H, t, J 7.5, Ar-H), 7.60 
(2H, d, J 7.9, Ar-H), 7.56 (2H, s, Ar-H), 7.47 (2H, t, J 7.6, Ar-H), 7.37 (1H, t, J 
180 
 
7.4, Ar-H), 7.27 (1H, d, J 9.4, Ar-H), 5.07 (1H, t, J 8.8, CHAr), 4.17 (1H, br s, 
NCHH), 3.33 (1H, br s, NCHH), 2.58-2.49 (1H, m, CHArCHH), 2.46-2.35 (4H, 
m, CH3 and CHNCHH), 1.30 (9H, s, C(CH3)3); δC (125 MHz; CDCl3) 156.8 
(C=O seen on HMBC), 150.5 (Ar-C), 144.6 (Ar-C), 140.9 (Ar-C), 140.1 (Ar-C), 
133.8 (Ar-C), 129.6 (Ar-CH), 129.4 (Ar-CH), 128.8 (Ar-CH), 127.2 (Ar-CH), 
127.1 (Ar-CH), 82.1 (C), 65.3 (CH), 49.3 (CH2), 36.0 (CH2), 27.9 (CH3) 21.6 
(CH3), 2 Ar-CH not seen; HRMS (ESI
+) calculated for C27H30N2O4S [M+Na]
+ 
501.1818; found 501.1819. 
 
tert-Butyl (S)-5-(3,5-difluorophenyl)-2-tosylpyrazolidine-
1-carboxylate (313). Following general procedure 7, 
alcohol 302 (239 mg, 0.50 mmol, 1.0 equiv), 
triphenylphosphine (330 mg, 1.26 mmol, 2.5 equiv), 
diethylazodicarboxylate (198 µL, 1.26 mmol, 2.5 equiv) and 
tetrahydrofuran (50 mL, 0.01 M) yielded 313 as a white solid (193 mg, 0.44 
mmol, 88%). Rf = 0.08 (15% EtOAc in petroleum ether); [α]D
24 –16.4 (c 0.11, 
CHCl3); Enantiomeric excess (93% ee) was determined by HPLC analysis (15 
°C). [Chiralcel OD column 2-propanol/hexane = 1/99; flow rate = 1.0 mL/min; 
detection wavelength = 254 nm] tR 34.7 min; tR 43.2 min. M.p. 103-104 °C; IR 
(film) 2974, 1721, 1680, 1155, 1113 cm-1; δH (500 MHz; CDCl3) 7.85 (2H, d, J 
8.2, Ar-H), 7.28 (2H, d, J 8.1, Ar-H), 6.98 (2H, d, J 6.0, Ar-H), 6.70 (1H, tt, J 
8.8, 2.2, Ar-H), 6.33 (1H, s, NH), 4.98 (1H, d, J 8.9, CHAr), 4.24-4.12 (1H, br 
m, CHHN), 3.33-3.21 (1H, br m, CHHN), 2.54-2.46 (1H, m, CHArCHH), 2.42 
(3H, s, CH3), 2.36-2.24 (1H, br m, CHArCHH), 1.27 (9H, s, C(CH3)3); δC (125 
MHz; CDCl3) 162.9 (dd, J 246.3, 12.5, Ar-CF), 145.5 (Ar-C), 145.0 (Ar-C), 
133.5 (Ar-C), 129.6 (Ar-CH), 129.5 (Ar-CH), 109.6 (d, J 25.0, Ar-CH), 102.6 
(t, J 25.0, Ar-CH), 82.5 (C), 64.8 (CH), 49.2 (CH2), 35.7 (CH2), 27.8 (CH3), 21.6 
(CH3), C=O not seen; δF (376 MHz; CDCl3) -109.7 (Ar-CF); HRMS (ESI
+) 
calculated for C21H24N2NaO4SF2 [M+Na]





carboxylate (329). Following general procedure 4, 323 (46 
mg, 0.10 mmol, 1.0 equiv), triphenylphosphine (39 mg, 0.15 
mmol, 1.5 equiv), diethylazodicarboxylate (23 µL, 0.15 mmol, 1.5 equiv) and 
tetrahydrofuran (10 mL, 0.01 M) yielded 329 as a colourless oil (29 mg, 0.06 
mmol, 63%). Rf = 0.29 (25% EtOAc in petroleum ether); [α]
32
D +43.8 (c 0.04, 
CHCl3). Enantiomeric excess (94% ee) was determined by HPLC analysis (25 
°C). [Chiralpak IA column 2-propanol/hexane = 1.5/98.5; flow rate = 1.0 
mL/min; detection wavelength = 254 nm] tR 34.0 min; tR 36.3 min. IR (film) 
2953, 2925, 1706, 1353, 1260 cm-1; δH (500 MHz; CDCl3) 7.79-7.66 (2H, m, 
Ar-H), 7.60-7.31 (6H, m, Ar-H) 7.22-7.06 (6H, m, Ar-H), 5.21-5.08 (1H, m, 
CHPh), 4.85 (1H, d, J 11.8, CO2CHH), 4.70 (1H, d, J 11.9, CO2CHH), 4.28-4.02 
(1H, m, NCHH), 3.71-3.44 (1H, m, NCHH), 2.43-2.31 (4H, m, CH3 and 
CHPhCHH), 2.17-2.10 (1H, m, CHPhCHH), 1.97 (1H, br s, CH2CHHCH2), 
1.78-1.71 (1H, m, CH2CHHCH2); δC (125 MHz; CDCl3) 155.9 (C=O), 144.4 
(Ar-C), 138.6 (Ar-C) 135.5 (Ar-C), 134.9 (Ar-C), 132.2 (Ar-CH), 132.0 (Ar-
CH), 129.4 (Ar-CH), 128.8 (Ar-CH), 128.5 (Ar-CH), 128.4 (Ar-CH), 128.2 (Ar-
CH), 127.4 (Ar-CH), 68.2 (CH2), 57.4 (CH), 43.6 (CH2), 29.7 (CH2), 21.7 (CH3), 
19.1 (CH2); HRMS (ESI





(330). Following general procedure 7, 324 (27 mg, 56 µmol, 1.0 
equiv), triphenylphosphine (22 mg, 84 µmol, 1.5 equiv), 
diethylazodicarboxylate (13 µL, 84 µmol, 1.5 equiv) and tetrahydrofuran (5.6 
mL, 0.01 M) yielded 330 as a colourless oil (17 mg, 38 µmol, 67%). Rf = 0.31 
(25% EtOAc in petroleum ether); [α]32D +22.3 (c 0.09, CHCl3). Enantiomeric 
excess (90% ee) was determined by HPLC analysis (25 °C). [Chiralpak OD-H 
column 2-propanol/hexane = 2/98; flow rate = 1.0 mL/min; detection 
wavelength = 254 nm] tR 14.8 min; tR16.8 min. IR (film) 2925, 2856, 1705, 1401, 
1126 cm-1; δH (500 MHz; CDCl3) 7.34-7.23 (5H, m, Ar-CH), 7.15-7.00 (6H, m, 
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Ar-H) 6.90-6.84 (3H, m, Ar-H), 5.11-5.00 (1H, m, CHPh), 4.85 (1H, d, J 11.8, 
CO2CHHPh), 4.70 (1H, d, J 11.9, CO2CHHPh), 4.28-4.02 (1H, m, NCHH), 
3.71-3.44 (1H, m, NCHH), 2.43-2.31 (4H, m, CH3 and CHPhCHH) 2.17-2.10 
(1H, m, CHPhCHH), 1.99-1.72 (4H, br s, CH2(CH2)2CH2),; δC (125 MHz; 
CDCl3) 156.2 (minor rotamer) and 156.1 (C=O), 143.5 (Ar-C) and 143.4 (minor 
rotamer), 142.6 (Ar-C) and 142.3 (minor rotamer), 136.3 (minor rotamer) and 
136.2 (Ar-C), 136.1 (minor rotamer) and 135.0 (Ar-C), 129.1 (Ar-CH), 128.9 
(Ar-CH), 128.7 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.4 (Ar-CH), 128.3 
(Ar-CH), 128.3 (Ar-CH), 128.2 (Ar-CH), 128.0 (Ar-CH), 127.9 (Ar-CH), 127.8 
(Ar-CH), 127.5 (Ar-CH), 127.2 (Ar-CH), 127.0 (Ar-CH), 126.9 (Ar-CH), 68.5 
(minor rotamer) and 67.0 (CH2), 68.4 (CH), 54.1 (minor rotamer) and 52.9 
(CH2), 36.2 (minor rotamer) and 36.1 (CH2), 28.3 (CH2) and 28.2 (minor 
rotamer), 27.2 (minor rotamer) and 26.3 (CH2), 21.5 (CH3); HRMS (ESI
+) 
calculated for C26H28N2O4S [M+Na]
+ 487.1662; found 487.1656. 
 
Yoshida’s Explosion Propagation Correlation Raw Data 
The exotherm data was taken directly from the DSC traces and used without 
modification. The DSC data was generated using a Mettler Toledo DSC 3 
Calorimeter equipped with an FRS 5+ sensor. The compounds were weighed 
into a gold crucible and sealed, and all samples were measured against an empty 
plate as a reference. They were analysed from 40-450 °C and heated at a rate of 
10 °C per minute. Each sample was analysed twice and the average of each 
exotherm energy and initiation temperature was used to generate the plot, the 
error bars were from the two values. This gave the raw data that was 

















25)/ oC EP 
Error 
Bar 
1 Max 932 130 2.35 2.02 -0.09 2.35 
1 Min 818 130 2.29 2.02 -0.15 -2.29 
2 Max 593 170 2.15 2.16 -0.34 2.15 
2 Min 563 170 2.13 2.16 -0.36 -2.13 
3 Max 584 160 2.14 2.13 -0.34 2.14 
3 Min 464 190 2.04 2.22 -0.47 -2.04 
4 Max 437 180 2.02 2.19 -0.48 2.02 
4 Min 308 180 1.87 2.19 -0.64 -1.87 
5 Max 370 180 1.95 2.19 -0.56 1.95 
5 Min 281 180 1.83 2.19 -0.68 -1.83 
6 Max 284 200 1.83 2.24 -0.69 1.83 
6 Min 276 200 1.82 2.24 -0.70 -1.82 
7 Max 348 185 1.92 2.20 -0.59 1.92 
7 Min 240 185 1.76 2.20 -0.75 -1.76 
Table 6.1 Raw data used to plot Yoshida’s explosion propagation correlation 
 
methyl (R)-5-phenylpyrazolidine-1-carboxylate 
(350) and benzyl (R)-5-phenylpyrazolidine-1-
carboxylate (349) 306 (200 mg, 0.46 mmol 1.0 
equiv), activated magnesium turnings (56 mg, 2.29 mmol, 5.0 equiv) and MeOH 
(5 mL, 0.1 M) were combined and stirred (800 rpm) at room temperature for 2 
hours. The solution was quenched with saturated ammonium chloride solution 
(5 mL), then extracted with dichloromethane (3 x 5 mL). The combined organic 
extracts were dried over MgSO4 and concentrated in vacuo to give a colourless 
oil. This contained a mixture of 349 and 350, these were separated using prep 
HPLC: The residue was taken up in MeOH (to a total volume of 9.8 ml), filtered 
and purified by prep-HPLC  (Phenomenex Gemini-NX 10 Micron 50*150mm 
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C-18) (CH3CN & Water with 10 mM ammonium bicarbonate adjusted to pH 9 
with ammonium hydroxide, 30 % to 100% CH3CN over 11 minutes at 
120ml/min) (1 injection) (220 nm). They were used directly in the synthesis of 
351 and 352 without further purification or characterisation. 
 
Benzyl (R)-5-phenyl-2-(pyridin-2-yl)pyrazolidine-1-
carboxylate (351). 349 (77 mg, 0.28 mmol, 1.0 equiv), 
palladium dibenzylacetone (18.9 mg, 0.021 mmol, 0.075 
equiv), 1,1′-Ferrocenediyl-bis(diphenylphosphine) (33.5 mg, 0.061 mmol, 0.22 
equiv), cesium carbonate (108.0 mg, 0.33 mmol, 1.2 equiv) and 2-
bromopyridine (27.6 µL, 0.29 mmol, 1.05 equiv) in toluene (0.92 mL, 0.3 M) 
were heated to 90 °C and stirred for 20 h. The solution was then quenched with 
saturated ammonium chloride solution (5 mL), extracted with dichloromethane 
(3 x 5 mL), dried over MgSO4 and concentrated in vacuo to give a yellow oil. 
This was purified by flash chromatography (10% to 60% EtOAc/hexane) to yield 
351 as a white solid (40 mg, 0.11 mmol, 41%). Rf = 0.11 (10% EtOAc/hexane); 
M. P. 108-110 °C [α]32D  –  68.8 (c 0.03, CH2Cl2). IR (film) 2924, 1721, 1342, 
1121 cm-1; δH (400 MHz; CH2Cl2) 8.25 (1H, d, J 3.8, Ar-H), 7.53 (1H, td, J 8.0 
and 2.0, Ar-H), 7.30-7.15 (10H, m, Ar-H), 6.93 (1H, d, J 8.4 Ar-H), 6.82 (1H, 
dd, J 7.0 and 5.1, Ar-H), 5.27-5.14 (3H, m, CHPh and CH2Ph), 4.96-4.90 (1H, 
m, NCHH), 3.40 (1H, td, J 11.1 and 6.0, NCHH), 2.55 (1H, dddd, J 13.7, 7.9, 
6.1, 2.2, CHPhCH2), 2.11-1.97 (1H, m, CHPhCHH); δC (100 MHz; CDCl3) 
160.8 (Ar-C) 158.0 (C=O), 147.5 (Ar-CH), 141.4 (Ar-C), 137.5 (Ar-CH), 136.1 
(Ar-C), 128.5 (Ar-CH), 128.4 (Ar-CH), 127.8 (Ar-CH), 127.4 (Ar-CH), 126.8 
(Ar-CH), 116.3 (Ar-CH), 110.6 (Ar-CH), 67.9 (CH), 64.8 (CH2), 48.6 (CH2), 
36.0 (CH2); HRMS (ESI
+) calculated for C22H21N3O2 [M+H]






carboxylate (352).  350 (82 mg, 0.40 mmol, 1.0 equiv), 
palladium dibenzylacetone (27 mg, 30 µmol, 0.075 equiv), 
1,1′-Ferrocenediyl-bis(diphenylphosphine) (49 mg, 87 µmol, 0.22 equiv), 
cesium carbonate (155 mg, 0.48 mmol, 1.2 equiv) and 2-bromopyridine (40 µL, 
0.42 mmol, 1.05 equiv) in toluene (1.3 mL, 0.3 M) were heated to 90 °C and 
stirred for 20 h. The solution was then quenched with saturated ammonium 
chloride solution (5 mL), extracted with dichloromethane (3 x 5 mL), dried over 
MgSO4 and concentrated in vacuo to give a yellow oil. This was purified by 
flash chromatography (10% to 60% EtOAc/hexane) to yield 352 as a white solid 
(58 mg, 0.20 mmol, 51%). Rf = 0.19 (25% ethyl acetate in petroleum ether); M. 
p. 102-104 °C; [α]32D  –  92.1 (c 0.16, CH2Cl2). IR (film) 2924, 1717, 1426, 1344, 
1201 cm-1; δH (400 MHz; CDCl3) 8.25 (1H, dd, J 4.9, 1.1, Ar-H), 7.56 (1H, td, 
J 8.0, 2.0, Ar-H), 7.32-7.17 (5H, m, Ar-H), 6.96 (1H, d, J 8.4 Ar-H), 6.83 (1H, 
ddd, J 7.2, 4.9, 0.7, Ar-H), 5.25 (1H, t, J 8.2, CHPh), 4.92 (1H, ddd, J 11.1, 7.0, 
1.8, NCHH), 3.78 (3H, s, OCH3), 3.39 (1H, td, J 11.1, 6.0, NCHH), 2.57 (1H, 
dddd, J 12.7, 8.0, 6.0, 2.3, CHPhCHH), 2.07 (1H, dddd, J 12.7, 8.0, 6.0, 2.3, 
CHPhCHH); δC (100 MHz; CDCl3) 160.8 (Ar-C) 158.9 (C=O), 147.5 (Ar-CH), 
141.3 (Ar-C), 137.6 (Ar-CH), 128.5 (Ar-CH), 127.4 (Ar-CH), 126.8 (Ar-CH), 
116.4 (Ar-CH), 110.6 (Ar-CH), 64.7 (CH), 53.6 (CH3), 48.7 (CH2), 35.8 (CH2); 
HRMS (ESI+) calculated for C16H17N3O2 [M+H]
+ 284.1399; found 284.1400. 
 
2-(3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)pyridine 353 
351 (10 mg, 28 µmol, 1.0 equiv), palladium on charcoal 
(10 mg, 100 wt%), and ethanol (10 mL) were shaken in a 
parr hydrogenator for 21 h. The resulting solution was filtered through a plug of 
celite and concentrated in vacuo to give a white solid (7 mg, 28 µmol, quant.). 
Alternatively, 354 (35.0 mg, 0.11 mmol, 1.0 equiv), trifluoroacetic acid (1 mL) 
and dichloromethane (2 mL) were combined and stirred at rt for 1 h. The reaction 
was quenched with saturated sodium hydrogen carbonate (5 mL) and extracted 
with dichloromethane (3 x 5 mL). The combined organic extracts were dried 
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over magnesium sulphate and concentrated in vacuo to yield 351 as a white solid 
(19.9 mg, 0.90 µmol, 83%). Rf = 0.21 (10% EtOAc in petroleum ether).  M. p. 
68-69 °C. IR (film) 2851, 1672, 2980, 1586, 1502, 1468, 1348, 1250 cm-1; δH 
(500 MHz; CDCl3); 8.13 (1H, d, J 4.9, Ar-CH), 7.69 (2H, d, J 7.3, Ar-CH), 7.51-
7.45 (1H, m, Ar-CH), 7.40-7.27 (4H, m, Ar-CH), 6.65-6.61 (1H, m, Ar-CH), 
4.10 (2H, t, J 10.5 CH2), 3.21 (2H, t, J 10.5, CH2); δC (125 MHz; CDCl3) 156.3 
(Ar-C), 151.5 (Ar-C), 147.5 (Ar-CH), 137.2 (Ar-CH), 132.6 (C), 129.0 (Ar-CH), 
128.6 (Ar-CH), 125.9 (Ar-CH), 114.3 (Ar-CH), 109.3 (Ar-CH), 46.5 (CH2), 31.7 
(CH2); HRMS (ESI
+) calculated for C14H14N3 [M+Na]
+ 224.1182; found 
224.1183. 
 
Buchwald-Hartwig Amination Screen 1 – 96 Well Screen 
 
Scheme 6.5 Buchwald-Hartwig Amination Screen 1. 
The reactions were performed in an aluminium heating block with 96 x 750 µL 
vials, each with a teflon coated magnetic stirrer bar. These vials were arranged 
in 12 columns (labelled 1-12) and 8 rows (labelled A-H). The following powders 
were weighed into the vials using a Mettler Toledo QX96 powder dispenser 
inside a glovebox.  
All vials in rows A, E: Sodium tert-butoxide (4.3 mg, 44 µmol, 2.0 equiv). 
All vials in rows B, F: Caesium carbonate (14.4 mg, 44 µmol, 2.0 equiv). 
All vials in rows C, G: Potassium carbonate (6.1 mg, 44 µmol, 2.0 equiv). 
All vials in rows D, H: Potassium phosphate tribasic (9.4 mg, 44 µmol, 2.0 
equiv). 
All vials in column 1: [XantPhos Pd(allyl)]Cl (1.7 mg, 2.2 µmol, 0.1 equiv). 
All vials in column 2: [(R)-BINAP Pd(allyl)]Cl (1.9 mg, 2.2 µmol, 0.1 equiv). 
All vials in column 3: Pd(dppf)Cl2 · dichloromethane (1.8 mg, 2.2 µmol, 0.1 
equiv). 
All vials in column 4: [P(tBu)3] Pd(crotyl) Cl (0.9 mg, 2.2 µmol, 0.1 equiv). 
187 
 
All vials in column 5: JohnPhos (0.8 mg, 2.2 µmol, 0.1 equiv) and palladium (II) 
acetate (0.5 mg, 2.2 µmol, 1.0 equiv). 
All vials in column 6: AdBrettPhos (1.7 mg, 2.7 µmol, 0.12 equiv) and palladium 
(II) acetate (0.5 mg, 2.2 µmol, 0.1 equiv). 
All vials in column 7: [tBuBrettPhos Pd(allyl)]OTf (1.7 mg, 2.2 µmol, 0.1 
equiv). 
All vials in column 8: MorDalPhos (1.2 mg, 2.6 µmol, 0.12 equiv) and palladium 
(II) acetate (0.5 mg, 2.2 µmol, 0.1 equiv). 
All vials in column 9: [BrettPhos Pd(crotyl)]OTf (1.9 mg, 2.2 µmol, 0.1 equiv). 
All vials in column 10: [tBuXPhos Pd(allyl)]OTf (1.6 mg, 2.2 µmol, 0.1 equiv). 
All vials in column 11: XPhos Pd(crotyl)Cl (1.5 mg, 2.2 µmol, 0.1 equiv). 
All vials in column 12: RuPhos Pd(crotyl)Cl (1.5 mg, 2.2 µmol, 0.1 equiv). 
The following stock solutions were then made: 
Stock Solution 1: tert-butyl (R)-5-phenylpyrazolidine-1-carboxylate (355) (286 
mg, 1.15 mmol) and 2-bromopyridine (333 mg, 2.10 mmol) in toluene (4.42 
mL). 
Stock Solution 2: tert-butyl (R)-5-phenylpyrazolidine-1-carboxylate (355) (286 
mg, 1.15 mmol) and 2-bromopyridine (333 mg, 2.10 mmol) in dioxane (4.42 
mL). 
All vials in rows A-D were dosed with 85 µL of Stock Solution 1 which 
contained tert-butyl (R)-5-phenylpyrazolidine-1-carboxylate (355) (5.5 mg, 22 
µmol, 1.0 equiv, obtained by deprotection of 308 using procedure in general 
method 5) and 2-bromopyridine (6.4 mg, 41 µmol, 1.8 equiv). 
All vials in rows E-H were dosed with 85 µL of Stock Solution 2 which 
contained tert-butyl (R)-5-phenylpyrazolidine-1-carboxylate (355) (5.5 mg, 2.2 
µmol, 1.0 equiv) and 2-bromopyridine (6.4 mg, 41 µmol, 1.8 equiv). 
The plate was sealed with a silicone and PFA mat and placed on an HEL 
polyblock. The plate was then heated at 90 °C for 16 h. The vials were then 
cooled to rt and DMSO (300 µL) was added to each using a multichannel pipette. 
A 5 µL aliquot was extracted from each then added to a 96-well analyical plate 
and diluted with DMSO (50 µL). The plate was analyzed by reverse phase 
LCMS (XBridge C18 3.5-μm 2.1 × 35 mm Column, 1.6 mL min
-1, 50 °C; gradient 
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5:95 to 99:1 (pH 9 H2O + 10 mM NH4HCO2) / MeCN over 0.7 min + 0.3 min 
hold). The LCMS traces were processed using in-house software and the results 
visualized using Spotfire software to give Figure 3.1. 
 
Buchwald-Hartwig Amination Screen 2 – 24 Well Halide Screen 
 
Scheme 6.7 Buchwald-Hartwig Amination screen 2. 
The reactions were performed in an aluminium heating block with 96 x 750 µL 
vials, each with a teflon coated magnetic stirrer bar. These vials were arranged 
in 12 columns (labelled 1-12) and 8 rows (labelled A-H). The following powders 
were weighed into the vials using a Mettler Toledo QX96 powder dispenser 
inside a glovebox.  
Vials in rows A-D (columns 1-6 only): Sodium tert-butoxide (4.3 mg, 44 µmol, 
2.0 equiv). 
Vials in rows A-D (columns 1-6 only): XPhos Pd(crotyl)Cl (1.5 mg, 2.2 µmol, 
0.1 equiv). 
Vial A03: 4-Bromo-N,N-dimethylaniline (8.8 mg, 44 µmol, 2.0 equiv). 
Vial B01: 2-Bromobenzonitrile (8.0 mg, 44 µmol, 2.0 equiv). 
Vial B02: 3-Bromobenzonitrile (8.0 mg, 44 µmol, 2.0 equiv). 
Vial B03: 4-Bromobenzenethiol (8.4 mg, 44 µmol, 2.0 equiv). 
Vial B04: 2-Bromo-4-fluorophenol (8.4 mg, 44 µmol, 2.0 equiv). 
Vial B05: 4-Bromo-3-nitroanisole (10.3 mg, 44 µmol, 2.0 equiv). 
Vial B06: 5-Bromo-1-methylindole (9.3 mg, 44 µmol, 2.0 equiv). 
Vial C01: 5-Bromo-1H-benzotriazole (8.8 mg, 44 µmol, 2.0 equiv). 
Vial C02: 6-Bromobenzo[d]oxazole (8.8 mg, 44 µmol, 2.0 equiv). 
Vial C03: 3-Bromophenyl Methyl Sulfone (10.4 mg, 44 µmol, 2.0 equiv). 




Vial C05: 6-Bromo-2,3-dihydrobenzofuran (8.8 mg, 44 µmol, 2.0 equiv). 
Vial D04: 5-bromopyrimidine (7.0 mg, 44 µmol, 2.0 equiv). 
Vial D05: 2-chloropyrimidine (5.1 mg, 44 µmol, 2.0 equiv). 
All vials in rows A-D (columns 1-6 only) were dosed with 45 µL of Stock 
Solution 1 which contained tert-butyl (R)-5-phenylpyrazolidine-1-carboxylate 
(355) (5.5 mg, 2.2 µmol, 1.0 equiv). 
Vials A03, B01-B06, C01-C05, D04 and D05 were dosed with 40 µL toluene. 
Vial A01 was dosed with stock solution 2 which contained 40 µL toluene and 
bromobenzene (4.7 µL, 44 µmol, 2.0 equiv). 
Vial A02 was dosed with stock solution 3 which contained 40 µL toluene and 4-
bromo-1,2-dimethylbenzene (6.0 µL, 44 µmol, 2.0 equiv). 
Vial A04 was dosed with stock solution 4 which contained 40 µL toluene and 1-
bromo-3-fluorobenzene (4.9 µL, 44 µmol, 2.0 equiv). 
Vial A05 was dosed with stock solution 5 which contained 40 µL toluene and 1-
bromo-2,4-difluorobenzene (5.0 µL, 44 µmol, 2.0 equiv). 
Vial A06 was dosed with stock solution 6 which contained 40 µL toluene and 3-
bromobenzotrifluoride (6.2 µL, 44 µmol, 2.0 equiv). 
Vial C06 was dosed with stock solution 7 which contained 40 µL toluene and 1-
bromo-3-propylbenzene (6.7 µL, 44 µmol, 2.0 equiv). 
Vial D01 was dosed with stock solution 8 which contained 40 µL toluene and 1-
bromo-4-tert-butylbenzene (7.7 µL, 44 µmol, 2.0 equiv). 
Vial D02 was dosed with stock solution 9 which contained 40 µL toluene and 1-
bromo-4-methoxybenzene (5.5 µL, 44 µmol, 2.0 equiv). 
Vial D03 was dosed with stock solution 10 which contained 40 µL toluene and 
3-bromothiophene (4.1 µL, 44 µmol, 2.0 equiv). 
Vial D06 was dosed with stock solution 11 which contained 40 µL toluene and 
4-chlorotoluene (5.2 µL, 44 µmol, 2.0 equiv). 
The plate was sealed with a silicone and PFA mat and placed on an HEL 
polyblock. The plate was then heated at 90 °C for 16 h. The vials were then 
cooled to rt and DMSO (300 µL) was added to each using a multichannel pipette. 
A 5 µL aliquot was extracted from each then added to a 96-well analyical plate 
and diluted with DMSO (50 µL). The plate was analyzed by reverse phase 
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LCMS (XBridge C18 3.5-μm 2.1 × 35 mm Column, 1.6 mL min
-1, 50 °C; gradient 
5:95 to 99:1 (pH 9 H2O + 10 mM NH4HCO2) / MeCN over 0.7 min + 0.3 min 
hold). All 24 halides were analysed using the same methodology so their peaks 
could be ignored in the purity analysis. The LCMS traces were processed using 
in-house software and the results visualized using ChemDraw to give Figure 3.2. 
The raw data is given below (Table 6.2) 
Vial Ret Halide / min Ret Product / 
min 
LCMS Purity 
A01 0.51 0.61 68% 
A02 0.60 0.66 62% 
A03 0.56 0.60 50% 
A04 0.52 0.62 73% 
A05 0.52 0.42 66% 
A06 0.58 0.66 77% 
B01 0.42 0.59 50% 
B02 0.45 0.59 56% 
B03 0.21/0.75 N/A 0% (SM) 
B04 0.38 N/A 0% (SM) 
B05 0.49 0.62 40% 
B06 0.55 0.60 56% 
C01 0.26/0.42 N/A 42% (SM) 
C02 0.26 0.57 21% (SM) 
C03 0.36 0.66 12% 
C04 0.42 N/A 0% 
C05 0.49 0.60 53% 
C06 0.49 0.69 71% 
D01 0.67 0.70 62% 
D02 0.51 0.59 80% 
D03 0.47 0.59 43% 
D04 0.20 0.46 86% 
D05 0.15 0.51 66% 
D06 0.55 0.64 76% 




General procedure 8: Buchwald-Hartwig Amination 
 
Scheme 6.8 General procedure for the Buchwald-Hartwig Amination 
N.B. Magnesium turnings were activated by washing them with 1 M 
hydrochloric acid solution (2 × 20 mL), water (20 mL) and methanol (20 mL). 
 
tert-Butyl-(R)-5-phenyl-2-tosylpyrazolidine-1-carboxylate (308) (1.0 equiv), 
activated magnesium turnings (5.0 equiv) and MeOH (0.1 M) were combined 
and stirred (800 rpm) at room temperature for 2 hours. The solution was 
quenched with saturated ammonium chloride solution (5 mL), then extracted 
with dichloromethane (3 x 5 mL). The combined organic extracts were dried 
over MgSO4 and concentrated in vacuo to give a colourless oil. To this was 
added toluene (1.0 M) was added XPhos Pd(crotyl)Cl (0.1 equiv), sodium tert-
butoxide (2.0 equiv) and aryl halide (2.0 equiv). The reaction mixture was stirred 
at 90 °C for 16 h. The mixture was cooled to rt then quenched with saturated 
ammonium chloride solution (5 mL) and extracted with dichloromethane (3 × 5 
mL). The combined organic extracts were dried over magnesium sulphate and 
concentrated in vacuo. The crude product was purified by column 




carboxylate (354). Following general procedure 8, 308 (72 
mg, 0.18 mmol, 1.0 equiv), magnesium turnings (22 mg, 
0.90 mmol, 5.0 equiv) and methanol (1.8 mL, 0.1 M), then XPhos Pd(crotyl)Cl 
(12 mg, 18 µmol, 0.1 equiv), sodium tert-butoxide (35 mg, 0.36 mmol, 2.0 
equiv) and 2-bromopyridine (34 µL, 0.36 mmol, 2.0 equiv) in toluene (0.18 mL, 
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1.0 M) yielded 354 as a white solid (50 mg, 0.16 mmol, 85%). M.p. 98-99 °C; 
Rf = 0.34 (30% ethyl acetate in petroleum ether); [α]
32
D –91.3 (c 0.04, CHCl3); 
IR (film) 2989, 1698, 1588, 1388, 1161 cm-1; δH (500 MHz; CDCl3) 8.25 (1H, 
d, J 4.8, Ar-H), 7.59 (1H, td, J 7.8, 1.8, Ar-H), 7.30-7.18 (5H, m, Ar-H), 6.95 
(1H, d, J 8.4, Ar-H), 6.82 (1H, dd, J 6.7, 5.3, Ar-H), 5.19 (1H, t, J 8.1, CHPh), 
4.89 (1H, t, J 10.3, NCHH), 3.49-3.41 (1H, m, NCHH), 2.58-2.51 (1H, m, 
CHPhCHH), 2.09-1.98 (1H, m, CHPhCHH), 1.43 (9H, s, C(CH3)3); δC (125 
MHz; CDCl3) 160.9 (Ar-C), 156.8 (C=O), 147.3 (Ar-CH), 142.1 (Ar-C), 137.5 
(Ar-CH), 128.4 (Ar-CH), 127.2 (Ar-CH), 126.6 (Ar-CH), 115.8 (Ar-CH), 110.4 
(Ar-CH), 81.5 (C), 65.5 (CH), 48.2 (CH2), 36.2 (CH2), 28.2 (CH3); HRMS 
(ESI+) calculated for C19H24N3O2 [M+Na]




(360). Following general procedure 8, 308 (85 mg, 0.21 
mmol, 1.0 equiv), magnesium turnings (26 mg, 1.05 
mmol, 5.0 equiv) and methanol (2.1 mL, 0.1 M), then XPhos Pd(crotyl)Cl (7 
mg, 10 µmol, 0.05 equiv), sodium tert-butoxide (40 mg, 0.42 mmol, 2.0 equiv) 
and 3-bromobenzotrifluoride (55 µL, 0.42 mmol, 2.0 equiv) in toluene (0.21 mL, 
1.0 M) yielded 360 as a colourless oil (69 mg, 0.18 mmol, 85%). Rf = 0.28 (20% 
ethyl acetate in petroleum ether); [α]32D –9.8 (c 0.25, dichloromethane). IR (film) 
2978, 2930, 1704, 1451, 1367, 1164 cm-1; δH (500 MHz; CDCl37.37 (1H, t, J 
8.0, Ar-CH), 7.30-7.21 (5H, m, Ar-H), 7.19 (1H, s, Ar-H), 7.15 (1H, d, J 7.6, 
Ar-H), 7.11 (1H, dd, J 8.3, 1.6, Ar-CH), 5.20 (1H, t, J 7.5, CHPh), 3.85 (1H, 
ddd, J 11.0, 6.5, 4.5, NCHH), 3.69 (1H, ddd, J 11.0, 8.9, 6.3, NCHH), 2.54 (1H, 
qd, J 6.3, 4.5, CHPhCHH), 2.13 (1H, dt, J 15.7, 7.2, CHPhCHH), 1.39 (9H, s, 
C(CH3)3); δC (125 MHz; CDCl3) 156.1 (C=O), 150.7 (Ar-C), 141.4 (Ar-C), 
131.1 (q, J 32.5, Ar-C), 129.3 (Ar-CH), 128.5 (Ar-CH), 127.4 (Ar-CH), 126.7 
(Ar-CH), 124.3 (q, J 271.3, CF3), 118.2 (Ar-CH), 117.9 (q, J 3.8, Ar-CH), 111.9 
(q, J 3.8, Ar-CH), 81.7 (C), 63.3 (CH), 52.3 (CH2), 35.4 (CH2), 28.1 (CH3); δF 
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(282 MHz; CDCl3) -62.8 (CF3); HRMS (ESI
+) calculated for F3C21H23N2O2 
[M+Na]+ 415.1604; found 415.1597. 
 
tert-Butyl (R)-5-phenyl-2-(p-tolyl)pyrazolidine-1-
carboxylate (357). Following general procedure 8, 308 
(105 mg, 0.26 mmol, 1.0 equiv), magnesium turnings (32 
mg, 1.30 mmol, 5.0 equiv) and methanol (2.6 mL, 0.1 M), then XPhos 
Pd(crotyl)Cl (18 mg, 26 µmol, 0.1 equiv), sodium tert-butoxide (50 mg, 0.52 
mmol, 2.0 equiv) and 4-chlorotoluene (63 µL, 0.52 mmol, 2.0 equiv) in toluene 
(0.26 mL, 1.0 M) yielded 357 as an orange oil (73 mg, 0.22 mmol, 82%). Rf = 
0.30 (30% ethyl acetate in petroleum ether); [α]32D –27.5 (c 0.26, 
dichloromethane); IR (film) 2978, 2924, 1697, 1512, 1366, 1134 cm-1; δH (400 
MHz; CDCl3) 7.30-7.23 (5H, m, Ar-H), 7.08 (2H, d, J 8.4, Ar-H), 6.91 (2H, d, 
J 8.5, Ar-H) 5.09 (1H, t, J 7.8, CHPh), 3.95-3.80 (1H, m, NCHH), 3.62-3.54 
(1H, m, NCHH), 2.54-2.42 (1H, m, CHPhCHH), 2.29 (3H, s, Ar-CH3), 2.09-
1.99 (1H, m, CHPhCHH), 1.35 (9H, s, C(CH3)3); δC (100 MHz; CDCl3) 148.3 
(Ar-C) 142.2 (Ar-C), 130.3 (Ar-C), 129.4 (Ar-CH), 128.3 (Ar-CH), 127.1 (Ar-
CH), 126.9 (Ar-CH), 115.8 (Ar-CH), 81.0 (C), 63.6 (CH), 53.0 (CH2), 35.7 
(CH2), 28.2 (CH3), 20.5 (CH3), C=O not seen; HRMS (ESI
+) calculated for 
C21H26N2O2 [M+Na]
+ 361.1892; found 361.1896. 
 
tert-Butyl (R)-2-([1,1'-biphenyl]-4-yl)-5-
phenylpyrazolidine-1-carboxylate (361). Following 
general procedure 8, 308 (101 mg, 0.25 mmol, 1.0 
equiv), magnesium turnings (30 mg, 1.25 mmol, 5.0 equiv) and methanol (2.5 
mL, 0.1 M), then XPhos Pd(crotyl)Cl (8 mg, 12 µmol, 0.05 equiv), sodium tert-
butoxide (48 mg, 0.50 mmol, 2.0 equiv) and 4-bromobiphenyl (116 mg, 0.50 
mmol, 2.0 equiv) in toluene (0.25 mL, 1.0 M) yielded 361 as a colourless oil (73 
mg, 0.18 mmol, 73%). Rf = 0.17 (15% ethyl acetate in petroleum ether); [α]
32
D –




(500 MHz; CDCl3) 7.61 (2H, d, J 7.4, Ar-H), 7.56 (2H, d, J 8.7, Ar-CH), 7.44 
(2H, t, J 7.7, Ar-CH), 7.31-7.27 (6H, m, Ar-H), 7.10 (2H, d, J 8.6, Ar-H), 5.18 
(1H, t, J 7.6, CHPh), 3.96 (1H, ddd, J 10.7, 6.2, 4.2, NCHH), 3.74-3.64 (1H, m, 
NCHH), 2.61-2.53 (1H, m, CHPhCHH), 2.20-2.10 (1H, m, CHPhCHH), 1.41 
(9H, s, C(CH3)3); δC (125 MHz; CDCl3) 155.9 (C=O), 149.7 (Ar-C), 141.9 (Ar-
C), 140.9 (Ar-C), 133.8 (Ar-C), 128.7 (Ar-CH), 128.4 (Ar-CH), 127.5 (Ar-CH), 
127.3 (Ar-CH), 126.9 (Ar-CH), 126.6 (Ar-CH), 126.6 (Ar-CH), 115.9 (Ar-CH), 
81.4 (C), 63.6 (CH), 52.8 (CH2), 35.7 (CH2), 28.2 (CH3); HRMS (ESI
+) 
calculated for C26H28N2O2 [M+Na]
+ 423.2043; found 423.2037. 
 
tert-Butyl (R)-2-(2-cyanophenyl)-5-phenylpyrazolidine-
1-carboxylate (359).  Following general procedure 8, 308 
(65 mg, 0.26 mmol, 1.0 equiv.), XPhos Pd(crotyl)Cl (18 mg, 
26 µmol, 0.1 equiv.), sodium tert-butoxide (50 mg, 0.52 
mmol, 2.0 equiv.) and 2-bromobenzonitrile (95 mg, 0.52 mmol, 2.0 equiv.) in 
toluene (0.26 mL, 1.0 M) yielded 359 as a yellow oil (87 mg, 0.25 mmol, 95%). 
Rf = 0.35 (30% ethyl acetate in petroleum ether); [α]
32
D + 7.3 (c 0.22, 
Dichloromethane). IR (film) 2971, 2924, 1713, 1450, 1304, 1142 cm-1; δH (400 
MHz; CDCl3) 7.56 (1H, dd, J 7.7, 1.4, Ar-H), 7.45-7.27 (6H, m, Ar-H), 7.16 
(1H, d, J 8.3, Ar-H), 6.96 (1H, td, J 7.6, 0.9, Ar-H), 5.21 (1H, t, J 7.3 CHPh), 
4.08-3.90 (2H, m, NCH2), 2.57 (1H, td, J 12.8, 6.4, CHPhCHH), 2.21 (1H, td, J 
14.6, 7.1, CHPhCHH), 1.32 (9H, s, C(CH3)3); δC (100 MHz; CDCl3) 154.4 (Ar-
C), 141.3 (Ar-C), 134.3 (Ar-CH), 133.1 (Ar-CH), 128.6 (Ar-CH), 127.5 (Ar-
CH), 126.8 (Ar-CH), 121.4 (Ar-CH), 118.6 (Ar-C) 117.3 (Ar-CH), 100.5 (CN), 
81.6 (C), 62.5 (CH), 54.4 (CH2), 34.7 (CH2), 28.1 (CH3), C=O not seen; HRMS 
(ESI+) calculated for C21H23N3O2 [M+Na]
+ 372.1688; found 372.1690. 
 
tert-Butyl (R)-2-(4-methoxyphenyl)-5-
phenylpyrazolidine-1-carboxylate (358).  
Following general procedure 8, 308 (64 mg, 0.26 
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mmol, 1.0 equiv.), XPhos Pd(crotyl)Cl (17 mg, 26 µmol, 0.1 equiv.), sodium 
tert-butoxide (50 mg, 0.52 mmol, 2.0 equiv.) and 4-bromoanisole (97 mg, 0.52 
mmol, 2.0 equiv.) in toluene (0.26 mL, 1.0 M) yielded 358 as an orange oil (72 
mg, 0.20 mmol, 79%). Rf = 0.22 (30% ethyl acetate in petroleum ether); [α]
32
D 
– 18.2 (c 0.09, Dichloromethane). IR (film) 2924, 2338, 1697, 1504, 1366, 1250 
cm-1; δH (400 MHz; CDCl3) 7.28-7.20 (5H, m, Ar-H), 6.96 (2H, dt, J 9.4, 3.0, 
Ar-H), 6.85 (2H, dt, J 9.0, 2.2, Ar-H), 5.09 (1H, t, J 7.7, CHPh), 3.87-3.80 (1H, 
m, NCHH), 3.79 (3H, s, OCH3), 3.55 (1H, ddd, J 11.4, 9.2, 5.8, NCHH), 2.53-
2.44 (1H, m, CHPhCHH), 2.09-1.99 (1H, m, CHPhCHH), 1.35 (9H, s, C(CH3)3); 
δC (100 MHz; CDCl3) 154.5 (Ar-C), 144.5 (Ar-C), 142.2 (Ar-C), 128.3 (Ar-
CH), 127.1 (Ar-CH), 126.9 (Ar-CH), 117.2 (Ar-CH), 114.2 (Ar-CH), 81.0 (C), 
63.6 (CH), 55.6 (CH3), 53.4 (CH2), 35.5 (CH2), 28.2 (CH3), C=O not seen; 
HRMS (ESI+) calculated for C21H26N2O3 [M+Na]




(365). To a solution of 312 (40 mg, 0.12 mmol, 
1.0 equiv) in methanol (1.2 mL, 0.1 M) was added activated magnesium turnings 
(15 mg, 0.60 mmol, 5.0 equiv), and the mixture was stirred vigorously (800 rpm) 
for 2 h at rt. The reaction mixture was quenched with saturated ammonium 
chloride solution (10 mL) and extracted with dichloromethane (3 × 5 mL). The 
combined organic extracts were washed with brine (30 mL), dried over MgSO4, 
filtered, and concentrated in vacuo. The residue was dissolved in toluene (0.12 
mL, 1.0 M), and palladium acetate (3 mg, 12 µmol, 0.1 equiv), Xantphos (14 
mg, 25 µmol, 0.2 equiv), sodium tert-butoxide (24 mg, 0.25 mmol, 2.0 equiv) 
and 4-bromobenzonitrile (45 mg, 0.25 mmol, 2.0 equiv) were added. The 
solution was stirred at 90 °C for 20 h. The reaction mixture was then quenched 
with saturated ammonium chloride solution (5 mL), extracted with 
dichloromethane (3 × 5 mL), dried over magnesium sulphate and then 
concentrated in vacuo. The crude product was purified by column 
chromatography (25% ethyl acetate in petroleum ether) to give 365 as a 
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colourless oil (45 mg, 0.11 mmol, 86%). Rf = 0.23 (25% ethyl acetate in 
petroleum ether); [α]32D –10.7 (c 0.42, CHCl3); IR (film) 2977, 2928, 2218, 1705, 
1603, 1509, 1338, 1142 cm-1; δH (500 MHz; CDCl3) 7.48 (4H, dd, J 8.0, 4.8, 
Ar-H), 7.44 (2H, d, J 8.2, Ar-H), 7.35 (2H, t, J 7.6, Ar-H), 7.27 (1H, t, J 7.4, Ar-
H), 7.21 (2H, d, J 8.2, Ar-H), 6.86 (2H, d, J 8.8, Ar-H), 5.26 (1H, t, J 6.9, CHPh), 
3.77-3.70 (1H, m, NCHH), 3.66 (1H, dt, J 10.5, 7.4, NCHH), 2.53 (1H, td, J 
12.5, 7.1, CHPhCHH), 2.23-2.12 (1H, m, CHPhCHH), 1.36 (9H, s, C(CH3)3); 
δC (125 MHz; CDCl3) 152.8 (C=O), 140.5 (Ar-C), 139.8 (Ar-C), 133.2 (Ar-C), 
128.8 (Ar-CH), 127.4 (Ar-CH), 127.3 (Ar-CH), 127.0 (Ar-CH), 127.0 (Ar-CH), 
126.6 (Ar-C), 126.6 (Ar-CH), 119.9 (Ar-C) 114.2 (Ar-CH), 102.1 (CN), 82.3 
(C), 62.8 (CH), 50.6 (CH2), 35.1 (CH2), 28.2 (CH3); HRMS (ESI
+) calculated 
for C27H27N3O2 [M+Na]
+ 448.1995; found 448.1999. 
 
tert-Butyl (R)-2-isobutyl-5-phenylpyrazolidine-1-carboxylate 
(369). Cyclic hydrazine 308 (84 mg, 0.20 mmol, 1.0 equiv), 
activated magnesium turnings (24 mg, 1.0 mmol, 5.0 equiv) and 
methanol (2.0 mL, 0.1 M) were combined and stirred (800 rpm) at room 
temperature for 2 hours. The solution was quenched with saturated ammonium 
chloride solution (5 mL), then extracted with dichloromethane (3 x 5 mL). The 
combined organic extracts were dried over MgSO4 and concentrated in vacuo to 
give a colourless oil. To this was added sodium triacetoxyborohydride (212 mg, 
1.00 mmol, 5.0 equiv), isobutyraldehyde (91 µL, 1.0 mmol, 5.0 equiv) and 
tetrahydrofuran (2 mL, 0.1 M). The reaction mixture was stirred at room 
temperature for 18 hours. The reaction mixture was quenched with 1 M NaOH 
(5 mL), extracted with dichloromethane (3 x 5 mL). The combined organic 
extracts were dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography twice (5-10% ethyl acetate in 
petroleum ether) to give 369 as a colourless oil (39 mg, 0.13 mmol, 63%). Rf = 
0.38 (15% ethyl acetate in heptane). [α]32D +35.8 (c 0.30, dichloromethane). IR 
(film) 2955, 2878, 1690, 1366, 1173 cm-1; δH (400 MHz; CDCl3) 7.39-7.15 (5H, 
m, Ar-H), 4.97 (1H, t, J 8.4, CHPh), 3.15 (1H, td, J 11.3, 5.9, NCHHCH2), 3.03 
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(1H, ddd, J 11.6, 6.6, 2.3, NCHHCH2), 2.71 (1H, dd, J 11.5, 7.1, 
NCHHCH(CH3)2), 2.56-2.43 (2H, m, NCHHCH(CH3)2 and CHHCHPh), 2.23-
2.10 (1H, m, CHHCHPh), 1.80 (1H, nonet, J 7.0, CH(CH3)2), 1.36 (9H, s, 
C(CH3)3), 1.05 (3H, d, J 6.6, CHCH3), 1.02 (3H, d, J 6.6, CHCH3); δC (100 
MHz; CDCl3) 143.8 (Ar-C), 128.3 (Ar-CH), 126.6 (Ar-CH), 125.7 (Ar-CH), 
80.1 (C), 66.8 (CH2), 63.1 (CH), 53.3 (CH2), 34.9 (CH2), 28.3 (CH3), 27.5 (CH), 
21.3 (CH3), 20.9 (CH3), C=O not seen; HRMS (ESI
+) calculated for C18H28N2O2 
[M+Na]+ 327.2048; found 327.2052. 
 
tert-Butyl (R)-2-(2-methylbenzyl)-5-phenylpyrazolidine-
1-carboxylate (367).  Cyclic hydrazine 308 (40 mg, 0.16 
mmol, 1.0 equiv), activated magnesium turnings (19 mg, 0.8 
mmol, 5.0 equiv) and methanol (1.6 mL, 0.1 M) were 
combined and stirred (800 rpm) at room temperature for 2 hours. The solution 
was quenched with saturated ammonium chloride solution (5 mL), then 
extracted with dichloromethane (3 x 5 mL). The combined organic extracts were 
dried over MgSO4 and concentrated in vacuo to give a colourless oil. To this was 
added sodium triacetoxyborohydride (170 mg, 0.80 mmol, 5.0 equiv.), 2-
tolualdehyde (93 µL, 0.80 mmol, 5.0 equiv.) in tetrahydrofuran (0.16 mL, 1.0 
M). The reaction mixture was stirred at room temperature for 18 hours. The 
reaction mixture was quenched with 1 M NaOH (5 mL), extracted with 
dichloromethane (3 x 5 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography twice (20% ethyl acetate in hexane) to give 367 as a colourless 
oil (18 mg, 50 µmol, 32%). Rf = 0.35 (20% ethyl actate in hexane). [α]
32
D + 28.7 
(c 0.06, CH2Cl2). IR (film) 2970, 2924, 1697, 1366, 1134 cm
-1; δH (400 MHz; 
CDCl3) 7.41-7.22 (6H, m, Ar-H), 7.19-7.06 (3H, m, Ar-H), 5.02 (1H, t, J 8.2 
CHPh), 4.15 (1H, d, J 11.9, NCHHAr), 3.88 (1H, d, J 11.9, NCHHAr), 3.06 (1H, 
ddd, J 11.8, 6.2, 2.8, NCHH), 3.00-2.89 (1H, m, NCHH), 2.60-2.49 (1H, m, 
CHPhCHH and CH3), 2.30-2.17 (1H, m, CHPhCHH), 1.33 (9H, s, C(CH3)3); δC 
(100 MHz; CDCl3) 143.7 (Ar-C), 138.2 (Ar-C), 135.6 (Ar-C), 130.9 (Ar-CH), 
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130.4 (Ar-CH), 128.4 (Ar-CH), 127.7 (Ar-CH), 126.8 (Ar-CH), 125.8 (Ar-CH), 
125.6 (Ar-CH), 80.3 (C), 63.5 (CH), 59.3 (CH2), 50.4 (CH2), 34.6 (CH2), 28.3 
(CH3), 19.5 (CH3), C=O not seen; HRMS (ESI
+) calculated for C22H28N2O2 
[M+Na]+ 375.2048; found 375.2049. 
 
tert-Butyl (R)-2-(3-fluorobenzyl)-5-
phenylpyrazolidine-1-carboxylate (368).  Cyclic 
hydrazine 308 (40 mg, 0.16 mmol, 1.0 equiv.), activated 
magnesium turnings (19 mg, 0.8 mmol, 5.0 equiv) and 
methanol (1.6 mL, 0.1 M) were combined and stirred (800 rpm) at room 
temperature for 2 hours. The solution was quenched with saturated ammonium 
chloride solution (5 mL), then extracted with dichloromethane (3 x 5 mL). The 
combined organic extracts were dried over MgSO4 and concentrated in vacuo to 
give a colourless oil. To this was added sodium triacetoxyborohydride (170 mg, 
0.80 mmol, 5.0 equiv.), 3-fluorobenzaldehyde (72 µL, 0.80 mmol, 5.0 equiv.) 
and tetrahydrofuran (1.6 mL, 0.1 M). The reaction mixture was stirred at room 
temperature for 18 hours. The reaction mixture was quenched with 1 M NaOH 
(5 mL), extracted with dichloromethane (3 x 5 mL). The combined organic 
extracts were dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by column chromatography twice (15% ethyl acetate in heptane) to 
give 368 as a colourless oil (24 mg, 70 µmol, 42%).  Rf = 0.35 (15% ethyl acetate 
in heptane). [α]32D + 40.0 (c 0.27, Dichloromethane). IR (film) 2970, 2924, 1697, 
1366, 1142 cm-1; δH (400 MHz; CDCl3) 7.39-7.17 (8H, m, Ar-H), 6.97 (1H, dd, 
J 8.2 and 2.1, Ar-H), 5.00 (1H, t, J 8.0 CHPh), 4.16 (1H, d, J 12.4, NCHHAr), 
3.85 (1H, d, J 12.4, NCHHAr), 3.09-2.98 (2H, m, NCH2), 2.55-2.49 (1H, m, 
CHPhCHH), 2.28-2.14 (1H, m, CHPhCHH), 1.34 (9H, s, C(CH3)3); δC (100 
MHz; CDCl3) 162.9 (d, J 244, Ar-CF), 154.9 (C=O), 143.4 (Ar-C), 140.4 (d, J 
8.0, Ar-C), 129.7 (d, J 8.0, Ar-CH), 128.4 (Ar-CH), 126.9 (Ar-CH), 125.8 (Ar-
CH), 125.0 (d, J 2.0, Ar-CH), 116.4 (d, J 22.0, Ar-CH), 114.4 (d, J 21, Ar-CH), 
80.4 (C), 63.3 (CH), 61.2 (CH2), 51.2 (CH2), 34.7 (CH2), 28.3 (CH3); δF (376 
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MHz; CDCl3) -113.5 (CF);  HRMS (ESI
+) calculated for C21H25N2NaFO2 
[M+Na]+ 379.1798; found 379.1800. 
 
 tert-Butyl (R)-2-pentyl-5-phenylpyrazolidine-1-
carboxylate (371).  Cyclic hydrazine 308 (75 mg, 0.30 
mmol, 1.0 equiv.), activated magnesium turnings (36 mg, 
1.5 mmol, 5.0 equiv) and methanol (3.0 mL, 0.1 M) were combined and stirred 
(800 rpm) at room temperature for 2 hours. The solution was quenched with 
saturated ammonium chloride solution (5 mL), then extracted with 
dichloromethane (3 x 5 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo to give a colourless oil. To this was added 
sodium triacetoxyborohydride (370 mg, 1.51 mmol, 5.0 equiv.), valeraldehyde 
(161 µL, 1.51 mmol, 5.0 equiv.) and tetrahydrofuran (3.0 mL, 0.1 M). The 
reaction mixture was stirred at room temperature for 18 hours. The reaction 
mixture was quenched with 1 M NaOH (5 mL), extracted with dichloromethane 
(3 x 5 mL). The combined organic extracts were dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by column 
chromatography twice (15% ethyl acetate in heptane) to give XX as a colourless 
oil (54 mg, 0.17 mmol, 56%). Rf = 0.38 (15% ethyl acetate in heptane). [α]
32
D + 
35.5 (c 0.17, Dichloromethane). IR (film) 2932, 2862, 1697, 1366, 1173 cm-1; 
δH (400 MHz; CDCl3) 7.35-7.19 (5H, m, Ar-H), 4.96 (1H, t, J 8.2, CHPh), 3.20-
3.13 (1H, m, NCHH), 3.10-3.04 (1H, m, NCHH), 2.91 (1H, dt, J 11.3, 7.7, 
NCHH(CH2)3), 2.71 (1H, dt, J 11.3, 7.7, NCHH(CH2)3),  2.55-2.45 (1H, m, 
CHArCHH), 2.20-2.10 (1H, m, CHArCHH), 1.61 (2H, quin, J 7.1, CH2), 1.41-
1.28 (4H, m, 2 x CH2), 0.92 (3H, t, J 7.3, CH2CH3); δC (100 MHz; CDCl3) 154.4 
(C=O seen by HMBC), 142.7 (Ar-C), 127.3 (Ar-CH), 125.7 (Ar-CH), 124.7 (Ar-
CH), 79.1 (C), 62.2 (CH), 57.4 (CH2), 52.9 (CH2) 33.9 (CH2), 28.5 (CH2), 27.2 
(CH3), 21.7 (CH2), 13.0 (CH3), 1 CH2 not seen; HRMS (ESI
+) calculated for 
C19H30N2NaO2 [M+Na]





carboxylate (370).  Cyclic hydrazine 308 (75 mg, 0.30 
mmol, 1.0 equiv.), activated magnesium turnings (36 mg, 
1.5 mmol, 5.0 equiv) and methanol (3.0 mL, 0.1 M) were combined and stirred 
(800 rpm) at room temperature for 2 hours. The solution was quenched with 
saturated ammonium chloride solution (5 mL), then extracted with 
dichloromethane (3 x 5 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo to give a colourless oil. To this was added 
sodium triacetoxyborohydride (320 mg, 1.51 mmol, 5.0 equiv.), 
cinnamaldehyde (191 µL, 1.51 mmol, 5.0 equiv.) and tetrahydrofuran (3 mL, 0.1 
M). The reaction mixture was stirred at room temperature for 18 hours. The 
reaction mixture was quenched with 1 M NaOH (5 mL), extracted with 
dichloromethane (3 x 5 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (15% ethyl acetate in hexane) to give 370 as a colourless oil (84 
mg, 0.26 mmol, 76%).  Rf = 0.36 (15% ethyl acetate in hexane). [α]
32
D + 42.9 (c 
0.02, Dichloromethane). IR (film) 2963, 2924, 1697, 1366, 1134 cm-1; δH (400 
MHz; CDCl3) 7.41-7.20 (10H, m, Ar-H), 6.53 (1H, d, J 16.1, CHCHCH2), 6.44 
(1H, dt, J 15.9, 6.3, CHCHCH2), 4.98 (1H, t, J 7.9, CHPh), 3.77 (1H, dd, J 12.7, 
5.8, NCHHCH), 3.57 (1H, dd, J 12.8, 6.8, NCHHCH), 3.25-3.14  (2H, m, 
NCH2CH2), 2.55 (1H, qd, J 9.0, 4.7, NCHHCH2), 2.17 (1H, dq, J 12.5, 8.3, 
NCHHCH2), 1.30 (9H, s, C(CH3)3); δC (100 MHz; CDCl3) 143.5 (Ar-C), 136.9 
(Ar-C), 133.1 (CH), 128.6 (Ar-CH), 128.4 (Ar-CH), 127.6 (Ar-CH), 126.8 (CH), 
126.5 (Ar-CH), 126.4 (Ar-CH), 125.8 (Ar-CH), 80.3 (C), 63.2 (CH) 60.5 (CH2), 
51.5 (CH2), 34.9 (CH2), 28.2 (CH3), C=O not seen; HRMS (ESI
+) calculated for 
C23H28N2NaO2 [M+Na]





1(2H)-carboxylate (440). Cyclic hydrazine 332 (134 mg, 0.31 
mmol, 1.0 equiv), activated magnesium turnings (38 mg, 1.55 
mmol, 5.0 equiv) and methanol (3.1 mL, 0.1 M) were combined 
and stirred (800 rpm) at room temperature for 2 h. The solution 
was quenched with saturated ammonium chloride solution (5 mL), then 
extracted with dichloromethane (3 x 5 mL). The combined organic extracts were 
dried over MgSO4 and concentrated in vacuo to give a colourless oil. To this was 
added sodium triacetoxyborohydride (323 mg, 1.52 mmol, 5.0 equiv), E-
cinnamaldehyde (193 µL, 1.52 mmol, 5.0 equiv) and tetrahydrofuran (3.1 mL, 
0.1 M). The reaction mixture was stirred at room temperature for 18 hours. The 
reaction mixture was quenched with 1 M NaOH (5 mL), extracted with 
dichloromethane (3 x 5 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (5-10% ethyl acetate in petroleum ether) to give 440 as a 
colourless oil (105 mg, 0.28 mmol, 91%). Rf = 0.16 (10% ethyl acetate in 
heptane); [α]32D +24.0 (c 0.35, CHCl3). IR (film) 3007, 2866, 1681, 1390, 1069 
cm-1; δH (500 MHz; CDCl3) 7.48-7.43 (2H, m, Ar-H), 7.35 (2H, t, J 7.5, Ar-H), 
7.32-7.27 (5H, m, Ar-H), 7.25-7.20 (1H, m, Ar-H), 6.22 (1H, d, J 15.9, C=CH), 
6.09 (1H, dt, J 15.8, 6.3, C=CH), 5.37 (1H, s, CHPh), 3.58 (2H, d, J 7.0, 
NCH2CH=C), 3.22-3.07 (1H, m, NCHHCH2), 2.99-2.92 (1H, m, NCHHCH2), 
2.42-2.21 (1H, m, CHHCHPh), 2.09-1.95 (2H, m, CHHCHPh and NCH2CHH), 
1.53 (10H, s, NCH2CHH and C(CH3)3); δC (125 MHz; CDCl3) 142.0 (Ar-C), 
137.2 (Ar-C), 131.7 (C=CH) 128.5 (Ar-CH), 128.2 (Ar-CH), 127.4 (C=CH), 
127.2 (Ar-CH), 127.1 (Ar-CH), 126.6 (Ar-CH), 126.3 (Ar-CH), 80.5 (C), 57.9 
(CH2), 55.2 (CH, seen on HSQC), 49.0 (CH2), 29.7 (CH2), 28.5 (CH3), 25.6 
(CH2), 17.9 (CH3), C=O not seen; HRMS (ESI
+) calculated for C24H30N2O2 





phenylpyrazolidine-1-carboxylate (373). Cyclic 
hydrazine 308 (36 mg, 90 µmol, 1.0 equiv), 
magnesium turnings (11 mg, 0.45 mmol, 5.0 equiv) 
and methanol (0.9 mL, 0.1 M) were combined and stirred (800 rpm) at room 
temperature for 2 hours. The solution was quenched with saturated ammonium 
chloride solution (5 mL), then extracted with dichloromethane (3 x 5 mL). The 
combined organic extracts were dried over magnesium sulphate and 
concentrated in vacuo to give a colourless oil. Then a solution of 4-
methoxybenzoyl chloride (30 µL, 0.23 mmol, 2.5 equiv) in dichloromethane (0.9 
mL) were added. The reaction mixture was stirred at rt for 18 h. The mixture 
was concentrated in vacuo. The crude product was purified by column 
chromatography (25% ethyl acetate in petroleum ether) to give 373 as a 
colourless oil (27 mg, 70 µmol, 80%). Rf = 0.21 (25% ethyl acetate in petroleum 
ether); [α]32D +19.6 (c 0.18, dichloromethane); IR (film) 2989, 2924, 1712, 1611, 
1388, 1161 cm-1; δH (400 MHz; CDCl3) 7.58-7.49 (2H, m, Ar-H), 7.36-7.23 
(5H, m, Ar-H), 6.79 (2H, d, J 8.4, Ar-H), 5.32 (1H, br s, CHPh), 4.34-4.17 (1H, 
m, NCHH), 3.81 (3H, s, OCH3), 3.54 (1H, d, J 8.6, NCHH), 2.55 (1H, dtd, J 
12.5, 8.3, 4.2, CHPhCHH), 2.27 (1H, br s, CHPhCHH), 1.35 (9H, s, C(CH3)3); 
δC (100 MHz; CDCl3) 161.6 (C=O), 140.6 (Ar-C), 132.2 (Ar-C), 130.2 (Ar-
CH), 128.6 (Ar-CH), 127.5 (Ar-CH), 126.5 (Ar-CH), 113.1 (Ar-CH), 82.3 (C), 
62.9 (CH), 55.3 (CH3), 36.2 (CH2), 28.0 (CH3), C=O, Ar-C and CH2 not seen; 
HRMS (ESI+) calculated for C22H26N2O4 [M+Na]
+ 405.1790; found 405.1793. 
 
tert-butyl (R)-2-(3-methoxybenzoyl)-5-
phenylpyrazolidine-1-carboxylate (374).  Cyclic 
hydrazine 308 (22 mg, 90 µmol, 1.0 equiv.), magnesium 
turnings (11 mg, 0.45 mmol, 5.0 equiv) and methanol (0.9 
mL, 0.1 M) were combined and stirred (800 rpm) at room 
temperature for 2 hours. The solution was quenched with saturated ammonium 
chloride solution (5 mL), then extracted with dichloromethane (3 x 5 mL). The 
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combined organic extracts were dried over magnesium sulphate and 
concentrated in vacuo to give a colourless oil.  4-methoxybenzoyl chloride (30 
µL, 0.23 mmol, 2.5 equiv.) and dichloromethane (5 mL) were added. The 
reaction mixture was stirred at rt for 18 h. The mixture was concentrated in 
vacuo. The crude product was purified by column chromatography (25% ethyl 
acetate in petroleum ether) to give 374 as a colourless oil (21 mg, 64 µmol, 71%).  
Rf = 0.23 (25% ethyl acetate in petroleum ether). [α]
32
D + 5.7 (c 0.40, CH2Cl2). 
IR (film) 2989, 2922, 1712, 1617, 1378, 1161 cm-1; δH (400 MHz; CDCl3) 7.40-
7.27 (5H, m, Ar-H), 7.24-6.87 (4H, m, Ar-H), 5.35 (1H, br s, CHPh), 4.63-4.05 
(1H, m, NCHH), 3.71-3.45 (4H, m, OCH3 and NCHH), 2.73-2.48 (1H, m, 
CHPhCHH), 2.32 (1H, br s, CHPhCHH), 1.35 (9H, s, C(CH3)3); δC (100 MHz; 
CDCl3) 159.0 (C=O), 136.0 (Ar-C), 128.9 (Ar-CH), 128.7 (Ar-CH), 127.6 (Ar-
CH), 126.7 (Ar-CH), 120.5 (Ar-CH), 117.2 (Ar-CH), 82.5 (C), 62.8 (CH), 55.2 
(CH3), 28.0 (CH3), 2 x CH2, 2 x Ar-C and 1 C=O not seen; HRMS (ESI
+) 
calculated for C22H26N2O4 [M+Na]
+ 405.1790; found 405.1790. 
 
tert-Butyl (R)-2-(4-bromobenzoyl)-5-
phenylpyrazolidine-1-carboxylate (375).  Cyclic 
hydrazine 308 (68 mg, 0.27 mmol, 1.0 equiv.), 
magnesium turnings (33 mg, 1.35 mmol, 5.0 equiv) 
and methanol (2.7 mL, 0.1 M) were combined and stirred (800 rpm) at room 
temperature for 2 hours. The solution was quenched with saturated ammonium 
chloride solution (5 mL), then extracted with dichloromethane (3 x 5 mL). The 
combined organic extracts were dried over magnesium sulphate and 
concentrated in vacuo to give a colourless oil.  4-bromoxybenzoyl chloride (150 
mg, 0.69 mmol, 2.5 equiv.) and dichloromethane (2.7 mL, 0.1 M) were added. 
The reaction mixture was stirred at rt for 18 h. The mixture was concentrated in 
vacuo. The crude product was purified by column chromatography (25% ethyl 
acetate in petroleum ether) to give 375 as a colourless oil (21 mg, 55 µmol, 61%). 
Rf = 0.24 (25% ethyl acetate in petroleum ether). [α]
32
D + 32.3 (c 0.12, CH2Cl2). 
IR (film) 2978, 2932, 1721, 1659, 1366, 1157 cm-1; δH (400 MHz; CDCl3) 7.42-
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7.15 (9H, m, Ar-H), 5.37 (1H, br s, CHPh), 4.49-4.08 (1H, m, NCHH), 3.53 (1H, 
q, J 8.3, NCHH), 2.63-2.48 (1H, m, CHPhCHH), 2.38 (1H, br s, CHPhCHH), 
1.36 (9H, s, C(CH3)3); δC (100 MHz; CDCl3) 133.7 (Ar-C), 131.8 (Ar-C), 130.9 
(Ar-CH), 129.6 (Ar-CH), 128.7 (Ar-CH), 127.8 (Ar-CH), 126.7 (Ar-CH), 82.8 
(C), 62.9 (CH), 28.0 (CH3), 2 x CH2, 2 x C=O and 1 x Ar-C not seen; HRMS 
(ESI+) calculated for C21H23N2O2Br
79 [M+Na]+ 453.0790; found 453.0791. 
 
tert-Butyl (R)-2-(2-fluorobenzoyl)-5-
phenylpyrazolidine-1-carboxylate (376). Cyclic 
hydrazine 308 (64 mg, 0.16 mmol, 1.0 equiv), magnesium 
turnings (19 mg, 0.80 mmol, 5.0 equiv) and methanol (1.6 
mL, 0.1 M) were combined and stirred (800 rpm) at room temperature for 2 
hours. The solution was quenched with saturated ammonium chloride solution 
(5 mL), then extracted with dichloromethane (3 x 5 mL). The combined organic 
extrcts were dried over MgSO4 and concentrated in vacuo to give a colourless 
oil. To this was added then 2-fluorobenzoyl chloride (48 µL, 0.40 mmol, 2.5 
equiv) in dichloromethane (1.6 mL). The reaction mixture was stirred at rt for 
18 h. The mixture was concentrated in vacuo. The crude product was purified by 
column chromatography (25% ethyl acetate in petroleum ether) to give 376 as a 
colourless oil (46 mg, 0.12 mmol, 77%). Rf = 0.21 (25% ethyl acetate in 
petroleum ether). [α]32D +7.1 (c 0.12, CHCl3). IR (film) 2978, 1725, 1714, 1368, 
1154 cm-1; δH (500 MHz; d6-DMSO at 373 K) 7.47 (1H, d, J 5.3, Ar-H), 7.39-
7.25 (5H, m, Ar-H), 7.25-7.13 (3H, m, Ar-H), 5.27 (1H, t, J 6.6, CHPh), 4.05-
3.91 (1H, br m, NCHH), 3.47 (1H, dd, J 17.9 and 8.5, NCHH), 2.69-2.60 (1H, 
m, CHPhCHH), 2.23-2.16 (1H, br m, CHPhCHH), 1.38 (9H, s, C(CH3)3); δC 
(125 MHz; d6-DMSO at 373 K) 159.9 (C=O), 157.9 (C=O), 143.7 (Ar-C, seen 
on HMBC), 141.7 (Ar-C, seen on HMBC), 141.3 (Ar-C, seen on HMBC), 132.5 
(d, J 7.5, Ar-CH), 129.2 (d, J 2.5, Ar-CH), 129.1 (Ar-CH), 128.7 (Ar-CH), 127.6 
(Ar-CH), 127.0 (Ar-CH), 126.7 (Ar-CH), 116.2 (d, J 21.3, 82.1 Ar-C), 63.5 
(CH), 28.0 (CH3), 2 x CH2, 2 x C=O and 1 x Ar-C not seen; δF (282 MHz; 
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CDCl3) -112.3 (CF); HRMS (ESI
+) calculated for C21H23N2O3F [M+Na]
+ 
393.1585; found 393.1587. 
 
(R)-(4-Methoxyphenyl)(5-phenyl-2-(pyridin-2-
yl)pyrazolidin-1-yl)methanone (377). Cyclic 
hydrazine 354 (29 mg, 90 µmol, 1.0 equiv) was 
dissolved in 4 M HCl/dioxane solution (2 mL) and 
stirred for 2 h. It was then concentrated in vacuo and 4-methoxybenzoyl chloride 
(38 mg, 0.23 mmol, 2.5 equiv) in dichloromethane (90 µL, 0.1 M) was added. 
The reaction mixture was cooled over an ice bath then N,N-
diisopropylethylamine (31 µL, 0.18 mmol, 2.0 equiv) in dichloromethane (2 mL) 
was added dropwise over 30 min. The reaction mixture was allowed to warm to 
rt then stirred for 18 h. The mixture was then quenched with 1 M hydrochloric 
acid (5 mL), extracted with dichloromethane (3 x 5 mL) and dried over MgSO4. 
It was then concentrated in vacuo and the crude product was purified by column 
chromatography (25% ethyl acetate in petroleum ether) to give 377 as a white 
solid (26 mg, 70 µmol, 82%). Rf = 0.21 (25% ethyl acetate in petroleum ether); 
M.p. 131-132 °C; [α]32D –26.7 (c 0.06, CH2Cl2). IR (film) 2924, 1643, 1597, 
1466, 1258 cm-1; δH (400 MHz; CDCl3) 8.25 (1H, d, J 4.0, Ar-H), 7.78 (2H, d, 
J 8.4, Ar-H), 7.45 (1H, t, J 7.6, Ar-H), 7.26-7.19 (5H, m, Ar-H), 6.88-6.74 (4H, 
m, Ar-H), 5.60 (1H, s, CHPh), 4.65 (1H, br s, NCHH), 3.78 (3H, s, OCH3), 3.60 
(1H, s, NCHH), 2.63 (1H, dt, J 12.4, 6.1, CHPhCHH), 2.22 (1H, td, J 13.4, 7.2, 
CHPhCHH); δC (100 MHz; CDCl3) 161.9 (C=O), 147.8 (Ar-CH), 141.0 (Ar-C), 
137.5 (Ar-CH), 130.7 (Ar-C), 128.5 (Ar-CH), 127.3 (Ar-CH), 126.9 (Ar-CH), 
126.4 (Ar-C), 116.4 (Ar-CH), 113.3 (Ar-CH), 110.6 (Ar-CH), 69.6 (CH), 55.3 
(CH3), 34.0 (CH2), 1 Ar-CH, 1 CH2 and 1 Ar-C not seen; HRMS (ESI
+) 
calculated for C22H21N3O2 [M+H]
+ 360.1712; found 360.1712. 
Crystal Structure of 377. Single crystals of C44H42.5N6O4.25 were grown from a 
9:1 mix of hexane and isopropanol. A suitable crystal was selected and mounted 
on a glass fibre with Fomblin oil and placed on a Rigaku Oxford Diffraction 
SuperNova diffractometer with a duel source (Cu at zero) equipped with an 
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AtlasS2 CCD area detector. The crystal was kept at 150(2) K during data 
collection. Crystal Data for C44H42.5N6O4.25 (M =723.34 g/mol): monoclinic, 
space group P21 (no. 4), a = 10.18405(5) Å, b = 9.71457(5) Å, c = 18.82762(9) 
Å, β = 93.0169(4)°, V = 1860.102(16) Å3, Z = 2, T = 150(2) K, μ(CuKα) = 0.679 
mm-1, Dcalc = 1.291 g/cm3, 35330 reflections measured (8.694° ≤ 2Θ ≤ 
147.052°), 7385 unique (Rint = 0.0176, Rsigma = 0.0104) which were used in all 
calculations. The final R1 was 0.0257 (I > 2σ(I)) and wR2 was 0.0682 (all data). 
Data has been deposited at the Cambridge Crystallographic Data Centre as 
CCDC 1944269. 
Flack x: -0.05(3) Shelx2018, Hooft y: -0.045(2) Olex2. Both the Flack parameter 
and associated Hooft y parameter are realtively small for a structure with no 




(378). Cyclic hydrazine 360 (41 mg, 0.10 mmol, 1.0 equiv) 
was dissolved in 4 M HCl/dioxane solution (2 mL) and 
stirred for 2 h. It was then concentrated in vacuo then 2-furoyl chloride (26 µL, 
0.26 mmol, 2.5 equiv) and dichloromethane (100 µL, 0.1 M) were added. The 
reaction mixture was cooled over an ice bath then a solution of N,N-
diisopropylethylamine (37 µL, 0.21 mmol, 2.0 equiv) in dichloromethane (2 mL) 
was added dropwise over 30 minutes. The mixture was allowed to warm to rt 
then stirred for 18 h. The mixture was then quenched with 1 M hydrochloric acid 
(5 mL), extracted with dichloromethane (3 × 5 mL) and dried over magnesium 
sulphate. It was then concentrated in vacuo and the crude product was purified 
by column chromatography (25% ethyl acetate in petroleum ether) to give 378 
as a yellow solid (28 mg, 71 µmol, 69%). Rf = 0.18 (25% ethyl acetate in 
petroleum ether); [α]32D +0.9 (c 0.33, CHCl3). IR (film) 2927, 1649, 1470, 1337, 
1124 cm-1; δH (500 MHz; CDCl3) 7.55 (1H, s, Ar-H), 7.40-7.21 (9H, m, Ar-H), 
6.95 (1H, d, J 3.0, Ar-H), 6.38 (1H, dd, J 3.5 and 1.6, Ar-H), 5.75 (1H, t, J 8.2, 
CHPh), 4.12-4.07 (1H, br m, NCHH), 3.62-3.48 (1H, br m, NCHH), 2.68-2.62 
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(1H, m, CHPhCHH), 2.37-2.28 (1H, m, CHPhCHH); δC (125 MHz; CDCl3) 
162.5 (C=O, seen on HMBC), 150.3 (Ar-C), 145.7 (Ar-CH), 139.8 (Ar-C), 131.6 
(q, J 31.3, Ar-C), 129.7 (Ar-CH), 128.4 (Ar-CH), 127.6 (Ar-CH), 123.9 (q, J 
270, Ar-C), 119.5 (Ar-CH), 118.7 (Ar-CH), 118.2 (Ar-CH), 112.9 (Ar-CH), 
111.7 (Ar-CH), 62.5 (CH), 54.3 (CH2), 32.6 (CH2), 1 Ar-C and 1 Ar-CH not 
seen; δF (282 MHz; CDCl3) -62.8 (CF3); HRMS (ESI
+) calculated for 
F3C21H17N2O2 [M+Na]
+ 409.1134; found 409.1131. 
 
(R)-1-(2-([1,1'-Biphenyl]-4-yl)-5-phenylpyrazolidin-
1-yl)-2-methoxyethan-1-one (379). Cyclic hydrazine 
361 (45 mg, 0.11 mmol, 1.0 equiv) was dissolved in 4 
M HCl/dioxane solution (2.0 mL) and stirred for 2 h. It 
was then concentrated in vacuo and methoxyacetyl chloride (26 µL, 0.28 mmol, 
2.5 equiv) and dichloromethane (110 µL, 0.1 M) were added. The reaction 
mixture was cooled over an ice bath then a solution of N,N-
diisopropylethylamine (39 µL, 0.22 mmol, 2.0 equiv) in dichloromethane (2.0 
mL) was added dropwise over 30 minutes. The reaction mixture was allowed to 
warm to rt then stirred for 18 h. The reaction mixture was then quenched with 1 
M hydrochloric acid (5 mL), extracted with dichloromethane (3 × 5 mL) and 
dried over magnesium sulphate. It was then concentrated in vacuo and the crude 
product was purified by column chromatography (50% ethyl acetate in 
petroleum ether) to give 379 as a white solid (28 mg, 74 µmol, 66%). Rf = 0.16 
(50% ethyl acetate in petroleum ether); [α]32D –17.5 (c 0.35, CHCl3). IR (film) 
2926, 1686, 1485, 1197, 1128 cm-1; δH (500 MHz; CDCl3) 7.57 (2H, d, J 7.3, 
Ar-H), 7.51 (2H, d, J 8.4, Ar-CH), 7.46-7.38 (4H, m, Ar-H), 7.37-7.23 (4H, m, 
Ar-H), 7.06 (2H, d, J 8.5, Ar-H), 5.46 (1H, t, J 8.5, CHPh), 4.48 (1H, d, J 15.5, 
NCHH), 4.06 (2H, d, J 15.6, CH2OMe) 3.49-3.43 (4H, m, NCHH and OCH3), 
2.63-2.56 (1H, m, CHPhCHH), 2.35-2.25 (1H, br m, CHPhCHH); δC (125 MHz; 
CDCl3) 174.5 (C=O), 148.9 (Ar-C), 140.3 (Ar-C), 140.1 (Ar-C), 135.0 (Ar-C), 
128.8 (Ar-CH), 128.4 (Ar-CH), 127.8 (Ar-CH), 127.5 (Ar-CH), 127.0 (Ar-CH), 
126.7 (Ar-CH), 116.3 (Ar-CH), 70.5 (CH2), 61.8 (CH), 59.4 (OCH3), 54.4 
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(CH2), 32.0 (CH2), 1 Ar-CH not seen; HRMS (ESI
+) calculated for C24H24N2O2 
[M+Na]+ 395.1730; found 395.1721. 
 
(R)-(2-Isobutyl-5-phenylpyrazolidin-1-yl)(4-
nitrophenyl)methanone (380). Cyclic hydrazine 369 
(43 mg, 0.14 mmol, 1.0 equiv) was dissolved in 4 M 
HCl/dioxane solution (2 mL) and stirred for 2 h. It was 
then concentrated in vacuo and a solution of 4-
nitrobenzoyl chloride (63 mg, 0.34 mmol, 2.5 equiv) in dichloromethane (135 
µL, 0.1 M) were added. The mixture was cooled over an ice bath then N,N-
diisopropylethylamine (47 µL, 0.27 mmol, 2.0 equiv) in dichloromethane (2.0 
mL) was added dropwise over 30 minutes. The reaction mixture was allowed to 
warm to rt then stirred for 18 h. The reaction mixture was then quenched with 1 
M hydrochloric acid (5 mL), extracted with dichloromethane (3 × 5 mL) and 
dried over magnesium sulphate. It was then concentrated in vacuo and the crude 
product was purified by column chromatography (20% ethyl acetate in 
petroleum ether) to give 380 as a white solid (37 mg, 0.1 mmol, 77%). Rf = 0.18 
(20% ethyl acetate in petroleum ether); [α]32D + 5.2 (c 0.17, CHCl3); 
Enantiomeric excess (95% ee) was determined by HPLC analysis (25 °C). 
[Chiralpak IA column 2-propanol/hexane = 10/90; flow rate = 1.0 mL/min; 
detection wavelength = 254 nm] tR 17.4 min; tR 36.3 min; IR (film) 2923, 2851, 
1635, 1521, 1346 cm-1; δH (500 MHz; CDCl3) 8.24 (2H, d, J 8.6, Ar-H), 7.84-
7.74 (2H, br m, Ar-H), 7.33 (5H, br m, Ar-H), 5.48 (1H, br s, CHPh), 3.24-3.09 
(1H, br m, NCH2CH2), 2.83-2.74 (1H, br m, CHPhCHH), 2.49-2.29 (3H, br m, 
CHPhCHH and CH2CH(CH3)2) 1.45 (1H, br s, CH(CH3)2), 0.55 (6H, s, 
CH(CH3)2); δC (125 MHz; CDCl3) 166.6 (C=O), 148.2 (Ar-C), 142.8 (Ar-C), 
142.1 (Ar-C), 129.0 (Ar-CH), 128.6 (Ar-CH), 125.7 (Ar-CH), 123.6 (Ar-CH), 
122.9 (Ar-CH), 65.8 (CH2), 61.8 (CH), 33.2 (CH2), 27.2 (CH), 20.5 (CH3), 20.2 
(CH3), 1 CH2 not seen; HRMS (ESI
+) calculated for C20H23N3O3 [M+Na]
+ 
376.1632; found 376.1632. 
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Crystal Structure of (rac)-380. Single crystals of C20H23N3O3 were grown from 
9:1 hexane and isopropanol. A suitable crystal was selected and mounted on a 
glass fibre with Fomblin oil and placed on a Rigaku Oxford Diffraction 
SuperNova diffractometer with a duel source (Cu at zero) equipped with an 
AtlasS2 CCD area detector. The crystal was kept at 150(2) K during data 
collection. Using Olex2, the structure was solved with the ShelXT structure 
solution program using Intrinsic Phasing and refined with the ShelXL 
refinement package using Least Squares minimisation. Crystal Data for 
C20H23N3O3 (M =353.41 g/mol): orthorhombic, space group P212121 (no. 
19), a = 7.19100(10) Å, b = 13.50450(10) Å, c = 18.6644(2) Å, V = 
1812.52(3) Å3, Z = 4, T = 150(2) K, μ(CuKα) = 0.716 mm-1, Dcalc = 
1.295 g/cm3, 10496 reflections measured (8.082° ≤ 2Θ ≤ 147.174°), 3514 unique 
(Rint = 0.0227, Rsigma = 0.0229) which were used in all calculations. The 
final R1 was 0.0325 (I > 2σ(I)) and wR2 was 0.1083 (all data). Data has been 
deposited at the Cambridge Crystallographic Data Centre as CCDC 1944270. 




tolyl)pyrazolidin-1-yl)methanone (381). Cyclic 
hydrazine 357 (34 mg, 0.1 mmol, 1.0 equiv) was 
dissolved in 4 M HCl/dioxane solution (2 mL) 
and stirred for 2 h. It was then concentrated in vacuo and 4-methoxybenzoyl 
chloride (34 µL, 0.25 mmol, 2.5 equiv) and dichloromethane (100 µL, 0.1 M) 
were added. The reaction mixture was cooled over an ice bath then a solution of 
N,N-diisopropylethylamine (36 µL, 0.21 mmol, 2.0 equiv) in dichloromethane 
(2.0 mL) was added dropwise over 30 minutes. The mixture was allowed to 
warm to rt then stirred for 18 h. The mixture was then quenched with 1 M 
hydrochloric acid (5 mL), extracted with dichloromethane (3 x 5 mL) and dried 
over magnesium sulphate. It was then concentrated in vacuo. The crude product 
was purified by column chromatography (25% ethyl acetate in petroleum ether) 
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to give 381 as a white solid (32 mg, 86 µmol, 84%). Rf = 0.18 (25% ethyl acetate 
in petroleum ether); M.p. 165-166 °C; [α]32D –3.8 (c 0.17, CHCl3); IR (film) 
2923, 1635, 1509, 1254, 1175 cm-1; δH (400 MHz; CDCl3) 7.81-7.73 (2H, br m, 
Ar-H), 7.78 (2H, d, J 8.4, Ar-CH), 7.32 (2H, t, J 7.4, Ar-H), 7.26 (1H, t, J 7.2, 
Ar-H), 7.05 (2H, d, J 8.2, Ar-H), 6.91 (2H, d, J 8.1, Ar-H), 6.78 (2H, d, J 8.8, 
Ar-H), 5.72-5.64 (1H, br m, CHPh), 3.92-3.79 (1H, br m, NCHH), 3.80 (3H, s, 
OCH3), 3.60-3.39 (1H, br m, NCHH), 2.58 (1H, sextet, J 12.0, CHPhCHH), 
2.32-2.18 (4H, br m, CHPhCHH and CH3Ar); δC (100 MHz; CDCl3) 161.7 (Ar-
C), 132.3 (Ar-CH), 130.9 (Ar-CH), 129.5 (Ar-CH), 128.4 (Ar-CH), 127.2 (Ar-
CH), 126.9 (Ar-C), 113.8 (Ar-CH), 113.0 (Ar-CH), 62.8 (CH, seen on HSQC), 
55.2 (OCH3), 29.7 (CH2), 20.5 (CH3), 3 Ar-C, 1 CH2 and 1 C=O not seen; HRMS 
(ESI+) calculated for C24H24N2O2 [M+Na]




(382). Cyclic hydrazine 365 (20 mg, 47 µmol, 
1.0 equiv) was dissolved in 4 M HCl/dioxane 
solution (2.0 mL) and stirred for 2 h. It was then concentrated in vacuo then 
propionyl chloride (12 µL, 0.14 mmol, 2.5 equiv) and dichloromethane (47 µL, 
0.1 M) were added. The reaction mixture was cooled over an ice bath then a 
solution of N,N-diisopropylethylamine (16 µL, 94 µmol, 2.0 equiv) in 
dichloromethane (2 mL) was added dropwise over 30 minutes. The mixture was 
allowed to warm to rt then stirred for 18 h. The mixture was then quenched with 
1 M hydrochloric acid (5 mL), extracted with dichloromethane (3 × 5 mL) and 
dried over magnesium sulphate. It was then concentrated in vacuo and the crude 
product was purified by column chromatography (50% ethyl acetate in 
petroleum ether) to give 382 as a yellow oil (12 mg, 31 µmol, 66%). Rf = 0.16 
(50% ethyl acetate in petroleum ether); [α]32D – 22.2 (c 0.12, CHCl3). IR (film) 
2925, 2220, 1675, 1603, 1504, 1175 cm-1; δH (500 MHz; CDCl3) 7.56 (4H, t, J 
7.7, Ar-H), 7.53 (2H, d, J 8.3, Ar-H), 7.45 (2H, t, J 7.6, Ar-H), 7.40-7.34 (3H, 
m, Ar-H), 7.03 (2H, d, J 8.4, Ar-H), 5.51 (1H, t, J 7.3, CHPh), 4.12-4.04 (1H, br 
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m, NCHH), 3.60-3.52 (1H, m, NCHH), 2.67-2.52 (2H, m, CHPhCHH and 
CO2CHH), 2.35-2.20 (2H, m, CHPhCHH and CO2CHH), 1.12 (3H, t, J 7.4, 
CH3); δC (125 MHz; CDCl3) 153.5 (C=O), 140.7 (Ar-C), 140.5 (Ar-C), 139.1 
(Ar-C), 133.5 (Ar-CH), 128.8 (Ar-CH), 128.1 (Ar-CH), 127.4 (Ar-CH), 127.3 
(Ar-CH), 127.1 (Ar-CH), 119.2 (Ar-C), 115.3 (Ar-CH), 114.1 (Ar-CH), 104.0 
(CN), 61.2 (CH), 53.1 (CH2), 33.7 (CH2), 26.4 (CH2), 8.6 (CH3); HRMS (ESI
+) 
calculated for C25H23N3O [M+Na]
+ 404.1733; found 404.1732. 
 
Buchwald-Hartwig Amination Screen 3 – Screen of 385•X 
Initially product 384 was analysed by GCMS to determine its retention time and 
the relationship between peak area and concentration. The following solutions 
were made using dichloromethane to test this (Table 6.3).  
Solution Method Concentration / ng 
mL-1 
Stock 1 9.6 mg 384 in 10 mL 9,600,000 
Stock 2 1 mL Stock 1 in 50 mL 192,000 
Cal 9 2 mL Stock 2 in 10 mL 38,400 
Cal 8 1 mL Stock 2 in 10 mL 19,200 
Cal 7 2 mL Cal 9 in 5 mL 15,360 
Cal 6 2 mL Cal 8 in 5 mL 7,680 
Cal 5 1.25 mL Cal 8 in 5 mL 4,800 
Cal 4 0.5 mL Cal 9 in 5 mL 3,840 
Cal 3 0.75 mL Cal 8 in 5 mL 2,880 
Cal 2 0.6 mL Cal 8 in 5 mL 2,300 
Cal 1 1 mL Cal 8 in 10 mL 1,920 
Table 6.3 Dilutions used to develop calibration standards for 384. 
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1 mL of each of these calibration solutions (Cal 1-9) was transferred to a 2 mL 
Agilent GCMS vial. Each vial was injected into the GCMS then the peak at a 
retention time of 16.8 min was integrated to give a peak area in arbitrary units, 
which gave Table 6.4 
Cal 
Standard 
Concentration / ng mL-1 Peak Area / 
arbitrary units 
9 38,400 1,315,842 
8 19,200 824,285 
7 15,360 717,993 
6 7,680 340,497 
5 4,800 243,299 
4 3,840 167,593 
3 2,880 170,035 
2 2,300 131,578 
1 1920 82,854 
Table 6.4 Peak area data for the GCMS calibration of 384. 
When this was plotted (Figure 6.2) Cal 9 was omitted as this was clearly an 
outlier. This was likely due to the sample concentration being too high which 
saturated the UV detector on the GCMS. The remaining samples gave a strong 
linear relationship between peak area and concentration (R2 = 0.9901), with a 




Figure 6.2 Calibration curve of 384. 
 
Scheme 6.9 Optimisation of the synthesis of 384. 
The reactions were performed in an aluminium heating block with 9 x 4 mL 
Fisher Scientific Reactivials, each with a teflon coated magnetic stirrer bar. 
These vials were labelled R1-R9 then the following reagents were added to each: 
R1: 385•TFA (4.2 mg, 11 µmol, 1.0 equiv), XPhos Pd(crotyl)Cl (0.8 mg, 1.1 
µmol, 0.1 equiv), sodium tert-butoxide (4.3 mg, 44 µmol, 4.0 equiv) and toluene 
(1 mL). 
R2: 385•TFA (5.8 mg, 15 µmol, 1.0 equiv), XPhos Pd(crotyl)Cl (1.1 mg, 1.5 
µmol, 0.1 equiv), sodium tert-butoxide (5.9 mg, 60 µmol, 4.0 equiv) and dioxane 
(1 mL).  
 R3: 385•TFA (4.4 mg, 12 µmol, 1.0 equiv), XPhos Pd(crotyl)Cl (0.8 mg, 1.2 
µmol, 0.1 equiv), potassium carbonate (6.6 mg, 48 µmol, 4.0 equiv) and toluene 


































R4: 385•TFA (7.4 mg, 19 µmol, 1.0 equiv), Pd(OAc)2 (0.4 mg, 1.9 µmol, 0.1 
equiv), Xantphos (2.2 mg, 3.8 µmol, 0.2 equiv), sodium tert-butoxide (10.5 mg, 
76 µmol, 4.0 equiv) and toluene (1 mL).  
R5: 385•TFA (5.9 mg, 15 µmol, 1.0 equiv), Pd(OAc)2 (0.3 mg, 1.5 µmol, 0.1 
equiv), Xphos (2.4 mg, 3.0 µmol, 0.2 equiv), sodium tert-butoxide (5.9 mg, 60 
µmol, 4.0 equiv) and toluene (1 mL). 
R6: 385•HCl (3.6 mg, 12 µmol, 1.0 equiv), Pd(OAc)2 (0.2 mg, 1.2 µmol, 0.1 
equiv), Xantphos (1.4 mg, 2.4 µmol, 0.2 equiv), sodium tert-butoxide (4.7 mg, 
48 µmol, 4.0 equiv) and toluene (1 mL). 
R7: 385•HCl (7.1 mg, 23 µmol, 1.0 equiv), Pd(OAc)2 (0.2 mg, 2.3 µmol, 0.1 
equiv), Xantphos (2.7 mg, 4.6 µmol, 0.2 equiv), sodium tert-butoxide (9.0 mg, 
92 µmol, 4.0 equiv) and dioxane (1 mL). 
R8: 385•HCl (3.7 mg, 12 µmol, 1.0 equiv), Pd(OAc)2 (0.2 mg, 1.2 µmol, 0.1 
equiv), Xantphos (1.4 mg, 2.4 µmol, 0.2 equiv), potassium carbonate (6.6 mg, 
48 µmol, 4.0 equiv) and toluene (1 mL). 
R9: 385•HCl (2.7 mg, 9 µmol, 1.0 equiv), Pd(OAc)2 (0.2 mg, 0.9 µmol, 0.1 
equiv), Xantphos (1.1 mg, 1.8 µmol, 0.2 equiv), potassium carbonate (5.0 mg, 
36 µmol, 4.0 equiv) and dioxane (1 mL). 
All vials were sealed with subaseals and then placed under an atmosphere of 
nitrogen. The reactions were heated for 20 hours at 90 °C, then the crude reaction 
mixture of each was filtered through a plug of cotton wool into a 5 mL 
volumetric flask using dichloromethane as the eluent. Each flask was made up 
to volume with dichloromethane and 20 µL of each solution was removed using 
a Hamilton syringe and transferred to a 2 mL Agilent GCMS vial. 980 µL of 
dichloromethane was added to each then the samples were analysed by GCMS. 



















R1 11 187,078 1,039,322 1.0 2.5 23 
R2 15 78,101 433,894 0.4 1.0 7 
R3 12 74,351 413,061 0.4 1.0 9 
R4 19 603,309 3,351,717 3.4 8.1 42 
R5 15 433,784 2,409,911 2.4 5.8 38 
R6 12 517,164 2,873,133 2.9 6.9 59 
R7 23 908,105 5,045,028 5.0 12.2 53 
R8 12 70,578 392,100 0.4 1.0 8 
R9 9 0 0 0.0 0.0 0 
Table 6.5 Raw data used to calculate yield of 385. 
N.B. Impurities 386 and 387 identified in Scheme 6.9 were seen in multiple 
reactions and were assigned retention times. 386 was consistently seen at 14.9 
min and 387 was consistently seen at 13.6 min. As these were only seen in the 
small scale reactions they were never isolated and fully characterised, however 
crude NMR data and the mass peaks seen in the GCMS strongly suggested that 
the structures proposed are plausible. 
 
Buchwald-Hartwig Amination Screen 4 – Second Screen of 385•HCl 
 
Scheme 6.10 Buchwald-Hartwig Amination screen of 385•HCl 
The reactions were performed in an aluminium heating block with 48 x 750 µL 
vials, each with a teflon coated magnetic stirrer bar. These vials were arranged 
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in 12 columns (labelled 1-12) and 4 rows (labelled A-D). The following powders 
were weighed into the vials using a Mettler Toledo QX96 powder dispenser 
inside a glovebox.  
All vials in row A: Sodium tert-butoxide (4.7 mg, 49 µmol, 3.0 equiv). 
All vials in rows B, F: Caesium carbonate (15.9 mg, 49 µmol, 3.0 equiv). 
All vials in rows C, G: Potassium carbonate (6.8 mg, 49 µmol, 3.0 equiv). 
All vials in rows D, H: Potassium phosphate tribasic (10.4 mg, 49 µmol, 3.0 
equiv). 
All vials in column 1: [XantPhos Pd(allyl)]Cl (1.2 mg, 1.6 µmol, 0.1 equiv). 
All vials in column 2: [(R)-BINAP Pd(allyl)]Cl (1.4 mg, 1.6 µmol, 0.1 equiv). 
All vials in column 3: Pd(dppf)Cl2 · Dichloromethane (1.3 mg, 1.6 µmol, 0.1 
equiv). 
All vials in column 4: [P(tBu)3] Pd(crotyl) Cl (0.7 mg, 2.0 µmol, 0.12 equiv). 
All vials in column 5: [BippyPhos Pd(allyl)]OTf (1.3 mg, 1.6 µmol, 0.1 equiv)  
All vials in column 6: AdBettPhos (1.3 mg, 2.0 µmol, 0.12 equiv) and palladium 
(II) acetate (0.5 mg, 2.2 µmol, 0.1 equiv). 
All vials in column 7: [tBuBrettPhos Pd(allyl)]OTf (1.3 mg, 1.7 µmol, 0.1 
equiv). 
All vials in column 8: MorDalPhos (0.9 mg, 2.0 µmol, 0.12 equiv) and palladium 
(II) acetate (0.5 mg, 2.2 µmol, 0.1 equiv). 
All vials in column 9: [BrettPhos Pd(crotyl)]OTf (1.4 mg, 1.7 µmol, 0.1 equiv). 
All vials in column 10: [tBuXPhos Pd(allyl)]OTf (1.2 mg, 1.7 µmol, 0.1 equiv). 
All vials in column 11: XPhos Pd(crotyl)Cl (1.1 mg, 1.6 µmol, 0.1 equiv). 
All vials in column 12: RuPhos Pd(crotyl)Cl (1.1 mg, 1.7 µmol, 0.1 equiv). 
Stock Solution: (2-Fluorophenyl)-[(3R)-3-phenylpyrazolidin-1-yl]methanone 
hydrochloride (14) (258 mg, 0.78 mmol) and 3-bromobenzotrifluoride (265 mg, 
164 µL, 1.18 mmol) in toluene (3.60 mL). 
All vials were dosed with 75 µL of Stock Solution which contained (2-
fluorophenyl)-[(3R)-3-phenylpyrazolidin-1-yl]methanone hydrochloride (385) 
(5.4 mg, 16 µmol, 1.0 equiv) and 3-bromobenzotrifluoride (5.5 mg, 34 µL, 25 
µmol, 1.5 equiv). 
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N.B. 385 was obtained by stirring 376 (1 g) in HCl/dioxane solution (10 mL) for 
2 h. This solution was then concentrated in vacuo to give 385 as a pale yellow 
solid which was used in the screen without further purification. 
The plate was sealed with a silicone and PFA mat and placed on an HEL 
polyblock. The plate was then heated at 90 °C for 16 h. The vials were the cooled 
to rt and DMSO (300 µL) was added to each using a multichannel pipette. A 5 
µL aliquot was extracted from each then added to a 96-well analyical plate and 
diluted with DMSO (50 µL). The plate was analyzed by reverse phase LCMS 
(XBridge C18 3.5-μm 2.1 × 35 mm Column, 1.6 mL min
-1, 50 °C; gradient 5:95 
to 99:1 (pH 9 H2O + 10 mM NH4HCO2) / MeCN over 0.7 min + 0.3 min hold). 
The LCMS traces were processed using in-house software and the results 




(384). cyclic hydrazine 376 (26 mg, 70 µmol, 1.0 equiv) 
was dissolved in 4M HCl/dioxane solution (2.0 mL) and 
stirred for 2 h at rt. It was then concentrated in vacuo. Pd-
180 (3 mg, 4 µmol, 0.05 equiv), caesium carbonate (68 mg, 0.21 mmol, 3.0 
equiv), 3-bromobenzotrifluoride (15 µL, 0.11 mmol, 1.5 equiv) and toluene (70 
µL) were added and the reaction was stirred at 90 °C for 20 h. The reaction 
mixture was then quenched with saturated ammonium chloride solution (5 mL), 
extracted with dichloromethane (3 x 5 mL) and dried over magnesium sulphate. 
It was then concentrated in vacuo and the crude product was purified by column 
chromatography (15% ethyl acetate in petroleum ether) to give 384 as a 
colourless oil (21 mg, 54 µmol, 77%). Rf = 0.15 (15% ethyl acetate in petroleum 
ether); [α]32D – 8.5 (c 0.14, CHCl3); Enantiomeric excess (94% ee) was 
determined by HPLC analysis (25 °C). [Chiralpak IA column 2-propanol/hexane 
= 1/99; flow rate = 1.0 mL/min; detection wavelength = 254 nm] tR 33.9 min; tR 
37.8 min; IR (film) 2925, 1659, 1491, 1382, 1211 cm-1; δH (500 MHz; d6-
DMSO at 373 K) 7.60-7.03 (13H, m, Ar-H), 5.04 (1H, t, J 5.5, CHPh), 4.09-3.87 
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(1H, br m, NCHH), 3.65 (1H, dd, J 17.3, 8.9, NCHH), 2.68-2.58 (1H, br m, 
CHPhCHH), 2.34-2.22 (1H, br m, CHPhCHH); δC (125 MHz, d6-DMSO at 373 
K) 159.7 (C=O), 157.8 (Ar-C), 145.7 (Ar-CH), 132.2 (Ar-CH), 130.5 (q, J 31.3, 
Ar-C), 130.5 (Ar-CH), 129.0 (Ar-CH), 127.9 (Ar-CH), 126.8 (Ar-CH), 124.6 (q, 
J 271, CF3), 124.5 (d, J 15, Ar-C), 116.2 (d, J 23, Ar-CH), 2 CH2, 1 CH and 4 
Ar-CH not seen; δF (276 MHz; d6-DMSO) -61.1 (minor), -61.4 (CF3), -114.7 
(minor), -115.1 (Ar-CF); HRMS (ESI+) calculated for F4C23H18N2O [M+Na]
+ 
437.1247; found 437.1248. 
 
(R)-(4-Methoxyphenyl)(3-phenyl-2-(pyridin-2-
yl)pyrazolidin-1-yl)methanone (389). cyclic 
hydrazine 373 (25 mg, 65 µmol, 1.0 equiv) was 
dissolved in 4M HCl/dioxane solution (2.0 mL) and 
stirred for 2 h at rt. It was then concentrated in vacuo. 
Pd-180 (3 mg, 3 µmol, 0.05 equiv), caesium carbonate (64 mg, 0.20 mmol, 3.0 
equiv), 2-bromopyridine (9 µL, 0.10 mmol, 1.5 equiv) and toluene (65 µL) were 
added and the reaction was stirred at 90 °C for 20 h. The reaction mixture was 
then quenched with saturated ammonium chloride solution (5 mL), extracted 
with dichloromethane (3 x 5 mL) and dried over magnesium sulphate. It was 
then concentrated in vacuo and the crude product was purified by column 
chromatography (33% ethyl acetate in petroleum ether) to give gave 389 as a 
colourless oil (19 mg, 52 µmol, 80%). Rf = 0.13 (33% ethyl acetate in petroleum 
ether); [α]32D + 9.2 (c 0.23, dichloromethane). IR (film) 2932, 1651, 1597, 1461, 
1432, 1258, 1173 cm-1; δH (400 MHz; CDCl3) 8.32 (1H, s, Ar-CH), 7.60 (1H, t, 
J 7.3, Ar-H), 7.53-6.87 (9H, m, Ar-H), 6.69 (1H, s, Ar-H), 5.88 (1H, t, J 7.5, 
CHPh), 4.70-3.39 (1H, br m, NCHH), 3.76 (3H, s, CH3), 3.52-3.49 (1H, br m, 
NCHH), 2.53-2.31 (2H, br m, CHPhCH2); δC (100 MHz; CDCl3) 161.5 (C=O), 
148.4 (Ar-C), 138.2 (Ar-C), 130.3 (Ar-CH), 128.4 (Ar-CH), 127.2 (Ar-CH), 
126.7 (Ar-CH), 117.5 (Ar-CH), 113.0 (Ar-CH), 109.1 (Ar-CH), 66.1 (CH), 55.2 
(CH3), 44.7 (CH2), 2 Ar-C, 2 Ar-CH and 1 CH2 not seen; HRMS (ESI
+) 
calculated for C22H21N3O2 [M+H]






Cyclic hydrazine 440 (100 mg, 0.26 mmol, 1.0 equiv) 
was dissolved in 4 M HCl/dioxane solution (2.0 mL) and 
stirred for 2 h. It was then concentrated in vacuo and 2,3-
dichlorobenzoyl chloride (139 mg, 0.66 mmol, 2.5 equiv) and dichloromethane 
(100 µL and 2 mL) were added. The reaction mixture was cooled over an ice 
bath then a solution of N,N-diisopropylethylamine (93 µL, 0.53 mmol, 2.0 equiv) 
in dichloromethane (2 mL) was added dropwise over 30 min. The mixture was 
allowed to warm to rt then stirred for 18 h. The mixture was then quenched with 
1.0 M hydrochloric acid (5.0 mL), extracted with dichloromethane (3 × 5.0 mL) 
and dried over magnesium sulphate. It was then concentrated in vacuo. and the 
crude product was purified by column chromatography (10% ethyl acetate in 
petroleum ether) to give XX as a colourless oil (95 mg, 0.21 mmol, 80%). Rf = 
0.10 (10% ethyl acetate in petroleum ether); [α]32D + 2.1 (c 0.61, CHCl3). IR 
(film) 2934, 2866, 1642, 1414, 970 cm-1; δH (500 MHz; CDCl3) 7.63 (2H, d, J 
7.4, Ar-H), 7.47 (1H, d, J 7.2, Ar-H), 7.44 (2H, t, J 7.6, Ar-H), 7.35 (1H, t, J 7.3, 
Ar-H), 7.27-7.18 (5H, m, Ar-H), 7.09 (2H, d, J 7.3, Ar-H), 6.09 (1H, d, J 3.5, 
C=CH), 5.76 (1H, d, J 15.9, C=CH), 5.43-5.33 (1H, br m, CHPh), 3.14 (1H, dd, 
J 12.9, 7.6, NCHH), 2.90 (1H, d, J 11.5, NCHHCH=CH), 2.69 (1H, d, J 11.3, 
NCHH), 2.27-2.15 (2H, m, CHPhCHH and NCHHCH=CH), 1.69-1.50 (2H, m, 
CHPhCHH and CH2CHHCH2), 1.52-1.46 (1H, m, CH2CHHCH2); δC (125 
MHz; CDCl3) 169.9 (C=O), 140.8 (Ar-C), 136.5 (Ar-C), 133.1 (Ar-C), 131.9 
(C=CH) 129.6 (Ar-CH), 128.7 (Ar-CH), 128.5 (Ar-CH), 128.3 (Ar-C), 127.5 
(Ar-CH), 127.4 (Ar-CH), 127.3 (Ar-CH), 127.3 (Ar-CH), 126.1 (Ar-CH), 125.5 
(Ar-CH), 57.8 (CH2), 48.4 (CH), 40.8 (CH2), 24.4 (CH2), 14.0 (CH2), 1 Ar-C not 
seen; HRMS (ESI+) calculated for C26H24N2O
35Cl2 [M+Na]





tert-Butyl 1,2-diazetidine-1-carboxylate (398) 198 (50 mg, 0.17 
mmol, 1.0 equiv.) and Pd/C (5 mg, 10 wt%) were stirred in ethyl 
acetate (5 mL) under an H2 atmosphere (1 atm.) for 1 h, at which 
point TLC showed complete consumption of starting material. The solution was 
filtered through a plug of Celite and silica using ethyl acetate as the eluent and 
the resulting colourless solution was concentrated in vacuo to give a colourless 
oil (26 mg, 0.16 mmol 96%), which required no further purification; Rf = 0.11 
(40% ethyl acetate in petroleum ether);  IR (Film) 3263, 2976, 2931, 2902, 1698, 
1365, 1147; 1H NMR (500 MHz, CDCl3) δH 5.41 (1H, br s, NH), 4.33 (2H, t, J  
7.9, NHCH2), 3.77 (2H, br s, NBocCH2), 1.50 (9H, s, C(CH3)3); 
13C NMR (125 
MHz, CDCl3) δC 160.1 (C=O), 81.0 (C), 51.9 (CH2), 41.4 (CH2), 29.3 (CH3); 
HRMS (ESI+) calculated for C7H14N2O2 (M+Na)
+: 181.0947; found: 181.0948. 
202 (100 mg, 0.32 mmol, 1.0 equiv.) and activated magnesium turnings (78 mg, 
3.2 mmol, 10 equiv.) were stirred in methanol (3 mL) for 5 h. Brine (10 mL) and 
saturated ammonium chloride (10 mL) were then added and the crude mixture 
was extracted with dichloromethane (3 x 10 mL), dried over MgSO4 and then 
concentrated in vacuo to give a colourless oil (50 mg, 0.31 mmol, 98%) which 
required no further purification; Data is consistent with that reported above. 
 
TFA salt of benzyl 1,2-diazetidine-1-carboxylate 
(399•TFA) 198 (100 mg, 0.34 mmol, 1.0 equiv.) was 
dissolved in dichloromethane (5 mL). Trifluoroacetic acid (0.26 mL, 3.4 mmol, 
10.0 equiv.) was added dropwise and the resulting pale-yellow solution was 
stirred for monitored by TLC and was complete after 3 h. the solution was 
concentrated in vacuo to give a yellow oil. This gave the desired product as a 
yellow oil (66 mg, 0.34 mmol, 100%) which required no further purification; IR 
(film) 1740, 1667, 1394, 1310, 1136; 1H NMR (500 MHz, CDCl3) δH 7.79 (2H, 
s, NH2), 7.27 (5H, m, Ar-CH), 5.05 (2H, s, CH2Ph), 4.35 (2H, t, J 7.9, NCH2), 
4.11 (2H, t, J 7.9, NCH2); 
13C NMR (125 MHz, CDCl3) δC 157.0 (C=O), 129.0 
(Ar-CH), 128.8 (Ar-C), 128.7 (Ar-CH), 128.5 (Ar-CH), 69.6 (CH2), 51.21 
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(CH2), 42.6 (CH2), 1 C=O and CF3 not seen; HRMS (ES
+) calculated for 
C10H12N2O2 (M+Na)
+: 215.0791; found: 215.0792. 
 
Benzyl 1,2-diazetidine-1-carboxylate and Benzyl 1,2-
diazetidine (399) 399•TFA (66 mg, 0.34 mmol, 1.0 equiv.) was 
dissolved in dichloromethane (10 mL) and then washed with 
saturated sodium hydrogen carbonate (10 mL) and water (10 mL). The aqueous 
layer was then washed with dichloromethane and the combined organic extracts 
were dried over MgSO4 and concentrated in vacuo to give 399 as an orange oil 
which required no further purification (53 mg, 0.28 mmol 82%); Rf = 0.11 (40% 
ethyl acetate in petroleum ether); IR (film) 3245, 2902, 1701, 1497, 1305, 1142; 
1H NMR (300 MHz, CDCl3) δH 7.36 (5H, m, Ar-CH), 5.19 (2H, s, CH2Ph), 4.43 
(2H t, J 8.0, NCH2), 3.82 (2H, br s, NCH2); 
13C NMR (125 MHz, CDCl3) δC 
135.5 (C=O), 128.8 (Ar-C), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.3 (Ar-CH), 68.2 
(CH2), 51.0 (CH2), 41.0 (CH2); HRMS (ES
+) calculated for C10H12N2O2 
(M+Na)+: 215.0791; found: 215.0781. 
 
TFA salt of 1-tosyl-1,2-diazetidine (401•2TFA) 203 
(0.50 g, 1.6 mmol, 1.0 equiv.), trifluoroacetic acid (1.23 
mL, 16 mmol, 10.0 equiv.) and dichloromethane (10 mL) 
were combined to give a pale yellow solution that was stirred at room 
temperature for 24 h. The solution was then concentrated in vacuo to give a 
yellow crystalline solid. This was purified by recrystallisation from hot toluene 
(approx. 15 mL) to give a white crystalline solid (281 mg, 0.64 mmol, 40%); 
M.p. 79-81 °C; IR (film) 2963, 2954, 2915, 2849, 1773, 1732, 1664, 1370; 1H 
NMR (500 MHz, CDCl3) δH 7.92 (2H, d, J 8.2, Ar-CH), 7.43 (2H, d, J 8.0, Ar-
CH), 4.46 (2H, s, NH2), 4.15 (2H, t, J 8.2, NCH2), 3.60 (2H, t, J 8.2, NCH2), 
2.51 (3H, s, CH3); 
13C NMR (125 MHz, CDCl3) δC 158.6 (C=O), 145.1 (Ar-C), 
130.2 (Ar-CH), 129.6 (Ar-CH), 129.1 (Ar-C), 51.2 (CH2), 41.4 (CH2), 21.7 
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(CH3), 2 x CF3 not seen; HRMS (ES
+) calculated for C9H12N2O2S (M+Na)
+: 
235.0512; found: 235.0510. 
Single crystals of 401•2TFA were grown from dichloromethane/hexane. A 
suitable crystal was selected and mounted on a glass fibre with Fromblin oil and 
placed on a Rigaku Oxford Diffraction SuperNova diffractometer with a duel 
source (Cu at zero) equipped with an AtlasS2 CCD area detector. The crystal 
was kept at 150(2) K during data collection. Using Olex2, the structure was 
solved with the ShelXT structure solution program using Intrinsic Phasing and 
refined with the ShelXL refinement package using Least Squares minimisation. 
Crystal Data for 401•2TFA (M =440.32 g/mol): monoclinic, space group P21/c 
(no. 14), a = 13.07690(10) Å, b = 24.3100(2) Å, c = 11.26310(10) Å, β = 
91.5510(10)°, V = 3579.22(5) Å3, Z = 8, T = 150(2) K, μ(CuKα) = 2.527 mm-1, 
Dcalc = 1.634 g/cm3, 82190 reflections measured (6.762° ≤ 2Θ ≤ 148.27°), 7207 
unique (Rint = 0.0945, Rsigma = 0.0330) which were used in all calculations. The 
final R1 was 0.0518 (I > 2σ(I)) and wR2 was 0.1347 (all data). 
 
1-Tosyl-1,2-diazetidine (401) 401•2TFA (25 mg, 80 µmol) was 
dissolved in dichloromethane (10 mL) and then washed with 
saturated sodium hydrogen carbonate (10 mL). The organic layer was dried over 
MgSO4 and then concentrated in vacuo to give 401 as a colourless oil (17 mg, 
quant.); Rf = 0.13 (50% ethyl acetate in petroleum ether);  IR (film) 3242, 2990, 
1745, 1695, 1530, 1159; 1H NMR (500 MHz, CDCl3) δH 7.92 (2H, d, J 8.2, Ar-
H), 7.43 (2H, d, J 8.0, Ar-H), 6.40 (1H, br s, NH), 3.75 (2H, t, J 8.2, NCH2), 
3.45 (2H, t, J 8.2, NCH2) 2.51 (3H, s, CH3); 
13C NMR (126 MHz, CDCl3) δc 
145.7 (C), 130.3 (CH), 129.4 (CH), 129.0 (C), 51.5 (CH2), 41.3 (CH2), 21.7 
(CH3); MS (ES
+) m/z = 447 ([2M+Na]+, 62); HRMS (ES+) calculated for 
C9H12N2O2SNa (M+Na)




Benzyl 2-tosyl-1,2-diazetidine-1-carboxylate (402) To a 
solution of sodium hydroxide (12 mg, 0.30 mmol, 2.0 equiv) in 
water (5 mL), dichloromethane (5 mL) was added. 401•2TFA (50 
mg, 0.15 mmol, 1.0 equiv) was added and the mixture was cooled over an ice 
bath. Benzyl chloroformate (22 µL, 0.15 mmol, 1.0 equiv) was added. The 
mixture was left to warm to rt and stirred for 20 h. After this time, the organic 
layer was collected and washed with water (5 mL) and 20% citric acid solution 
(5 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo to 
give a colourless oil (20 mg, 57 µmol 38%) which required no further 
purification; Rf 0.15 (15% EtOAc in petroleum ether); IR (film) 2979, 2928, 
1714, 1330, 1305, 1137; 1H NMR (500 MHz, CDCl3) δH 7.78 (2H, d, J  8.2, Ar-
H), 7.28 (7H, m, Ar-H), 5.08 (2H, s, CH2Ph), 4.03 (2H, t, J 8.3, CH2), 3.90 (2H, 
t, J  8.0, CH2), 2.38 (3H, s, CH3), 
13C NMR (125 MHz, CDCl3) δC 160.1 (C=O), 
145.3 (Ar-C), 135.3 (Ar-C), 130.1 (Ar-CH), 129.9 (Ar-C), 129.6 (Ar-CH), 128.5 
(Ar-CH), 128.3 (Ar-CH), 128.0 (Ar-CH), 68.4 (CH2), 49.4 (CH2), 47.9 (CH2), 
21.8 (CH3); HRMS (ESI




N-Phenyl-2-tosyl-1,2-diazetidine-1-carboxamide (404) 401 
(80 mg, 0.38 mmol, 1.0 equiv), dichloromethane (5 mL) and 
phenylisocyanate (40 µL, 0.38 mmol, 1.0 equiv) were 
combined and stirred at room temperature for 24 h. The solution was then 
concentrated in vacuo to give a yellow solid (124 mg, 0.37 mmol, 98%), which 
required no further purification; Rf  0.27 (33% EtOAc in petroleum ether);  M.p. 
141-142 °C; IR (film) 3347, 2950, 1697, 1596, 1540, 1345; 1H NMR (600 MHz, 
d6-DMSO at 353 K) δH 8.44 (1 H, s, NH), 7.94 (2H, d, J 8.2, Ar-H), 7.59 (2H, 
d, J 8.2, Ar-H), 7.49 (2H, d, J 7.9, Ar-H), 7.35 (2H, t, J 7.9, Ar-H), 7.10 (1H, t, 
J 7.4, Ar-H), 4.09 (2H, t, J 8.1, NCH2), 3.79 (2H, t, J 8.1, NCH2), 2.50 (3H, s, 
CH3); 
13C NMR (125 MHz, d6-DMSO) δC 158.5 (C=O), 146.4 (Ar-C), 138.4 
(Ar-C), 130.6 (Ar-CH), 130.5 (Ar-CH), 129.4 (Ar-CH), 128.2 (Ar-C), 123.9 
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(Ar-CH), 119.4 (Ar-CH), 49.0 (CH2), 48.8 (CH2), 21.7 (CH3); HRMS (ES
+) 
calculated for  C16H17N3O3S (M+Na)
+: 354.0883; found: 354.0876. 
 
tert-Butyl 2-(phenylcarbamoyl)-1,2-diazetidine-1-
carboxylate (405) 398 (100 mg, 0.32 mmol, 1.0 equiv), 
activated magnesium turnings (39 mg, 1.60 mmol, 5.0 equiv) 
and methanol (5 mL) were stirred at rt for 2 h. This was then quenched with 
saturated ammonium chloride solution (5 mL) and extracted with 
dichloromethane (3 x 5 mL). The organic was dried over MgSO4 and 
concentrated in vacuo to give a colourless oil. Dichloromethane (5 mL) and  
phenylisocyanate (38 µL, 0.35 mmol, 1.1 equiv) were combined and stirred at rt 
for 24 h. The solution was then concentrated in vacuo to give a colourless oil. 
This was purified by column chromatography (25% EtOAc in petroleum ether) 
to give the desired product as a white solid (53 mg, 0.19 mmol, 60%); Rf  0.38 
(25% EtOAc in petroleum ether);  M.p. 125-126 °C; IR (film) 3394, 2982, 1712, 
1670, 1536, 1290, 1143; 1H NMR (500 MHz, CDCl3) δH 8.62 (1 H, s, NH), 7.48 
(2H, d, J 7.7, Ar-H), 7.33 (2H, t, J 7.9, Ar-H), 7.08 (1H, t, J 7.4, Ar-H), 4.22 
(4H, s, 2 x CH2), 1.58 (9H, s, (CH3)3); 
13C NMR (125 MHz, CDCl3) δC 161.4 
(C=O), 161.3 (C=O), 138.2 (Ar-C), 129.0 (Ar-CH), 123.4 (Ar-CH), 119.2 (Ar-
CH), 83.8 (C) 48.5 (CH2), 46.4 (CH2), 28.2 (CH3); HRMS (ES
+) calculated for  
C14H19N3O3 (M+Na)
+: 300.1319; found: 300.1322. 
 
Buchwald-Hartwig Amination Screen 5 – Screen of 410 
 
Scheme 6.11 Buchwald-Hartwig Amination screen of 410. 
Authentic examples of 410, 411 and 2-bromopyridine were run on the GCMS and were 
found to have retention times of 9.7 min, 11.0 min and 7.5 min respectively.  
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The reactions were performed in an aluminium heating block with 9 x 4 mL 
Fisher Scientific Reactivials, each with a teflon coated magnetic stirrer bar. 
These vials were labelled R1-R9 then the following reagents were added to each: 
R1: 410 (5.0 mg, 13 µmol, 1.0 equiv), palladium acetate (0.3 mg, 1.3 µmol, 0.1 
equiv), Xantphos (1.5 mg, 2.6 µmol, 0.2 equiv), sodium tert-butoxide (2.5 mg, 
26 µmol, 2.0 equiv), toluene (1 mL). 
R2: 410 (5.0 mg, 13 µmol, 1.0 equiv), palladium acetate (0.3 mg, 1.3 µmol, 0.1 
equiv), Xantphos (1.5 mg, 2.6 µmol, 0.2 equiv), cesium carbonate (8.5 mg, 26 
µmol, 2.0 equiv), toluene (1 mL). 
R3: 410 (5.0 mg, 13 µmol, 1.0 equiv), palladium acetate (0.3 mg, 1.3 µmol, 0.1 
equiv), Xantphos (1.5 mg, 2.6 µmol, 0.2 equiv), sodium tert-butoxide (2.5 mg, 
26 µmol, 2.0 equiv), dioxane (1 mL). 
R4: 410 (5.0 mg, 13 µmol, 1.0 equiv), palladium dibenzylacetone (1.2 mg, 1.3 
µmol, 0.1 equiv), Xantphos (1.5 mg, 2.6 µmol, 0.2 equiv), sodium tert-butoxide 
(2.5 mg, 26 µmol, 2.0 equiv), toluene (1 mL). 
R5: 410 (5.0 mg, 13 µmol, 1.0 equiv), palladium acetate (0.3 mg, 1.3 µmol, 0.1 
equiv), tert-butyl-Xphos (1.1 mg, 2.6 µmol, 0.2 equiv), sodium tert-butoxide 
(2.5 mg, 26 µmol, 2.0 equiv), toluene (1 mL). 
R6: 410 (5.0 mg, 13 µmol, 1.0 equiv), palladium acetate (0.3 mg, 1.3 µmol, 0.1 
equiv), cyJonphos (0.9 mg, 2.6 µmol, 0.2 equiv), sodium tert-butoxide (2.5 mg, 
26 µmol, 2.0 equiv), toluene (1 mL). 
R7: 410 (5.0 mg, 13 µmol, 1.0 equiv), palladium acetate (0.3 mg, 1.3 µmol, 0.1 
equiv), 1,1′-Ferrocenediyl-bis(diphenylphosphine) (1.4 mg, 2.6 µmol, 0.2 
equiv), sodium tert-butoxide (2.5 mg, 26 µmol, 2.0 equiv), toluene (1 mL). 
R8: 410 (5.0 mg, 13 µmol, 1.0 equiv), palladium dibenzylacetone (1.2 mg, 1.3 
µmol, 0.1 equiv), 1,1′-Ferrocenediyl-bis(diphenylphosphine) (1.4 mg, 2.6 µmol, 
0.2 equiv), cesium carbonate (8.5 mg, 26 µmol, 2.0 equiv), toluene (1 mL). 
R9: 410 (5.0 mg, 13 µmol, 1.0 equiv), palladium dibenzylacetone (1.2 mg, 1.3 
µmol, 0.1 equiv), 1,1′-Ferrocenediyl-bis(diphenylphosphine) (1.4 mg, 2.6 µmol, 
0.2 equiv), cesium carbonate (8.5 mg, 26 µmol, 2.0 equiv), dioxane (1 mL). 
All vials were sealed with subaseals and then placed under an atmosphere of 
nitrogen. The reactions were heated for 20 hours at 90 °C, then the crude reaction 
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mixture of each was filtered through a plug of cotton wool into a vial using 
dichloromethane as the eluent. Each vial had approximately 5 mL of 
dichloromethane added. 20 µL of each solution was removed using a Hamilton 
syringe and transferred to a 2 mL Agilent GCMS vial. 980 µL of 
dichloromethane was added to each then the samples were analysed by GCMS. 
As the screen was not designed to be quantitative, GCMS traces were simply 
analysed for the presence or absence of peaks with retention times corresponding 
to 410 and 411. This analysis was used to generate Table 3.3. 
 
tert-Butyl (S)-3-phenyl-2-(pyridin-2-yl)-1,2-diazetidine-1-
carboxylate 411 cyclic hydrazine 212 (100 mg, 0.26 mmol, 1.0 
equiv), activated magnesium turnings (31 mg, 1.29 mmol, 5.0 
equiv) and methanol (2.6 mL, 0.1 M) were combined and 
stirred (800 rpm) at room temperature for 2 hours. The solution was quenched 
with saturated ammonium chloride solution (5 mL), then extracted with 
dichloromethane (3 x 5 mL). The combined organic extrcts were dried over 
MgSO4 and concentrated in vacuo to give a colourless oil. palladium acetate (6 
mg, 26 µmol, 0.1 equiv), Xantphos (30 mg, 51 µmol, 0.2 equiv), sodium tert-
butoxide (49 mg, 0.51 mmol, 2.0 equiv), 2-bromopyridine (49 µL, 0.51 mmol, 
2.0 equiv) and toluene (2.6 mL, 0.1 M) were combined and stirred at 90 °C for 
18 h. The reaction was quenched with saturated ammonium chloride (5 mL) and 
extracted with dichloromethane (3 x 5 mL). The combined organic extracts were 
dried over magnesium sulphate and concentrated in vacuo to give a brown oil. 
This was purified by column chromatography (10% ethyl acetate and 1% 
triethylamine in petroleum ether) to yield 411 as a pale yellow solid (33 mg, 0.11 
mmol, 41%). Rf = 0.29 (10% EtOAc and 1% triethylamine in petroleum ether); 
M.p. 68-69 °C; [α]32D + 8.20 (c 0.02, CHCl3). IR (film) 3234, 2925 1714, 1591, 
1368, 1072 cm-1; δH (500 MHz; CDCl3); 8.16 (1H, d, J 4.6, Ar-CH), 7.55-7.41 
(1H, m, Ar-CH), 7.48 (1H, d, Ar-CH), 7.48 (2H, d, J 7.5, Ar-CH), 7.34 (2H, t, J 
7.7, Ar-CH), 7.25 (1H, t, J 7.4, Ar-CH), 6.95 (1H, d, J 8.3, Ar-CH), 6.79 (1H, 
dd, J 6.8 and 5.4, Ar-CH), 5.33 (1H, dd, J 8.4 and 7.0, CHPh), 4.57 (1H, t, J 8.5, 
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NCHH) 4.10 (1H, dd, J 7.8, 7.0, NCHH), 1.47 (9H, s, C(CH3)3); δC (125 MHz; 
CDCl3) 164.4 (C=O), 161.3 (Ar-C), 147.7 (Ar-CH), 140.4 (Ar-C), 137.3 (Ar-
CH), 128.8 (Ar-CH), 127.9 (Ar-CH), 126.2 (Ar-CH), 117.2 (Ar-CH), 109.8 (Ar-
CH), 82.3 (C), 64.3 (CH), 57.3 (CH2), 28.3 (CH3); HRMS (ESI
+) calculated for 
C18H21N3O2 [M+Na]




carboxylate (413). Cyclic hydrazine 212 (100 mg, 0.26 
mmol, 1.0 equiv), magnesium turnings (31 mg, 1.29 
mmol, 5.0 equiv) and methanol (2.6 mL, 0.1 M) were combined and stirred (800 
rpm) at room temperature for 2 hours. The solution was quenched with saturated 
ammonium chloride solution (5 mL), then extracted with dichloromethane (3 x 
5 mL). The combined organic extracts were dried over MgSO4 and concentrated 
in vacuo to give a colourless oil. Palladium acetate (6.0 mg, 26 µmol, 0.1 equiv), 
Xantphos (30 mg, 51 µmol, 0.2 equiv), sodium tert-butoxide (49 mg, 0.51 mmol, 
2.0 equiv), 3-trifluoromethyl-bromobenzene (71 µL, 0.51 mmol, 2.0 equiv) and 
toluene (2.6 mL, 0.1 M) were combined and stirred at 90 °C for 18 h. The 
reaction was quenched with saturated ammonium chloride (5 mL) and extracted 
with dichloromethane (3 x 5 mL). The combined organic extracts were dried 
over magnesium sulphate and concentrated in vacuo to give a brown oil. This 
was purified by column chromatography (25% ethyl acetate in petroleum ether) 
to yield 413 as an orange oil (35 mg, 90 µmol, 35%). Rf = 0.78 (25% 
EtOAc/petroleum ether); [α]24D + 4.6 (c 0.23, CHCl3); IR (film) 2978, 1715, 
1327, 1120, 1028 cm-1; δH (500 MHz; CDCl3); 7.56 (2H, d, J 7.3, Ar-H), 7.48 
(2H, t, J 7.5, Ar-H), 7.42 (1H, d, J 7.2, Ar-H), 7.33 (1H, t, J 7.9, Ar-H), 7.22 
(1H, d, J 7.7, Ar-H), 7.15 (1H, s, Ar-H), 6.94 (1H, d, J 8.6, Ar-H), 4.94 (1H, t, J 
8.4, CHPh), 4.58 (1H, t, J 8.5, NCHH) 4.10 (1H, t, J 7.6, NCHH), 1.56 (9H, s, 
C(CH3)3); δC (125 MHz; CDCl3) 161.1 (C=O), 153.6 (Ar-C), 139.1 (Ar-C), 
130.9 (q, J 31.3, Ar-C), 129.1 (Ar-CH), 129.0 (Ar-CH), 128.7 (Ar-CH), 126.7 
(Ar-CH), 124.1 (q, J 271.3, CF3), 118.4 (q, J 3.8, Ar-CH), 117.4 (Ar-CH), 111.3 
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(q, J 5.0, Ar-CH), 82.5 (C), 67.7 (CH), 56.8 (CH2), 28.2 (CH3); δF (376 MHz; 
CDCl3) -62.8 (CF3); HRMS (ESI
+) calculated for C20H21N2O2F3 [M+Na]
+ 
401.1447; found 401.1450. 
 
(S)-4-Phenyl-1-(3-trifluoromethyl)phenyl-1,2-
diazetidine trifluoroacetic acid (414•TFA). Cyclic 
hydrazine 414 (14 mg, 38 µmol, 1.0 equiv), 
trifluoroacetic acid (30 µL, 0.38 mmol, 10.0 equiv) and 
dichloromethane (1.0 mL) were stirred at rt for 2 h then concentrated in vacuo 
to yield 414•TFA as an orange oil (13 mg, 33 µmol, 88%). [α]24D – 4.8 (c 0.36, 
CHCl3); IR (film) 2920, 2852 1759, 1460, 1232, 1032 cm
-1; δH (500 MHz; 
CDCl3); 7.46-7.37 (6H, m, Ar-H), 7.20 (1H, d, J 7.6, Ar-H), 7.05 (1H, s, Ar-H), 
6.99 (1H, d, J 8.1, Ar-H), 5.69 (1H, t, J 8.0, CHPh), 4.20 (1H, t, J 8.3, NCHH), 
3.73 (1H, t, J 8.3, NCHH), δC (125 MHz; CDCl3) 146.4 (Ar-C), 137.1 (Ar-C), 
130.0 (Ar-CH), 129.4 (Ar-CH), 129.1 (Ar-CH), 125.7 (Ar-CH), 118.2 (q, J 3.8, 
Ar-CH), 116.4 (Ar-CH), 109.7 (q, J 2.5, Ar-CH), 74.5 (CH), 53.9 (CH2), 28.2 
(CH3), 1 C=O, 2 CF3 and 1 Ar-C not seen; δF (376 MHz; CDCl3) –62.9 (CF3), 
–70.8 and –70.9 (1:1 rotamer, CF3CO2H); HRMS (ESI
+) calculated for 
C15H13N2F3 [M+Na]




(415). Cyclic hydrazine rac-218 (100 mg, 0.24 mmol, 1.0 
equiv), magnesium turnings (29 mg, 1.19 mmol, 5.0 equiv) 
and methanol (5 mL) were combined and stirred (800 rpm) at room temperature 
for 2 h. The solution was quenched with saturated ammonium chloride solution 
(5 mL), then extracted with dichloromethane (3 x 5 mL). The combined organic 
extracts were dried over MgSO4 and concentrated in vacuo to give a colourless 
oil. Palladium acetate (4.5 mg, 20 µmol, 0.1 equiv), Xantphos (29 mg, 50 µmol, 
0.2 equiv), sodium tert-butoxide (48 mg, 0.5 mmol, 2.0 equiv), 3-
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trifluoromethyl-bromobenzene (70 µL, 0.5 mmol, 2.0 equiv) and toluene (5 mL) 
were combined and stirred at 90 °C for 18 h. The reaction was quenched with 
saturated ammonium chloride (5 mL) and extracted with dichloromethane (3 x 
5 mL). The combined organic extracts were dried over MgSO4 and concentrated 
in vacuo to give a brown oil. This was purified by column chromatography (15% 
ethyl acetate in petroleum ether) to yield 415 as an orange oil (12 mg, 28 µmol, 
12%). M.p. 108-109 °C; Rf = 0.49 (15% EtOAc/petroleum ether); IR (film) 
2918, 1737, 1709, 1334, 1076, cm-1; δH (500 MHz; CDCl3); 7.42-7.38 (2H, m, 
Ar-H), 7.34-7.30 (2H, m, Ar-H), 7.25-7.20 (2H, m, Ar-H), 7.00 (1H, tt, J 7.5, 
1.0, Ar-H), 6.96 (2H, ddd, J 4.5, 3.3, 1.8, Ar-H), 4.45-4.39 (2H, m, CHHOPh 
and NCHH), 4.36-4.30 (1H, m, NCH), 4.26 (1H, dd, J 9.8, 3.8, CHHOPh), 4.21 
(1H, dd, J 8.3, 6.3, NCHH), 1.52 (9H, s, C(CH3)3); δC (125 MHz; CDCl3) 160.7 
(C=O), 158.2 (Ar-C), 153.0 (Ar-C), 139.1 (Ar-C), 130.9 (q, J 31.3, Ar-C), 129.6 
(Ar-CH), 129.0 (Ar-CH), 121.5 (Ar-CH), 118.6 (q, J 3.8, Ar-CH), 117.8 (Ar-
CH), 114.5 (Ar-CH), 111.8 (q, J 3.8, Ar-CH), 82.5 (C), 69.4 (CH2), 64.0 (CH), 
50.7 (CH2), 28.2 (CH3), CF3 not seen; δF (376 MHz; CDCl3) -62.7 (CF3); HRMS 
(ESI+) calculated for C21H23N2O3F3 [M+Na]
+ 431.1553; found 431.1549. 
 
tert-Butyl (rac)-2-isobutyl-3-(phenoxymethyl)-1,2-diazetidine-
1-carboxylate (416). Cyclic hydrazine rac-218 (100 mg, 0.24 
mmol, 1.0 equiv), magnesium turnings (29 mg, 1.19 mmol, 5.0 
equiv) and methanol (5 mL) were combined and stirred (800 rpm) 
at room temperature for 2 h. The solution was quenched with saturated 
ammonium chloride solution (5 mL), then extracted with dichloromethane (3 x 
5 mL). The combined organic extracts were dried over MgSO4 and concentrated 
in vacuo to give a colourless oil. Isobutyraldehyde (109 µL, 1.19 mmol, 5.0 
equiv), sodium triacetoxyborohydride (252 mg, 1.19 mmol, 5.0 equiv), and 
dichloromethane (5 mL) were combined and stirred at rt for 24 h. The reaction 
was quenched with 1 M NaOH solution (5 mL) and extracted with 
dichloromethane (3 x 5 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo to give a colourless oil. This was purified by 
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column chromatography (10% ethyl acetate in petroleum ether) to yield 416 as 
a colourless oil (29 mg, 91 µmol, 38%). Rf = 0.47 (10% EtOAc/petroleum ether); 
IR (film) 2973, 1681, 1495, 1388, 1242, cm-1; δH (500 MHz; CDCl3); 7.30-7.26 
(2H, m, Ar-H), 6.98-6.94 (1H, m, Ar-H), 6.89-6.86 (2H, m, Ar-H), 4.26 (1H, t, 
J 8.4, NCHH), 4.09 (2H, qd, J 9.7, 6.0, CHHOPh and CHHOPh), 3.92 (1H, t, J 
7.5, NCHH), 3.57 (1H, quintet, J 6.5, NCH), 2.94 (1H, dd, J 11.5, 8.5, 
CHHCH(CH3)2), 2.67 (1H, dd, J 11.5, 6.0, CHHCH(CH3)2), 1.87-1.78 (1H, m, 
CH(CH3)2), 1.47 (9H, s, C(CH3)3), 0.96 (6H, d, J 6.7, (CH3)2); δC (125 MHz; 
CDCl3) 160.7 (C=O), 158.5 (Ar-C), 129.5 (Ar-CH), 121.1 (Ar-CH), 114.5 (Ar-
CH), 80.9 (C), 70.3 (CH2), 69.7 (CH2), 60.6 (CH), 50.8 (CH2), 28.2 (CH3), 25.7 
(CH), 21.4 (CH3), 20.9 (CH3); HRMS (ESI
+) calculated for C18H28N2O3 




(340). 313 (200 mg, 0.46 mmol, 1.0 equiv), activated 
magnesium turnings (55 mg, 2.28 mmol, 5.0 equiv), and 
methanol (10 mL) were stirred at rt for 2 h. The solution 
was quenched with saturated ammonium chloride solution 
(5 mL), extracted with dichloromethane (3 x 5 mL) and 
dried over MgSO4. The solution was concentrated in vacuo to give a colourless 
oil. To this was added 338 (364 mg, 2.30 mmol, 5.0 equiv), sodium 
triacetoxyborohydride (487 mg, 2.30 mmol, 5.0 equiv) and dichloromethane (5 
mL, 0.1 M) and the mixture was stirred at rt. After 20 hours it was quenched 
with 2 M sodium hydroxide solution (10 mL), extracted with dichloromethane 
(3 X 10 mL), dried over MgSO4 and concentrated in vacuo to give a brown oil. 
The crude material was purified by column chromatography (10% ethyl acetate 
in petroleum ether) to give 340 as colourless oil (118 mg, 0.28 mmol, 61%). Rf 
= 0.38 (50% EtOAc in petroleum ether); [α]24D –8.8 (c 0.27, CHCl3); IR (film) 
2955, 1737, 1457, 1317, 1056, cm-1; δH (500 MHz; CDCl3 at 323 K); N.B. This 
compound was obtained as a mixture of 2 rotamers, only the peaks of the major 
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rotamer are reported. 6.77 (1H, dd, J 6.5, Ar-H), 6.67 (1H, t, J 8.8, Ar-H), 4.94 
(1H, t, J 8.3, CHAr), 3.66 (3H, s, CO2CH3), 3.41 (1H, dd, J 11.0, 6.5, NCHH), 
3.15 (1H, td, J 11.3, 6.0, NCHH), 3.10-3.00 (1H, m, NCHH), 2.69-2.63 (1H, 
m, NCHH), 2.50 (1H, ddd, J 11.2, 6.8, 2.6, ArCHCHH), 2.12 (1H, ddd, J 10.9, 
8.5, 2.6, ArCHCHH), 1.65-1.63 (2H, m, CH2), 1.57-1.53 (2H, m, CH2), 1.27 
(9H, s, (CH3)3), 1.21 (6H, s, (CH3)2); δC (125 MHz; CDCl3 at 323 K) 178.2 
(C=O), 162.3 (d, J 10.0, Ar-CF), 148.2 (C=O), 108.5 (t, J 18.1, Ar-H), 102.1 
(t, J 21.3, Ar-CH), 80.7 (C), 62.7 (CH), 58.7 (CH2), 51.5 (CH3), 38.1 (CH2), 
34.5 (CH2), 35.4 (CH2), 29.6 (CH2), 28.2 (CH3), 25.1 (CH3), 25.0 (CH3), 24.1 
(C), Ar-C not seen; δF (376 MHz; CDCl3) -109.7 (Ar-CF); HRMS (ESI
+) 
calculated for C22H32N2O4F2 [M+Na]




Toluenesulfonyl hydrazide(1.94 g, 10.1 mmol, 0.9 
equiv), dichloromethane (20 mL) and triethylamine (2.10 mL, 15.1 mmol, 1.3 
equiv) were stirred at 0 °C, then 342111 (1.49 g, 11.6 mmol, 1.0 equiv) in 
dichloromethane (30 mL) was added dropwise. The solution was allowed to 
warm to rt and stirred for 18 h. The solution was then quenched with saturated 
sodium hydrogen carbonate solution (10 mL), extracted with dichloromethane 
(3 x 10 mL), dried over magnesium sulphate and concentrated in vacuo. The 
crude material was purified by column chromatography to give 343 as a white 
solid (914 mg, 3.1 mmol, 30%). Rf = 0.52 (33% EtOAc in petroleum ether); 
M.p. 123-124 °C;   IR (film) 3341, 2973, 1681, 1494, 1164, cm-1; δH (500 
MHz; CDCl3); 7.82 (2H, d, J 8.3, Ar-H), 7.45 (1H, d, J 6.5, NH), 7.31 (2H, d, 
J 8.2, Ar-H), 5.65 (1H, ddt, J 19.5, 9.7, 6.5, HC=CHH), 4.93-4.89 (2H, m, 
HC=CHH), 2.43 (3H, s, Ar-CH3), 1.63 (2H, m, CH2), 1.42 (2H, m, CH2), 1.06 
(6H, s, 2 x CH3); δC (125 MHz; CDCl3) 175.9 (C=O), 145.0 (Ar-C), 137.9 
(HC=CH2), 132.9 (Ar-C), 129.5 (Ar-CH), 129.0 (Ar-CH), 114.7 (HC=CH2), 
39.7 (CH2), 28.7 (CH2), 24.5 (CH3), 21.7 (CH3); HRMS (ESI
+) calculated for 
C15H22N2O3S [M+Na]







(345). 343 (495 mg, 2.42 mmol, 1.0 equiv), 344 (751 mg, 2.42 mmol, 1.0 
equiv), potassium carbonate (368 mg, 2.66 mmol) and acetonitrile (50 mL) 
were stirred at rt for 24 h. The solution was then quenched with water (25 mL), 
extracted with dichloromethane (3 x 25 mL), dried over MgSO4 and 
concentrated in vacuo. The crude material was purified by column 
chromatography (15% ethyl acetate in petroleum ether) to give 345 as a white 
solid (975 mg, 2.03 mmol, 84%). Rf = 0.16 (15% EtOAc in petroleum ether); 
M.p. 108-109 °C; IR (film) 2932, 1686, 1594, 1474, 1311, 1045 cm-1; δH (500 
MHz; CDCl3); 7.80 (2H, d, J 8.3, Ar-H), 7.59 (1 H, s, Ar-H) 7.47 (2H, dd, J 
7.6, 2.0, Ar-H), 7.32 (2H, d, J 8.2, Ar-H), 7.05 (1H, tt, J 8.4, 2.3, HC=CHH), 
5.71 (1H, ddt, J 16.8, 10.2, 6.5, C=CHH), 5.00-4.89 (1H, m, HC=CHH), 3.97 
(2H, t, J 6.3, NCH2), 3.37 (2H, t, J 6.3, COCH2), 2.43 (3H, s, Ar-CH3), 1.85-
1.79 (2H, m, HHC=CHCH2), 1.54-1.46 (2H, m, C(CH3)2CH2), 1.12 (6H, s, 2 x 
CH3); δC (125 MHz; CDCl3) 195.7 (C=O), 175.7 (C=O), 163.1 (dd, J 261.3, 
11.3, Ar-CF), 144.7 (Ar-C), 139.2 (t, J 7.5, Ar-C), 138.0 (HC=CH2), 134.3 (Ar-
C), 129.6 (Ar-CH), 128.5 (Ar-CH), 114.6 (HC=CH2), 111.1 (dd, J 20.0, 6.3, 
Ar-CH), 108.8 (t, J 25.0, Ar-CH), 45.8 (CH2), 41.7 (C(CH3)2), 39.9 (CH2), 38.1 
(CH2), 28.9 (CH2), 25.0 (CH3), 21.7 (CH3); δF (376 MHz; CDCl3) -107.7 (Ar-
CF); HRMS (ESI+) calculated for C24H28N2O4SF2 [M+H]







(441). 345 (760 mg, 1.59 mmol, 1.0 equiv),  (R,R)-247 (11 mg, 16 µmol, 0.01 
equiv), 5 : 2 formic acid : triethylamine solution (1.6 mL, 1.0 M) and 
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dichloromethane (6.4 mL, 0.25 M) were stirred at 24 °C for 24 hours. The 
solution was concentrated in vacuo to give a red oil. The crude material was 
purified by column chromatography to give 441 as a white solid (759 mg, 1.58 
mmol, 99%). Rf = 0.31 (33% EtOAc in petroleum ether); M.p. 91-92 °C; [α]
24
D 
+ 25.3 (c 0.18, CHCl3); Enantiomeric excess (98% ee) was determined by 
HPLC analysis (25 °C). [Chiralcel OD-H column 2-propanol/hexane = 3/97; 
flow rate = 1.0 mL/min; detection wavelength = 254 nm] tR 32.6 min; tR 38.7 
min; IR (film) 3320, 2969, 2924 1684, 1624, 1317, 1116 cm-1; δH (500 MHz; 
CDCl3); 7.86 (2H, d, J 8.3, Ar-H), 7.39-7.33 (3H, m, Ar-H), 6.97-6.91 (2H, m, 
Ar-H), 6.70 (1H, tt, J 8.9, 2.3, HC=CHH), 5.72 (1H, ddt, J 16.8, 10.2, 6.5, 
C=CHH), 5.12-5.03 (1H, m, CHOH), 4.99-4.93 (1H, m, HC=CHH), 3.77-3.67 
(1H, m, NCHH), 3.65-3.59 (1H, m, NCHH), 2.45 (3H, s, Ar-CH3), 2.00-1.93 
(1H, m, CHOHCHH), 1.83-1.78 (3H, m, H2C=CHCH2, CHOHCHH), 1.56-
1.49 (2H, m, C(CH3)2CH2), 1.14 (3H, s, CH3), 1.13 (3H, s, CH3); δC (125 MHz; 
CDCl3) 176.5 (C=O), 163.1 (dd, J 246.2, 11.3, Ar-CF), 149.0 (t, J 8.8, Ar-C), 
145.1 (Ar-C), 137.8 (HC=CH2), 133.5 (Ar-C), 129.7 (Ar-H), 128.7 (Ar-H), 
114.8 (HC=CH2), 108.5 (dd, J 20.0, 5.0, Ar-H), 102.4 (t, J 25.0, Ar-H), 70.8 
(CH), 47.8 (CH2), 41.8 (C(CH3)2), 39.9 (CH2), 36.3 (CH2), 28.9 (CH2), 25.2 
(CH3), 25.1 (CH3), 21.7 (CH3); δF (376 MHz; CDCl3) -109.5 (Ar-CF); HRMS 
(ESI+) calculated for C24H30N2O4SF2 [M+Na]
+ 503.1787; found 503.1786. 
 
(S)-1-(5-(3,5-Difluorophenyl)-2-tosylpyrazolidin-1-
yl)-2,2-dimethylhex-5-en-1-one (346). 441 (759 mg, 
1.58 mmol, 1.0 equiv), triphenylphosphine (1.04 g, 
3.95 mmol, 2.5 equiv), diethylazodicarboxylate (0.62 
mL, 2.5 equiv) and tetrahydrofuran (158 mL, 0.01 M) 
were stirred at rt for 24 hours. The solution was concentrated in vacuo to give 
a yellow oil. The crude material was purified by column chromatography to 
give 346 as an off white solid (453 mg, 0.98 mmol, 62%). Rf = 0.08 (10% 
EtOAc in petroleum ether); M.p. 82-83 °C; [α]24D –80.0 (c 0.19, CHCl3); 
Enantiomeric excess (95% ee) was determined by HPLC analysis (25 °C). 
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[Chiralcel OD-H column 2-propanol/hexane = 2/98; flow rate = 1.0 mL/min; 
detection wavelength = 254 nm] tR 16.3 min; tR 30.9 min; IR (film) 3322, 2972, 
2925 1686, 1642, 1626, 1366, 1203 cm-1; δH (500 MHz; CDCl3); 7.81 (2H, d, 
J 8.2, Ar-H), 7.32 (2H, d, J 8.1, Ar-H), 6.88-6.81 (2H, m, Ar-H), 6.75 (1H, tt, 
J 8.9, 2.3, HC=CHH), 5.75-5.63 (2H, m, C=CH2), 4.91-4.87 (1H, m, CHAr), 
4.00 (1H, ddd, J 13.2, 7.6, 2.5, NCHH), 3.16 (1H, m, NCHH), 2.49-2.39 (4H, 
m, Ar-CH3, ArCHCHH), 2.11-2.03 (1H, m, ArCHCHH), 1.93-1.77 (2H, m, 
H2C=CHCHH, C(CH3)2CHH), 1.55-1.49 (1H, m, H2C=CHCHH), 1.43 (1H, 
ddd, J 13.5, 11.5, 5.3, C(CH3)2CHH), 1.08(4) (3H, s, CH3), 1.08(1) (3H, s, 
CH3); δC (125 MHz; CDCl3) 163.1 (dd, J 247.5, 11.3, Ar-CF), 159.5 (C=O), 
143.5 (t, J 8.8, Ar-C), 144.1 (Ar-C), 137.6 (HC=CH2), 132.4 (Ar-C), 129.2 (Ar-
H), 129.0 (Ar-H), 114.3 (HC=CH2), 108.3 (dd, J 20.0, 5.0, Ar-CH), 103.5 (t, J 
25.0, Ar-CH), 78.6 (CH), 49.5 (CH2), 40.8 (C(CH3)2), 39.5 (CH2), 35.4 (CH2), 
29.0 (CH2), 26.0 (CH3), 25.7 (CH3), 21.6 (CH3); δF (376 MHz; CDCl3) -107.1 
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